text	label
multi	O
drug	O
resistant	O
 P. falciparum	B-Organism
P. vivax	B-Organism
 P. malariae	B-Organism
 malaria	S-Disease
cytotoxicity	S-Chemical_Substance
drug	S-Chemical_Substance
artesunate	B-Chemical_Substance
3-Chloro-4(4-chlorophenoxy)	I-Chemical_Substance
aniline	E-Chemical_Substance
ATSA	S-Chemical_Substance
P	O
falciparum	O
activity	O
The	O
global	O
spread	O
of	O
and	O
strains	O
and	O
absence	O
of	O
long	O
term	O
effective	O
vaccine	O
makes	O
the	O
mainstay	O
of	O
control	O
strategies	O
in	O
endemic	O
settings	O
The	O
Mossman	O
s	O
assay	O
and	O
the	O
Organization	O
for	O
Economic	O
Co	O
operation	O
and	O
Development	O
OECD	O
2001	O
guideline	O
423	O
were	O
used	O
to	O
determine	O
the	O
and	O
using	O
3D	O
P. falciparum	B-Organism
in	O
vitro	O
and	O
in	O
vivo	O
respectively	O
A	O
modified	O
Desjardins	O
method	O
was	O
used	O
to	O
screen	O
for	O
of	O
a	O
novel	O
hybrid	O
multi	O
drug	O
resistan	O
chemotherapy	O
chemotherapy	O
malaria	O
 malaria	S-Disease
Since	O
2004	O
transmission	O
on	O
Bioko	O
Island	O
has	O
declined	O
significantly	O
as	O
a	O
result	O
of	O
the	O
scaling	O
up	O
of	O
control	O
interventions	O
The	O
aim	O
of	O
eliminating	O
from	O
the	O
Island	O
remains	O
elusive	O
however	O
underscoring	O
the	O
need	O
to	O
adapt	O
control	O
to	O
the	O
local	O
context	O
Understanding	O
the	O
factors	O
driving	O
the	O
risk	O
of	O
malaria 	B-Disease
 infection	I-Disease
is	O
critical	O
to	O
inform	O
optimal	O
suits	O
of	O
interventions	O
in	O
this	O
adaptive	O
approach	O
This	O
study	O
used	O
individual	O
and	O
household	O
level	O
data	O
from	O
the	O
2015	O
and	O
2018	O
annual	O
malaria	S-Disease
indicator	O
surveys	O
on	O
Bioko	O
Island	O
as	O
well	O
as	O
remotely	O
sensed	O
environmental	O
data	O
in	O
multilevel	O
logistic	O
regression	O
models	O
to	O
quantify	O
the	O
odds	O
of	O
malaria	B-Disease
infection	I-Disease
The	O
analyses	O
were	O
stratified	O
by	O
urban	O
and	O
rural	O
settings	O
and	O
by	O
survey	O
year	O
Malaria	S-Disease
prevalence	O
was	O
higher	O
in	O
10	O
14	O
year	O
old	O
children	O
and	O
similar	O
between	O
female	O
and	O
male	O
individuals	O
After	O
adjusting	O
for	O
demographic	O
factors	O
and	O
other	O
covariates	O
many	O
of	O
the	O
variables	O
investigated	O
showed	O
no	O
significant	O
association	O
with	O
malaria 	B-Disease
infection	I-Disease
infection	I-Disease
The	O
factor	O
most	O
strongly	O
associated	O
was	O
history	O
of	O
travel	O
to	O
mainland	O
Equatorial	O
Guinea	O
mEG	O
which	O
increased	O
the	O
odds	O
significantly	O
both	O
in	O
urban	O
and	O
rural	O
settings	O
people	O
who	O
travelled	O
had	O
4	O
times	O
the	O
odds	O
of	O
 malaria	S-Disease
Sleeping	O
under	O
a	O
long	O
lasting	O
insecticidal	O
net	O
decreased	O
significantly	O
the	O
odds	O
of	O
infection	I-Disease
across	O
urban	O
and	O
rural	O
settings	O
and	O
survey	O
years	O
net	O
users	O
had	O
around	O
30	O
less	O
odds	O
of	O
highlighting	O
their	O
contribution	O
to	O
malaria	S-Disease
control	O
on	O
the	O
Island	O
Improved	O
housing	O
conditions	O
indicated	O
some	O
protection	O
though	O
this	O
was	O
not	O
consistent	O
across	O
settings	O
and	O
survey	O
year	O
Malaria	S-Disease
risk	O
on	O
Bioko	O
Island	O
is	O
heterogeneous	O
and	O
determined	O
by	O
a	O
combination	O
of	O
factors	O
interacting	O
with	O
local	B-Organism
mosquito	I-Organism
ecology	O
These	O
interactions	O
grant	O
further	O
investigation	O
in	O
order	O
to	O
better	O
adapt	O
control	O
according	O
to	O
need	O
The	O
single	O
most	O
important	O
risk	O
factor	O
identified	O
was	O
travel	O
to	O
mEG	O
in	O
line	O
with	O
previous	O
investigations	O
and	O
represents	O
a	O
great	O
challenge	O
for	O
the	O
success	O
of	O
malaria	O
control	O
on	O
the	O
Island	O
Malaria 	S-Disease
is	O
a	O
major	O
public	O
health	O
issue	O
with	O
substantial	O
risks	O
among	O
vulnerable	O
populations	O
Currently	O
the	O
World	O
Health	O
Organization	O
WHO	O
recommends	O
Plasmodium	B-Gene
 falciparum 	I-Gene
dihydrofolate reductase	E-Gene
dihydropteroate	B-Gene
 synthetase 	I-Gene
genes	E-Gene
sulfadoxine	B-Chemical_Substance
pyrimethamine 	I-Chemical_Substance
malaria	B-Organism
 parasite	I-Organism
in	O
the	O
second	O
and	O
third	O
trimesters	O
However	O
the	O
efficacy	O
of	O
is	O
threatened	O
by	O
the	O
emergence	O
of	O
resistant	O
due	O
to	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
SP	O
IPTp	O
i	O
SP	O
IPTp	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
current	O
prevalence	O
of	O
 Pfdhfr	S-Gene
Pfdhps	S-Gene
mutations	O
in	O
 P. falciparum 	S-Organism
isolates	O
collected	O
from	O
individuals	O
residing	O
in	O
Ile	O
Ife	O
Nigeria	O
and	O
also	O
present	O
maps	O
of	O
the	O
prevalence	O
of	O
Pfdhps 431V	S-Gene
 581G	S-Gene
and	O
within	O
Nigeria	O
and	O
surrounding	O
countries	O
nBetween	O
October	O
2020	O
and	O
April	O
2021	O
samples	O
were	O
collected	O
as	O
dried	O
blood	O
spots	O
among	O
188	O
participants	O
who	O
showed	O
 malaria	S-Organism
positivity	O
with	O
a	O
histidine	B-Protien
rich	I-Protien
-protein	E-Protien
based	O
rapid	O
diagnostic	O
test	O
RDT	O
 falciparum 	S-Organism
Nested	O
PCR	O
assays	O
were	O
used	O
to	O
confirm	O
n	O
the	O
samples	O
with	O
RDT	O
positivity	O
and	O
to	O
amplify	O
fragments	O
of	O
the	O
Pfdhfr/Pfdhps	B-Gene
 genes	I-Gene
followed	O
by	O
targeted	O
amplicon	O
sequencing	O
Published	O
data	O
since	O
2007	O
on	O
the	O
prevalence	O
of	O
the	O
 Pfdhps	B-Gene
 genotypes	I-Gene
in	O
Nigeria	O
and	O
the	O
neighbouring	O
countries	O
were	O
used	O
to	O
produce	O
maps	O
to	O
show	O
the	O
distribution	O
of	O
the	O
mutant	O
genotypes	O
nOnly	O
74	O
and	O
61	O
samples	O
were	O
successfully	O
amplified	O
for	O
the	O
Pfdhfr	S-Gene
and	O
Pfdhps 	B-Gene
genes	I-Gene
respectively	O
At	O
codons	O
resulting	O
in	O
Pfdhps gene 	S-Gene
Pfdhfr 	S-Gene
Pfdhps genes	S-Gene
Pfdhfr	S-Gene
N51I	O
C59R	O
and	O
S108N	O
carried	O
mutant	O
alleles	O
of	O
97	O
3	O
72	O
74	O
97	O
3	O
72	O
74	O
and	O
98	O
6	O
73	O
74	O
respectively	O
The	O
carried	O
mutations	O
at	O
codons	O
resulting	O
in	O
Pfdhfr	S-Gene
 Pfdhps	S-Gene
 ISGKAA	S-Gene
 ISGKGS	S-Gene
 VAGKAA	S-Gene
VAGKAS	S-Gene
 VAGKGS	S-Gene
Pfdhps 431V	S-Gene
 581G	S-Gene
 613S	S-Gene
 Pfdhps	B-Gene
-VAGKGS	I-Gene
haplotype.	E-Gene
 431V/581G	S-Gene
A581G	S-Gene
A613S	S-Gene
51I-59R-108N	S-Gene
amino	O
acid	O
changes	O
at	O
431	O
436	O
437	O
540	O
581	O
613	O
I431V	O
45	O
9	O
28	O
61	O
This	O
study	O
showed	O
that	O
the	O
prevalence	O
of	O
VAGKGS	O
haplotype	O
seems	O
to	O
be	O
increasing	O
in	O
prevalence	O
If	O
this	O
is	O
similar	O
in	O
effect	O
to	O
the	O
emergence	O
of	O
581G	O
in	O
East	O
Africa	O
the	O
efficacy	O
of	O
SP	O
IPTp	O
in	O
the	O
presence	O
of	O
these	O
novel	O
Pfdhps	O
mutants	O
should	O
be	O
re	O
assessed	O
often	O
co	O
occur	O
as	O
mutations	O
was	O
found	O
in	O
the	O
study	O
population	O
It	O
seems	O
quite	O
evident	O
that	O
the	O
Constructed	O
haplotypes	O
were	O
mainly	O
the	O
triple	O
95	O
9	O
and	O
the	O
most	O
common	O
haplotypes	O
observed	O
for	O
the	O
9	O
8	O
and	O
14	O
8	O
mutant	O
31	O
1	O
19	O
61	O
and	O
14	O
8	O
In	O
the	O
context	O
of	O
the	O
previously	O
publishe	O
data	O
a	O
high	O
prevalence	O
o	O
49	O
2	O
30	O
61	O
gene	O
were	O
the	O
32	O
8	O
8	O
2	O
malaria	S-Disease
Immunity	O
to	O
cytokine	S-Protien
pro-inflammatory 	B-Protien
anti-inflammatory	B-Protien
cytokines	I-Protien
RBC	O
lymphocyte	S_Anatomical_Substances
platelet counts,	S_Anatomical_Substances
 falciparum	B-Organism
malaria	I-Organism
 P. falciparum	S-Disease
has	O
a	O
major	O
role	O
in	O
controlling	O
disease	O
and	O
TNFα	S-Protien
 IFNγ	S-Protien
 IL10	S-Protien
TNFα/IL10	S-Protien
TNFα	S-Protien
 IFNγ 	S-Protien
 IL10 	S-Protien
 IL10	S-Protien
 TNFα	S-Protien
pathogenesis	O
with	O
production	O
being	O
involved	O
in	O
almost	O
every	O
phase	O
of	O
the	O
immune	O
response	O
The	O
present	O
study	O
aimed	O
to	O
assess	O
hematological	O
variables	O
and	O
to	O
measure	O
plasm	S_Anatomical_Substances
their	O
ratios	O
and	O
their	O
relation	O
to	O
parasitemia	O
among	O
patients	O
with	O
uncomplicated	O
in	O
Hodeidah	O
Yemen	O
Forty	O
patients	O
with	O
uncomplicated	O
monoinfection	S-Disease
and	O
40	O
healthy	O
age	O
and	O
sex	O
matched	O
controls	O
were	O
enrolled	O
in	O
the	O
study	O
Plasma	B-Chemical_Substance
cytokine	I-Chemical_Substance
Parasitological	O
diagnosis	O
was	O
confirmed	O
and	O
parasite	O
density	O
was	O
estimated	O
levels	O
hematologic	O
parameters	O
and	O
the	O
presence	O
of	O
gametocytes	O
were	O
determined	O
Results	O
revealed	O
highe	O
and	O
in	O
patients	O
than	O
in	O
controls	O
A	O
relatively	O
higher	O
 IL10	S-Protien
IFNγ/IL10 	S-Protien
production	O
was	O
demonstrated	O
by	O
the	O
significantly	O
lowe	O
and	O
ratios	O
in	O
patients	O
than	O
in	O
controls	O
and	O
correlated	O
positively	O
with	O
parasite	O
density	O
Hb	B-Anatomical_Substances
Lower	O
and	O
higher	O
neutrophil	S_Anatomical_Substances
 reticulocyte	S_Anatomical_Substances
counts	O
were	O
observed	O
in	O
patients	O
compared	O
to	O
controls	O
Reticulocyte 	S_Anatomical_Substances
IFNγ	S-Protien
level	O
was	O
lower	O
in	O
the	O
presence	O
of	O
gametocytes	O
Conclusively	O
uncomplicated	O
falciparum	B-Organism
malaria	I-Organism
is	O
associated	O
with	O
the	O
ability	O
to	O
regulate	O
the	O
production	O
of	O
This	O
mediates	O
parasite	O
clearance	O
while	O
simultaneously	O
avoiding	O
severe	O
pathology	O
was	O
higher	O
and	O
Chitinases	S-Chemical_Substance
fungicides 	S-Chemical_Substance
 insecticides	S-Chemical_Substance
 Chitinase	S-Chemical_Substance
 Chitinase	S-Chemical_Substance
malaria	B-Disease
dengue	I-Disease
fever	E-Disease
mosquitoes	S-Organism
Chitinases	S-Chemical_Substance
 chitinases	S-Chemical_Substance
Chitinases	S-Chemical_Substance
pesticides	S-Chemical_Substance
chitooligosaccharides	S-Chemical_Substance
Chitinase	S-Chemical_Substance
 chitinase	S-Chemical_Substance
chitinase i	S-Chemical_Substance
multifunctional	B-Organism
 biocatalysts	I-Organism
chitin	S-Chemical_Substance
for	O
the	O
pest	O
control	O
and	O
useful	O
in	O
modern	O
biotechnology	O
and	O
pharmaceutical	O
industries	O
Chemical	O
have	O
caused	O
more	O
severe	O
effects	O
on	O
environment	O
and	O
human	O
health	O
Many	O
 pathogenic	B-Organism
 fungal	I-Organism
 species	E-Organism
insects	S-Organism
became	O
resistant	O
to	O
the	O
chemical	O
 resistant	B-Organism
fungi	I-Organism
emerged	O
as	O
a	O
multidrug	O
resistant	O
also	O
and	O
less	O
susceptible	O
insects	O
are	O
not	O
possible	O
to	O
control	O
adequately	O
have	O
an	O
immense	O
potential	O
to	O
be	O
exploited	O
as	O
a	O
 biopesticide	S-Chemical_Substance
fungi	S-Organism
 insects	S-Organism
iquid	O
formulation	O
or	O
whole	O
microbial	O
enzyme	O
producing	O
cells	O
both	O
act	O
as	O
antagonistically	O
against	O
the	O
pests	O
s	O
Present	O
review	O
is	O
illustrating	O
the	O
updated	O
information	O
on	O
the	O
state	O
of	O
the	O
art	O
of	O
different	O
in	O
agriculture	O
and	O
biotechnology	O
industry	O
It	O
also	O
bestows	O
the	O
understanding	O
to	O
the	O
readers	O
about	O
the	O
areas	O
of	O
extensively	O
studied	O
and	O
the	O
field	O
where	O
there	O
is	O
still	O
much	O
left	O
to	O
be	O
done	O
is	O
valuable	O
for	O
the	O
synthesis	O
of	O
management	O
of	O
sea	O
food	O
remains	O
like	O
shells	O
of	O
crustaceans	S-Organism
synthesis	O
of	O
pharmaceutically	O
important	O
producing	O
microbes	O
have	O
the	O
huge	O
potential	O
to	O
utilize	O
against	O
the	O
waste	O
lso	O
have	O
been	O
successfully	O
fungi	O
further	O
it	O
act	O
as	O
the	O
biocontrol	O
agent	O
o	O
used	O
in	O
wine	O
and	O
single	O
cell	O
protein	O
producing	O
industries	O
applications	O
of	O
disintegrate	O
the	O
fungal	O
cell	O
wall	O
and	O
insect	O
integument	O
that	O
holds	O
the	O
as	O
a	O
vital	O
structural	O
component	O
Moreove	O
against	O
protoplasts	O
from	O
industrially	O
important	O
is	O
applied	O
for	O
the	O
ausing	O
larvae	O
of	O
 malaria 	S-Disease
 malaria 	S-Disease
single drug	B-Chemical_Substance
primaquine,	I-Chemical_Substance
chemotherapeutics	S-Chemical_Substance
antimalarial	B-Chemical_Substance
 chemotherapeutics	I-Chemical_Substance
Safe	O
and	O
effective	O
transmission	O
blocking	O
would	O
allow	O
a	O
community	O
level	O
approach	O
to	O
ontrol	O
and	O
eradication	O
efforts	O
by	O
targeting	O
the	O
mosquito	S-Organism
exual	O
stage	O
of	O
the	O
parasite	O
life	O
cycle	O
However	O
only	O
a	O
s	O
currently	O
approved	O
for	O
use	O
in	O
reducing	O
transmission	O
and	O
drug	O
toxicity	O
limits	O
its	O
widespread	O
implementation	O
To	O
address	O
this	O
limitation	O
in	O
used	O
a	O
recently	O
developed	O
 transgenic 	B-Organism
Plasmodium 	I-Organism
berghei	E-Organism
line	O
Ookluc	O
to	O
perform	O
a	O
series	O
of	O
high	O
throughput	O
Vector	O
management	O
programs	O
rely	O
on	O
knowledge	O
of	O
the	O
biology	O
and	O
genetic	O
make	O
up	O
of	O
mosquitoes	S-Organism
Anopheles	B-Organism
stephens	I-Organism
is	O
a	O
major	O
invasive	O
urban	O
malaria	O
vector	O
distributed	O
throughout	O
the	O
Indian	O
subcontinent	O
and	O
Middle	O
East	O
and	O
has	O
recently	O
been	O
expanding	O
its	O
range	O
in	O
Africa	O
With	O
the	O
existence	O
of	O
three	O
biological	O
forms	O
distinctly	O
identifiable	O
based	O
on	O
the	O
number	O
of	O
ridges	O
on	O
eggs	O
and	O
varying	O
vectorial	O
competence	O
An	O
stephensi	O
is	O
a	O
perfect	O
species	O
for	O
developing	O
isofemale	O
lines	O
which	O
can	O
be	O
tested	O
for	O
insecticide	O
susceptibility	O
and	O
vectorial	O
competence	O
of	O
various	O
biological	O
forms	O
Anopheles	B-Organism
We	O
describe	O
key	O
steps	O
involved	O
in	O
establishment	O
and	O
validation	O
of	O
isofemale	O
lines	O
Isofemale	O
colonies	O
were	O
further	O
used	O
for	O
the	O
characterization	O
of	O
insecticide	O
susceptibility	O
and	O
differential	O
vector	O
competence	O
The	O
results	O
were	O
statistically	O
evaluated	O
through	O
descriptive	O
and	O
inferential	O
statistics	O
using	O
Vassar	O
Stat	O
and	O
Prism	O
GraphPad	O
software	O
packages	O
nThrough	O
a	O
meticulous	O
selection	O
process	O
we	O
overcame	O
an	O
initial	O
inbreeding	O
depression	O
and	O
found	O
no	O
significant	O
morphometric	O
differences	O
in	O
wings	O
and	O
egg	O
size	O
between	O
the	O
parental	O
and	O
respective	O
isofemale	O
lines	O
in	O
later	O
generations	O
IndCh	O
and	O
IndInt	O
strains	O
showed	O
variations	O
in	O
resistance	O
to	O
different	O
insecticides	O
belonging	O
to	O
all	O
four	O
major	O
classes	O
We	O
observed	O
a	O
significant	O
change	O
in	O
vectorial	O
competence	O
between	O
the	O
respective	O
isofemale	O
and	O
parental	O
lines	O
Isofemale	O
lines	O
can	O
be	O
a	O
valuable	O
resource	O
for	O
characterizing	O
and	O
enhancing	O
several	O
genotypic	O
and	O
phenotypic	O
traits	O
This	O
is	O
the	O
first	O
detailed	O
report	O
of	O
the	O
establishment	O
of	O
two	O
isofemale	O
lines	O
of	O
type	O
and	O
intermediate	O
biological	O
forms	O
in	O
The	O
work	O
encompasses	O
characterization	O
of	O
fitness	O
traits	O
among	O
two	O
lines	O
through	O
a	O
transgenerational	O
study	O
Furthermore	O
isofemale	O
colonies	O
were	O
established	O
and	O
used	O
to	O
characterize	O
insecticide	O
susceptibility	O
and	O
vector	O
competence	O
The	O
study	O
provides	O
valuable	O
insights	O
into	O
differential	O
susceptibility	O
status	O
of	O
the	O
parental	O
and	O
isofemale	O
lines	O
to	O
different	O
insecticides	O
belonging	O
to	O
the	O
same	O
class	O
Corroborating	O
an	O
earlier	O
hypothesis	O
we	O
demonstrate	O
the	O
high	O
vector	O
competence	O
of	O
the	O
type	O
form	O
relative	O
to	O
the	O
intermediate	O
form	O
using	O
homozygous	O
lines	O
Using	O
these	O
lines	O
it	O
is	O
now	O
possible	O
to	O
study	O
host	O
parasite	O
interactions	O
and	O
identify	O
factors	O
that	O
might	O
be	O
responsible	O
for	O
altered	O
susceptibility	O
and	O
increased	O
vector	O
competence	O
in	O
An	O
stephensi	O
biological	O
forms	O
that	O
would	O
also	O
pave	O
the	O
way	O
for	O
developing	O
better	O
vector	O
management	O
strategies	O
stephensi.	I-Organism
mosquitoes	S-Organism
Anopheles	B-Organism
funestus	I-Organism
An. gambiae	S-Organism
malaria 	S-Disease
used	O
in	O
combination	O
with	O
conventional	O
control	O
methods	O
IRS	O
or	O
LLIN	O
These	O
results	O
supported	O
the	O
decision	O
to	O
implement	O
a	O
large	O
scale	O
epidemiological	O
cluster	O
randomized	O
controlled	O
trial	O
of	O
ATSB	O
in	O
Zambia	O
deploying	O
2	O
ATSB	O
stations	O
per	O
eligible	O
structure	O
station	O
Observed	O
feeding	O
rates	O
are	O
in	O
line	O
with	O
those	O
thought	O
to	O
be	O
required	O
for	O
ATSB	O
stations	O
to	O
achieve	O
reductions	O
in	O
vector	O
populations	O
in	O
Western	O
Province	O
Zambia	O
readily	O
fed	O
from	O
the	O
prototype	O
Sarabi	O
v1	O
1	O
1	O
ASB	O
sugar	O
bait	O
transmission	O
when	O
and	O
Anopheles	B-Organism
gambiae	I-Organism
An. funestus 	S-Organism
An. funestus	S-Organism
 Anopheles	B-Organism
arabiensis	I-Organism
Attractive	B-Organism
targeted 	I-Organism
sugar bait	E-Organism
ATSB	S-Organism
 An. funestus	S-Organism
Anopheles	B-Organism
squamosus	I-Organism
An. gambiae 	S-Organism
An. gambiae	S-Organism
 An. funestus	S-Organism
mosquitoes 	S-Organism
Anopheles	B-Organism
 funestus	I-Organism
 ATSB	S-Organism
malaria 	S-Disease
The	O
product	O
evaluated	O
was	O
the	O
Sarabi	O
v1	O
1	O
1	O
ASB	O
station	O
which	O
did	O
not	O
include	O
insecticide	O
but	O
did	O
include	O
0	O
8	O
uranine	O
as	O
a	O
dye	O
allowing	O
for	O
the	O
detection	O
using	O
UV	O
fluorescence	O
light	O
microscopy	O
of	O
mosquitoes	O
that	O
have	O
acquired	O
a	O
sugar	O
meal	O
from	O
the	O
ASB	O
A	O
two	O
phase	O
crossover	O
study	O
design	O
was	O
conducted	O
in	O
10	O
village	O
based	O
clusters	O
in	O
Western	O
Province	O
Zambia	O
One	O
study	O
arm	O
initially	O
received	O
2	O
ASB	O
stations	O
per	O
eligible	O
structure	O
while	O
the	O
other	O
initially	O
received	O
3	O
Primary	O
mosquito	O
sampling	O
occurred	O
via	O
indoor	O
and	O
outdoor	O
CDC	O
Miniature	O
UV	O
Light	O
Trap	O
collection	O
from	O
March	O
01	O
through	O
April	O
09	O
2021	O
Phase	O
1	O
and	O
from	O
April	O
19	O
to	O
May	O
28	O
2021	O
Phase	O
2	O
stations	O
are	O
a	O
promising	O
new	O
approach	O
to	O
vector	O
control	O
that	O
could	O
compliment	O
current	O
tools	O
by	O
xploiting	O
the	O
natural	O
sugar	O
feeding	O
behaviors	O
of	O
Recent	O
proof	O
of	O
concept	O
work	O
with	O
a	O
prototype	O
he	O
dominant	O
vector	O
in	O
the	O
study	O
area	O
is	O
s	O
l	O
which	O
was	O
the	O
most	O
abundant	O
species	O
group	O
collected	O
31	O
of	O
all	O
Anophelines	S-Organism
45	O
038	O
144	O
5550	O
had	O
the	O
highest	O
sporozoite	O
rate	O
3	O
16	O
66	O
positives	O
out	O
of	O
2	O
090	O
tested	O
and	O
accounted	O
for	O
94	O
3	O
66	O
70	O
of	O
all	O
sporozoite	O
from	O
clusters	O
with	O
2	O
or	O
3	O
ASBs	O
per	O
eligible	O
structure	O
Similarly	O
there	O
were	O
no	O
correlations	O
observed	O
between	O
feeding	O
rates	O
and	O
the	O
average	O
number	O
of	O
ASB	O
stations	O
per	O
hectare	O
or	O
with	O
weekly	O
rainfall	O
amounts	O
 mosquitoes	S-Organism
inter	O
cluster	O
range	O
of	O
1	O
0	O
5	O
2	O
Feeding	O
rates	O
were	O
no	O
different	O
among	O
positive	O
for	O
uranine	O
translating	O
into	O
an	O
estimated	O
daily	O
feeding	O
rate	O
of	O
8	O
9	O
7	O
7	O
9	O
9	O
fo	O
specimens	O
further	O
identified	O
to	O
species	O
97	O
2	O
2	O
090	O
2	O
150	O
were	O
in	O
transmission	O
Overall	O
21	O
6	O
9	O
218	O
42	O
587	O
o	O
specimens	O
and	O
10	O
4	O
201	O
1	O
940	O
of	O
inter	O
cluster	O
range	O
of	O
5	O
5	O
to	O
12	O
7	O
and	O
specimens	O
collected	O
wer	O
may	O
play	O
a	O
minor	O
role	O
positive	O
specimens	O
Of	O
those	O
s	O
l	O
96	O
8	O
of	O
which	O
were	O
is	O
a	O
likely	O
secondary	O
vector	O
an	O
sensu	O
stricto	O
s	O
s	O
3	O
9	O
3	O
3	O
4	O
7	O
for	O
collected	O
indoors	O
or	O
outdoor	O
 malaria, 	S-Disease
mosquitoes	S-Organism
humans 	S-Organism
 malaria 	S-Disease
control	O
using	O
GDTs	O
Our	O
ethical	O
analysis	O
shows	O
that	O
this	O
context	O
invokes	O
the	O
principle	O
of	O
self	O
defence	O
which	O
could	O
override	O
the	O
pro	O
tanto	O
concerns	O
that	O
a	O
biocentrist	O
would	O
have	O
against	O
modifying	O
malaria	O
mosquitoes	O
in	O
this	O
way	O
if	O
certain	O
conditions	O
are	O
met	O
At	O
the	O
same	O
time	O
the	O
case	O
study	O
of	O
GDTs	O
underlines	O
the	O
relevance	O
of	O
previously	O
posed	O
questions	O
and	O
criticism	O
regarding	O
the	O
internal	O
consistency	O
of	O
Taylor	O
s	O
egalitarian	O
biocen	O
and	O
non	O
human	O
organisms	O
should	O
be	O
factored	O
into	O
determining	O
this	O
Existing	O
analyses	O
of	O
this	O
matter	O
have	O
thus	O
far	O
generally	O
relied	O
on	O
anthropocentric	O
and	O
zoocentric	O
perspectives	O
and	O
rejected	O
an	O
individualist	O
biocentric	O
outlook	O
in	O
which	O
all	O
living	O
organisms	O
are	O
taken	O
to	O
matter	O
morally	O
for	O
their	O
own	O
sake	O
In	O
this	O
paper	O
we	O
reconsider	O
the	O
implications	O
of	O
taking	O
a	O
biocentric	O
approach	O
and	O
highlight	O
nuances	O
that	O
may	O
not	O
be	O
evident	O
at	O
first	O
glance	O
First	O
we	O
shortly	O
discuss	O
biocentric	O
perspectives	O
in	O
general	O
and	O
then	O
outline	O
Paul	O
Taylor	O
s	O
biocentric	O
theory	O
of	O
respect	O
for	O
nature	O
Second	O
we	O
explore	O
how	O
conflicting	O
claims	O
towards	O
different	O
organisms	O
should	O
be	O
prioritised	O
from	O
this	O
perspective	O
and	O
subsequently	O
apply	O
this	O
to	O
the	O
context	O
of	O
Gene	O
drive	O
technologies	O
GDTs	O
have	O
been	O
proposed	O
as	O
a	O
potential	O
new	O
way	O
to	O
alleviate	O
the	O
burden	O
of	O
questions	O
A	O
central	O
ethical	O
question	O
regarding	O
GDTs	O
relates	O
to	O
whether	O
it	O
is	O
morally	O
permissible	O
to	O
intentionally	O
modify	O
or	O
eradicate	O
yet	O
have	O
also	O
raised	O
ethical	O
this	O
way	O
and	O
how	O
the	O
inherent	O
worth	O
o	O
trism	O
Urothelial 	B-Disease
carcinoma	I-Disease
UC	S-Disease
may	O
arise	O
from	O
the	O
of	O
the	O
upper	O
tract	O
and	O
the	O
bladder	O
 Cisplatin	S-Chemical_Substance
urothelium	O
based	O
therapy	O
remains	O
the	O
gold	O
standard	O
for	O
UC	O
treatment	O
The	O
poor	O
5	O
year	O
survival	O
rate	O
of	O
UC	O
patients	O
creates	O
an	O
urgent	O
need	O
to	O
develop	O
new	O
drugs	O
for	O
advanced	O
UC	O
therapy	O
malaria	S-Disease
Artesunate	O
ART	O
a	O
traditional	O
Chinese	O
medicine	O
for	O
treating	O
is	O
a	O
potential	O
anticancer	O
agent	O
but	O
its	O
antigrowth	O
effects	O
on	O
upper	O
tract	O
and	O
bladder	O
UC	O
have	O
not	O
been	O
investigated	O
cisplatin	S-Chemical_Substance
urothelial	B-Anatomical_Substances
carcinoma 	I-Anatomical_Substances
 cells]	E-Anatomical_Substances
CCK	O
8	O
assay	O
Flow	O
cytometric	O
analysis	O
was	O
used	O
to	O
evaluate	O
the	O
cell	O
cycle	O
distribution	O
and	O
apoptosis	O
The	O
cell	O
cycle	O
apoptosis	O
and	O
autophagy	O
related	O
protein	O
expression	O
were	O
analyzed	O
by	O
western	O
blotting	O
The	O
efficacy	O
of	O
combination	O
treatment	O
with	O
cisplatin	O
was	O
determined	O
by	O
the	O
Calcusyn	O
software	O
The	O
antigrowth	O
effect	O
of	O
ART	O
in	O
HT	O
1376	O
bladder	O
UC	O
cells	O
and	O
BFTC	O
909	O
upper	O
tract	O
UTUC	O
was	O
determined	O
by	O
the	O
ART	O
induced	O
HT	O
1376	O
and	O
BFTC	O
909	O
cell	O
death	O
in	O
a	O
concentration	O
and	O
time	O
dependent	O
manner	O
inducing	O
G	O
nART	O
may	O
be	O
a	O
candidate	O
drug	O
for	O
treating	O
UTUC	O
and	O
bladder	O
UC	O
while	O
increasing	O
the	O
therapeutic	O
effect	O
of	O
f self-peptide-MHC-I/TCR (SMT	S-Chemical_Substance
interaction	O
in	O
the	O
survival	O
of	O
CD8	O
The	O
significance	O
o	O
 prolyl	B-Protien
tRNA	I-Protien
synthetase 	E-Protien
febrifugine	S-Chemical_Substance
halofuginone	S-Chemical_Substance
apicomplexan parasites 	B-Organism
Plasmodium	I-Organism
falciparum	E-Organism
Toxoplasma	I-Organism
gondii	B-Organism
PRS	O
is	O
a	O
validated	O
drug	O
target	O
for	O
and	O
its	O
synthetic	O
analog	O
HFG	O
against	O
multiple	O
ncluding	O
and	O
Here	O
a	O
nove	O
Toxoplasma	B-Organism
 gondii 	I-Organism
toxoplasma	B-Organism
 parasites.	I-Organism
T. gondii parasites	S-Organism
 human 	S-Organism
Cell	O
based	O
chemical	O
mutagenesis	O
was	O
employed	O
to	O
determine	O
the	O
mechanism	O
of	O
action	O
via	O
a	O
forward	O
genetic	O
screen	O
 ATP, tRNA, or L-pro sites	S_Anatomical_Substances
supported	O
by	O
the	O
structural	O
data	O
from	O
high	O
resolution	O
crystal	O
structures	O
of	O
drug	O
bound	O
enzyme	O
complexes	O
These	O
data	O
provide	O
an	O
avenue	O
for	O
structure	O
based	O
activity	O
enhancement	O
of	O
this	O
chemical	O
series	O
as	O
anti	O
infectives	O
T477A and T592S	S-Protien
RNA	O
seq	O
to	O
identify	O
mutations	O
in	O
the	O
coding	O
sequence	O
conferring	O
drug	O
resistance	O
by	O
computational	O
analysis	O
of	O
variants	O
DNA	O
sequencing	O
inhibition	O
at	O
the	O
cellular	O
proximal	O
to	O
terminals	O
of	O
the	O
PPL	O
scaffold	O
and	O
not	O
directly	O
in	O
the	O
g	O
resistant	O
parasites	O
were	O
analyzed	O
with	O
wild	O
established	O
two	O
mutations	O
type	O
strain	O
by	O
and	O
enzymatic	O
TgPRS	O
levels	O
compared	O
to	O
the	O
counterparts	O
PPL	O
series	O
exhibited	O
poten	O
 1-(pyridin-4-yl)	S-Chemical_Substance
pyrrolidin-2-one (PPL) scaffold 	S-Chemical_Substance
has	O
been	O
validated	O
to	O
bind	O
to	O
PRS	O
and	O
kill	O
ATP	O
mimetic	O
centered	O
on	O
cancer,	S-Disease
Notch	O
signaling	O
pathway	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
development	O
and	O
progression	O
of	O
various	O
types	O
of	O
cholangiocarcinoma (CCA	S-Disease
Compounds	O
that	O
modulate	O
this	O
signaling	O
pathway	O
could	O
be	O
promising	O
candidates	O
for	O
 CCA	S-Disease
ncluding	O
treatment	O
and	O
control	O
The	O
study	O
investigated	O
the	O
antiproliferative	O
activities	O
and	O
modulatory	O
effects	O
o	O
atractylodin	S-Chemical_Substance
β-eudesmol	S-Chemical_Substance
and	O
Atractylodes lancea (Thunb.) DC.	B-Chemical_Substance
Notch1 and Notch2 receptors, JAG1, mTOR, PI3K, and YAP	I-Chemical_Substance
(Snail) in HuCCT-1 (CCA cell line) and OUMS-36T-1 (normal fibroblast cell line).	E-Chemical_Substance
Gemcitabine 	S-Chemical_Substance
 (DAPT and zebularine	S-Chemical_Substance
on	O
Notch	O
signaling	O
and	O
upstream	O
molecules	O
the	O
two	O
bioactive	O
compounds	O
of	O
nd	O
downstream	O
molecules	O
CCA	O
and	O
Notch	O
inhibitors	O
were	O
included	O
in	O
the	O
experiments	O
as	O
positive	O
control	O
compounds	O
standard	O
drug	O
for	O
he	O
antiproliferative	O
activity	O
was	O
evaluated	O
using	O
MTT	O
assay	O
mRNA	O
and	O
protein	O
expression	O
of	O
Notch	O
signaling	O
molecules	O
were	O
evaluated	O
using	O
real	O
time	O
PCR	O
and	O
Western	O
blot	O
analysis	O
Atractylodin	S-Chemical_Substance
β-eudesmol	S-Chemical_Substance
atractylodin 	S-Chemical_Substance
β-eudesmo	S-Chemical_Substance
atractylodin	S-Chemical_Substance
 β-eudesmol	S-Chemical_Substance
moderately	O
inhibited	O
HuCCT	O
1	O
cell	O
growth	O
with	O
IC50	O
concentration	O
that	O
inhibits	O
cell	O
growth	O
by	O
50	O
of	O
29	O
00	O
6	O
44	O
and	O
16	O
80	O
4	O
41	O
µg	O
ml	O
mean	O
SD	O
respectively	O
The	O
direction	O
and	O
extent	O
of	O
the	O
modulatory	O
effects	O
on	O
mRNA	O
and	O
protein	O
expression	O
in	O
the	O
CCA	O
cell	O
line	O
varied	O
with	O
the	O
signaling	O
molecules	O
Notch1	O
receptor	O
was	O
shown	O
to	O
be	O
the	O
most	O
promising	O
target	O
of	O
CCA	O
The	O
level	O
of	O
gene	O
expression	O
was	O
significantly	O
downregulated	O
0	O
042	O
to	O
0	O
195	O
fold	O
of	O
control	O
after	O
treating	O
HuCC	O
T1	O
cells	O
with	O
both	O
compounds	O
at	O
low	O
and	O
high	O
concentrations	O
The	O
extent	O
and	O
change	O
in	O
Notch1	O
gene	O
expression	O
correlated	O
well	O
with	O
protein	O
expression	O
The	O
notch	O
signaling	O
pathway	O
could	O
be	O
a	O
promising	O
target	O
of	O
in	O
CCA	O
br	O
and	O
antimalarial	B-Chemical_Substance
chemotypes,	I-Chemical_Substance
The	O
development	O
of	O
new	O
antimalarials	O
is	O
required	O
because	O
of	O
the	O
threat	O
of	O
resistance	O
to	O
current	O
antimalarial	O
therapies	O
To	O
discover	O
new	O
we	O
screened	O
the	O
Janssen	O
Jumpstarter	O
library	O
against	O
the	O
Cerebral 	B-Disease
malaria (	I-Disease
CM	O
the	O
deadliest	O
complication	O
of	O
Despite	O
significant	O
scientific	O
progress	O
over	O
the	O
last	O
two	O
decades	O
malaria	S-Disease
remains	O
a	O
global	O
burden	O
that	O
causes	O
thousands	O
of	O
deaths	O
every	O
year	O
In	O
the	O
absence	O
of	O
effective	O
and	O
practical	O
preventive	O
measures	O
the	O
only	O
current	O
option	O
for	O
reducing	O
the	O
mortality	O
and	O
morbidity	O
of	O
malaria	S-Disease
is	O
chemotherapy	O
However	O
due	O
to	O
the	O
minimal	O
stock	O
of	O
active	O
antiparasitic	O
analogs	O
issues	O
of	O
toxicity	O
and	O
the	O
repeated	O
appearance	O
of	O
drug	O
resistance	O
scientists	O
must	O
broaden	O
the	O
arsenal	O
of	O
existing	O
therapies	O
beyond	O
conventional	O
medicinal	O
chemistry	O
To	O
curb	O
this	O
menace	O
a	O
series	O
of	O
potential	O
metal	O
based	O
hybrids	O
have	O
been	O
synthesized	O
and	O
screened	O
Ferrocene	S-Chemical_Substance
potent	B-Chemical_Substance
organometallic 	I-Chemical_Substance
is	O
one	O
of	O
the	O
candidates	O
and	O
the	O
hybridization	O
of	O
ferrocene 	S-Chemical_Substance
pharmacophores	S-Chemical_Substance
with	O
other	O
results	O
in	O
compounds	O
with	O
enhanced	O
biological	O
activities	O
Many	O
researchers	O
have	O
reported	O
the	O
ferrocene	B-Chemical_Substance
compounds	I-Chemical_Substance
 pharmacophores	S-Chemical_Substance
as	O
potent	O
anticancer and antimalarial agents	B-Chemical_Substance
and	O
useful	O
as	O
when	O
hybridized	O
with	O
other	O
pharmaceutical	O
hybrids	O
 Drug, 	B-Chemical_Substance
Ferroquine (FQ, SSR97193),	I-Chemical_Substance
 organometallic compound 	E-Chemical_Substance
is	O
currently	O
the	O
most	O
advanced	O
developed	O
from	O
the	O
hybridization	O
of	O
 ferrocene	S-Chemical_Substance
chloroquine 	S-Chemical_Substance
and	O
has	O
demonstrated	O
great	O
potency	O
in	O
clinical	O
trials	O
against	O
both	O
drug-sensitive 	B-Disease
drug-resistant	I-Disease
malaria. 	S-Disease
ferroquine 	S-Chemical_Substance
Not	O
only	O
but	O
its	O
derivatives	O
have	O
shown	O
significant	O
activity	O
as	O
antimalarial	O
agents	O
The	O
present	O
review	O
focuses	O
on	O
the	O
discovery	O
of	O
FQ	O
the	O
hypothesis	O
of	O
its	O
mode	O
of	O
action	O
and	O
recent	O
clinical	O
trials	O
of	O
ferrocene	O
compounds	O
as	O
a	O
new	O
class	O
of	O
antimalarial	O
agents	O
The	O
structure	O
activity	O
relationship	O
SAR	O
of	O
ferrocene	O
derivatives	O
is	O
also	O
discussed	O
to	O
provide	O
insight	O
into	O
the	O
rational	O
design	O
of	O
more	O
effective	O
antimalarial	O
candidates	O
Finally	O
efforts	O
have	O
been	O
made	O
to	O
discuss	O
the	O
future	O
expectations	O
for	O
ferrocene-based	B-Chemical_Substance
antimalarial drugs.	I-Chemical_Substance
Background	O
Ensuring	O
blood	O
safety	O
is	O
the	O
primary	O
goal	O
of	O
transfusion	O
medicine	O
Despite	O
extensive	O
serological	O
tests	O
and	O
strict	O
safety	O
measures	O
the	O
risk	O
of	O
 transfusion-	B-Disease
transmitted 	I-Disease
infections 	E-Disease
TTIs	O
still	O
exists	O
As	O
applied	O
to	O
blood	O
screening	O
Nucleic	O
Acid	O
Amplification	O
Test	O
NAT	O
offers	O
much	O
higher	O
sensitivity	O
for	O
detecting	O
viral	O
infections	O
It	O
is	O
however	O
currently	O
available	O
to	O
a	O
handful	O
of	O
centers	O
due	O
to	O
the	O
high	O
cost	O
This	O
study	O
aims	O
to	O
establish	O
the	O
Effectiveness	O
of	O
NAT	O
by	O
assessing	O
the	O
NAT	O
yield	O
and	O
residual	O
risk	O
of	O
transmission	O
of	O
Hepatitis	B-Organism
B	I-Organism
virus 	E-Organism
hepatitis 	B-Organism
C	I-Organism
 virus	E-Organism
 HIV 	S-Disease
with	O
and	O
without	O
NAT	O
testing	O
Material	O
and	O
method	O
This	O
prospective	O
cross	O
sectional	O
study	O
recruited	O
blood	O
donors	O
from	O
January	O
2020	O
to	O
November	O
2022	O
All	O
donors	O
underwent	O
routine	O
serologic	O
screening	O
Only	O
serologically	O
negative	O
donors	O
were	O
tested	O
fo	O
HBV, HCV, and HIV	S-Disease
by	O
NAT	O
The	O
NAT	O
yield	O
and	O
residual	O
risk	O
RR	O
per	O
million	O
donors	O
were	O
computed	O
for	O
viral	O
infections	O
in	O
seronegative	O
blood	O
donors	O
and	O
calculated	O
using	O
the	O
incidence	O
window	O
period	O
model	O
Result	O
A	O
total	O
of	O
59708	O
donors	O
were	O
included	O
during	O
the	O
study	O
period	O
The	O
overall	O
prevalence	O
of	O
TTI	O
s	O
were	O
HCV	S-Disease
HBV	S-Disease
 HIV	S-Disease
Syphilis 	S-Disease
malaria	S-Disease
Fo	O
1	O
7	O
n	O
1018	O
1	O
5	O
n	O
918	O
0	O
07	O
n	O
47	O
1	O
2	O
n	O
758	O
and	O
0	O
3	O
n	O
218	O
Out	O
of	O
57759	O
seronegative	O
donors	O
thirty	O
four	O
NAT	O
reactive	O
samples	O
were	O
identified	O
with	O
3	O
cases	O
of	O
HCV	S-Disease
HBV,	S-Disease
HIV 	S-Disease
1	O
cases	O
cases	O
NAT	O
yield	O
o	O
nd	O
Ni	O
HBV 	S-Disease
 HCV 	S-Disease
HCV	S-Disease
by	O
94	O
5	O
Conclusion	O
Our	O
study	O
showed	O
that	O
NAT	O
detected	O
34	O
out	O
of	O
57759	O
cases	O
initially	O
missed	O
by	O
serological	O
tests	O
The	O
study	O
suggests	O
that	O
the	O
parallel	O
use	O
of	O
serology	O
and	O
NAT	O
screening	O
of	O
donated	O
blood	O
would	O
be	O
beneficial	O
with	O
a	O
NAT	O
yield	O
of	O
1	O
in	O
19253	O
and	O
RR	O
of	O
0	O
8	O
per	O
million	O
donations	O
NAT	O
testing	O
was	O
1	O
in	O
1863	O
with	O
an	O
RR	O
of	O
8	O
6	O
per	O
million	O
followed	O
by	O
reduced	O
RR	O
for	O
by	O
48	O
9	O
and	O
 HBV	S-Disease
We	O
conducted	O
a	O
study	O
on	O
the	O
Trobriand	O
Islands	O
of	O
Papua	O
New	O
Guinea	O
PNG	O
in	O
2018	O
to	O
verify	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
 artemisinin	B-Chemical_Substance
-piperaquine	I-Chemical_Substance
mass drug	E-Chemical_Substance
administration	O
MDA	O
campaign	O
in	O
regions	O
with	O
moderate	O
to	O
high	O
mixed	O
malaria	S-Disease
transmission	O
Based	O
on	O
the	O
natural	O
topography	O
of	O
the	O
Trobriand	O
Islands	O
44	O
855	O
residents	O
from	O
92	O
villages	O
on	O
the	O
islands	O
were	O
enrolled	O
and	O
divided	O
into	O
the	O
main	O
and	O
outer	O
islands	O
Three	O
rounds	O
of	O
MDA	O
were	O
conducted	O
using	O
grid	O
based	O
management	O
The	O
primary	O
endpoint	O
was	O
the	O
coverage	O
rate	O
Adverse	O
reactions	O
 parasitemi	S-Disease
 malaria	S-Disease
parasitemia, 	S-Disease
morbidity	O
were	O
the	O
secondary	O
endpoints	O
There	O
were	O
36	O
716	O
people	O
living	O
in	O
75	O
villages	O
on	O
the	O
main	O
island	O
and	O
the	O
MDA	O
coverage	O
rate	O
was	O
92	O
58	O
95	O
68	O
Furthermore	O
8	O
139	O
people	O
living	O
in	O
17	O
villages	O
on	O
the	O
outer	O
islands	O
had	O
a	O
coverage	O
rate	O
of	O
94	O
93	O
96	O
11	O
The	O
adverse	O
reactions	O
were	O
mild	O
in	O
both	O
groups	O
and	O
parasitemia 	S-Disease
decreased	O
by	O
87	O
2	O
after	O
one	O
year	O
of	O
surveillance	O
The	O
average	O
annual	O
malaria	O
morbidity	O
has	O
decreased	O
by	O
89	O
3	O
after	O
the	O
program	O
for	O
four	O
years	O
High	O
compliance	O
and	O
mild	O
adverse	O
reactions	O
indicated	O
that	O
the	O
MDA	O
campaign	O
with	O
AP	O
was	O
safe	O
The	O
short	O
term	O
effect	O
is	O
relatively	O
ideal	O
but	O
the	O
evidence	O
for	O
long	O
term	O
effect	O
evaluation	O
is	O
insufficient	O
Malaria	S-Disease
health threat	E-Disease
is	O
still	O
a	O
known	O
especially	O
in	O
parts	O
of	O
sub	O
Saharan	O
Africa	O
It	O
is	O
one	O
of	O
the	O
frequently	O
mentioned	O
issues	O
with	O
hospital	O
admission	O
and	O
outpatient	O
care	O
in	O
Ethiopia	O
nThis	O
study	O
aimed	O
to	O
determine	O
the	O
nThe	O
i	O
methanol 	S-Chemical_Substance
The	O
findings	O
of	O
the	O
present	O
study	O
collectively	O
indicate	O
the	O
root	O
extract	O
of	O
The	O
80	O
extract	O
of	O
The	O
prevalence	O
and	O
distribution	O
of	O
African	B-Organism
alphaviruses	I-Organism
chikungunya	S-Disease
such	O
a	O
have	O
increased	O
in	O
recent	O
years	O
Therefore	O
a	O
better	O
understanding	O
of	O
the	O
local	O
distribution	O
of	O
alphaviruses	S-Organism
in	O
vectors	O
across	O
the	O
African	O
continent	O
is	O
important	O
Here	O
entomological	O
surveillance	O
was	O
performed	O
from	O
2014	O
to	O
2018	O
at	O
selected	O
sites	O
in	O
north	O
eastern	O
parts	O
of	O
South	O
Africa	O
where	O
alphaviruses	S-Organism
have	O
been	O
identified	O
during	O
outbreaks	O
in	O
 humans 	S-Organism
animals	S-Organism
in	O
the	O
past	O
Mosquitoes 	S-Organism
were	O
collected	O
using	O
a	O
net	O
CDC	O
light	O
and	O
BG	O
traps	O
An	O
alphavirus	O
genus	O
specific	O
nested	O
RT	O
PCR	O
was	O
used	O
for	O
screening	O
and	O
positive	O
pools	O
were	O
confirmed	O
by	O
sequencing	O
and	O
phylogenetic	O
analysis	O
We	O
collected	O
64	O
603	O
mosquitoes	O
from	O
11	O
genera	O
of	O
which	O
39	O
035	O
females	O
were	O
tested	O
Overall	O
1462	O
 mosquito 	S-Organism
pools	O
were	O
tested	O
of	O
which	O
21	O
were	O
positive	O
for	O
alphaviruses	B-Organism
Sindbis	S-Organism
Middelburg 	S-Organism
viruses	O
were	O
the	O
most	O
prevalent	O
Ndumu	B-Organism
virus 	I-Organism
as	O
detected	O
in	O
two	O
pools	O
9	O
5	O
N	O
2	O
No	O
chikungunya	S-Disease
positive	O
pools	O
were	O
identified	O
Arboviral	O
activity	O
was	O
concentrated	O
in	O
peri	O
urban	O
rural	O
and	O
conservation	O
areas	O
A	O
range	O
of	O
Culicidae	O
species	O
including	O
Barmah 	B-Organism
Fores	I-Organism
virus (	E-Organism
Chikungunya 	B-Organism
virus 	I-Organism
 Ross 	B-Organism
River	I-Organism
 virus	E-Organism
belong	O
to	O
the	O
BFV)	S-Organism
CHIKV	S-Organism
 (RRV)	S-Organism
Virus	O
like	O
particles	O
VLPs	O
composed	O
of	O
the	O
small 	B-Protien
hepatitis B	I-Protien
virus surface antigen	E-Protien
(HBsAgS	S-Protien
hepatitis B	S-Disease
are	O
the	O
antigenic	O
components	O
of	O
the	O
virus	O
HBV	O
vaccine	O
and	O
represent	O
the	O
backbones	O
for	O
a	O
chimeric	B-Chemical_Substance
anti-malaria	I-Chemical_Substance
 vaccine	E-Chemical_Substance
and	O
various	O
vaccine	O
candidates	O
Biological	O
vectors	O
have	O
to	O
face	O
pre	O
existing	O
anti	O
vector	O
immune	O
responses	O
due	O
to	O
previous	O
immune	O
exposure	O
Vector	O
recognition	O
after	O
natural	O
infections	O
or	O
vaccinations	O
can	O
result	O
in	O
unwarranted	O
outcomes	O
with	O
compromising	O
effects	O
on	O
clinical	O
outcomes	O
In	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
a	O
pre	O
existing	O
 anti-HBsAgS	S-Protien
mmune	O
response	O
we	O
developed	O
mutant	O
VLPs	O
composed	O
of	O
subunits	O
with	O
reduced	O
 HBsAgS	S-Protien
specific	O
antigenicity	O
The	O
insertion	O
of	O
a	O
malaria	S-Disease
accine	O
candidate	O
is	O
a	O
multi	O
stage	O
The	O
GMZ2	O
6c	O
Primaquine (PQ)	S-Chemical_Substance
is	O
the	O
only	O
antimalarial	O
medication	O
used	O
to	O
eradicate	O
many	O
species	O
of	O
Anaemia	S-Disease
among	O
children	O
under	O
age	O
five	O
is	O
a	O
major	O
public	O
health	O
issue	O
Although	O
anaemia	S-Disease
prevalence	O
is	O
declining	O
in	O
Ghana	O
the	O
severity	O
among	O
anaemic	O
children	O
is	O
worsening	O
This	O
study	O
aims	O
to	O
investigate	O
the	O
determinants	O
of	O
anaemia 	S-Disease
severity	O
among	O
children	O
aged	O
6	O
to	O
59	O
months	O
in	O
Ghana	O
nThe	O
study	O
utilized	O
a	O
weighted	O
sample	O
of	O
1	O
258	O
children	O
with	O
anaemia	O
with	O
data	O
obtained	O
from	O
the	O
2019	O
Ghana	O
Malaria	S-Disease
Indicator	O
Survey	O
The	O
predictor	O
variables	O
included	O
maternal	O
household	O
child	O
and	O
health	O
system	O
characteristics	O
SPSS	O
version	O
At	O
the	O
multivariate	O
level	O
three	O
different	O
multinomial	O
logistic	O
models	O
were	O
run	O
with	O
selected	O
predictor	O
variables	O
All	O
tests	O
were	O
conducted	O
at	O
the	O
95	O
confidence	O
level	O
nThe	O
overall	O
anaemia	O
prevalence	O
among	O
children	O
under	O
age	O
five	O
was	O
43	O
5	O
Of	O
these	O
2	O
6	O
were	O
severely	O
anaemic	O
48	O
5	O
were	O
moderately	O
anaemic	O
and	O
48	O
9	O
had	O
mild	O
anaemia	O
The	O
multinomial	O
analysis	O
showed	O
that	O
maternal	O
household	O
child	O
and	O
health	O
system	O
factors	O
significantly	O
predicted	O
anaemia 	S-Disease
 anaemia 	S-Disease
evels	O
among	O
anaemic	O
children	O
The	O
results	O
indicate	O
that	O
a	O
lower	O
likelihood	O
of	O
severity	O
is	O
likely	O
to	O
be	O
found	O
among	O
children	O
whose	O
mothers	O
belong	O
to	O
Pentecostal	O
Charismatic	O
faith	O
AOR	O
0	O
18	O
model	O
I	O
AOR	O
0	O
15	O
model	O
III	O
and	O
children	O
who	O
tested	O
negative	O
for	O
malaria	O
AOR	O
0	O
28	O
model	O
II	O
and	O
III	O
Again	O
a	O
higher	O
probability	O
of	O
anaemia	O
severity	O
was	O
found	O
among	O
anaemic	O
children	O
whose	O
mothers	O
were	O
not	O
aware	O
of	O
NHIS	O
coverage	O
of	O
malaria	O
AOR	O
2	O
41	O
model	O
II	O
AOR	O
2	O
60	O
model	O
III	O
With	O
regard	O
to	O
moderate	O
anaemia	O
level	O
children	O
who	O
belong	O
to	O
the	O
poorest	O
poorer	O
and	O
middle	O
household	O
wealth	O
index	O
had	O
a	O
higher	O
likelihood	O
of	O
being	O
moderately	O
anaemic	O
compared	O
to	O
those	O
in	O
rich	O
households	O
Similarly	O
anaemic	O
children	O
who	O
were	O
less	O
than	O
12	O
months	O
old	O
AOR	O
2	O
21	O
model	O
II	O
AOR	O
2	O
29	O
model	O
III	O
and	O
those	O
between	O
the	O
ages	O
of	O
1	O
2	O
years	O
AOR	O
1	O
84	O
model	O
II	O
AOR	O
1	O
83	O
model	O
III	O
were	O
more	O
likely	O
to	O
have	O
moderate	O
anaemia	O
levels	O
nThe	O
study	O
findings	O
show	O
the	O
importance	O
of	O
understanding	O
the	O
interrelation	O
among	O
different	O
factors	O
that	O
influence	O
anaemia	O
severity	O
among	O
children	O
under	O
age	O
five	O
as	O
critical	O
in	O
developing	O
strategies	O
and	O
programmes	O
aimed	O
at	O
addressing	O
childhood	O
anaemia	O
 ATP2B4	S-Gene
Genome	O
wide	O
association	O
studies	O
have	O
identified	O
as	O
a	O
severe	O
malaria	O
resistance	O
gene	O
Recently	O
8	O
potential	O
causal	O
regulatory	O
variants	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
severe	O
malaria.	S-Disease
 rs10900585	S-Gene
 rs11240734	S-Gene
rs1541252	S-Gene
 rs1541253	S-Gene
rs1541254, rs1541255, rs10751450, rs10751451 and rs10751452 	S-Gene
rs10751450, rs10751451 and rs10751452 	S-Gene
rs10900585, rs11240734, rs1541252, rs1541253, rs1541254, rs1541255, rs10751450, rs10751451 and rs10751452. 	S-Gene
malaria	S-Disease
Genotyping	O
o	O
in	O
154	O
unrelated	O
individuals	O
79	O
controls	O
and	O
75	O
mild	O
assays	O
whereas	O
the	O
fragment	O
of	O
the	O
ATP2B4 gene	S-Gene
containing	O
the	O
remaining	O
SNPs	O
was	O
sequenced	O
Logistic	O
regression	O
analysis	O
was	O
used	O
to	O
assess	O
the	O
association	O
between	O
the	O
SNPs	O
and	O
mild	O
malaria.	S-Disease
malaria	S-Disease
The	O
results	O
showed	O
that	O
mild	O
was	O
associated	O
with	O
patients	O
The	O
homozygous	O
genotypes	O
for	O
the	O
major	O
alleles	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
mild	O
malaria	O
Furthermore	O
the	O
haplotype	O
containing	O
the	O
major	O
alleles	O
and	O
that	O
containing	O
the	O
minor	O
alleles	O
were	O
the	O
most	O
frequent	O
haplotypes	O
Individuals	O
with	O
the	O
major	O
haplotypes	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
mild	O
malaria	O
compared	O
to	O
the	O
carriers	O
of	O
the	O
minor	O
allele	O
haplotype	O
nATP2B4	O
polymorphisms	O
that	O
have	O
been	O
associated	O
with	O
severe	O
malaria	O
are	O
also	O
associated	O
with	O
mild	O
malaria	O
were	O
genotyped	O
by	O
Taqman	O
was	O
performed	O
Malaria 	S-Disease
disproportionately	O
affects	O
low	O
income	O
households	O
in	O
rural	O
communities	O
where	O
poor	O
housing	O
is	O
common	O
Despite	O
evidence	O
that	O
well	O
constructed	O
and	O
mosquito-	B-Organism
proofed	O
houses	O
can	O
reduce	O
malaria	O
risk	O
housing	O
improvement	O
is	O
rarely	O
included	O
in	O
malaria	O
control	O
toolboxes	O
This	O
study	O
assessed	O
the	O
need	O
magnitude	O
and	O
opportunities	O
for	O
housing	O
improvement	O
to	O
control	O
malaria	O
in	O
rural	O
Tanzania	O
A	O
mixed	O
methods	O
study	O
was	O
conducted	O
in	O
19	O
villages	O
across	O
four	O
district	O
councils	O
in	O
southern	O
Tanzania	O
A	O
structured	O
survey	O
was	O
administered	O
to	O
1292	O
community	O
members	O
to	O
assess	O
need	O
perceptions	O
and	O
opportunities	O
for	O
housing	O
improvement	O
for	O
malaria	O
control	O
Direct	O
observations	O
of	O
802	O
houses	O
and	O
surrounding	O
environments	O
were	O
done	O
to	O
identify	O
the	O
actual	O
needs	O
and	O
opportunities	O
and	O
to	O
validate	O
the	O
survey	O
findings	O
A	O
market	O
survey	O
was	O
done	O
to	O
assess	O
availability	O
and	O
cost	O
of	O
resources	O
and	O
services	O
necessary	O
for	O
mosquito	O
proofing	O
homes	O
Focus	O
group	O
discussions	O
were	O
conducted	O
with	O
key	O
stakeholders	O
to	O
explore	O
insights	O
on	O
the	O
potential	O
and	O
challenges	O
of	O
housing	O
improvement	O
as	O
a	O
malaria	O
intervention	O
nCompared	O
to	O
other	O
methods	O
for	O
malaria	O
control	O
housing	O
improvement	O
was	O
among	O
the	O
best	O
understood	O
and	O
most	O
preferred	O
by	O
community	O
members	O
Of	O
the	O
735	O
survey	O
respondents	O
who	O
needed	O
housing	O
improvements	O
a	O
majority	O
needed	O
window	O
screening	O
91	O
1	O
repairs	O
of	O
holes	O
in	O
walls	O
79	O
4	O
door	O
covers	O
41	O
6	O
closing	O
of	O
eave	O
spaces	O
31	O
2	O
and	O
better	O
roofs	O
19	O
0	O
Community	O
members	O
invested	O
significant	O
efforts	O
to	O
improve	O
their	O
own	O
homes	O
against	O
malaria	O
and	O
other	O
dangers	O
but	O
these	O
efforts	O
were	O
often	O
slow	O
and	O
delayed	O
due	O
to	O
high	O
costs	O
and	O
limited	O
household	O
incomes	O
Study	O
participants	O
suggested	O
several	O
mechanisms	O
of	O
support	O
to	O
improve	O
their	O
homes	O
including	O
government	O
loans	O
and	O
subsidies	O
Addressing	O
the	O
need	O
for	O
housing	O
improvement	O
is	O
a	O
critical	O
component	O
of	O
malaria	O
control	O
efforts	O
in	O
southern	O
Tanzania	O
In	O
this	O
study	O
a	O
majority	O
of	O
the	O
community	O
members	O
surveyed	O
needed	O
modest	O
modifications	O
and	O
had	O
plans	O
to	O
work	O
on	O
those	O
modifications	O
Without	O
additional	O
support	O
their	O
efforts	O
were	O
however	O
generally	O
slow	O
households	O
would	O
take	O
years	O
to	O
sufficiently	O
mosquito	O
proof	O
their	O
houses	O
It	O
is	O
therefore	O
crucial	O
to	O
bring	O
together	O
the	O
key	O
players	O
across	O
sectors	O
to	O
reduce	O
barriers	O
in	O
malaria	O
proofing	O
housing	O
in	O
endemic	O
settings	O
These	O
may	O
include	O
government	O
subsidies	O
or	O
partnerships	O
with	O
businesses	O
to	O
make	O
housing	O
improvement	O
more	O
accessible	O
and	O
affordable	O
to	O
residents	O
The	O
only	O
drugs	O
approved	O
by	O
the	O
U	O
S	O
Food	O
and	O
Drug	O
Administration	O
for	O
oral	O
treatment	O
of	O
 trichomoniasis	S-Disease
belong	O
to	O
the	O
5-nitroimidazole	S-Chemical_Substance
group	O
Most	O
individuals	O
infected	O
with	O
 Trichomonas	B-Disease
vaginalis	I-Disease
can	O
be	O
cured	O
with	O
a	O
standard	O
treatment	O
of	O
metronidazole 	S-Chemical_Substance
tinidazole	S-Chemical_Substance
but	O
it	O
is	O
estimated	O
that	O
more	O
than	O
159	O
000	O
people	O
fail	O
treatment	O
each	O
year	O
Although	O
a	O
minimal	O
lethal	O
concentration	O
MLC	O
corresponding	O
to	O
treatment	O
failure	O
has	O
been	O
reported	O
for	O
metronidazole,	S-Chemical_Substance
tinidazole 	S-Chemical_Substance
the	O
MLC	O
fo	O
associated	O
with	O
treatment	O
failure	O
has	O
not	O
been	O
determined	O
We	O
conducted	O
a	O
study	O
using	O
 T. vaginalis	S-Organism
isolates	O
from	O
women	O
with	O
reported	O
treatment	O
success	O
or	O
failure	O
to	O
determine	O
these	O
values	O
We	O
measured	O
MLCs	O
of	O
47	O
isolates	O
obtained	O
from	O
women	O
who	O
had	O
failed	O
metronidazole 	S-Chemical_Substance
metronidazole	S-Chemical_Substance
treatment	O
33	O
isolates	O
from	O
women	O
who	O
had	O
failed	O
tinidazole 	S-Chemical_Substance
treatment	O
and	O
48	O
isolates	O
from	O
women	O
successfully	O
cured	O
with	O
The	O
cutoff	O
was	O
calculated	O
as	O
the	O
95th	O
percentile	O
of	O
MLCs	O
of	O
susceptible	O
isolates	O
for	O
each	O
drug	O
Our	O
data	O
confirmed	O
the	O
MLC	O
previously	O
associated	O
with	O
metronidazole	S-Chemical_Substance
treatment	O
failure	O
is	O
50	O
μg	O
ml	O
and	O
identified	O
the	O
MLC	O
associated	O
with	O
tinidazole	S-Chemical_Substance
 metronidazole,	S-Chemical_Substance
tinidazole 	S-Chemical_Substance
treatment	O
failure	O
as	O
6	O
3	O
μg	O
ml	O
For	O
the	O
agreement	O
between	O
laboratory	O
result	O
and	O
treatment	O
outcome	O
was	O
93	O
7	O
for	O
this	O
agreement	O
was	O
88	O
9	O
The	O
T. vaginalis 	S-Organism
susceptibility	O
assay	O
is	O
useful	O
for	O
determining	O
whether	O
 5-nitroimidazole 	S-Chemical_Substance
treatment	O
failure	O
in	O
persons	O
with	O
 trichomoniasis	S-Disease
can	O
be	O
attributed	O
to	O
drug	O
resistance	O
These	O
results	O
are	O
useful	O
for	O
establishing	O
interpretive	O
guidance	O
of	O
test	O
results	O
and	O
MLC	O
levels	O
can	O
help	O
guide	O
appropriate	O
patient	O
treatment	O
Malaria 	B-Disease
infectious	I-Disease
 disease	E-Disease
transmitted	O
by	O
the	O
female	B-Organism
Anopheles 	I-Organism
mosquito	E-Organism
and	O
poses	O
a	O
severe	O
threat	O
to	O
human	O
health	O
At	O
present	O
antimalarial drugs 	S-Chemical_Substance
are	O
the	O
primary	O
treatment	O
for	O
malaria.	S-Disease
The	O
widespread	O
use	O
o	O
 artemisinin-based	B-Chemical_Substance
 combination	I-Chemical_Substance
therapies (ACTs)	E-Chemical_Substance
has	O
dramatically	O
reduced	O
the	O
number	O
of	O
malaria	O
related	O
deaths	O
however	O
the	O
emergence	O
of	O
resistance	O
has	O
the	O
potential	O
to	O
reverse	O
this	O
progress	O
Accurate	O
and	O
timely	O
diagnosis	O
of	O
drug	O
resistant	O
strains	O
of	O
Plasmodium 	B-Organism
parasites 	I-Organism
via	O
detecting	O
molecular	O
markers	O
such	O
as	O
Pfnhe1, Pfmrp, Pfcrt, Pfmdr1, Pfdhps, Pfdhfr, and Pfk13	S-Gene
malaria 	S-Disease
is	O
essential	O
for	O
control	O
and	O
elimination	O
Here	O
we	O
review	O
the	O
current	O
techniques	O
which	O
commonly	O
used	O
for	O
molecular	O
diagnosis	O
of	O
antimalarial	O
resistance	O
in	O
 P. falciparum 	S-Organism
and	O
discuss	O
their	O
sensitivities	O
and	O
specificities	O
for	O
different	O
drug	O
resistance	O
associated	O
molecular	O
markers	O
with	O
the	O
aim	O
of	O
providing	O
insights	O
into	O
possible	O
directions	O
for	O
future	O
precise	O
point	O
of	O
care	O
testing	O
POCT	O
of	O
antimalarial	O
drug	O
resistance	O
of	O
malaria	O
parasites	O
Malaria 	S-Disease
Lymphatic	B-Disease
filariasis 	I-Disease
are	O
considered	O
significant	O
public	O
health	O
concerns	O
in	O
several	O
countries	O
As	O
a	O
researcher	O
controlling	O
those	O
mosquitos	O
using	O
safe	O
and	O
eco	O
friendly	O
insecticides	O
is	O
essential	O
Thus	O
we	O
aimed	O
to	O
explore	O
the	O
potential	O
use	O
of	O
seaweed	B-Organism
Sargassum	I-Organism
 wightii	E-Organism
for	O
the	O
biosynthesis	O
of	O
TiO	O
Metropolitan	O
Santo	O
Domingo	O
has	O
accounted	O
for	O
a	O
majority	O
of	O
reported	O
malaria	S-Disease
cases	O
in	O
the	O
Dominican	O
Republic	O
in	O
recent	O
years	O
To	O
inform	O
malaria	S-Disease
control	O
and	O
elimination	O
efforts	O
a	O
cross	O
sectional	O
survey	O
of	O
malaria	S-Disease
knowledge	O
attitudes	O
and	O
practices	O
collected	O
489	O
adult	O
household	O
level	O
questionnaires	O
across	O
20	O
neighborhoods	O
in	O
the	O
city	O
s	O
two	O
main	O
 malaria 	S-Disease
 malaria 	S-Disease
malaria	S-Disease
 malaria 	S-Disease
 malaria	S-Disease
transmission	O
foci	O
Los	O
Tres	O
Brazos	O
n	O
286	O
and	O
La	O
Ciénaga	O
n	O
203	O
in	O
December	O
2020	O
Overall	O
most	O
residents	O
69	O
were	O
aware	O
of	O
the	O
problem	O
of	O
malaria	O
in	O
Santo	O
Domingo	O
but	O
less	O
than	O
half	O
knew	O
that	O
mosquitos	O
transmit	O
the	O
disease	O
46	O
or	O
took	O
any	O
correct	O
preventative	O
measure	O
45	O
More	O
residents	O
of	O
Los	O
Tres	O
Brazos	O
where	O
incidence	O
is	O
higher	O
than	O
in	O
La	O
Ciénaga	O
said	O
that	O
they	O
had	O
never	O
been	O
visited	O
by	O
active	O
surveillance	O
teams	O
80	O
versus	O
66	O
respectively	O
P	O
0	O
001	O
did	O
not	O
link	O
mosquitos	S-Organism
with	O
malaria 	S-Disease
transmission	O
59	O
versus	O
48	O
P	O
0	O
013	O
and	O
did	O
not	O
know	O
medication	O
can	O
cure	O
42	O
versus	O
27	O
P	O
0	O
005	O
Fewer	O
residents	O
of	O
Los	O
Tres	O
Brazos	O
said	O
that	O
was	O
a	O
problem	O
in	O
their	O
neighborhoods	O
43	O
versus	O
49	O
P	O
0	O
021	O
and	O
fewer	O
had	O
mosquito	S-Organism
bed	O
nets	O
in	O
their	O
homes	O
42	O
versus	O
60	O
P	O
0	O
001	O
The	O
majority	O
75	O
of	O
questionnaire	O
respondents	O
in	O
both	O
foci	O
did	O
not	O
have	O
enough	O
mosquito 	S-Organism
nets	O
for	O
all	O
household	O
residents	O
These	O
findings	O
demonstrate	O
gaps	O
in	O
knowledge	O
and	O
community	O
based	O
interventions	O
and	O
highlight	O
the	O
need	O
to	O
improve	O
community	O
engagement	O
for	O
elimination	O
in	O
affected	O
areas	O
of	O
Santo	O
Domingo	O
Malaria	S-Disease
is	O
a	O
major	O
global	O
health	O
issue	O
due	O
to	O
the	O
emergence	O
of	O
resistance	O
to	O
most	O
of	O
the	O
available	O
antimalarial drugs	S-Chemical_Substance
There	O
is	O
an	O
urgent	O
need	O
to	O
discover	O
new	O
antimalarials	O
to	O
tackle	O
the	O
resistance	O
issue	O
The	O
present	O
study	O
aims	O
to	O
explore	O
the	O
antimalarial	O
potential	O
of	O
chemical	O
constituents	O
reported	O
from	O
Cissampelos	O
pareira	O
L	O
a	O
medicinal	O
plant	O
traditionally	O
known	O
for	O
treating	O
malaria	O
Phytochemically	O
 benzylisoquinolines 	S-Chemical_Substance
bisbenzylisoquinolines 	S-Chemical_Substance
are	O
the	O
major	O
classes	O
of	O
alkaloids 	B-Chemical_Substance
reported	O
from	O
this	O
plant	O
In	O
silico	O
molecular	O
docking	O
revealed	O
prominent	O
interactions	O
of	O
bisbenzylisoquinolines	S-Chemical_Substance
hayatinine 	S-Chemical_Substance
curine 	S-Chemical_Substance
Pfdihydrofolate	B-Protien
reductase	I-Protien
 PfcGMP	B-Protien
protein kinase	B-Protien
Pfprolyl	B-Protien
-tRNA 	I-Protien
synthetase 	E-Protien
such	O
a	O
6	O
983	O
Kcal	O
mol	O
and	O
6	O
237	O
Kcal	O
mol	O
dependent	O
6	O
652	O
Kcal	O
mol	O
and	O
7	O
158	O
Kcal	O
mol	O
and	O
7	O
569	O
Kcal	O
mol	O
and	O
7	O
122	O
Kcal	O
mol	O
The	O
binding	O
affinity	O
of	O
hayatinine	S-Chemical_Substance
curine 	S-Chemical_Substance
with	O
identified	O
antimalarial	O
targets	O
was	O
further	O
evaluated	O
using	O
MD	O
simulation	O
analysis	O
Among	O
the	O
identified	O
antimalarial	O
targets	O
the	O
RMSD	O
RMSF	O
the	O
radius	O
of	O
gyration	O
and	O
PCA	O
indicated	O
the	O
formation	O
of	O
stable	O
complexes	O
of	O
 hayatinine	S-Chemical_Substance
 curine 	S-Chemical_Substance
 Pfprolyl	B-Protien
tRNA	I-Protien
synthetase	E-Protien
Plasmodium	B-Organism
parasite 	I-Organism
The	O
outcomes	O
of	O
in	O
silico	O
investigation	O
putatively	O
suggested	O
that	O
may	O
act	O
on	O
the	O
translation	O
of	O
the	O
bis	O
to	O
exhibit	O
antimalarial	O
potency	O
 bisbenzylisoquinolines	S-Chemical_Substance
erythropoietin 	S_Anatomical_Substances
acute 	B-Disease
respiratory 	I-Disease
coronavirus 2 (SARS-CoV-2) infection	E-Disease
Severe	O
in	O
the	O
young	O
and	O
healthy	O
usually	O
results	O
in	O
an	O
asymptomatic	O
or	O
mild	O
viral	O
syndrome	O
possibly	O
through	O
an	O
EPO	O
dependent	O
protective	O
evolutionary	O
landscape	O
In	O
the	O
old	O
and	O
in	O
the	O
presence	O
of	O
co	O
morbidities	O
however	O
a	O
potentially	O
lethal	O
coronavirus 	B-Disease
disease	I-Disease
2019	O
COVID	O
19	O
cytokine	S-Protien
storm	O
through	O
renin	B-Anatomical_Substances
-angiotensin	I-Anatomical_Substances
 aldosterone system (	E-Anatomical_Substances
unrestrained	O
hyperactivity	O
has	O
been	O
described	O
 malaria	S-Disease
dengue virus	S-Disease
thalassemias	S-Disease
CoV	O
1	O
2	O
plays	O
critical	O
antiviral	O
and	O
cardiovascular	O
roles	O
through	O
its	O
targeted	O
translational	O
repression	O
of	O
over	O
140	O
genes	O
In	O
the	O
present	O
review	O
we	O
propose	O
a	O
Multifunctional	O
microRNA	O
155	O
miR	O
155	O
elevation	O
in	O
plausible	O
miR	O
155	O
dependent	O
mechanism	O
whereby	O
the	O
translational	O
repression	O
o	O
AGRT1, Arginase-2 and Ets-	S-Protien
Angiotensin I	S_Anatomical_Substances
Ang	O
II	O
type	O
2	O
AT2R	O
mediated	O
balanced	O
tolerable	O
and	O
SARS	O
CoV	O
2	O
protective	O
cardiovascular	O
phenotypes	O
In	O
addition	O
it	O
enhances	O
EPO	O
secretion	O
and	O
endothelial	O
nitric	O
oxide	O
synthase	O
activation	O
and	O
substrate	O
availability	O
and	O
negates	O
proinflammatory	O
Ang	O
II	O
effects	O
Disrupted	O
miR	O
155	O
repression	O
of	O
AT1R	O
1166C	O
allele	O
significantly	O
associated	O
with	O
adverse	O
cardiovascular	O
and	O
COVID	O
19	O
outcomes	O
manifests	O
its	O
decisive	O
role	O
in	O
RAAS	O
modulation	O
BACH1	O
and	O
SOCS1	O
repression	O
creates	O
an	O
anti	O
inflammatory	O
and	O
cytoprotective	O
milieu	O
robustly	O
inducing	O
antiviral	O
interferons	O
MiR	O
155	O
dysregulation	O
in	O
the	O
elderly	O
and	O
in	O
comorbidities	O
allows	O
unimpeded	O
RAAS	O
hyperactivity	O
to	O
progress	O
towards	O
a	O
particularly	O
aggressive	O
COVID	O
19	O
course	O
Elevated	O
miR	O
155	O
in	O
thalassemia	O
plausibly	O
engenders	O
a	O
favorable	O
cardiovascular	O
profile	O
and	O
protection	O
against	O
malaria	O
DENV	O
and	O
SARS	O
CoV	O
2	O
MiR	O
155	O
modulating	O
pharmaceutical	O
approaches	O
could	O
offer	O
novel	O
therapeutic	O
options	O
in	O
COVID	O
19	O
Plasmodium	B-Organism
falciparum	I-Organism
 P. vivax 	B-Organism
 human	S-Organism
malaria	S-Disease
are	O
the	O
major	O
causes	O
of	O
a	O
and	O
P	O
knowlesi	O
is	O
an	O
important	O
additional	O
cause	O
in	O
SE	O
Asia	O
Binding	O
of	O
rhoptry	B-Protien
neck	I-Protien
protein 2	E-Protien
apical membrane antigen 1 	S-Chemical_Substance
 erythrocytes	S_Anatomical_Substances
 merozoite 	S-Organism
RON2	O
was	O
thought	O
to	O
be	O
essential	O
fo	O
nvasion	O
of	O
by	O
Plasmodium spp.	B-Organism
 P. falciparum	B-Organism
P. vivax	B-Organism
Our	O
findings	O
reveal	O
that	O
have	O
diverged	O
and	O
show	O
species	O
specific	O
binding	O
of	O
AMA1	O
to	O
RON2	O
determined	O
by	O
a	O
erythrocyte	S_Anatomical_Substances
P. vivax 	B-Organism
P. knowlesi.	B-Organism
caused	O
by	O
three	O
species	O
including	O
the	O
potential	O
for	O
cross	O
species	O
vaccines	O
 malaria	S-Disease
interactions	O
involved	O
in	O
invasion	O
may	O
enable	O
vaccines	O
that	O
generate	O
more	O
potent	O
inhibitory	O
antibodies	O
and	O
address	O
the	O
capacity	O
for	O
immune	O
evasion	O
Findings	O
on	O
specific	O
residues	O
for	O
invasion	O
function	O
and	O
species	O
divergence	O
and	O
conservation	O
can	O
inform	O
novel	O
vaccines	O
and	O
therapeutics	O
agains	O
 β-hairpin	B-Protien
 loop	I-Protien
 in RON2 	E-Protien
pecific residues	B-Protien
in AMA1	I-Protien
Loop1E.	E-Protien
binding	O
was	O
ablated	O
suggesting	O
this	O
domain	O
is	O
a	O
promising	O
additional	O
target	O
for	O
vaccine	O
development	O
Targeting	O
multiple	O
AMA1	S-Protien
 RON2-	S-Protien
 AMA1-RON2	S-Protien
AMA1-RON2	S-Protien
 AMA1	S-Protien
RON2	S-Protien
RON2	S-Protien
AMA1	S-Protien
 RON2 	S-Protien
AMA1 Loop1E	S-Protien
P. falciparum	B-Organism
P. vivax 	B-Organism
interaction	O
Antibodies	O
targeting	O
AMA1	O
domain	O
3	O
had	O
greater	O
invasion	O
inhibitory	O
activity	O
when	O
loop	O
interaction	O
is	O
not	O
essential	O
for	O
invasion	O
and	O
additional	O
 AMA1	S-Protien
interactions	O
are	O
involved	O
Mutations	O
in	O
binding	O
also	O
enable	O
escape	O
of	O
invasion	O
inhibitory	O
antibodies	O
Therefore	O
vaccines	O
and	O
therapeutics	O
will	O
need	O
to	O
be	O
broader	O
than	O
targeting	O
only	O
the	O
Mutation	O
of	O
specific	O
amino	O
acids	O
in	O
In	O
contrast	O
cross	O
species	O
binding	O
invasion	O
This	O
indicates	O
that	O
the	O
impacting	O
between	O
binding	O
withou	O
AMA1)	S-Protien
Malaria	S-Disease
causing	O
Malaria	S-Disease
vector	B-Disease
-borne	I-Disease
diseases	E-Disease
inflicts	O
the	O
highest	O
rate	O
of	O
morbidity	O
and	O
mortality	O
among	O
the	O
The	O
dramatic	O
bottleneck	O
of	O
parasite	O
numbers	O
that	O
occurs	O
in	O
the	O
gut	O
of	O
the	O
obligatory	O
mosquito	S-Organism
vector	O
provides	O
a	O
promising	O
target	O
for	O
novel	O
control	O
strategies	O
Using	O
single	O
cell	O
transcriptomics	O
we	O
analyzed	O
Plasmodium	B-Organism
 falciparum	I-Organism
development	O
in	O
the	O
mosquito	S-Organism
gut	O
from	O
unfertilized	O
female	O
gametes	O
through	O
the	O
first	O
20	O
h	O
after	O
blood	O
feeding	O
including	O
the	O
zygote	O
and	O
ookinete	O
stages	O
This	O
study	O
revealed	O
the	O
temporal	O
gene	O
expression	O
of	O
the	O
ApiAP2	S-Gene
family	O
of	O
transcription	O
factors	O
and	O
of	O
parasite	O
stress	O
genes	O
in	O
response	O
to	O
the	O
harsh	O
environment	O
of	O
the	O
 mosquito	S-Organism
midgut	O
Further	O
employing	O
structural	O
protein	O
prediction	O
analyses	O
we	O
found	O
several	O
upregulated	O
genes	O
predicted	O
to	O
encode	O
 intrinsically	B-Protien
disordered	I-Protien
proteins	E-Protien
IDPs	S-Protien
a	O
category	O
of	O
proteins	O
known	O
for	O
their	O
importance	O
in	O
regulation	O
of	O
transcription	O
translation	O
and	O
protein	O
protein	O
interactions	O
IDPs	O
are	O
known	O
for	O
their	O
antigenic	O
properties	O
and	O
may	O
serve	O
as	O
suitable	O
targets	O
for	O
antibody	O
or	O
peptide	O
based	O
transmission	O
suppression	O
strategies	O
In	O
total	O
this	O
study	O
uncovers	O
the	O
P. falciparum	B-Organism
ranscriptome	O
from	O
early	O
to	O
late	O
parasite	O
development	O
in	O
the	O
mosquito	O
midgut	O
inside	O
its	O
natural	O
vector	O
which	O
provides	O
an	O
important	O
resource	O
for	O
future	O
malaria	O
transmission	O
blocking	O
initiatives	O
Dengue	S-Disease
dengue 	B-Organism
virus	I-Organism
DENV	S-Organism
 vector-	B-Disease
borne 	I-Disease
viral disease	E-Disease
is	O
the	O
most	O
prevalent	O
posing	O
a	O
serious	O
health	O
concern	O
to	O
2	O
5	O
billion	O
people	O
worldwide	O
DENV	O
is	O
primarily	O
transmitted	O
among	O
humans	S-Organism
mosquito 	S-Organism
Aedes	B-Organism
aegypti	I-Organism
by	O
its	O
vecto	O
hence	O
the	O
identification	O
of	O
a	O
novel	O
dengue	O
virus	O
receptor	O
in	O
mosquitoes 	S-Organism
is	O
critical	O
for	O
the	O
development	O
of	O
new	O
anti	O
mosquito	O
measures	O
In	O
the	O
current	O
study	O
we	O
have	O
identified	O
peptides	O
which	O
potentially	O
interact	O
with	O
the	O
surface	O
of	O
the	O
virion	O
particles	O
and	O
facilitate	O
virus	O
infection	O
and	O
movement	O
during	O
their	O
life	O
cycle	O
in	O
the	O
mosquito	O
vector	O
To	O
identify	O
these	O
candidate	O
proteins	O
we	O
performed	O
phage	O
display	O
library	O
screening	O
against	O
domain	O
III	O
of	O
the	O
envelope 	B-Protien
protein (	I-Protien
which	O
plays	O
an	O
essential	O
role	O
during	O
host	O
cell	O
receptor	O
binding	O
for	O
viral	O
entry	O
The	O
mucin	O
protein	O
which	O
shared	O
sequence	O
similarity	O
with	O
the	O
peptide	O
identified	O
the	O
screening	O
was	O
cloned	O
expressed	O
and	O
purified	O
for	O
Vivax	B-Disease
 malaria	I-Disease
Plasmodium	B-Organism
 vivax	I-Organism
parasitic protozoan	S-Organism
s	O
an	O
infectious	O
disease	O
caused	O
by	O
transmitted	O
by	O
female	B-Organism
 Anopheline 	I-Organism
mosquitoes.	E-Organism
Historically	O
vivax 	B-Disease
malaria	I-Disease
has	O
often	O
been	O
regarded	O
as	O
a	O
benign	O
self	O
limiting	O
infection	O
due	O
to	O
the	O
observation	O
of	O
low	O
parasitemia 	S-Disease
in	O
Duffy	O
positive	O
patients	O
in	O
endemic	O
transmission	O
areas	O
and	O
the	O
virtual	O
absence	O
of	O
infections	O
in	O
Duffy	O
negative	O
individuals	O
in	O
Sub	O
Saharan	O
Africa	O
However	O
the	O
latest	O
estimates	O
show	O
that	O
the	O
burden	O
of	O
the	O
disease	O
is	O
not	O
decreasing	O
in	O
many	O
countries	O
and	O
cases	O
of	O
vivax	O
infections	O
in	O
Duffy	O
negative	O
individuals	O
are	O
increasingly	O
reported	O
throughout	O
Africa	O
This	O
raised	O
questions	O
about	O
the	O
accuracy	O
of	O
diagnostics	O
and	O
the	O
evolution	O
of	O
interactions	O
between	O
humans	S-Organism
parasites	S-Organism
and	O
For	O
a	O
long	O
time	O
our	O
knowledge	O
on	O
 P. vivax	B-Organism
biology	O
has	O
been	O
hampered	O
due	O
to	O
the	O
limited	O
access	O
to	O
biological	O
material	O
and	O
the	O
lack	O
of	O
robust	O
in	O
vitro	O
culture	O
methods	O
Consequently	O
little	O
is	O
currently	O
known	O
about	O
P. vivax	B-Organism
blood	O
stage	O
invasion	O
mechanisms	O
The	O
introduction	O
of	O
omics	O
technologies	O
with	O
novel	O
and	O
accessible	O
techniques	O
such	O
as	O
third	O
generation	O
sequencing	O
and	O
RNA	O
sequencing	O
at	O
single	O
cell	O
level	O
two	O
dimensional	O
electrophoresis	O
liquid	O
chromatography	O
and	O
mass	O
spectrometry	O
has	O
progressively	O
improved	O
our	O
understanding	O
of	O
P. vivax	B-Organism
 P. vivax	B-Organism
genetics	O
transcripts	O
and	O
proteins	O
This	O
review	O
aims	O
to	O
provide	O
broad	O
insights	O
into	O
nvasion	O
mechanisms	O
generated	O
by	O
genomics	O
transcriptomics, and proteomics and to illustrate the importance of integrated multi-omics studies	B-Organism
 Plasmodium	B-Organism
 vivax	I-Organism
Le	O
paludisme	O
à	O
Plasmodium	B-Organism
 vivax	I-Organism
est	O
une	O
maladie	O
infectieuse	O
causée	O
par	O
un	O
parasite	O
protozoair	O
P. vivax	B-Organism
transmis	O
par	O
les	O
moustiques	O
Anophèle	O
femelles	O
Historiquement	O
le	O
paludisme	O
à	O
P	O
vivax	O
a	O
souvent	O
été	O
considéré	O
comme	O
une	O
infection	O
bénigne	O
en	O
raison	O
de	O
l	O
observation	O
d	O
une	O
faible	O
parasitémie	O
chez	O
les	O
patients	O
Duffy	O
positifs	O
dans	O
les	O
zones	O
d	O
endémie	O
et	O
de	O
la	O
quasi	O
absence	O
d	O
infections	O
chez	O
les	O
individus	O
Duffy	O
négatifs	O
vivant	O
majoritairement	O
en	O
Afrique	O
subsaharienne	O
Cependant	O
les	O
dernières	O
estimations	O
montrent	O
que	O
le	O
poids	O
de	O
la	O
maladie	O
ne	O
diminue	O
pas	O
dans	O
de	O
nombreux	O
pays	O
et	O
que	O
des	O
cas	O
d	O
infections	O
à	O
P	O
vivax	O
chez	O
des	O
individus	O
Duffy	O
négatifs	O
sont	O
de	O
plus	O
en	O
plus	O
souvent	O
observés	O
en	O
Afrique	O
Cela	O
soulève	O
des	O
interrogations	O
sur	O
la	O
précision	O
des	O
diagnostics	O
et	O
l	O
évolution	O
des	O
interactions	O
hôte	O
parasite	O
Pendant	O
longtemps	O
nos	O
connaissances	O
sur	O
la	O
biologie	O
de	O
P	O
vivax	O
ont	O
été	O
entravées	O
par	O
un	O
accès	O
limité	O
au	O
matériel	O
biologique	O
et	O
un	O
manque	O
de	O
méthodes	O
robustes	O
pour	O
la	O
culture	O
in	O
vitro	O
Par	O
conséquent	O
nous	O
n	O
avons	O
encore	O
que	O
peu	O
d	O
informations	O
concernant	O
les	O
mécanismes	O
d	O
invasion	O
des	O
stades	O
sanguins	O
de	O
P	O
vivax	O
L	O
introduction	O
des	O
technologies	O
dites	O
omiques	O
avec	O
le	O
développement	O
de	O
techniques	O
innovantes	O
et	O
abordables	O
telles	O
que	O
le	O
séquençage	O
d	O
ADN	O
de	O
troisième	O
génération	O
le	O
séquençage	O
ARN	O
à	O
l	O
échelle	O
de	O
la	O
cellule	O
single	O
cell	O
l	O
électrophorèse	O
bidimensionnelle	O
la	O
chromatographie	O
liquide	O
et	O
la	O
spectrométrie	O
de	O
masse	O
a	O
progressivement	O
amélioré	O
notre	O
compréhension	O
des	O
gènes	O
des	O
transcrits	O
et	O
des	O
protéines	O
de	O
éomiques	O
mais	O
également	O
d	O
illustrer	O
l	O
importance	O
de	O
la	O
complémentarité	O
de	O
ces	O
approches	O
Cette	O
revue	O
a	O
non	O
seulement	O
pour	O
but	O
de	O
fournir	O
un	O
aperçu	O
général	O
des	O
mécanismes	O
d	O
invasion	O
de	O
P	O
vivax	O
acquis	O
grâce	O
aux	O
techniques	O
génomiques	O
transcriptomiques	O
et	O
protéo	O
malaria	S-Disease
free	O
countries	O
imported	O
cases	O
are	O
challenging	O
because	O
interconnections	O
with	O
neighboring	O
countries	O
with	O
higher	O
transmission	O
rates	O
increase	O
the	O
risk	O
of	O
parasite	O
reintroduction	O
Establishing	O
a	O
genetic	O
database	O
for	O
rapidly	O
identifying	O
malaria	O
importation	O
or	O
reintroduction	O
is	O
crucial	O
in	O
addressing	O
these	O
challenges	O
This	O
study	O
aimed	O
to	O
examine	O
genomic	O
epidemiology	O
during	O
the	O
pre	O
elimination	O
stage	O
by	O
retrospectively	O
reporting	O
whole	O
genome	O
sequence	O
variation	O
of	O
10	O
nThe	O
samples	O
were	O
collected	O
during	O
the	O
last	O
few	O
inland	O
outbreaks	O
from	O
2011	O
to	O
2012	O
when	O
China	O
implemented	O
a	O
malaria	O
control	O
plan	O
After	O
next	O
generation	O
sequencing	O
we	O
completed	O
a	O
genetic	O
analysis	O
of	O
the	O
population	O
explored	O
the	O
geographic	O
specificity	O
of	O
the	O
samples	O
and	O
examined	O
clustering	O
of	O
selection	O
pressures	O
We	O
also	O
scanned	O
genes	O
for	O
signals	O
of	O
positive	O
selection	O
China	O
s	O
inland	O
populations	O
were	O
highly	O
structured	O
compared	O
to	O
the	O
surrounding	O
area	O
with	O
a	O
single	O
potential	O
ancestor	O
Additionally	O
we	O
identified	O
genes	O
under	O
selection	O
and	O
evaluated	O
the	O
selection	O
pressure	O
on	O
drug	O
resistance	O
genes	O
In	O
the	O
inland	O
population	O
positive	O
selection	O
was	O
detected	O
in	O
some	O
critical	O
gene	O
families	O
including	O
nOur	O
data	O
provides	O
an	O
opportunity	O
to	O
investigate	O
the	O
molecular	O
epidemiology	O
of	O
pre	O
elimination	O
inland	O
malaria 	B-Organism
populations	O
which	O
exhibited	O
lower	O
selection	O
pressure	O
on	O
invasion	O
and	O
immune	O
evasion	O
genes	O
than	O
neighbouring	O
areas	O
but	O
increased	O
drug	O
resistance	O
in	O
low	O
transmission	O
settings	O
Our	O
results	O
revealed	O
that	O
the	O
inland	O
population	O
was	O
severely	O
fragmented	O
with	O
low	O
relatedness	O
among	O
infections	O
despite	O
a	O
higher	O
incidence	O
of	O
multiclonal	O
infections	O
suggesting	O
that	O
superinfection	O
or	O
co	O
transmission	O
events	O
are	O
rare	O
in	O
low	O
endemic	O
circumstances	O
We	O
identified	O
selective	O
signatures	O
of	O
resistance	O
and	O
found	O
that	O
the	O
proportion	O
of	O
susceptible	O
isolates	O
fluctuated	O
in	O
response	O
to	O
the	O
prohibition	O
of	O
specific	O
drugs	O
This	O
finding	O
is	O
consistent	O
with	O
the	O
alterations	O
in	O
medication	O
strategies	O
during	O
the	O
malaria	O
elimination	O
campaign	O
in	O
inland	O
China	O
Such	O
findings	O
could	O
provide	O
a	O
genetic	O
basis	O
for	O
future	O
population	O
studies	O
assessing	O
changes	O
in	O
other	O
pre	O
elimination	O
countries	O
Blood-	B-Organism
feeding	I-Organism
 arthropods	E-Organism
rely	O
on	O
robust	O
cellular	O
and	O
humoral	O
immunity	O
to	O
control	O
pathogen 	S-Organism
invasion	O
and	O
replication	O
Tick	O
hemocytes	S_Anatomical_Substances
produce	O
factors	O
that	O
can	O
facilitate	O
or	O
suppress	O
microbial 	B-Disease
infection	I-Disease
 pathogenesis.	E-Disease
Despite	O
the	O
importance	O
of	O
 hemocytes	S_Anatomical_Substances
in	O
regulating	O
microbial	O
infection	O
understanding	O
of	O
their	O
basic	O
biology	O
and	O
molecular	O
mechanisms	O
remains	O
limited	O
Here	O
we	O
combined	O
histomorphology	O
and	O
functional	O
analysis	O
to	O
identify	O
five	O
distinct	O
 phagocytic	B-Anatomical_Substances
 non-phagocytic 	I-Anatomical_Substances
hemocyte	E-Anatomical_Substances
populations	O
circulating	O
within	O
the	O
Gulf	O
Coast	O
tick	O
Depletion	O
of	O
 phagocytic	B-Anatomical_Substances
hemocytes 	I-Anatomical_Substances
 clodronate liposomes 	S-Chemical_Substance
revealed	O
their	O
function	O
in	O
eliminating	O
bacterial	B-Disease
infection.	I-Disease
We	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
an	O
intracellular	O
tick	O
borne	O
pathogen	O
nTogether	O
these	O
findings	O
represent	O
a	O
significant	O
step	O
forward	O
in	O
understanding	O
how	O
hemocytes	O
regulate	O
microbial	O
homeostasis	O
and	O
vector	O
competence	O
Malaria	S-Disease
control	O
can	O
significantly	O
benefit	O
from	O
a	O
holistic	O
and	O
precise	O
way	O
of	O
quantitatively	O
measuring	O
the	O
transmission	O
intensity	O
which	O
needs	O
to	O
incorporate	O
spatiotemporally	O
varying	O
risk	O
factors	O
In	O
this	O
study	O
we	O
conduct	O
a	O
systematic	O
investigation	O
to	O
characterize	O
malaria	O
transmission	O
intensity	O
by	O
taking	O
a	O
spatiotemporal	O
network	O
perspective	O
where	O
nodes	O
capture	O
the	O
local	O
transmission	O
intensities	O
resulting	O
from	O
dominant	O
vector	O
species	O
the	O
population	O
density	O
and	O
land	O
cover	O
and	O
edges	O
describe	O
the	O
cross	O
region	O
human	O
mobility	O
patterns	O
The	O
inferred	O
network	O
enables	O
us	O
to	O
accurately	O
assess	O
the	O
transmission	O
intensity	O
over	O
time	O
and	O
space	O
from	O
available	O
empirical	O
observations	O
Our	O
study	O
focuses	O
on	O
malaria	O
severe	O
districts	O
in	O
Cambodia	O
The	O
malaria	O
transmission	O
intensities	O
determined	O
using	O
our	O
transmission	O
network	O
reveal	O
both	O
qualitatively	O
and	O
quantitatively	O
their	O
seasonal	O
and	O
geographical	O
characteristics	O
the	O
risks	O
increase	O
in	O
the	O
rainy	O
season	O
and	O
decrease	O
in	O
the	O
dry	O
season	O
remote	O
and	O
sparsely	O
populated	O
areas	O
generally	O
show	O
higher	O
transmission	O
intensities	O
than	O
other	O
areas	O
Our	O
findings	O
suggest	O
that	O
the	O
human	O
mobility	O
e	O
g	O
in	O
planting	O
harvest	O
seasons	O
environment	O
e	O
g	O
temperature	O
and	O
contact	O
risk	O
coexistences	O
of	O
human	O
and	O
vector	O
occurrence	O
contribute	O
to	O
malaria	O
transmission	O
in	O
spatiotemporally	O
varying	O
degrees	O
quantitative	O
relationships	O
between	O
these	O
influential	O
factors	O
and	O
the	O
resulting	O
malaria	O
transmission	O
risk	O
can	O
inform	O
evidence	O
based	O
tailor	O
made	O
responses	O
at	O
the	O
right	O
locations	O
and	O
times	O
malaria	S-Disease
 long-term 	B-Disease
neuropsychiatric	I-Disease
complications.	E-Disease
This	O
article	O
focuses	O
on	O
the	O
cases	O
of	O
two	O
British	O
ex	O
servicemen	O
who	O
contracted	O
malaria	O
during	O
or	O
immediately	O
after	O
the	O
First	O
World	O
War	O
were	O
charged	O
with	O
murder	O
in	O
the	O
1920s	O
and	O
pled	O
insanity	O
due	O
to	O
their	O
 malaria 	S-Disease
and	O
insanity	O
were	O
received	O
inconsistently	O
by	O
inter	O
war	O
British	O
courts	O
Class	O
education	O
social	O
status	O
institutional	O
support	O
and	O
the	O
nature	O
of	O
the	O
crime	O
all	O
mattered	O
as	O
they	O
had	O
in	O
the	O
diagnoses	O
treatment	O
and	O
trials	O
of	O
other	O
ex	O
servicemen	O
with	O
psychiatric	O
illnesses	O
insane	O
and	O
committed	O
to	O
Broadmoor	O
Criminal	O
Lunatic	O
Asylum	O
in	O
June	O
1923	O
while	O
the	O
other	O
was	O
convicted	O
and	O
hanged	O
in	O
July	O
1927	O
It	O
argues	O
that	O
at	O
a	O
time	O
when	O
the	O
medical	O
community	O
sought	O
out	O
the	O
causes	O
of	O
mental	O
disease	O
in	O
the	O
physical	O
body	O
medico	O
legal	O
arguments	O
abou	O
One	O
was	O
found	O
guilty	O
but	O
Thelazia	B-Disease
californiensis	I-Disease
ocular infestation	E-Disease
A	O
rare	O
case	O
of	O
was	O
diagnosed	O
and	O
treated	O
in	O
an	O
11	O
month	O
old	O
patient	O
The	O
patient	O
presented	O
with	O
a	O
visual	O
acuity	O
of	O
20	O
130	O
OU	O
by	O
Teller	O
cards	O
Exam	O
demonstrated	O
a	O
white	O
mobile 	B-Organism
worm	I-Organism
in	O
the	O
inferomedial	O
fornix	O
of	O
the	O
right	O
eye	O
The	O
remainder	O
of	O
the	O
exam	O
was	O
otherwise	O
normal	O
The	O
worm	O
was	O
removed	O
under	O
anesthesia	O
and	O
identified	O
as	O
Thelazia 	B-Organism
 californiensis	I-Organism
by	O
the	O
Division	O
of	O
Parasitic	O
Diseases	O
and	O
 Malaria, 	S-Disease
at	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
Thelazia	B-Organism
species.	I-Organism
This	O
case	O
demonstrates	O
a	O
rare	O
but	O
important	O
cause	O
of	O
follicular	O
conjunctivitis	O
and	O
mobile	O
foreign	O
bodies	O
especially	O
in	O
patients	O
with	O
a	O
supportive	O
history	O
of	O
exposure	O
to	O
the	O
intermediate	O
and	O
definitive	O
hosts	O
of	O
Cerebral	B-Disease
malaria 	I-Disease
s	O
a	O
major	O
cause	O
of	O
mortality	O
in	O
Plasmodium	B-Organism
 falciparum	I-Organism
e	O
infection	O
and	O
is	O
associated	O
with	O
the	O
sequestration	O
of	O
parasitised 	B-Anatomical_Substances
erythrocytes	I-Anatomical_Substances
in	O
the	O
microvasculature	O
of	O
the	O
host	O
s	O
vital	O
organs	O
Prompt	O
diagnosis	O
and	O
treatment	O
are	O
key	O
to	O
a	O
positive	O
outcome	O
in	O
CM	S-Disease
However	O
current	O
diagnostic	O
tools	O
remain	O
inadequate	O
to	O
assess	O
the	O
degree	O
of	O
brain 	B-Disease
dysfunction	I-Disease
ssociated	O
with	O
CM	O
before	O
the	O
window	O
for	O
effective	O
treatment	O
closes	O
Several	O
host	O
and	O
parasite	S-Organism
factor	O
based	O
biomarkers	O
have	O
been	O
suggested	O
as	O
rapid	O
diagnostic	O
tools	O
with	O
potential	O
for	O
CM	S-Disease
earl	O
diagnosis	O
however	O
no	O
specific	O
biomarker	O
signature	O
has	O
been	O
validated	O
Here	O
we	O
provide	O
an	O
updated	O
review	O
on	O
promising	O
 CM	S-Disease
biomarker	O
candidates	O
and	O
evaluate	O
their	O
applicability	O
as	O
point	O
of	O
care	O
tools	O
in	O
malaria	O
endemic	O
areas	O
Each	O
year	O
92	O
million	O
pregnant	O
women	O
are	O
at	O
risk	O
of	O
contracting	O
malaria 	S-Disease
during	O
pregnancy	O
with	O
the	O
underestimation	O
of	O
the	O
mortality	O
and	O
morbidity	O
burden	O
associated	O
with	O
Initially	O
the	O
pregnant	O
women	O
were	O
stratified	O
into	O
two	O
groups	O
1	O
recurrence	O
and	O
2	O
or	O
more	O
recurrences	O
in	O
which	O
no	O
differences	O
were	O
observed	O
in	O
clinical	O
gestational	O
outcomes	O
or	O
in	O
placental	O
histological	O
changes	O
between	O
the	O
two	O
groups	O
Then	O
we	O
evaluated	O
the	O
parasites	O
genetically	O
An	O
average	O
of	O
18	O
5	O
distinct	O
alleles	O
were	O
found	O
at	O
each	O
of	O
the	O
MS	O
loci	O
and	O
the	O
H	O
 polyclonal 	B-Disease
infections 	I-Disease
Most	O
pregnant	O
women	O
had	O
that	O
could	O
be	O
the	O
result	O
of	O
relapses	O
and	O
or	O
re	O
infections	O
The	O
high	O
percentage	O
of	O
H1 	B-Organism
parasites	I-Organism
along	O
with	O
the	O
low	O
frequency	O
of	O
many	O
other	O
haplotypes 	S-Organism
are	O
suggestive	O
of	O
a	O
clonal	O
expansion	O
Phylogenetic	O
analysis	O
shows	O
that	O
FAPESP	O
and	O
CNPq	O
Brazil	O
Brazil	O
is	O
a	O
unique	O
and	O
understudied	O
setting	O
for	O
malaria	S-Disease
human	S-Organism
with	O
complex	O
foci	O
of	O
transmission	O
associated	O
with	O
An	O
understanding	O
of	O
the	O
population	O
genomic	O
diversity	O
of	O
nThrough	O
whole	O
genome	O
sequencing	O
of	O
nWe	O
confirm	O
that	O
South	O
American	O
isolates	O
are	O
distinct	O
have	O
more	O
ancestral	O
populations	O
than	O
the	O
other	O
global	O
regions	O
with	O
differentiating	O
mutations	O
in	O
genes	O
under	O
selective	O
pressure	O
linked	O
to	O
and	O
environmental	O
conditions	O
antimalarial drugs	S_Anatomical_Substances
Brazil	O
has	O
a	O
complex	O
population	O
structure	O
with	O
evidence	O
of	O
nAI	O
is	O
funded	O
by	O
an	O
MRC	O
LiD	O
PhD	O
studentship	O
TGC	O
is	O
funded	O
by	O
the	O
Medical	O
Research	O
Council	O
Grant	O
no	O
MR	O
M01360X	O
1	O
MR	O
N010469	O
1	O
MR	O
R025576	O
1	O
MR	O
R020973	O
1	O
and	O
MR	O
X005895	O
1	O
SC	O
is	O
funded	O
by	O
Medical	O
Research	O
Council	O
UK	O
grants	O
MR	O
M01360X	O
1	O
MR	O
R025576	O
1	O
MR	O
R020973	O
1	O
and	O
MR	O
X005895	O
1	O
and	O
Bloomsbury	O
SET	O
ref	O
CCF17	O
7779	O
FN	O
is	O
funded	O
by	O
The	O
Shloklo	O
Malaria	O
Research	O
Unit	O
part	O
of	O
the	O
Mahidol	O
Oxford	O
Research	O
Unit	O
supported	O
by	O
the	O
Wellcome	O
Trust	O
Grant	O
no	O
220211	O
ARSB	O
is	O
funded	O
by	O
São	O
Paulo	O
Research	O
Foundation	O
FAPESP	O
Grant	O
no	O
2002	O
09546	O
1	O
RLDM	O
is	O
funded	O
by	O
Brazilian	O
National	O
Council	O
for	O
Scientific	O
and	O
Technological	O
Development	O
CNPq	O
Grant	O
no	O
302353	O
2003	O
8	O
and	O
471605	O
2011	O
5	O
CRFM	O
is	O
funded	O
by	O
FAPESP	O
Grant	O
no	O
2020	O
06747	O
4	O
and	O
CNPq	O
Grant	O
no	O
302917	O
2019	O
5	O
and	O
408636	O
2018	O
1	O
JGD	O
is	O
funded	O
by	O
FAPESP	O
fellowships	O
2016	O
13465	O
0	O
and	O
2019	O
12068	O
5	O
and	O
CNPq	O
Grant	O
no	O
409216	O
2018	O
6	O
Malaria	S-Disease
is	O
a	O
public	O
health	O
problem	O
that	O
causes	O
thousands	O
of	O
deaths	O
primarily	O
in	O
children	O
in	O
African	O
regions	O
Artemisinin	B-Medication
based combination	I-Medication
therapies	E-Medication
(ACTs	S-Medication
have	O
helped	O
to	O
save	O
thousands	O
of	O
lives	O
however	O
due	O
to	O
Plasmodium's	B-Organism
resistance	O
to	O
available	O
treatments	O
there	O
is	O
a	O
need	O
to	O
search	O
for	O
new	O
low	O
cost	O
drugs	O
that	O
act	O
through	O
different	O
mechanisms	O
of	O
action	O
to	O
contain	O
this	O
disease	O
This	O
review	O
shows	O
that	O
compounds	O
with	O
 P. falciparum 	B-Chemical_Substance
carbonic	I-Chemical_Substance
 anhydrases	E-Chemical_Substance
sulfonamide moiety	S-Chemical_Substance
possibly	O
act	O
as	O
inhibitors	O
of	O
moreover	O
when	O
linked	O
to	O
a	O
variety	O
of	O
heterocycles	O
potentiate	O
the	O
activities	O
of	O
these	O
compounds	O
and	O
may	O
be	O
used	O
in	O
the	O
design	O
of	O
new	O
 antimalarial drugs.	S_Anatomical_Substances
Malaria	B-Disease
vector-borne	I-Disease
disease	E-Disease
remains	O
important	O
health	O
concern	O
with	O
over	O
200	O
million	O
cases	O
globally	O
Novel	O
antimalarial	B-Medication
medicines	I-Medication
and	O
more	O
effective	O
vaccines	O
must	O
be	O
developed	O
to	O
eliminate	O
and	O
eradicate	O
malaria. 	S-Disease
CRISPR-Cas	B-Medication
 nuclease 	I-Medication
 system	E-Medication
Appraisal	O
of	O
preceding	O
genome	O
editing	O
approaches	O
confirmed	O
the	O
as	O
a	O
novel	O
proficient	O
genome	O
editing	O
system	O
and	O
a	O
tool	O
for	O
species	O
specific	O
diagnosis	O
and	O
drug	O
resistance	O
researches	O
for	O
Plasmodium	B-Organism
 species	I-Organism
and	O
gene	O
drive	O
to	O
control	O
 Anopheles 	S-Organism
population	O
transgenic	B-Organism
malaria	I-Organism
parasites	E-Organism
Plasmodium	S-Organism
can	O
be	O
justified	O
for	O
the	O
production	O
of	O
Plasmodium 	B-Organism
species	I-Organism
malaria	S-Disease
 Cas9	S_Anatomical_Substances
chimeric	B-Anatomical_Substances
 Plasmodium	I-Anatomical_Substances
transgenic lines	E-Anatomical_Substances
transgenic	B-Organism
parasites	I-Organism
mosquito	S-Organism
Anopheles	B-Organism
settings	O
with	O
affordable	O
cost	O
and	O
high	O
speed	O
detection	O
Furthermore	O
the	O
advancement	O
of	O
genome	O
modifications	O
by	O
CRISPR	O
Cas	O
technologies	O
resolves	O
contemporary	O
restrictions	O
to	O
culturing	O
maintaining	O
and	O
analyzing	O
these	O
parasites	O
and	O
the	O
aptitude	O
to	O
investigate	O
parasite	O
genome	O
functions	O
opens	O
up	O
new	O
vistas	O
in	O
the	O
better	O
understanding	O
of	O
pathogenesis	O
 mosquitoes	S-Organism
and	O
creation	O
of	O
knock	O
out	O
knock	O
in	O
mutants	O
Though	O
the	O
incorporation	O
of	O
traditional	O
methods	O
and	O
novel	O
molecular	O
techniques	O
could	O
noticeably	O
enhance	O
the	O
quality	O
of	O
results	O
The	O
striking	O
development	O
of	O
a	O
CRISPR	O
Cas	O
based	O
diagnostic	O
kit	O
that	O
can	O
specifically	O
diagnose	O
the	O
or	O
drug	O
resistance	O
markers	O
is	O
highly	O
required	O
in	O
transgenic 	B-Organism
populations	O
generation	O
of	O
wingless	O
parasites	O
expressing	O
alternative	O
alleles	O
and	O
also	O
mutant	O
strains	O
of	O
transgenic	O
lines	O
expressing	O
CRISPR	O
Cas	O
technology	O
as	O
a	O
handy	O
tool	O
for	O
genome	O
editing	O
such	O
as	O
only	O
male	O
knockdown	O
and	O
knockout	O
The	O
Brazilian	O
Amazon	O
rainforest	O
region	O
has	O
a	O
significant	O
prevalence	O
of	O
malarial and	B-Disease
ntestinal parasitic	I-Disease
infections 	E-Disease
in	O
indigenous	O
populations	O
accounting	O
for	O
a	O
disproportionate	O
burden	O
Thus	O
a	O
cross	O
sectional	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
prevalence	O
and	O
association	O
between	O
malarial and	B-Organism
intestinal 	I-Organism
protozoan	E-Organism
helminth	B-Disease
infections	I-Disease
and	O
in	O
four	O
remote	O
indigenous	O
villages	O
in	O
the	O
Brazilian	O
Amazon	O
Forest	O
A	O
total	O
of	O
430	O
individuals	O
participated	O
in	O
the	O
study	O
and	O
Plasmodium	B-Disease
infections 	I-Disease
were	O
diagnosed	O
by	O
examination	O
of	O
thick	B-Anatomical_Substances
 blood 	I-Anatomical_Substances
smears	E-Anatomical_Substances
and	O
PCR	O
Stool	O
samples	O
295	O
individuals	O
69	O
were	O
examined	O
by	O
direct	O
smear	O
and	O
the	O
Kato	O
Katz	O
technique	O
The	O
overall	O
prevalence	O
of	O
malaria	S-Organism
intestinal	B-Disease
protozoan	I-Disease
infection	E-Disease
 intestinal	B-Disease
 helminth 	I-Disease
infection	E-Disease
was	O
14	O
2	O
100	O
and	O
39	O
3	O
respectively	O
Polyparasitism	O
was	O
predominant	O
83	O
7	O
and	O
most	O
infected	O
individuals	O
had	O
at	O
least	O
two	O
or	O
more	O
different	O
species	O
of	O
 intestinal	B-Organism
protozoan 	I-Organism
 helminth	B-Organism
 parasites	I-Organism
The	O
prevalence	O
of	O
co	O
infection	O
was	O
49	O
5	O
and	O
in	O
individuals	O
with	O
 intestinal	B-Organism
protozoa 	I-Organism
 Entamoeba. coli	S-Organism
Entamoeba	B-Organism
histolytica	I-Organism
 Ascaris	B-Organism
lumbricoides 	I-Organism
were	O
the	O
most	O
common	O
parasites	O
helminth	B-Disease
infections 	I-Disease
malaria and protozoa 	B-Disease
infections	I-Disease
In	O
individuals	O
with	O
P. vivax	S-Organism
E. coli,	S-Organism
E. histolytica	S-Organism
malaria, protozoa, and helminth	B-Disease
 infections	I-Disease
 P. vivax, E. coli, E. histolytica, and A. lumbricoides 	S-Organism
Intestinal	B-Disease
polyparasitism	I-Disease
was	O
common	O
in	O
the	O
study	O
population	O
and	O
the	O
presence	O
of	O
helminths 	S-Organism
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
intestina	O
parasitic	O
species	O
However	O
Plasmodium	B-Disease
 infections	I-Disease
were	O
neither	O
a	O
risk	O
nor	O
a	O
protective	O
factor	O
for	O
helminth	O
infections	O
the	O
same	O
was	O
true	O
for	O
helminth	O
infections	O
in	O
relation	O
to	O
Plasmodium.	S-Organism
The	O
high	O
prevalence	O
of	O
intestinal	O
polyparasitism	O
with	O
Plasmodium	O
co	O
infections	O
highlights	O
the	O
need	O
for	O
combining	O
strategies	O
that	O
may	O
help	O
control	O
both	O
malaria	O
and	O
intestinal	O
parasite	O
and	O
generate	O
a	O
health	O
approach	O
aligned	O
with	O
indigenous	O
perspectives	O
Malaria	S-Disease
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
hospital	O
admission	O
and	O
death	O
in	O
children	O
under	O
the	O
age	O
of	O
five	O
The	O
World	O
Health	O
Organization	O
WHO	O
has	O
issued	O
guidelines	O
for	O
the	O
identification	O
and	O
treatment	O
of	O
severe	O
malaria	O
Evidence	O
has	O
shown	O
that	O
adherence	O
to	O
standardized	O
malaria	O
treatment	O
protocols	O
improves	O
outcomes	O
As	O
a	O
baseline	O
assessment	O
in	O
preparation	O
for	O
a	O
malaria	O
treatment	O
quality	O
improvement	O
project	O
this	O
study	O
aimed	O
to	O
determine	O
adherence	O
to	O
the	O
WHO	O
severe	O
malaria	O
treatment	O
guidelines	O
in	O
children	O
at	O
a	O
Ugandan	O
Regional	O
Referral	O
Hospital	O
A	O
retrospective	O
review	O
was	O
performed	O
on	O
a	O
convenience	O
sample	O
of	O
children	O
discharged	O
between	O
June	O
2021	O
and	O
March	O
2022	O
from	O
the	O
Mbale	O
Regional	O
Referral	O
Hospital	O
Paediatrics	O
Ward	O
with	O
a	O
diagnosis	O
of	O
severe	O
malaria	O
Data	O
were	O
collected	O
using	O
a	O
standardized	O
case	O
report	O
form	O
Demographics	O
presenting	O
symptoms	O
laboratory	O
results	O
treatments	O
length	O
of	O
stay	O
and	O
mortality	O
were	O
extracted	O
Comparison	O
of	O
treatments	O
received	O
to	O
items	O
recommended	O
in	O
the	O
WHO	O
guidelines	O
was	O
undertaken	O
to	O
determine	O
adherence	O
47	O
patients	O
were	O
included	O
The	O
median	O
age	O
was	O
5	O
years	O
IQR	O
2	O
7	O
years	O
and	O
55	O
were	O
male	O
The	O
most	O
common	O
features	O
of	O
haemoglobinuria	S-Disease
altered	B-Disease
mentation	I-Disease
severe	O
malaria	O
were	O
49	O
haemoglobin 	S_Anatomical_Substances
5	O
mg	O
dL	O
34	O
and	O
Median	O
hospital	O
length	O
of	O
stay	O
was	O
3	O
days	O
IQR	O
2	O
4	O
days	O
and	O
the	O
mortality	O
rate	O
was	O
27	O
n	O
40	O
Overall	O
adherence	O
to	O
all	O
aspects	O
of	O
the	O
WHO	O
severe	O
malaria	O
guidelines	O
was	O
achieved	O
in	O
3	O
n	O
4	O
of	O
patients	O
The	O
most	O
common	O
areas	O
of	O
deficiency	O
were	O
not	O
testing	O
to	O
confirm	O
malaria	O
diagnosis	O
and	O
inadequate	O
administration	O
of	O
artesunate	O
82	O
Fewer	O
than	O
the	O
three	O
recommended	O
doses	O
of	O
artesunate	O
occurred	O
in	O
22	O
of	O
patients	O
Additionally	O
a	O
delay	O
in	O
the	O
administration	O
of	O
the	O
second	O
dose	O
occurred	O
in	O
67	O
n	O
78	O
and	O
in	O
the	O
third	O
dose	O
in	O
77	O
n	O
71	O
of	O
patients	O
While	O
the	O
recommended	O
time	O
between	O
doses	O
is	O
12	O
h	O
the	O
median	O
interval	O
between	O
dose	O
one	O
and	O
dose	O
two	O
was	O
15	O
h	O
12	O
20	O
and	O
the	O
median	O
interval	O
from	O
dose	O
two	O
to	O
dose	O
three	O
was	O
17	O
h	O
14	O
25	O
nCurrent	O
adherence	O
to	O
severe	O
malaria	O
treatment	O
guidelines	O
in	O
children	O
at	O
this	O
Ugandan	O
regional	O
referral	O
hospital	O
is	O
poor	O
but	O
this	O
study	O
has	O
identified	O
target	O
areas	O
for	O
improvement	O
 malaria 	B-Medication
vaccine	I-Medication
RTS,S 	E-Medication
In	O
October	O
2021	O
the	O
world	O
s	O
first	O
was	O
endorsed	O
by	O
WHO	O
for	O
broad	O
use	O
in	O
children	O
despite	O
its	O
low	O
efficacy	O
This	O
study	O
examined	O
polyclonal	O
infections	O
and	O
the	O
associations	O
of	O
parasite	O
genetic	O
variations	O
with	O
binding	O
affinity	O
to	O
human 	B-Anatomical_Substances
leukocyte 	I-Anatomical_Substances
antigen 	E-Anatomical_Substances
HLA	S_Anatomical_Substances
Multiplicity	O
of	O
infection	O
was	O
determined	O
by	O
amplicon	O
deep	O
sequencing	O
of	O
PfMSP1.	S-Protien
PfCSP	S-Protien
1655 PfCSP	S-Protien
Th2R/Th3R CSP	S-Protien
 PfCSP	S-Protien
multiple	B-Protien
non-3D7 PfCSP	I-Protien
variants.	S-Protien
 PfCSP	S-Protien
HLA.	S_Anatomical_Substances
HLA	S_Anatomical_Substances
3D7 and non-3D7 PfCSP	S-Protien
Ghana	B-Protien
CSP	I-Protien
 peptides	E-Protien
variants	O
and	O
HLA	O
were	O
predicted	O
using	O
NetChop	O
and	O
HADDOCK	O
High	O
polyclonality	O
was	O
detected	O
among	O
infections	O
with	O
each	O
infection	O
harboring	O
CSP	O
peptide	O
length	O
after	O
proteolytic	O
degradation	O
significantly	O
affects	O
its	O
molecular	O
weight	O
and	O
binding	O
affinity	O
to	O
Multiple	O
non	O
3D7	O
strains	O
among	O
P	O
falciparum	O
infections	O
could	O
impact	O
the	O
effectiveness	O
of	O
RTS	O
S	O
Longer	O
peptides	O
of	O
the	O
regions	O
should	O
be	O
considered	O
in	O
future	O
versions	O
of	O
RTS	O
S	O
HLA	O
the	O
majority	O
of	O
the	O
HLAI	O
and	O
II	O
alleles	O
interacted	O
bound	O
with	O
all	O
haplotypes	O
were	O
detected	O
in	O
the	O
Ghanaian	O
samples	O
and	O
they	O
broadly	O
represented	O
diversity	O
across	O
Africa	O
The	O
number	O
of	O
genetic	O
differences	O
between	O
variants	O
does	O
not	O
influence	O
binding	O
to	O
from	O
Ghana	O
and	O
analyzed	O
together	O
with	O
sequences	O
from	O
other	O
African	O
and	O
non	O
African	O
isolates	O
Binding	O
interactions	O
of	O
 PfCSP	B-Protien
peptide	I-Protien
Genetic	O
variations	O
in	O
were	O
examined	O
across	O
88	O
sample	O
Despite	O
the	O
high	O
diversity	O
of	O
mosquitoes	S-Organism
malaria 	B-Organism
parasites	I-Organism
During	O
their	O
development	O
i	O
undergo	O
massive	O
losses	O
that	O
are	O
in	O
part	O
due	O
to	O
a	O
potent	O
antiparasitic	O
response	O
mounted	O
by	O
the	O
vector	O
The	O
most	O
efficient	O
and	O
best	O
characterized	O
response	O
relies	O
on	O
a	O
complement	O
like	O
system	O
particularly	O
effective	O
against	O
parasites	O
as	O
they	O
cross	O
the	O
mosquito	B-Organism
midgut	O
epithelium	O
While	O
our	O
vision	O
of	O
the	O
molecular	O
and	O
cellular	O
events	O
that	O
lead	O
to	O
parasite	O
elimination	O
is	O
still	O
partial	O
our	O
understanding	O
of	O
the	O
steps	O
triggering	O
complement	O
activation	O
at	O
the	O
surface	O
of	O
invading	O
parasites	O
has	O
considerably	O
progressed	O
not	O
only	O
through	O
the	O
identification	O
of	O
novel	O
contributing	O
genes	O
but	O
also	O
with	O
the	O
recent	O
in	O
depth	O
characterization	O
of	O
the	O
different	O
mosquito	B-Anatomical_Substances
blood 	I-Anatomical_Substances
cell 	E-Anatomical_Substances
Here	O
we	O
propose	O
a	O
simple	O
model	O
based	O
on	O
the	O
time	O
of	O
invasion	O
to	O
explain	O
how	O
parasites	O
may	O
escape	O
complement	O
like	O
responses	O
during	O
midgut	O
infection	O
ability	O
to	O
track	O
them	O
in	O
live	O
 mosquitoes.	S-Organism
types	O
and	O
the	O
malaria	S-Disease
Molecular	O
surveillance	O
for	O
has	O
great	O
potential	O
to	O
support	O
national	O
malaria	O
control	O
programs	O
NMCPs	O
To	O
bridge	O
the	O
gap	O
between	O
research	O
and	O
implementation	O
several	O
applications	O
use	O
cases	O
have	O
been	O
identified	O
to	O
align	O
research	O
technology	O
development	O
and	O
public	O
health	O
efforts	O
For	O
implementation	O
at	O
NMCPs	O
there	O
is	O
an	O
urgent	O
need	O
for	O
feasible	O
and	O
cost	O
effective	O
tools	O
We	O
designed	O
a	O
new	O
highly	O
multiplexed	O
deep	O
sequencing	O
assay	O
Pf	O
AmpliSeq	O
which	O
is	O
compatible	O
with	O
benchtop	O
sequencers	O
that	O
allows	O
high	O
accuracy	O
sequencing	O
with	O
higher	O
coverage	O
and	O
lower	O
cost	O
than	O
whole	O
genome	O
sequencing	O
WGS	O
targeting	O
genomic	O
regions	O
of	O
interest	O
The	O
novelty	O
of	O
the	O
assay	O
is	O
its	O
high	O
number	O
of	O
targets	O
multiplexed	O
into	O
one	O
easy	O
workflow	O
combining	O
population	O
genetic	O
markers	O
with	O
13	O
nearly	O
full	O
length	O
resistance	O
genes	O
which	O
is	O
applicable	O
for	O
many	O
different	O
use	O
cases	O
We	O
provide	O
the	O
first	O
proof	O
of	O
principle	O
for	O
Medicinal	B-Medication
 plants 	I-Medication
have	O
historically	O
been	O
a	O
source	O
of	O
drugs	O
in	O
multiple	O
applications	O
including	O
the	O
treatment	O
of	O
malaria	B-Disease
 infections	I-Disease
 Cabo Verde	B-Medication
archipelago 	I-Medication
harbors	E-Medication
a	O
rich	O
diversity	O
of	O
native	O
plants	O
most	O
of	O
which	O
are	O
used	O
for	O
medicinal	O
purposes	O
The	O
present	O
study	O
investigated	O
the	O
in	O
vitro	O
antiplasmodial	O
activities	O
of	O
four	O
native	O
plants	O
from	O
Cabo	O
Verde	O
i	O
e	O
apicomplexan	B-Disease
infections	I-Disease
Interest	O
in	O
host	O
epigenetic	O
changes	O
during	O
increased	O
in	O
the	O
last	O
decade	O
mainly	O
due	O
to	O
the	O
emergence	O
of	O
new	O
therapies	O
directed	O
to	O
these	O
alterations	O
This	O
review	O
aims	O
to	O
carry	O
out	O
a	O
bibliometric	O
analysis	O
of	O
the	O
publications	O
related	O
to	O
host	O
epigenetic	O
changes	O
during	O
apicomplexan	B-Disease
 infections 	I-Disease
and	O
to	O
summarize	O
the	O
main	O
studied	O
pathways	O
in	O
this	O
context	O
pointing	O
out	O
those	O
that	O
represent	O
putative	O
drug	O
targets	O
We	O
used	O
four	O
databases	O
for	O
the	O
article	O
search	O
After	O
screening	O
116	O
studies	O
were	O
included	O
The	O
bibliometric	O
analysis	O
revealed	O
that	O
the	O
USA	O
and	O
China	O
had	O
the	O
highest	O
number	O
of	O
relevant	O
publications	O
The	O
evaluation	O
of	O
the	O
selected	O
studies	O
revealed	O
that	O
Malaria	S-Disease
parasitic	B-Disease
infection	I-Disease
is	O
a	O
that	O
is	O
a	O
great	O
public	O
health	O
concern	O
and	O
is	O
responsible	O
for	O
high	O
mortality	O
rates	O
worldwide	O
Different	O
strategies	O
have	O
been	O
employed	O
to	O
improve	O
disease	O
control	O
demonstrating	O
the	O
ineffectiveness	O
of	O
controlling	O
vectors	O
and	O
parasite	O
resistance	O
to	O
antimalarial	O
drugs	O
requires	O
the	O
development	O
of	O
an	O
effective	B-Medication
preventive 	I-Medication
vaccine. 	E-Medication
There	O
are	O
countless	O
challenges	O
to	O
the	O
development	O
of	O
such	O
a	O
vaccine	O
directly	O
related	O
to	O
the	O
parasite	O
s	O
complex	O
life	O
cycle	O
After	O
more	O
than	O
four	O
decades	O
of	O
basic	O
research	O
and	O
clinical	O
trials	O
the	O
World	O
Health	O
Organization	O
WHO	O
has	O
recommended	O
the	O
 pre-erythrocytic	B-Medication
Plasmodium falciparum	I-Medication
malaria vaccine	E-Medication
for	O
widespread	O
use	O
among	O
children	O
living	O
in	O
malaria	O
endemic	O
areas	O
However	O
there	O
is	O
a	O
consensus	O
that	O
major	O
improvements	O
are	O
needed	O
to	O
develop	O
a	O
vaccine	O
with	O
a	O
greater	O
epidemiological	O
impact	O
in	O
endemic	O
areas	O
This	O
review	O
discusses	O
novel	O
strategies	O
for	O
 malaria 	B-Medication
vaccine 	I-Medication
design	O
taking	O
the	O
target	O
stages	O
within	O
the	O
parasite	S-Organism
cycle	O
into	O
account	O
The	O
design	O
of	O
the	O
multi	O
component	O
vaccine	O
shows	O
considerable	O
potential	O
especially	O
as	O
it	O
involves	O
 transmission	B-Medication
blocking vaccines	I-Medication
TBVs	S-Medication
hat	O
eliminate	O
the	O
parasite	O
s	O
replication	O
towards	O
sporozoite	O
stage	O
parasites 	S-Organism
blood	B-Anatomical_Substances
during	O
a	O
meal	O
of	O
female	B-Organism
anopheline	I-Organism
mosquitoes	E-Organism
Significant	O
improvements	O
have	O
been	O
made	O
but	O
additional	O
efforts	O
to	O
achieve	O
an	O
efficient	O
vaccine	O
are	O
required	O
to	O
improve	O
control	O
measures	O
Different	O
strategies	O
have	O
been	O
employed	O
thus	O
demonstrating	O
the	O
ineffectiveness	O
in	O
controlling	O
vectors	O
and	O
 antimalarial drugs	S-Medication
requires	O
the	O
development	O
of	O
a	O
preventive	O
vaccine	O
Despite	O
having	O
a	O
vaccine	O
in	O
an	O
advanced	O
stage	O
of	O
development	O
such	O
as	O
the	O
RTS, S malaria vaccine	S-Medication
the	O
search	O
for	O
an	O
effective	O
vaccine	O
against	O
malaria	O
is	O
far	O
from	O
over	O
This	O
review	O
discusses	O
novel	O
strategies	O
for	O
malaria	O
vaccine	O
design	O
taking	O
into	O
account	O
the	O
target	O
stages	O
within	O
the	O
parasite	O
s	O
life	O
cycle	O
Canine babesiosis	S-Disease
 tick-borne 	B-Disease
protozoan	I-Disease
 disease	E-Disease
caused	O
by	O
intraerythrocytic	B-Organism
 parasites 	I-Organism
Environmental	O
stimuli	O
can	O
distress	O
the	O
internal	O
reaction	O
of	O
cells	O
and	O
their	O
normal	O
function	O
To	O
react	O
promptly	O
to	O
sudden	O
environmental	O
changes	O
a	O
cascade	O
of	O
heat	B-Protien
 shock	I-Protien
proteins	E-Protien
Hsps	S-Protien
functions	O
to	O
protect	O
and	O
act	O
as	O
housekeepers	O
inside	O
the	O
cells	O
In	O
parallel	O
to	O
the	O
heat	O
shock	O
response	O
the	O
metabolic	B-Chemical_Substance
 polyamin	I-Chemical_Substance
Hsps	S-Protien
polyamines	I-Chemical_Substance
parasitic	B-Organism
protozoa	I-Organism
eukaryotic model 	B-Organism
organisms 	I-Organism
PA	O
status	O
changes	O
Here	O
we	O
discuss	O
possible	O
ways	O
of	O
putative	O
interactions	O
between	O
with	O
a	O
particular	O
focus	O
on	O
in	O
a	O
wide	O
lineage	O
of	O
TORCH	B-Organism
 pathogens	I-Organism
are	O
a	O
group	O
of	O
globally	O
prevalent	O
infectious agents 	B-Organism
that	O
may	O
cross	O
the	O
placental	O
barrier	O
causing	O
s	O
neonates	S-Organism
in	O
including	O
fet	O
l	O
death	O
and	O
lifelong	O
morbidity	O
TORCH	O
infections	O
are	O
classically	O
defined	O
by	O
evere	O
n	O
egative	O
sequalae	O
in	O
Malaria	S-Disease
was	O
eradicated	O
in	O
Taiwan	O
in	O
1952	O
however	O
imported	O
malaria	S-Disease
s	O
are	O
reported	O
every	O
year	O
The	O
subtropical	O
climate	O
in	O
Taiwan	O
permits	O
mosquito 	S-Organism
ropagation	O
and	O
possible	O
outbreaks	O
mosquito-borne	B-Disease
diseases	I-Disease
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
travelers	O
compliance	O
and	O
side	O
effects	O
of	O
malaria	B-Medication
prophylaxis	B-Medication
to	O
prevent	O
a	O
malaria	O
outbreak	O
in	O
Taiwan	O
In	O
this	O
prospective	O
study	O
we	O
enrolled	O
travelers	O
who	O
visited	O
our	O
travel	O
clinic	O
before	O
going	O
to	O
mal	O
arious	O
areas	O
A	O
total	O
of	O
161	O
questionnaires	O
were	O
collected	O
and	O
analyzed	O
Associations	O
between	O
the	O
occurrence	O
of	O
side	O
effects	O
and	O
compliance	O
with	O
 antimalarial drug	S-Medication
were	O
analyzed	O
Adjusted	O
odds	O
ratios	O
were	O
calculated	O
after	O
adjusting	O
for	O
potential	O
risk	O
factors	O
in	O
multiple	O
logistic	O
regression	O
analysis	O
Of	O
the	O
161	O
enrolled	O
travelers	O
58	O
36	O
0	O
re	O
 Insomnia, somnolence, irritability, nausea,	S-Disease
anorexia	S-Disease
were	O
associated	O
with	O
poor	O
compliance	O
and	O
consequently	O
help	O
to	O
prevent	O
malaria	O
outbreaks	O
in	O
Taiwan	O
malaria 	B-Medication
prophylaxis	I-Medication
travel	O
clinic	O
more	O
than	O
1	O
week	O
before	O
the	O
trip	O
and	O
preferring	O
to	O
use	O
the	O
same	O
antimalarial	O
regimen	O
on	O
the	O
next	O
trip	O
Our	O
findings	O
could	O
provide	O
information	O
to	O
travelers	O
besides	O
labeled	O
side	O
effects	O
to	O
improve	O
compliance	O
with	O
compliance	O
was	O
affected	O
by	O
a	O
younger	O
age	O
visiting	O
friends	O
and	O
relatives	O
visiting	O
the	O
Mefloquine 	S-Medication
 doxycycline	S-Medication
was	O
not	O
associated	O
with	O
more	O
neuropsychological	O
side	O
effects	O
than	O
ported	O
side	O
effects	O
logistic	O
regression	O
analysis	O
showed	O
tha	O
Multiple	O
 chemoprophylaxis 	S-Medication
vector-borne	B-Disease
diseases	I-Disease
Efforts	O
to	O
eliminate	O
for	O
example	O
 malaria	S-Disease
which	O
caused	O
an	O
estimated	O
619	O
0	O
000	O
deaths	O
in	O
2021	O
The	O
identification	O
of	O
 mosquito	S-Organism
cytochrome	S_Anatomical_Substances
species	O
is	O
necessary	O
for	O
determining	O
the	O
entomological	O
components	O
of	O
disease	O
transmission	O
However	O
identification	O
can	O
be	O
difficult	O
in	O
species	O
that	O
are	O
morphologically	O
similar	O
The	O
 medicine	B-Medication
 tailored 	B-Medication
medical 	I-Medication
treatmen	E-Medication
antituberculosis drugs 	B-Chemical_Substance
bedaquiline 	I-Chemical_Substance
 linezolid	I-Chemical_Substance
antituberculosis	B-Chemical_Substance
antimalarial	I-Chemical_Substance
malaria	S-Disease
tuberculosis	S-Disease
artesunate, mefloquine,	S-Chemical_Substance
quinine, primaquine, and chloroquine.	S-Chemical_Substance
with	O
the	O
genotype	O
determining	O
the	O
therapeutic	O
strategy	O
the	O
appropriate	O
dosage	O
and	O
the	O
likelihood	O
of	O
benefit	O
or	O
toxicity	O
Cytochrome	O
P450	O
CYP	O
enzyme	O
families	O
1	O
2	O
and	O
3	O
play	O
a	O
pivotal	O
role	O
in	O
eliminating	O
most	O
drugs	O
Factors	O
that	O
affect	O
CYP	O
function	O
and	O
expression	O
have	O
a	O
major	O
impact	O
on	O
treatment	O
outcomes	O
Therefore	O
polymorphisms	O
of	O
these	O
enzymes	O
result	O
in	O
alleles	O
with	O
diverse	O
enzymatic	O
activity	O
and	O
drug	O
metabolism	O
phenotypes	O
Africa	O
has	O
the	O
highest	O
CYP	O
genetic	O
diversity	O
and	O
also	O
the	O
highest	O
burden	O
of	O
and	O
this	O
review	O
presents	O
current	O
general	O
information	O
on	O
CYP	O
enzymes	O
together	O
with	O
variation	O
data	O
concerning	O
antimalarial	O
and	O
antituberculosis	O
drugs	O
while	O
focusing	O
on	O
the	O
first	O
three	O
CYP	O
families	O
Afrocentric	O
alleles	O
such	O
as	O
CYP2A6	O
17	O
CYP2A6	O
23	O
CYP2A6	O
25	O
CYP2A6	O
28	O
CYP2B6	O
6	O
CYP2B6	O
18	O
CYP2C8	O
2	O
CYP2C9	O
5	O
CYP2C9	O
8	O
CYP2C9	O
9	O
CYP2C19	O
9	O
CYP2C19	O
13	O
CYP2C19	O
15	O
CYP2D6	O
2	O
CYP2D6	O
17	O
CYP2D6	O
29	O
and	O
CYP3A4	O
15	O
are	O
implicated	O
in	O
diverse	O
metabolic	O
phenotypes	O
of	O
different	O
antimalarials	O
such	O
as	O
and	O
other	O
drugs	O
are	O
explored	O
Moreover	O
a	O
mapping	O
of	O
Afrocentric	O
missense	O
mutations	O
to	O
CYP	O
structures	O
and	O
a	O
documentation	O
of	O
their	O
known	O
effects	O
provided	O
structural	O
insights	O
as	O
understanding	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
enzymes	O
and	O
how	O
the	O
different	O
alleles	O
influence	O
enzyme	O
function	O
is	O
invaluable	O
to	O
the	O
advancement	O
of	O
precision	O
medicine	O
Moreover	O
CYP3A4	O
CYP1A1	O
CYP2C8	O
CYP2C18	O
CYP2C19	O
CYP2J2	O
and	O
CYP1B1	O
are	O
implicated	O
in	O
the	O
polymorphisms	O
that	O
influence	O
the	O
metabolism	O
of	O
Drug	O
drug	O
interactions	O
induction	O
inhibition	O
and	O
enzyme	O
metabolism	O
of	O
some	O
second	O
line	O
 mosquitoes 	S-Organism
vector-borne	B-Disease
diseases 	I-Disease
malaria	S-Disease
dengue,	S-Disease
leishmaniasis.	S-Disease
he	O
diseases	O
transmitted	O
through	O
vectors	O
such	O
as	O
Anopheles	B-Organism
mosquitos	I-Organism
 Malaria 	S-Disease
spreads	O
by	O
a	O
vector	O
named	O
are	O
named	O
VBDs	O
such	O
a	O
 Dengue	S-Disease
is	O
transmitted	O
through	O
the	O
bite	O
of	O
the	O
 female vector 	B-Organism
Aedes	I-Organism
aegypt	I-Organism
 Aedes	B-Organism
 albopictus	I-Organism
mosquito	E-Organism
leishmaniasis	S-Disease
female	B-Organism
 Phlebotomine	I-Organism
 sandfly 	E-Organism
is	O
the	O
vec	O
tor	O
that	O
transmits	O
The	O
best	O
way	O
to	O
control	O
VBDs	O
is	O
to	O
identify	O
breeding	O
sites	O
for	O
their	O
vectors	O
This	O
can	O
be	O
efficiently	O
accomplished	O
by	O
the	O
Geographical	O
Information	O
System	O
GIS	O
The	O
objective	O
was	O
to	O
find	O
the	O
relation	O
between	O
climatic	O
factors	O
temperature	O
humidity	O
and	O
precipitation	O
to	O
identify	O
breeding	O
sites	O
for	O
these	O
vectors	O
Our	O
data	O
contained	O
imbalance	O
classes	O
so	O
data	O
oversampling	O
of	O
different	O
sizes	O
was	O
created	O
The	O
machine	O
learning	O
models	O
used	O
were	O
Light	O
Gradient	O
Boosting	O
Machine	O
Random	O
Forest	O
Decision	O
Tree	O
Support	O
Vector	O
Machine	O
and	O
Multi	O
Layer	O
Perceptron	O
for	O
model	O
training	O
Their	O
results	O
were	O
compared	O
and	O
analyzed	O
to	O
select	O
the	O
best	O
model	O
for	O
disease	O
prediction	O
in	O
Punjab	O
Pakistan	O
Random	O
Forest	O
was	O
the	O
selected	O
model	O
with	O
93	O
97	O
accuracy	O
Accuracy	O
was	O
measured	O
using	O
an	O
F	O
score	O
precision	O
or	O
recall	O
Temperature	O
precipitation	O
and	O
specific	O
humidity	O
significantly	O
affect	O
the	O
spread	O
of	O
dengue	S-Disease
malaria	S-Disease
 leishmaniasis	S-Disease
A	O
user	O
friendly	O
web	O
based	O
GIS	O
platform	O
was	O
also	O
developed	O
for	O
concerned	O
citizens	O
and	O
policymakers	O
Malaria	S-Disease
vector	O
surveillance	O
provides	O
important	O
data	O
to	O
inform	O
the	O
effective	O
planning	O
of	O
vector	O
control	O
interventions	O
at	O
a	O
local	O
level	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
species	O
diversity	O
and	O
abundance	O
biting	O
activity	O
and	O
Malaria 	S-Disease
 endemic	B-Disease
 disease	I-Disease
s	O
currently	O
a	O
in	O
Mexico	O
The	O
country	O
joined	O
the	O
WHO	O
s	O
E	O
25	O
initiative	O
for	O
the	O
elimination	O
of	O
Plasmodium	B-Organism
vivax	I-Organism
to	O
achieve	O
elimination	O
and	O
certification	O
within	O
the	O
established	O
period	O
Having	O
a	O
Web	O
based	O
information	O
system	O
was	O
therefore	O
deemed	O
necessary	O
to	O
assist	O
in	O
the	O
detection	O
investigation	O
and	O
elimination	O
of	O
transmission	O
in	O
the	O
foci	O
as	O
well	O
as	O
for	O
the	O
timely	O
treatment	O
of	O
malaria	O
positive	O
cases	O
The	O
Information	O
System	O
for	O
the	O
Elimination	O
of	O
Malaria	O
in	O
Mexico	O
was	O
designed	O
developed	O
and	O
implemented	O
with	O
a	O
geographic	O
vision	O
which	O
includes	O
a	O
Web	O
tool	O
to	O
georeference	O
homes	O
and	O
aquatic	O
systems	O
a	O
dashboard	O
and	O
an	O
indicator	O
evaluation	O
card	O
for	O
monitoring	O
activities	O
notification	O
of	O
probable	O
cases	O
and	O
vector	O
control	O
among	O
other	O
indicators	O
The	O
implementation	O
of	O
the	O
system	O
was	O
gradual	O
in	O
the	O
seven	O
states	O
that	O
are	O
currently	O
in	O
the	O
malaria	O
elimination	O
phase	O
subsequently	O
the	O
system	O
was	O
implemented	O
in	O
non	O
transmission	O
states	O
In	O
2020	O
the	O
system	O
implementation	O
stage	O
began	O
first	O
the	O
basic	O
data	O
of	O
more	O
than	O
96	O
000	O
homes	O
throughout	O
the	O
country	O
were	O
georeferenced	O
and	O
then	O
the	O
primary	O
data	O
capture	O
tools	O
of	O
17	O
formats	O
32	O
reports	O
and	O
2	O
geographic	O
viewers	O
were	O
enabled	O
for	O
information	O
queries	O
A	O
total	O
of	O
56	O
active	O
foci	O
have	O
been	O
identified	O
in	O
406	O
localities	O
as	O
well	O
as	O
71	O
residual	O
foci	O
in	O
320	O
localities	O
Recently	O
the	O
Foci	O
Manager	O
was	O
developed	O
which	O
is	O
a	O
specific	O
tool	O
for	O
the	O
study	O
evaluation	O
and	O
monitoring	O
of	O
active	O
foci	O
through	O
a	O
GIS	O
a	O
dashboard	O
and	O
a	O
systematized	O
evaluation	O
certificate	O
Georeferencing	O
tools	O
decreased	O
the	O
cost	O
of	O
spatial	O
data	O
collection	O
The	O
registration	O
of	O
individuals	O
with	O
designated	O
primary	O
medical	O
care	O
institutions	O
PMCIs	O
is	O
a	O
key	O
step	O
towards	O
their	O
empanelment	O
with	O
these	O
PMCIs	O
supported	O
by	O
the	O
Primary	O
Health	O
Care	O
System	O
Strengthening	O
Project	O
in	O
Sri	O
Lanka	O
We	O
conducted	O
an	O
explanatory	O
mixed	O
methods	O
study	O
to	O
assess	O
the	O
extent	O
of	O
registration	O
at	O
nine	O
selected	O
PMCIs	O
and	O
understand	O
the	O
challenges	O
therein	O
By	O
June	O
2021	O
36	O
999	O
19	O
2	O
95	O
CI	O
19	O
0	O
19	O
4	O
of	O
the	O
192	O
358	O
catchment	O
population	O
allotted	O
to	O
these	O
PMCIs	O
were	O
registered	O
At	O
this	O
rate	O
only	O
50	O
coverage	O
would	O
be	O
achieved	O
by	O
the	O
end	O
of	O
the	O
project	O
December	O
2023	O
Proportions	O
of	O
those	O
aged	O
35	O
years	O
and	O
males	O
among	O
those	O
registered	O
were	O
lower	O
compared	O
to	O
their	O
general	O
population	O
distribution	O
Awareness	O
activities	O
regarding	O
registration	O
were	O
conducted	O
in	O
most	O
of	O
the	O
PMCIs	O
but	O
awareness	O
in	O
the	O
community	O
was	O
low	O
Poor	O
registration	O
coverage	O
was	O
due	O
to	O
a	O
lack	O
of	O
dedicated	O
staff	O
for	O
registration	O
misconceptions	O
of	O
health	O
care	O
workers	O
about	O
individuals	O
needing	O
to	O
be	O
registered	O
reliance	O
on	O
opportunistic	O
or	O
passive	O
registration	O
and	O
lack	O
of	O
monitoring	O
mechanisms	O
these	O
were	O
further	O
compounded	O
by	O
the	O
 COVID-19	S-Disease
pandemic	O
Moving	O
forward	O
there	O
is	O
an	O
urgent	O
need	O
to	O
address	O
these	O
challenges	O
to	O
improve	O
registration	O
coverage	O
and	O
ensure	O
that	O
all	O
individuals	O
are	O
empaneled	O
before	O
the	O
close	O
of	O
the	O
project	O
for	O
it	O
to	O
have	O
a	O
meaningful	O
impact	O
Schistosomiasis	S-Disease
soil-transmitted	B-Disease
helminthiases	I-Disease
 parasitic diseases 	E-Disease
ainly	O
affecting	O
school	O
children	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
current	O
prevalence	O
and	O
infection	O
intensity	O
in	O
addition	O
to	O
the	O
associations	O
of	O
these	O
infections	O
with	O
age	O
and	O
sex	O
in	O
children	O
aged	O
4	O
17	O
years	O
living	O
in	O
Osun	O
State	O
Nigeria	O
From	O
each	O
participant	O
250	O
children	O
one	O
urine	O
and	O
one	O
stool	O
sample	O
were	O
taken	O
for	O
the	O
study	O
for	O
the	O
microscopic	O
detection	O
of	O
eggs	O
or	O
larvae	O
in	O
faeces	O
by	O
means	O
of	O
the	O
Kato	O
Katz	O
method	O
and	O
eggs	O
in	O
filtrated	O
u	O
urine	O
The	O
overall	O
prevalence	O
of	O
urinary	O
schistosomiasis 	S-Disease
 intestin	B-Organism
helminthic	I-Organism
species i	E-Organism
Maternal antibodies 	S_Anatomical_Substances
are	O
pa	O
vely	O
transferred	O
to	O
the	O
fetus	O
via	O
the	O
placenta	O
during	O
gestation	O
and	O
can	O
play	O
an	O
important	O
role	O
in	O
protecting	O
the	O
newborn	O
from	O
infection	O
For	O
example	O
in	O
malaria	O
endemic	O
regions	O
maternal	O
antibodies	O
likely	O
provide	O
substantial	O
protection	O
against	O
Malaria 	S-Disease
 deadliest	B-Disease
 infectious 	I-Disease
diseases	E-Disease
is	O
one	O
of	O
the	O
Licensed	O
vaccine	O
showed	O
just	O
over	O
30	O
of	O
efficacy	O
therefore	O
developing	O
new	O
vaccine	O
candidates	O
and	O
understanding	O
immune	O
responses	O
to	O
Plasmodium	B-Organism
is	O
necessary	O
malaria infection	S-Disease
 Plasmodium infection.	S-Disease
 cerebral	B-Disease
malaria	I-Disease
 Plasmodium infection	S-Disease
 malaria	S-Disease
malaria vaccine	B-Medication
malaria infection	S-Disease
γδ	O
T	O
cells	O
have	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
immune	O
responses	O
to	O
malaria	O
due	O
to	O
observation	O
of	O
γδ	O
T	O
cell	O
expansion	O
in	O
malaria	O
patients	O
and	O
experimental	O
models	O
of	O
malaria	O
γδ	O
T	O
cell	O
acts	O
both	O
innate	O
like	O
and	O
adaptive	O
like	O
cells	O
in	O
immune	O
response	O
to	O
malaria	O
Studies	O
have	O
found	O
that	O
γδ	O
T	O
cells	O
can	O
recognize	O
plasmodium	O
phosphoantigen	O
present	O
the	O
antigen	O
and	O
initiate	O
adaptive	O
immune	O
response	O
during	O
blood	O
stage	O
Recent	O
reports	O
also	O
suggested	O
phagocytic	O
and	O
cytotoxic	O
potential	O
of	O
γδ	O
T	O
cells	O
Furthermore	O
studies	O
suggested	O
that	O
γδ	O
T	O
cells	O
associate	O
protection	O
upon	O
immunization	O
with	O
whole	O
parasite	O
Also	O
γδ	O
T	O
cells	O
during	O
liver	O
stage	O
infection	O
were	O
able	O
to	O
prevent	O
experimental	O
Despite	O
these	O
new	O
findings	O
there	O
are	O
questions	O
related	O
to	O
γδ	O
T	O
cell	O
response	O
during	O
Especially	O
we	O
focus	O
on	O
the	O
mechanism	O
of	O
γδ	O
T	O
cell	O
associated	O
with	O
protective	O
immunity	O
during	O
malaria	O
infection	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
All	O
rights	O
reserved	O
remain	O
to	O
be	O
answered	O
Investigating	O
cells	O
in	O
human	O
is	O
difficult	O
in	O
many	O
ways	O
rodent	O
models	O
of	O
enable	O
to	O
study	O
the	O
cells	O
in	O
more	O
detail	O
The	O
insights	O
from	O
experimental	O
malaria	O
models	O
give	O
rise	O
to	O
new	O
cues	O
for	O
development	O
of	O
Here	O
we	O
review	O
our	O
current	O
knowledge	O
of	O
γδ	O
T	O
cell	O
immune	O
function	O
in	O
human	O
and	O
and	O
adjunctive	O
therapy	O
for	O
severe	O
 malaria	S-Disease
Measurement	O
of	O
prevalence	O
is	O
conventionally	O
estimated	O
through	O
infrequent	O
cross	O
sectional	O
household	O
surveys	O
that	O
do	O
not	O
provide	O
continuous	O
information	O
regarding	O
malaria 	B-Disease
parasitaemia	I-Disease
Recent	O
studies	O
have	O
suggested	O
that	O
malaria	B-Disease
parasitaemia	I-Disease
prevalence	O
among	O
women	O
attending	O
antenatal	O
care	O
ANC	O
correlates	O
with	O
prevalence	O
among	O
children	O
under	O
5	O
years	O
old	O
and	O
that	O
pregnant	O
women	O
could	O
be	O
a	O
sentinel	O
population	O
for	O
tracking	O
malaria	O
prevalence	O
In	O
mainland	O
Tanzania	O
97	O
of	O
women	O
are	O
tested	O
for	O
Measurement	O
malaria	B-Disease
parasitaemia 	I-Disease
during	O
first	O
ANC	O
visits	O
However	O
acceptability	O
among	O
pregnant	O
women	O
and	O
healthcare	O
providers	O
of	O
collecting	O
malaria	S-Disease
risk	O
factor	O
data	O
during	O
ANC	O
visits	O
is	O
limited	O
A	O
tablet	O
based	O
questionnaire	O
including	O
15	O
questions	O
on	O
insecticide	O
treated	O
net	O
ownership	O
and	O
use	O
and	O
care	O
seeking	O
for	O
febrile	O
children	O
was	O
introduced	O
at	O
40	O
healthcare	O
facilities	O
in	O
Geita	O
Region	O
Tanzania	O
Facilities	O
were	O
randomly	O
selected	O
from	O
among	O
those	O
with	O
15	O
120	O
first	O
ANC	O
visits	O
per	O
month	O
To	O
assess	O
perspectives	O
regarding	O
introduction	O
of	O
the	O
questionnaire	O
21	O
semi	O
structured	O
interviews	O
were	O
held	O
with	O
providers	O
and	O
facility	O
in	O
charges	O
at	O
12	O
facilities	O
Thirty	O
pregnant	O
and	O
recently	O
delivered	O
women	O
participated	O
in	O
focus	O
group	O
discussions	O
at	O
seven	O
facilities	O
to	O
assess	O
the	O
acceptability	O
of	O
spending	O
additional	O
time	O
answering	O
questions	O
about	O
malaria	O
risk	O
All	O
pregnant	O
women	O
reported	O
that	O
introduction	O
of	O
ANC	O
surveillance	O
and	O
spending	O
10	O
more	O
minutes	O
with	O
providers	O
answering	O
questions	O
about	O
their	O
health	O
would	O
be	O
neutral	O
or	O
beneficial	O
They	O
perceived	O
being	O
asked	O
about	O
their	O
health	O
as	O
standard	O
of	O
care	O
Providers	O
and	O
in	O
charges	O
reported	O
that	O
introduction	O
of	O
ANC	O
surveillance	O
was	O
within	O
their	O
scope	O
of	O
practice	O
Nine	O
of	O
21	O
indicated	O
it	O
could	O
potentially	O
benefit	O
women	O
s	O
health	O
Six	O
providers	O
expressed	O
concern	O
about	O
staffing	O
shortages	O
and	O
need	O
for	O
reimbursement	O
for	O
extra	O
time	O
and	O
noted	O
that	O
data	O
management	O
occurs	O
after	O
hours	O
nPregnant	O
women	O
and	O
providers	O
generally	O
perceived	O
ANC	O
surveillance	O
for	O
malaria	O
as	O
acceptable	O
and	O
positive	O
Pregnant	O
and	O
recently	O
delivered	O
women	O
saw	O
this	O
as	O
a	O
reasonable	O
and	O
even	O
helpful	O
intervention	O
To	O
be	O
seen	O
as	O
a	O
part	O
of	O
standard	O
practice	O
efforts	O
are	O
needed	O
to	O
ensure	O
providers	O
perceive	O
a	O
benefit	O
for	O
ANC	O
clients	O
and	O
that	O
staffing	O
concerns	O
are	O
addressed	O
In	O
addition	O
staff	O
should	O
receive	O
feedback	O
related	O
to	O
data	O
submissions	O
regarding	O
malaria	O
prevalence	O
and	O
risk	O
factors	O
among	O
women	O
at	O
their	O
facility	O
with	O
actions	O
to	O
take	O
vector-borne	B-Disease
diseases 	I-Disease
The	O
ecology	O
of	O
is	O
an	O
important	O
system	O
of	O
great	O
complexity	O
which	O
involves	O
the	O
knowledge	O
about	O
the	O
pathogens	S-Organism
animal species	S-Organism
entailed	O
in	O
maintaining	O
transmission	O
cycles	O
in	O
a	O
given	O
locality	O
including	O
those	O
that	O
act	O
as	O
vectors	O
and	O
reservoirs	O
for	O
the	O
transmitted	O
pathogens	S-Organism
To	O
understand	O
the	O
ecology	O
of	O
some	O
VBDs	O
we	O
studied	O
vectors	O
reservoirs	O
and	O
pathogens	O
of	O
different	O
VBDs	O
including	O
 dengue	S-Disease
leishmaniasis	S-Disease
Chagas	B-Disease
disease	I-Disease
, malaria	S-Disease
Zika	S-Disease
 chikungunya	S-Disease
in	O
the	O
municipality	O
of	O
La	O
Mesa	O
Cundinamarca	O
Colombia	O
a	O
locality	O
close	O
to	O
the	O
capital	O
Bogotá	O
Vectors	O
and	O
mammals	O
were	O
sampled	O
in	O
urban	O
and	O
rural	O
areas	O
between	O
May	O
and	O
August	O
2019	O
Molecular	O
analyses	O
were	O
performed	O
for	O
the	O
detection	O
of	O
 pathogens	S-Organism
mammals	S-Organism
and	O
vectors	O
and	O
of	O
blood	O
meal	O
sources	O
in	O
insects	O
Several	O
vectors	O
and	O
mammals	O
collected	O
in	O
this	O
study	O
have	O
been	O
involved	O
in	O
pathogen	O
transmission	O
cycles	O
or	O
may	O
have	O
a	O
potential	O
role	O
in	O
them	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
in	O
the	O
municipality	O
of	O
La	O
Mesa	O
there	O
are	O
both	O
vector	O
and	O
potential	O
reservoir	O
species	O
which	O
are	O
or	O
could	O
be	O
implicated	O
in	O
the	O
maintenance	O
of	O
the	O
cycles	O
of	O
vector-borne 	B-Disease
diseases	I-Disease
leishmaniasis	E-Disease
Chagas	B-Disease
disease.	I-Disease
arbovirus infections,	B-Disease
dengu	I-Disease
are	O
reported	O
in	O
the	O
municipality	O
arbovirus	O
presence	O
was	O
not	O
detected	O
These	O
findings	O
highlight	O
the	O
importance	O
of	O
ongoing	O
surveillance	O
of	O
vectors	O
and	O
associated	O
control	O
operations	O
in	O
La	O
Mesa	O
of	O
relevance	O
to	O
other	O
locations	O
where	O
vectors	O
and	O
animal	O
hosts	O
also	O
occur	O
 thick 	B-Anatomical_Substances
blood smear	I-Anatomical_Substances
malaria	B-Disease
associated with	I-Disease
pregnancy	E-Disease
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
accuracy	O
of	O
the	O
TBS	O
versus	O
quantitative	O
polymerase	O
chain	O
reaction	O
qPCR	O
for	O
the	O
diagnosis	O
Background	O
Angola	O
is	O
among	O
the	O
high	O
burden	O
countries	O
with	O
malaria	S-Disease
cases	O
globally	O
After	O
2013	O
we	O
suspected	O
an	O
increase	O
in	O
the	O
number	O
of	O
malaria	S-Disease
cases	O
in	O
Cubal	O
Angola	O
previously	O
in	O
decline	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
incidence	O
rate	O
in	O
Cubal	O
overall	O
and	O
by	O
neighborhood	O
for	O
2014	O
2015	O
and	O
2016	O
2	O
Methods	O
A	O
retrospective	O
observational	O
study	O
was	O
performed	O
in	O
Cubal	O
Angola	O
from	O
January	O
2014	O
to	O
December	O
2016	O
including	O
all	O
patients	O
with	O
a	O
microbiologically	O
confirmed	O
diagnosis	O
treated	O
at	O
Cubal	O
s	O
Hospitals	O
for	O
this	O
period	O
of	O
time	O
The	O
principal	O
variables	O
calculated	O
were	O
the	O
incidence	O
rates	O
of	O
2014	O
2015	O
and	O
2016	O
in	O
Cubal	O
overall	O
and	O
by	O
neighborhood	O
3	O
Results	O
There	O
were	O
3249	O
malaria	O
cases	O
The	O
incidence	O
rates	O
were	O
2	O
27	O
10	O
73	O
and	O
12	O
40	O
cases	O
per	O
1000	O
inhabitants	O
in	O
2014	O
2015	O
and	O
2016	O
respectively	O
In	O
the	O
neighborhood	O
Hamavoko	O
Kasseke	O
there	O
was	O
a	O
10	O
73	O
fold	O
increase	O
in	O
incidence	O
during	O
this	O
period	O
Additionally	O
Hamavoko	O
Kasseke	O
presents	O
an	O
anomalous	O
distribution	O
of	O
malaria	O
cases	O
4	O
Conclusions	O
We	O
observed	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
malaria	O
in	O
Cubal	O
during	O
the	O
three	O
year	O
study	O
period	O
The	O
case	O
distribution	O
was	O
highly	O
heterogeneous	O
with	O
hyperendemic	O
areas	O
and	O
we	O
found	O
a	O
chronobiological	O
association	O
between	O
the	O
construction	O
of	O
a	O
civil	O
engineering	O
project	O
This	O
information	O
could	O
be	O
useful	O
for	O
deciding	O
which	O
malaria	O
control	O
strategies	O
must	O
be	O
implemented	O
in	O
this	O
area	O
viral, bacterial, metabolic, and autoimmune 	B-Disease
diseases	I-Disease
To	O
assess	O
whether	O
are	O
missed	O
by	O
conventional	O
diagnostics	O
among	O
children	O
with	O
severe	B-Disease
acute encephalopathy	I-Disease
in	O
sub	O
Saharan	O
Africa	O
One	O
hundred	O
and	O
thirty	O
four	O
children	O
6m	O
18y	O
presenting	O
with	O
non	O
traumatic	O
coma	O
or	O
convulsive	O
status	O
epilepticus	S-Disease
to	O
one	O
of	O
four	O
medical	O
referral	O
centers	O
in	O
Uganda	O
Malawi	O
and	O
Rwanda	O
were	O
enrolled	O
between	O
2015	O
and	O
2016	O
Locally	O
available	O
diagnostic	O
tests	O
could	O
be	O
supplemented	O
in	O
117	O
patients	O
by	O
viral	O
bacterial	O
and	O
16s	O
quantitative	O
polymerase	O
chain	O
reaction	O
testing	O
metagenomics	O
untargeted	O
metabolomics	O
and	O
autoimmune	O
immunohistochemistry	O
screening	O
viral	B-Disease
 encephalopathies	I-Disease
 severe	B-Disease
acute	I-Disease
encephalopathy	S-Disease
 autoimmune	B-Disease
encephalitis	I-Disease
inherited	O
metabolic	O
disorders	O
IMDs	O
were	O
newly	O
identified	O
by	O
additional	O
diagnostic	O
testing	O
as	O
the	O
most	O
likely	O
cause	O
of	O
 encephalopathy	S-Disease
in	O
children	O
in	O
Uganda	O
Malawi	O
and	O
Rwanda	O
that	O
are	O
missed	O
by	O
conventional	O
diagnostics	O
and	O
are	O
associated	O
with	O
poor	O
outcome	O
of	O
disease	O
Improved	O
diagnostic	O
capacity	O
may	O
increase	O
diagnostic	O
yield	O
and	O
might	O
improve	O
outcome	O
of	O
disease	O
were	O
found	O
Patients	O
for	O
whom	O
additional	O
diagnostic	O
testing	O
aided	O
causal	O
evaluation	O
adjusted	O
odds	O
ratio	O
AOR	O
3	O
59	O
90	O
confidence	O
interval	O
1	O
57	O
8	O
36	O
patients	O
with	O
a	O
viral	O
CNS	O
infection	O
AOR	O
7	O
91	O
90	O
CI	O
2	O
49	O
30	O
07	O
and	O
patients	O
with	O
an	O
IMD	O
AOR	O
9	O
10	O
90	O
CI	O
1	O
37	O
110	O
45	O
were	O
at	O
increased	O
risk	O
for	O
poor	O
outcome	O
of	O
disease	O
Viral	O
and	O
bacterial	O
CNS	O
infections	O
and	O
IMDs	O
are	O
prevalent	O
causes	O
of	O
eight	O
7	O
cases	O
of	O
bacterial	O
central	O
nervous	O
system	O
CNS	O
infections	O
and	O
four	O
4	O
cases	O
Malaria	S-Disease
imposes	O
an	O
economic	O
burden	O
for	O
human	O
populations	O
in	O
many	O
African	O
countries	O
and	O
this	O
burden	O
may	O
be	O
reduced	O
through	O
house	O
screening	O
initiatives	O
We	O
use	O
a	O
randomized	O
controlled	O
trial	O
to	O
measure	O
the	O
economic	O
impacts	O
of	O
house	O
screening	O
against	O
 malaria 	B-Disease
infection.	I-Disease
We	O
use	O
a	O
sample	O
of	O
800	O
households	O
from	O
89	O
villages	O
in	O
rural	O
and	O
peri	O
urban	O
Zambia	O
to	O
collect	O
baseline	O
data	O
in	O
August	O
2019	O
and	O
endline	O
data	O
in	O
August	O
2020	O
The	O
main	O
outcome	O
variables	O
are	O
self	O
reported	O
malaria	O
prevalence	O
rates	O
labor	O
supply	O
and	O
income	O
and	O
consider	O
individual	O
and	O
household	O
level	O
outcomes	O
House	O
screening	O
reduces	O
malaria	O
prevalence	O
the	O
number	O
of	O
sick	O
days	O
due	O
to	O
malaria	O
and	O
the	O
number	O
of	O
malaria	O
episodes	O
Impacts	O
on	O
adults	O
are	O
more	O
pronounced	O
than	O
on	O
children	O
In	O
terms	O
of	O
economic	O
impacts	O
house	O
screening	O
increases	O
labor	O
supply	O
and	O
household	O
income	O
We	O
find	O
particularly	O
large	O
effects	O
on	O
labor	O
supply	O
for	O
women	O
household	O
members	O
A	O
cost	O
benefit	O
analysis	O
based	O
on	O
estimated	O
benefits	O
and	O
measured	O
costs	O
suggests	O
that	O
the	O
private	O
benefits	O
of	O
house	O
screening	O
exceed	O
the	O
costs	O
While	O
not	O
all	O
houses	O
are	O
suitable	O
for	O
house	O
screening	O
we	O
conclude	O
that	O
screening	O
is	O
a	O
promising	O
and	O
cost	O
effective	O
approach	O
to	O
reduce	O
malaria	O
infections	O
foodborne	B-Organism
pathogen	I-Organism
Cyclospora spp.	E-Organism
Cyclospora sp	S-Organism
Hierarchical	O
clustering	O
of	O
pathogen	O
genotypes	O
is	O
widely	O
used	O
to	O
complement	O
epidemiologic	O
investigations	O
of	O
outbreaks	O
Investigators	O
must	O
dissect	O
trees	O
to	O
obtain	O
genetic	O
partitions	O
that	O
provide	O
epidemiologists	O
with	O
meaningful	O
information	O
Statistical	O
approaches	O
to	O
tree	O
dissection	O
often	O
require	O
a	O
user	O
defined	O
parameter	O
to	O
predict	O
the	O
optimal	O
partition	O
number	O
and	O
augmenting	O
this	O
parameter	O
can	O
drastically	O
impact	O
resultant	O
partition	O
memberships	O
Here	O
we	O
demonstrate	O
how	O
to	O
optimize	O
a	O
given	O
tree	O
dissection	O
parameter	O
to	O
maximize	O
accuracy	O
irrespective	O
of	O
the	O
tree	O
dissection	O
method	O
used	O
We	O
hierarchically	O
clustered	O
1	O
873	O
genotypes	O
of	O
the	O
including	O
587	O
possessing	O
links	O
to	O
historic	O
outbreaks	O
We	O
dissected	O
the	O
resulting	O
tree	O
using	O
a	O
statistical	O
method	O
requiring	O
users	O
to	O
select	O
the	O
value	O
of	O
a	O
stringency	O
parameter	O
s	O
with	O
a	O
recommended	O
value	O
of	O
95	O
to	O
99	O
5	O
We	O
dissected	O
this	O
hierarchical	O
tree	O
across	O
s	O
values	O
from	O
94	O
to	O
99	O
5	O
at	O
increments	O
of	O
0	O
25	O
to	O
identify	O
a	O
value	O
that	O
maximized	O
partitioning	O
accuracy	O
defined	O
as	O
the	O
degree	O
to	O
which	O
genetic	O
partitions	O
conform	O
to	O
known	O
epidemiologic	O
groupings	O
We	O
show	O
that	O
s	O
values	O
of	O
96	O
5	O
and	O
96	O
75	O
yield	O
the	O
highest	O
accuracy	O
99	O
9	O
when	O
clustering	O
isolates	O
with	O
known	O
epidemiologic	O
linkages	O
In	O
practice	O
the	O
optimized	O
s	O
value	O
will	O
generate	O
robust	O
genetic	O
partitions	O
comprising	O
isolates	O
likely	O
derived	O
from	O
a	O
common	O
food	O
source	O
even	O
when	O
the	O
epidemiologic	O
grouping	O
is	O
not	O
known	O
prior	O
to	O
genetic	O
clustering	O
While	O
the	O
s	O
value	O
is	O
specific	O
to	O
the	O
tree	O
dissection	O
method	O
used	O
here	O
the	O
optimization	O
approach	O
described	O
could	O
be	O
applied	O
to	O
any	O
parameter	O
method	O
used	O
to	O
dissect	O
hierarchical	O
trees	O
Parasitic	B-Disease
diseases,	I-Disease
protozoans	S-Organism
 helminths	S-Organism
 malaria	S-Disease
trypanosomiasis, 	S-Disease
leishmaniasis,	S-Disease
Chagas disease,	S-Disease
schistosomiasis	S-Disease
onchocerciasis	S-Disease
 lymphatic filariasis	S-Disease
especially	O
those	O
caused	O
by	O
morbidities	S-Disease
are	O
the	O
cause	O
of	O
millions	O
of	O
and	O
deaths	O
every	O
year	O
mainly	O
in	O
tropical	O
regions	O
antiparasitic	B-Medication
agents	I-Medication
Nature	O
has	O
always	O
provided	O
valuable	O
and	O
efforts	O
targeting	O
the	O
identification	O
of	O
antiparasitic	B-Medication
drugs	I-Medication
from	O
plants	O
have	O
mainly	O
focused	O
on	O
glycophytes	S-Organism
However	O
 salt-tolerant 	B-Organism
plants	I-Organism
halophytes)	S-Organism
have	O
lately	O
attracted	O
the	O
interest	O
of	O
the	O
scientific	O
community	O
due	O
to	O
their	O
medicinal	O
assets	O
which	O
include	O
antiparasitic	O
properties	O
This	O
review	O
paper	O
gathers	O
the	O
most	O
relevant	O
information	O
on	O
antiparasitic	O
properties	O
of	O
halophyte	B-Organism
plants	I-Organism
human	S-Organism
targeting	O
uses	O
It	O
includes	O
an	O
introduction	O
section	O
containing	O
a	O
summary	O
of	O
some	O
of	O
the	O
most	O
pertinent	O
characteristics	O
of	O
halophytes	S-Organism
followed	O
by	O
information	O
rega	O
rding	O
the	O
ethnomedicinal	O
uses	O
of	O
several	O
species	O
towards	O
human	S-Organism
parasitic	B-Disease
diseases	I-Disease
Then	O
information	O
is	O
provided	O
related	O
to	O
the	O
antiprotozoal	O
and	O
anthelmintic	O
properties	O
of	O
halophytes	O
determined	O
by	O
in	O
vitro	O
and	O
in	O
vivo	O
methods	O
and	O
with	O
the	O
bioactive	O
metabolites	O
that	O
may	O
be	O
related	O
to	O
such	O
properties	O
Finally	O
a	O
conclusion	O
section	O
is	O
presented	O
addressing	O
perspectives	O
for	O
the	O
sustainable	O
exploitation	O
of	O
selected	O
species	O
This	O
evidence	O
synthesis	O
aimed	O
at	O
assessing	O
the	O
effectiveness	O
of	O
Faith	O
Based	O
Organisations	O
FBOs	O
on	O
Maternal	O
and	O
Child	O
Health	O
MCH	O
outcomes	O
and	O
explore	O
the	O
perceptions	O
and	O
experiences	O
of	O
the	O
users	O
and	O
providers	O
of	O
MCH	O
services	O
delivered	O
by	O
FBOs	O
in	O
Africa	O
This	O
review	O
considered	O
studies	O
from	O
African	O
countries	O
only	O
Both	O
reviews	O
and	O
primary	O
studies	O
focusing	O
on	O
MCH	O
services	O
provided	O
by	O
FBOs	O
were	O
considered	O
Quantitative	O
qualitative	O
and	O
mixed	O
methods	O
reviews	O
were	O
included	O
with	O
no	O
restriction	O
on	O
the	O
date	O
and	O
language	O
Primary	O
outcomes	O
included	O
maternal	O
mortality	O
ratio	O
neonatal	O
mortality	O
infant	O
mortality	O
child	O
mortality	O
quality	O
of	O
care	O
views	O
experiences	O
and	O
perceptions	O
of	O
users	O
of	O
FBOs	O
We	O
searched	O
up	O
to	O
November	O
2020	O
in	O
the	O
Joanna	O
Briggs	O
Institute	O
JBI	O
Database	O
of	O
Systematic	O
Reviews	O
and	O
Implementation	O
Reports	O
the	O
Cochrane	O
Database	O
of	O
Systematic	O
Reviews	O
Database	O
of	O
Abstracts	O
of	O
Reviews	O
of	O
Effects	O
PROSPERO	O
register	O
PDQ	O
evidence	O
Health	O
Systems	O
Evidence	O
CINAHL	O
EMBASE	O
and	O
PubMed	O
We	O
searched	O
references	O
cited	O
by	O
similar	O
studies	O
that	O
may	O
be	O
potentially	O
eligible	O
for	O
inclusion	O
We	O
then	O
updated	O
the	O
search	O
for	O
primary	O
studies	O
from	O
December	O
2009	O
October	O
2020	O
One	O
systematic	O
review	O
and	O
six	O
primary	O
studies	O
met	O
the	O
eligibility	O
criteria	O
for	O
inclusion	O
Methodological	O
quality	O
varied	O
These	O
observational	O
and	O
qualitative	O
studies	O
found	O
that	O
FBOs	O
offered	O
the	O
following	O
MCH	O
services	O
training	O
of	O
healthcare	O
workers	O
obstetric	O
services	O
health	O
promotion	O
sexual	O
education	O
immunization	O
services	O
and	O
intermittent	O
preventive	O
therapy	O
for	O
malaria	O
Maternal	O
and	O
Child	O
Health	O
MCH	O
services	O
provided	O
by	O
FBO	O
suggest	O
a	O
reduction	O
in	O
maternal	O
morbidity	O
and	O
mortality	O
Increased	O
uptake	O
of	O
maternal	O
healthcare	O
services	O
and	O
increased	O
satisfaction	O
were	O
reported	O
by	O
users	O
of	O
care	O
However	O
costs	O
of	O
providing	O
these	O
services	O
varied	O
across	O
the	O
studies	O
and	O
users	O
This	O
review	O
shows	O
that	O
FBOs	O
play	O
an	O
important	O
role	O
in	O
improving	O
access	O
and	O
delivery	O
of	O
MCH	O
services	O
and	O
have	O
the	O
potential	O
of	O
strengthening	O
the	O
health	O
system	O
at	O
large	O
Rigorous	O
research	O
is	O
needed	O
to	O
ascertain	O
the	O
effectiveness	O
of	O
FBO	O
based	O
interventions	O
in	O
strengthening	O
the	O
health	O
systems	O
in	O
Africa	O
malaria	B-Organism
parasites.	I-Organism
Changes	O
in	O
the	O
copy	O
number	O
of	O
large	O
genomic	O
regions	O
termed	O
copy	O
number	O
variations	O
or	O
CNVs	O
are	O
an	O
important	O
adaptive	O
strategy	O
for	O
Numerous	O
CNVs	O
across	O
the	O
Malaria	S-Disease
life-threatening	B-Disease
parasitic	I-Disease
disease 	E-Disease
that	O
continues	O
to	O
infect	O
millions	O
of	O
people	O
especially	O
in	O
endemic	O
regions	O
Despite	O
advancements	O
in	O
malaria	O
treatment	O
treating	O
the	O
disease	O
remains	O
challenging	O
One	O
major	O
challenge	O
is	O
identifying	O
the	O
disease	O
from	O
its	O
unconventional	O
manifestations	O
Therefore	O
recognizing	O
its	O
unusual	O
clinical	O
presentations	O
is	O
imperative	O
in	O
early	O
detection	O
and	O
management	O
with	O
a	O
better	O
prognosis	O
This	O
case	O
report	O
highlights	O
the	O
unique	O
finding	O
of	O
paralytic ileus	S-Disease
malaria	S-Disease
from	O
a	O
patient	O
with	O
confirmed	O
Further	O
investigation	O
on	O
the	O
concurrence	O
between	O
paralytic	S-Disease
ileus	S-Disease
malaria	S-Disease
may	O
aid	O
in	O
identifying	O
the	O
disease	O
and	O
subsequent	O
improvement	O
in	O
treatment	O
Malaria 	S-Disease
deaths	O
among	O
children	O
have	O
been	O
declining	O
worldwide	O
during	O
the	O
last	O
two	O
decades	O
Despite	O
preventive	O
epidemiologic	O
and	O
therapy	O
development	O
work	O
mortality	O
rate	O
decline	O
has	O
stagnated	O
in	O
western	O
Kenya	O
resulting	O
in	O
persistently	O
high	O
child	O
malaria	O
morbidity	O
and	O
mortality	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
public	O
health	O
determinants	O
influencing	O
the	O
high	O
burden	O
of	O
malaria	O
deaths	O
among	O
children	O
in	O
this	O
region	O
nA	O
total	O
of	O
221	O
929	O
children	O
111	O
488	O
females	O
and	O
110	O
441	O
males	O
under	O
the	O
age	O
of	O
5	O
years	O
were	O
enrolled	O
in	O
the	O
Kenya	O
Medical	O
Research	O
Institute	O
Center	O
for	O
Disease	O
Control	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
KEMRI	O
CDC	O
HDSS	O
study	O
area	O
in	O
Siaya	O
County	O
during	O
the	O
period	O
2003	O
2013	O
Cause	O
of	O
death	O
was	O
determined	O
by	O
use	O
of	O
verbal	O
autopsy	O
Age	O
specific	O
mortality	O
rates	O
were	O
computed	O
and	O
cox	O
proportional	O
hazard	O
regression	O
was	O
used	O
to	O
model	O
time	O
to	O
malaria	O
death	O
controlling	O
for	O
the	O
socio	O
demographic	O
factors	O
A	O
variety	O
of	O
demographic	O
social	O
and	O
epidemiologic	O
factors	O
were	O
examined	O
In	O
total	O
8	O
696	O
3	O
9	O
children	O
died	O
during	O
the	O
study	O
period	O
Malaria 	S-Disease
HIV/AIDS 	S-Disease
was	O
the	O
most	O
prevalent	O
cause	O
of	O
death	O
and	O
constituted	O
33	O
2	O
of	O
all	O
causes	O
of	O
death	O
followed	O
by	O
acute	B-Disease
respiratory	I-Disease
infections	E-Disease
elated	O
deaths	O
18	O
6	O
There	O
was	O
a	O
marked	O
decrease	O
in	O
overall	O
mortality	O
rate	O
from	O
2003	O
to	O
2013	O
except	O
for	O
a	O
spike	O
in	O
the	O
rates	O
in	O
2008	O
The	O
hazard	O
of	O
death	O
differed	O
between	O
age	O
groups	O
with	O
the	O
youngest	O
having	O
the	O
highest	O
hazard	O
of	O
death	O
HR	O
6	O
07	O
95	O
CI	O
5	O
10	O
7	O
22	O
Overall	O
the	O
risk	O
attenuated	O
with	O
age	O
and	O
mortality	O
risks	O
were	O
limited	O
beyond	O
4	O
years	O
of	O
age	O
Longer	O
distance	O
to	O
healthcare	O
HR	O
of	O
1	O
44	O
95	O
CI	O
1	O
29	O
1	O
60	O
l	O
ow	O
maternal	O
education	O
HR	O
3	O
91	O
95	O
CI	O
1	O
86	O
8	O
22	O
and	O
low	O
socioeconomic	O
status	O
HR	O
1	O
44	O
95	O
CI	O
1	O
26	O
1	O
64	O
were	O
all	O
significantly	O
associated	O
with	O
increased	O
hazard	O
of	O
malaria	O
death	O
among	O
children	O
nWhile	O
child	O
mortality	O
due	O
to	O
malaria	O
in	O
the	O
study	O
area	O
in	O
Western	O
Kenya	O
has	O
been	O
decreasing	O
a	O
final	O
step	O
toward	O
significant	O
risk	O
reduction	O
is	O
yet	O
to	O
be	O
accomplished	O
This	O
study	O
highlights	O
residual	O
proximal	O
determinants	O
of	O
risk	O
which	O
can	O
further	O
inform	O
preventive	O
actions	O
sporozoite	S-Organism
malaria	B-Organism
parasites	I-Organism
are	O
the	O
primary	O
cause	O
of	O
infection	O
of	O
the	O
vertebrate	O
host	O
and	O
are	O
targeted	O
by	O
experimental	O
vaccines	O
Yet	O
little	O
is	O
known	O
about	O
their	O
susceptibility	O
to	O
chemical	O
intervention	O
Phenotypic	O
high	O
throughput	O
screens	O
have	O
not	O
been	O
feasible	O
due	O
to	O
a	O
lack	O
of	O
in	O
vitro	O
systems	O
Here	O
we	O
tested	O
78	O
marketed	O
and	O
experimental	O
antimalarial	B-Chemical_Substance
compounds	I-Chemical_Substance
in	O
miniaturized	O
assays	O
addressing	O
sporozoite	O
viability	O
gliding	O
motility	O
hepatocyte	O
traversal	O
and	O
intrahepatocytic	O
schizogony	O
None	O
potently	O
interfered	O
with	O
sporozoite	O
viability	O
or	O
motility	O
but	O
ten	O
compounds	O
acted	O
at	O
the	O
level	O
of	O
schizogony	O
with	O
IC50s	O
100	O
nM	O
To	O
identify	O
compounds	O
directly	O
targeting	O
 sporozoites	S-Organism
we	O
screened	O
81	O
000	O
compounds	O
from	O
the	O
Global	O
Health	O
Diversity	O
and	O
reFRAME	O
libraries	O
in	O
a	O
porozoite	S-Organism
viability	O
assay	O
using	O
a	O
parasite	O
expressing	O
a	O
luciferase	B-Chemical_Substance
circumsporozoite 	S-Protien
 ionophore	B-Chemical_Substance
gramicidin	I-Chemical_Substance
emerged	O
as	O
the	O
single	O
hit	O
from	O
this	O
screening	O
campaign	O
Its	O
effect	O
on	O
sporozoite	S-Organism
viability	O
translated	O
into	O
reduced	O
gliding	O
motility	O
and	O
an	O
inability	O
of	O
sporozoites 	S-Organism
to	O
invade	O
human	B-Anatomical_Substances
primary 	I-Anatomical_Substances
hepatocytes	E-Anatomical_Substances
and	O
develop	O
into	O
hepatic 	B-Organism
schizonts	I-Organism
While	O
providing	O
proof	O
of	O
concept	O
for	O
a	O
small	O
molecule	O
sporontocidal	O
mode	O
of	O
action	O
our	O
combined	O
data	O
indicate	O
that	O
liver	S_Anatomical_Substances
schizogony	O
is	O
more	O
accessible	O
to	O
chemical	O
intervention	O
by	O
candidate	O
antimalarials	O
The malaria 	S-Disease
parasite	B-Organism
Plasmodium	I-Organism
falciparum	E-Organism
causes	O
substantial	O
human	S-Organism
mortality	O
primarily	O
in	O
equatorial	O
Africa	O
Enriched	O
in	O
affected	O
African	O
populations	O
the	O
 B*53	B-Protien
variant of	I-Protien
 HLA-B	S-Protien
a	O
cell	O
surface	O
protein	O
that	O
presents	O
peptide	B-Protien
antigens	I-Protien
cytotoxic	B-Anatomical_Substances
lymphocytes	I-Anatomical_Substances
confers	O
protection	O
against	O
severe	O
 malaria.	S-Disease
Gorilla, 	S-Organism
chimpanzee	S-Organism
bonobo	S-Organism
humans'	S-Organism
losest	O
living	O
relatives	O
These	O
African	O
apes	O
have	O
HLA-B 	S-Protien
 parasites	S-Organism
P. falciparum	S-Organism
Laverania	S-Organism
in	O
the	O
same	O
subgenus	O
but	O
the	O
consequences	O
of	O
these	O
infections	O
are	O
unclear	O
 Laverania 	B-Organism
parasites	I-Organism
bonobos 	S-Organism
Pan	B-Organism
paniscus	I-Organism
at	O
only	O
one	O
TL2	O
of	O
many	O
sites	O
sampled	O
across	O
their	O
range	O
bonobo	S-Organism
Papa-B	B-Anatomical_Substances
supertype	O
profile	O
Here	O
we	O
show	O
that	O
B07	O
Papa	O
B	O
occur	O
at	O
high	O
frequency	O
in	O
TL2	O
bonobos	O
and	O
that	O
malaria	O
appears	O
to	O
have	O
independently	O
selected	O
for	O
different	O
B07	O
alleles	O
in	O
the	O
two	O
subpopulations	O
ortholog	O
of	O
HLA	O
B	O
includes	O
variants	O
having	O
a	O
B	O
53	O
like	O
B07	O
peptide	O
binding	O
subpopulations	O
of	O
bonobos	O
on	O
each	O
side	O
TL2	O
spans	O
the	O
Lomami	O
River	O
and	O
has	O
genetically	O
divergent	O
malaria 	B-Organism
parasites 	I-Organism
A	O
fast	O
simple	O
easy	O
efficient	O
and	O
inexpensive	O
method	O
for	O
DNA	O
extraction	O
from	O
collected	O
on	O
filter	O
paper	O
would	O
be	O
very	O
useful	O
for	O
molecular	O
surveillance	O
The	O
quality	O
and	O
quantity	O
of	O
DNA	O
are	O
critical	O
to	O
molecular	O
diagnosis	O
and	O
analysis	O
Here	O
we	O
developed	O
a	O
simple	O
alkali	O
lysis	O
method	O
for	O
DNA	O
extraction	O
from	O
blood 	S_Anatomical_Substances
samples	O
on	O
filter	O
paper	O
The	O
results	O
showed	O
that	O
10	O
50	O
mM	O
NaOH	S-Chemical_Substance
 deionized	B-Chemical_Substance
water	I-Chemical_Substance
all	O
effectively	O
isolated	O
parasite	B-Organism
 parasitemia	S-Disease
 parasitemia	S-Disease
as	O
witnessed	O
by	O
successful	O
PCR	O
amplification	O
while	O
at	O
a	O
of	O
0	O
01	O
the	O
10	O
mM	O
 NaOH	S-Chemical_Substance
lysis	O
condition	O
generated	O
the	O
best	O
results	O
Furthermore	O
DNA	O
extracted	O
by	O
this	O
method	O
was	O
successfully	O
used	O
to	O
amplify	O
a	O
fragment	O
of	O
2000	O
bp	O
This	O
method	O
successfully	O
extracted	O
DNA	O
from	O
1	O
µl	O
of	O
blood	S_Anatomical_Substances
 parasitemia 	S-Disease
as	O
low	O
as	O
0	O
0001	O
equivalent	O
to	O
5	O
parasites	O
µl	O
The	O
DNA	O
isolated	O
by	O
the	O
10	O
mM	O
NaOH	S-Chemical_Substance
 Plasmodium	S-Organism
lysis	O
method	O
was	O
stable	O
to	O
yield	O
PCR	O
products	O
after	O
storage	O
at	O
4	O
C	O
or	O
20	O
C	O
for	O
12	O
months	O
These	O
results	O
indicate	O
that	O
this	O
alkali	O
lysis	O
method	O
is	O
simple	O
effective	O
sensitive	O
and	O
inexpensive	O
for	O
isolating	O
stable	O
DNA	O
from	O
dried	O
blood	O
spots	O
on	O
filter	O
paper	O
 Plasmodium	B-Organism
 falciparum	I-Organism
mefloquine	S-Medication
Declining	O
in	O
susceptibility	O
of	O
is reported in South-East Asia. A revisiting on	B-Medication
mefloquine	B-Medication
 pharmacokinetics-	I-Medication
pharmacodynamics 	E-Medication
could	O
assist	O
in	O
finding	O
new	O
appropriate	O
dosage	O
regimens	O
in	O
combination	O
with	O
artesunate	O
as	O
a	O
three	O
day	O
course	O
treatment	O
nThis	O
study	O
aimed	O
to	O
investigate	O
promising	O
alternative	O
artesunate-mefloquine 	S-Medication
combination	O
regimens	O
that	O
are	O
effective	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
mefloquine	S-Medication
P. falciparum	B-Organism
malaria.	I-Organism
Data	O
collected	O
during	O
2008	O
2009	O
from	O
124	O
patients	O
with	O
uncomplicated	O
 P. falciparum 	B-Organism
malaria 	I-Organism
were	O
included	O
in	O
the	O
analysis	O
90	O
and	O
34	O
patients	O
with	O
sensitive	O
and	O
recrudescence	O
response	O
respectively	O
All	O
patients	O
were	O
treated	O
with	O
a	O
three	O
day	O
combination	O
of	O
 artesunate-mefloquine	S-Medication
Population	O
PK	O
PD	O
models	O
were	O
developed	O
The	O
developed	O
models	O
were	O
validated	O
with	O
clinically	O
observed	O
data	O
Simulations	O
of	O
clinical	O
efficacy	O
of	O
alternative	O
mefloquine	S-Medication
regimens	O
were	O
performed	O
based	O
on	O
mefloquine 	S-Medication
sensitivity	O
patients	O
adherence	O
and	O
parasite	O
biomass	O
 mefloquine-resistant	B-Organism
P. falciparum, 	I-Organism
a	O
three	O
day	O
standard	O
regimen	O
of	O
artesunate-mefloquine 	S-Medication
is	O
suitable	O
50	O
efficacy	O
only	O
when	O
the	O
level	O
of	O
parasite	O
sensitivity	O
was	O
1	O
5	O
fold	O
of	O
the	O
cut	O
off	O
level	O
IC50	O
36	O
nM	O
For	O
mefloquine-sensitive 	B-Organism
parasite	I-Organism
with	O
IC50	O
23	O
19	O
nM	O
0	O
96	O
fold	O
all	O
regimens	O
provided	O
satisfactory	O
efficacy	O
In	O
the	O
isolates	O
with	O
IC50	O
of	O
24	O
nM	O
regimen	O
I	O
is	O
recommended	O
Curative	O
treatment	O
criteria	O
for	O
mefloquine 	S-Medication
artesunate	S-Medication
were	O
C336h	O
408	O
ng	O
mL	O
1	O
or	O
Cmax	O
IC50	O
130	O
1	O
g	O
m	O
M	O
and	O
Cmax	O
IC50	O
381	O
2	O
g	O
m	O
M	O
respectively	O
nClinical	O
use	O
of	O
a	O
three	O
day	O
standard	O
P. falciparum	S-Organism
artesunate-mefloquine 	S-Medication
isolates	O
is	O
lower	O
than	O
36	O
nM	O
Otherwise	O
other	O
ACT	O
regimens	O
should	O
be	O
replaced	O
For	O
mefloquine-sensitive	B-Organism
e parasite,	I-Organism
a	O
dose	O
reduction	O
is	O
recommended	O
with	O
the	O
IC50	O
is	O
lower	O
than	O
23	O
19	O
While	O
reductions	O
in	O
child	O
mortality	O
have	O
been	O
observed	O
across	O
sub	O
Saharan	O
African	O
countries	O
in	O
the	O
last	O
30	O
years	O
narrowing	O
the	O
gaps	O
in	O
under	O
five	O
mortality	O
across	O
socioeconomic	O
groups	O
also	O
requires	O
an	O
understanding	O
of	O
the	O
multiple	O
associations	O
between	O
health	O
and	O
welfare	O
and	O
socioeconomic	O
drivers	O
We	O
examined	O
the	O
probability	O
density	O
distributions	O
in	O
under	O
five	O
mortality	O
within	O
countries	O
and	O
joint	O
pathways	O
of	O
under	O
five	O
mortality	O
and	O
wealth	O
over	O
time	O
We	O
used	O
69	O
Demographic	O
and	O
Health	O
Surveys	O
and	O
19	O
 Malaria	S-Disease
Indicator	O
Surveys	O
from	O
30	O
sub	O
Saharan	O
African	O
countries	O
with	O
each	O
country	O
having	O
at	O
least	O
two	O
surveys	O
conducted	O
since	O
2000	O
We	O
constructed	O
a	O
cross	O
country	O
wealth	O
index	O
and	O
estimated	O
under	O
five	O
death	O
prevalence	O
We	O
examined	O
the	O
pure	O
distribution	O
in	O
under	O
five	O
mortality	O
prevalence	O
and	O
the	O
joint	O
probability	O
distribution	O
of	O
wealth	O
and	O
under	O
five	O
mortality	O
prevalence	O
over	O
time	O
including	O
the	O
area	O
of	O
confidence	O
ellipse	O
which	O
spanned	O
the	O
two	O
dimensions	O
of	O
mortality	O
and	O
wealth	O
and	O
covered	O
75	O
of	O
the	O
mass	O
of	O
the	O
joint	O
distribution	O
nMost	O
countries	O
experienced	O
decreases	O
in	O
under	O
five	O
mortality	O
along	O
with	O
increases	O
in	O
wealth	O
over	O
time	O
However	O
we	O
observed	O
great	O
variations	O
in	O
the	O
evolution	O
of	O
the	O
joint	O
distributions	O
across	O
countries	O
over	O
time	O
For	O
instance	O
the	O
areas	O
of	O
confidence	O
ellipse	O
ranged	O
from	O
0	O
178	O
in	O
Ethiopia	O
2000	O
to	O
1	O
119	O
in	O
Angola	O
2006	O
The	O
change	O
over	O
time	O
in	O
the	O
area	O
of	O
confidence	O
ellipses	O
ranged	O
from	O
0	O
010	O
in	O
Tanzania	O
to	O
0	O
844	O
in	O
Angola	O
between	O
the	O
2000s	O
and	O
2010s	O
The	O
ranking	O
of	O
country	O
performance	O
on	O
under	O
five	O
mortality	O
varied	O
greatly	O
depending	O
on	O
whether	O
performance	O
summary	O
indicators	O
were	O
based	O
on	O
disaggregation	O
by	O
wealth	O
or	O
on	O
full	O
non	O
disaggregated	O
distributions	O
nOur	O
analysis	O
points	O
to	O
the	O
relevance	O
of	O
full	O
distributions	O
of	O
health	O
and	O
joint	O
distributions	O
of	O
health	O
and	O
wealth	O
as	O
complementary	O
indicators	O
of	O
distributions	O
of	O
health	O
across	O
socioeconomic	O
status	O
in	O
assessing	O
country	O
performance	O
on	O
health	O
Eukaryotic	B-Organism
pathogens 	I-Organism
with	O
an	O
intracellular	O
parasitic	O
lifestyle	O
are	O
shielded	O
from	O
extracellular	O
threats	O
during	O
replication	O
and	O
growth	O
In	O
addition	O
to	O
many	O
nutrients	O
parasites 	S-Organism
scavenge	O
host	O
cell	O
lipids	O
to	O
establish	O
complex	O
membrane	O
structures	O
inside	O
their	O
host	O
cells	O
To	O
counteract	O
the	O
disturbance	O
of	O
the	O
host cell	B-Anatomical_Substances
plasma membrane	I-Anatomical_Substances
hey	O
have	O
evolved	O
strategies	O
to	O
regulate	O
 phospholipid	S-Chemical_Substance
asymmetry	O
In	O
this	O
review	O
the	O
function	O
and	O
importance	O
of	O
lipid	O
asymmetry	O
in	O
the	O
interactions	O
of	O
intracellular	O
protozoan	B-Organism
parasites	I-Organism
with	O
the	O
target	O
and	O
immune	O
cells	O
of	O
the	O
host	O
are	O
highlighted	O
The	O
malaria	S-Disease
parasite 	B-Organism
Plasmodium 	I-Organism
infects	O
red 	B-Anatomical_Substances
blood 	I-Anatomical_Substances
cells	E-Anatomical_Substances
and	O
extensively	O
refurbishes	O
these	O
terminally	O
differentiated	O
cells	O
Cholesterol 	S_Anatomical_Substances
depletion	O
and	O
an	O
altered	O
intracellular	O
calcium 	S-Chemical_Substance
ion	O
homeostasis	O
can	O
lead	O
to	O
disruption	O
in	O
erythrocyte 	B-Anatomical_Substances
membrane	I-Anatomical_Substances
asymmetry	O
and	O
increased	O
exposure	O
of	O
phosphatidylserine	S_Anatomical_Substances
PS	O
Binding	O
to	O
the	O
PS	O
receptor	O
on	O
monocytes	S_Anatomical_Substances
 macrophages	S_Anatomical_Substances
results	O
in	O
phagocytosis	O
and	O
destruction	O
of	O
infected	O
 erythrocytes	S_Anatomical_Substances
 Leishmania	B-Organism
parasites 	I-Organism
display	O
apoptotic	O
mimicry	O
by	O
actively	O
enhancing	O
PS	O
exposure	O
on	O
their	O
surface	O
to	O
trigger	O
increased	O
infection	O
of	O
macrophages.	S_Anatomical_Substances
extracellular	B-Organism
Toxoplasma	I-Organism
 gondii	E-Organism
P4-type ATPase/CDC50 co-chaperone	S-Protien
pair	O
functions	O
as	O
a	O
flippase	S-Protien
important	O
for	O
exocytosis	O
of	O
specialised	O
secretory	O
organelles	O
Identification	O
and	O
functional	O
analysis	O
of	O
parasite 	B-Protien
lipid-translocating	I-Protien
 proteins	E-Protien
flippases	S-Protien
floppases	S-Protien
scramblases	S-Protien
will	O
be	O
central	O
for	O
the	O
recognition	O
of	O
the	O
molecular	O
mechanisms	O
of	O
parasite	O
host	O
interactions	O
Ultimately	O
a	O
better	O
understanding	O
of	O
parasitic	O
diseases	O
host	O
immunity	O
and	O
immune	O
escape	O
by	O
parasites	O
require	O
more	O
research	O
on	O
the	O
dynamics	O
of	O
phospholipid	O
bilayers	O
of	O
parasites	O
and	O
the	O
infected	O
host	O
cell	O
Malaria	S-Disease
is	O
the	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
African	O
countries	O
We	O
aimed	O
this	O
study	O
at	O
evaluating	O
the	O
 ethanol	S-Chemical_Substance
extracts	O
were	O
obtained	O
by	O
maceration	O
It	O
tested	O
The	O
aqueous	O
and	O
According	O
to	O
these	O
findings	O
the	O
aqueous	O
and	O
ethanol	O
extracts	O
have	O
antiplasmodial	O
and	O
antioxidant	O
activity	O
but	O
with	O
no	O
cytotoxic	O
effects	O
on	O
red	O
blood	O
cells	O
or	O
RAW	O
cells	O
However	O
it	O
will	O
be	O
important	O
to	O
investiga	O
Regardless	O
of	O
various	O
prevention	O
and	O
control	O
strategies	O
 malaria 	S-Disease
continues	O
to	O
be	O
a	O
significant	O
public	O
health	O
problem	O
in	O
Ethiopia	O
As	O
there	O
are	O
few	O
studies	O
on	O
malaria	S-Disease
trend	O
analysis	O
in	O
Northeastern	O
Ethiopia	O
it	O
hinders	O
the	O
evaluation	O
of	O
ongoing	O
and	O
prioritization	O
of	O
new	O
malaria	S-Disease
intervention	O
strategies	O
particularly	O
during	O
the	O
period	O
of	O
pandemics	O
Therefore	O
the	O
present	O
study	O
investigated	O
the	O
trend	O
of	O
malaria 	S-Disease
prevalence	O
in	O
Northeastern	O
Ethiopia	O
from	O
2015	O
to	O
2020	O
nAn	O
institution	O
based	O
retrospective	O
study	O
was	O
employed	O
to	O
assess	O
the	O
trend	O
of	O
malaria	O
prevalence	O
over	O
a	O
6	O
year	O
period	O
2015	O
2020	O
in	O
three	O
districts	O
Jile	O
tumuga	O
Aruma	O
fursi	O
and	O
Dawachefa	O
of	O
Northeastern	O
Ethiopia	O
Data	O
were	O
extracted	O
from	O
clinical	O
records	O
of	O
malaria	O
cases	O
by	O
trained	O
medical	O
laboratory	O
technologists	O
The	O
associations	O
between	O
the	O
prevalence	O
of	O
malaria	O
and	O
independent	O
variables	O
age	O
group	O
malaria	O
transmission	O
season	O
and	O
districts	O
were	O
assessed	O
using	O
chi	O
square	O
test	O
nIn	O
our	O
study	O
area	O
a	O
total	O
of	O
212	O
952	O
malaria	O
suspected	O
patients	O
were	O
diagnosed	O
over	O
the	O
6	O
years	O
Of	O
these	O
33	O
005	O
15	O
5	O
were	O
confirmed	O
malaria	O
cases	O
The	O
identified	O
nIn	O
our	O
study	O
area	O
International	O
travels	O
with	O
children	O
need	O
special	O
planning	O
and	O
preparation	O
Besides	O
considering	O
general	O
aspects	O
such	O
as	O
the	O
age	O
of	O
the	O
child	O
physical	O
fitness	O
pre	O
existing	O
illnesses	O
type	O
and	O
extent	O
of	O
the	O
journey	O
climatic	O
conditions	O
at	O
the	O
destination	O
and	O
previous	O
travel	O
experiences	O
it	O
is	O
important	O
to	O
discuss	O
relevant	O
travel	O
associated	O
risks	O
in	O
the	O
context	O
of	O
travel	O
consulting	O
This	O
includes	O
extensive	O
advice	O
concerning	O
mosquito	O
protection	O
and	O
malaria	O
prophylaxis	O
and	O
counselling	O
and	O
implementation	O
of	O
travel	O
vaccinations	O
Depending	O
on	O
the	O
situation	O
of	O
the	O
family	O
an	O
individualized	O
travel	O
concept	O
can	O
be	O
prepared	O
creating	O
the	O
foundation	O
for	O
a	O
possible	O
problem	O
free	O
international	O
travel	O
Fernreisen	O
mit	O
Kindern	O
bedürfen	O
einer	O
besonderen	O
Planung	O
und	O
Vorbereitung	O
Neben	O
allgemeinen	O
Aspekten	O
die	O
zu	O
beachten	O
sind	O
wie	O
z	O
B	O
Alter	O
körperliche	O
Belastbarkeit	O
und	O
Vorerkrankungen	O
des	O
Kindes	O
sowie	O
Art	O
und	O
Umfang	O
der	O
Reise	O
klimatische	O
Bedingungen	O
am	O
Ort	O
und	O
Vorerfahrung	O
der	O
Reisenden	O
ist	O
es	O
wichtig	O
im	O
Rahmen	O
einer	O
Reiseberatung	O
auf	O
relevante	O
Risiken	O
der	O
Reise	O
einzugehen	O
und	O
entsprechende	O
Präventionsmaßnahmen	O
durchzuführen	O
Dazu	O
gehören	O
u	O
a	O
die	O
umfassende	O
Aufklärung	O
über	O
Mückenschutz	O
und	O
Malariaprophylaxe	O
sowie	O
die	O
Beratung	O
bezüglich	O
und	O
Durchführung	O
von	O
Reiseimpfungen	O
Je	O
nach	O
Situation	O
der	O
Familie	O
kann	O
ein	O
individuelles	O
Konzept	O
erstellt	O
werden	O
das	O
die	O
Grundlage	O
für	O
eine	O
möglichst	O
problemlose	O
Fernreise	O
schafft	O
nDie	O
Online	O
Version	O
dieses	O
Beitrags	O
10	O
1007	O
s00112	O
023	O
01699	O
6	O
enthält	O
einen	O
Vorschlag	O
für	O
eine	O
Reiseapotheke	O
und	O
eine	O
Übersicht	O
relevanter	O
Differenzialdiagnosen	O
bei	O
Fieber	O
nach	O
Tropenaufenthalt	O
Malaria	S-Disease
which	O
infected	O
more	O
than	O
240	O
million	O
people	O
and	O
killed	O
around	O
six	O
hundred	O
thousand	O
only	O
in	O
2021	O
has	O
reclaimed	O
territory	O
after	O
the	O
SARS-CoV-2	B-Disease
pandemic	I-Disease
Together	O
with	O
parasite	S-Organism
resistance	O
and	O
a	O
not	O
yet	O
optimal	O
vaccine	O
the	O
need	O
for	O
new	O
approaches	O
has	O
become	O
critical	O
While	O
earlier	O
limited	O
studies	O
have	O
suggested	O
that	O
malaria 	B-Organism
parasites 	I-Organism
are	O
affected	O
by	O
electromagnetic	O
energy	O
the	O
outcomes	O
of	O
this	O
affectation	O
vary	O
and	O
there	O
has	O
not	O
been	O
a	O
study	O
that	O
looks	O
into	O
the	O
mechanism	O
of	O
action	O
behind	O
these	O
responses	O
In	O
this	O
study	O
through	O
development	O
and	O
implementation	O
of	O
custom	O
applicators	O
for	O
SARS-CoV-2	B-Organism
 infection	I-Disease
that	O
led	O
to	O
the	O
COVID-19	S-Disease
pandemic	O
has	O
changed	O
human	S-Organism
health	O
and	O
the	O
economy	O
globally	O
SARS CoV-2 	S-Organism
SARS-CoV-2	B-Organism
is	O
a	O
type	O
of	O
Coronaviruses	S-Organism
 pneumonia	S-Disease
that	O
has	O
caused	O
and	O
its	O
complications	O
with	O
many	O
deaths	O
over	O
the	O
past	O
two	O
years	O
The	O
use	O
of	O
hydroxychloroquine 	S-Medication
chloroquine	S-Medication
malaria	S-Disease
 autoimmune	B-Disease
diseases 	I-Disease
accepted	O
as	O
generally	O
safe	O
for	O
patients	O
with	O
was	O
attempted	O
in	O
many	O
trials	O
for	O
 COVID-19	S-Disease
Nigella 	B-Organism
sativa 	B-Organism
black cumin	S-Organism
nigella	S-Organism
Kalonji	S-Organism
NS	O
black	O
caraway	O
also	O
known	O
as	O
is	O
an	O
annual	O
flowering	O
plant	O
of	O
the	O
Ranunculaceae	O
family	O
chemically	O
composed	O
of	O
the	O
main	O
constituent	O
natural	O
Thymoquinone	S-Chemical_Substance
thymohydroquinone,	S-Chemical_Substance
 dithymoquinone (	S-Chemical_Substance
Nigellone	S-Chemical_Substance
is	O
a	O
native	O
to	O
wider	O
regions	O
including	O
parts	O
of	O
eastern	O
Europe	O
west	O
Asia	O
North	O
of	O
Africa	O
and	O
east	O
of	O
Myanmar	O
In	O
this	O
review	O
we	O
explored	O
the	O
Randomized	O
Controlled	O
Trial	O
Controlled	O
Trial	O
and	O
Systematic	O
review	O
studies	O
that	O
support	O
 Nigella	B-Organism
sativa 	I-Organism
Thymoquinone	S-Chemical_Substance
SARS-CoV-2	B-Organism
targeting	O
Therefore	O
A	O
literature	O
search	O
was	O
performed	O
for	O
publications	O
published	O
on	O
the	O
electronic	O
databases	O
PubMed	O
Embase	O
Scopus	O
CNKI	O
and	O
Google	O
Scholar	O
Nigella sativa	B-Organism
 coronavirus	S-Organism
black seeds	I-Organism
Kalonji	E-Organism
SARS-CoV -2	B-Organism
COVID-19	S-Disease
This	O
review	O
aimed	O
to	O
find	O
relevant	O
evidence	O
of	O
Nigella	O
sativa	O
preferences	O
as	O
a	O
natural	O
feasible	O
remedy	O
with	O
no	O
side	O
effects	O
in	O
COVID-19	S-Disease
Studies	O
reported	O
the	O
benefits	O
of	O
NS	O
as	O
beneficial	O
another	O
appropriate	O
remedy	O
for	O
patients	O
with	O
 COVID-19.	S-Disease
 COVID-19	S-Disease
COVID-19	S-Disease
COVID-19	S-Disease
COVID-19	S-Disease
 asthma	S-Disease
bronchitis	S-Disease
However	O
all	O
studies	O
have	O
shown	O
limitations	O
such	O
as	O
limiting	O
clinical	O
symptom	O
outcomes	O
due	O
to	O
regulations	O
imposed	O
by	O
isolation	O
policies	O
and	O
lack	O
of	O
adequate	O
funding	O
Therefore	O
the	O
evidence	O
suggests	O
that	O
the	O
chemical	O
contents	O
of	O
NS	O
are	O
a	O
safe	O
and	O
possible	O
treatment	O
for	O
patients	O
that	O
helps	O
to	O
improve	O
nfection	O
in	O
patients	O
with	O
no	O
side	O
effects	O
nNigella	O
sativa	O
seeds	O
were	O
one	O
of	O
the	O
well	O
documented	O
herbal	O
products	O
Three	O
reviewed	O
randomized	O
controlled	O
trials	O
reported	O
that	O
NS	O
reduced	O
covid	O
19	O
risk	O
and	O
could	O
improve	O
immune	O
function	O
It	O
was	O
also	O
helpful	O
in	O
upper	O
respiratory	O
infections	O
such	O
as	O
showing	O
that	O
honey	O
and	O
NS	O
significantly	O
improved	O
symptoms	O
viral	O
clearance	O
and	O
mortality	O
o	O
patients	O
This	O
review	O
concludes	O
that	O
NS	O
has	O
a	O
positive	O
barrier	O
effect	O
on	O
people	O
at	O
risk	O
of	O
acquiring	O
a	O
Neuromeningeal 	B-Disease
cryptococcosis	I-Disease
 pulmonary 	B-Disease
tuberculosis 	I-Disease
are	O
respectively	O
serious	O
mycotic	O
and	O
bacterial	O
infections	O
occurring	O
in	O
a	O
subject	O
regardless	O
of	O
its	O
HIV	S-Disease
serological	O
status	O
We	O
report	O
here	O
a	O
case	O
of	O
 neuromeningeal 	B-Disease
cryptococcosis 	I-Disease
associated	O
with	O
pulmonary	B-Disease
 tuberculosis 	I-Disease
and	O
malnutrition	O
in	O
an	O
HIV-	S-Disease
seronegative	O
patient	O
with	O
a	O
CD4	O
count	O
of	O
750	O
mm	O
La	O
cryptococcose	O
neuroméningée	O
et	O
la	O
tuberculose	O
pulmonaire	O
sont	O
respectivement	O
des	O
infections	O
mycosique	O
et	O
bactérienne	O
graves	O
survenant	O
chez	O
un	O
sujet	O
quel	O
que	O
soit	O
son	O
statut	O
sérologique	O
au	O
VIH	O
Nous	O
rapportons	O
ici	O
un	O
cas	O
de	O
cryptococcose	O
neuroméningée	O
associée	O
à	O
une	O
tuberculose	O
pulmonaire	O
et	O
une	O
dénutrition	O
chez	O
une	O
patiente	O
séronégative	O
pour	O
le	O
VIH	O
ayant	O
un	O
taux	O
de	O
CD4	O
à	O
750	O
mm	O
Long-Lasting 	B-Medication
Insecticidal	I-Medication
 Nets 	E-Medication
indoor	B-Medication
 residual	I-Medication
spraying	E-Medication
The	O
effectiveness	O
of	O
LLINs	O
and	O
IRS	O
in	O
controlling	O
malaria vectors 	B-Organism
is	O
hampered	O
by	O
the	O
resistance	O
of	O
anopheles	S-Organism
insecticides	S-Chemical_Substance
A	O
good	O
knowledge	O
of	O
the	O
breeding	O
sites	O
and	O
of	O
the	O
resistance	O
profile	O
of	O
the	O
vectors	O
could	O
facilitate	O
the	O
development	O
of	O
an	O
appropriate	O
control	O
strategy	O
This	O
study	O
looks	O
at	O
the	O
larval	O
ecology	O
and	O
the	O
susceptibility	O
profile	O
of	O
Mosquito	S-Organism
breeding	O
sites	O
were	O
categorized	O
and	O
geo	O
referenced	O
For	O
each	O
site	O
larvae	O
were	O
collected	O
and	O
reared	O
and	O
physicochemical	O
parameters	O
were	O
measured	O
nNatural	O
breeding	O
sites	O
of	O
nL	O
efficacité	O
des	O
moustiquaires	O
imprégnées	O
d	O
insecticides	O
à	O
longue	O
durée	O
d	O
action	O
MILDA	O
et	O
des	O
aspersions	O
intradomiciliaires	O
AII	O
dans	O
le	O
contrôle	O
des	O
vecteurs	O
du	O
paludisme	O
est	O
mise	O
à	O
mal	O
par	O
la	O
résistance	O
des	O
anophèles	O
aux	O
insecticides	O
Une	O
bonne	O
connaissance	O
des	O
gîtes	O
larvaires	O
ainsi	O
que	O
du	O
profil	O
de	O
résistance	O
des	O
vecteurs	O
pourrait	O
faciliter	O
le	O
développement	O
d	O
une	O
stratégie	O
appropriée	O
de	O
lutte	O
La	O
présente	O
recherche	O
s	O
intéresse	O
à	O
l	O
écologie	O
larvaire	O
et	O
au	O
niveau	O
de	O
sensibilité	O
d	O
nLes	O
gîtes	O
de	O
moustiques	O
ont	O
été	O
typés	O
et	O
géo	O
référencés	O
Pour	O
chaque	O
gîte	O
les	O
larves	O
ont	O
été	O
prélevées	O
puis	O
mises	O
en	O
élevage	O
et	O
les	O
paramètres	O
physico	O
chimiques	O
mesurés	O
nLes	O
gîtes	O
naturels	O
d	O
An	O
Antimicrobials	S-Medication
are	O
among	O
the	O
most	O
widely	O
prescribed	O
therapeutic	O
agents	O
among	O
paediatric	O
population	O
Irrational	O
use	O
of	O
these	O
agents	O
increases	O
the	O
risk	O
of	O
antimicrobial	O
resistance	O
We	O
described	O
the	O
prevalence	O
and	O
pattern	O
of	O
antimicrobial	O
use	O
among	O
paediatric	O
inpatients	O
from	O
2017	O
to	O
2019	O
nThe	O
study	O
was	O
a	O
repeated	O
point	O
prevalence	O
survey	O
over	O
a	O
3	O
year	O
period	O
using	O
the	O
global	O
point	O
prevalence	O
standardized	O
tools	O
among	O
all	O
paediatric	O
inpatients	O
The	O
prevalence	O
of	O
antimicrobial	O
use	O
the	O
prescription	O
indicators	O
and	O
patterns	O
of	O
antimicrobial	O
use	O
were	O
estimated	O
nAmong	O
191	O
paediatric	O
inpatients	O
assessed	O
the	O
3	O
year	O
period	O
prevalence	O
antimicrobial	O
use	O
was	O
85	O
9	O
164	O
191	O
with	O
prevalence	O
of	O
80	O
6	O
in	O
2017	O
94	O
6	O
in	O
2018	O
and	O
83	O
6	O
in	O
2019	O
Antimicrobial	O
agents	O
used	O
ranged	O
from	O
one	O
agent	O
20	O
1	O
to	O
five	O
different	O
agents	O
5	O
5	O
Parenteral	O
route	O
66	O
6	O
was	O
the	O
preferred	O
route	O
of	O
administration	O
The	O
reason	O
for	O
the	O
use	O
of	O
antimicrobial	O
agents	O
92	O
6	O
and	O
the	O
stop	O
review	O
date	O
99	O
5	O
were	O
mostly	O
well	O
documented	O
Only	O
4	O
5	O
of	O
the	O
antimicrobial	O
use	O
were	O
targeted	O
There	O
were	O
no	O
antimicrobial	O
guidelines	O
or	O
policy	O
guiding	O
the	O
use	O
of	O
antimicrobial	O
agents	O
except	O
the	O
national	O
guideline	O
on	O
the	O
treatment	O
of	O
malaria	O
and	O
tuberculosis	O
Ceftriaxone	O
a	O
third	O
generation	O
cephalosporin	O
was	O
the	O
most	O
commonly	O
used	O
agent	O
across	O
the	O
period	O
under	O
review	O
Community	O
acquired	O
infection	O
was	O
the	O
commonest	O
indication	O
for	O
antimicrobial	O
use	O
nOur	O
findings	O
of	O
high	O
antimicrobial	O
prevalence	O
has	O
raised	O
the	O
attention	O
for	O
the	O
need	O
to	O
develop	O
hospital	O
based	O
antimicrobial	O
guideline	O
and	O
antimicrobial	O
stewardship	O
program	O
to	O
protect	O
the	O
vulnerable	O
children	O
their	O
contacts	O
and	O
the	O
environment	O
from	O
the	O
impact	O
of	O
antimicrobial	O
resistance	O
Until	O
recently	O
due	O
to	O
widespread	O
prevalence	O
of	O
molecular	O
markers	O
associated	O
with	O
sulfadoxine-pyrimethamine 	S-Medication
amodiaquine	S-Medication
resistance	O
in	O
east	O
and	O
southern	O
Africa	O
chemoprevention	S-Medication
 malaria 	S-Disease
has	O
not	O
been	O
used	O
at	O
scale	O
in	O
this	O
region	O
This	O
study	O
assessed	O
the	O
protective	O
effectiveness	O
of	O
monthly	O
administration	O
of	O
SP	O
AQ	O
SPAQ	O
to	O
children	O
aged	O
3	O
59	O
months	O
in	O
Karamoja	O
sub	O
region	O
Uganda	O
where	O
parasite	O
resistance	O
is	O
assumed	O
to	O
be	O
high	O
and	O
malaria	O
transmission	O
is	O
seasonal	O
A	O
two	O
arm	O
quasi	O
experimental	O
open	O
label	O
prospective	O
non	O
randomized	O
control	O
trial	O
nRCT	O
was	O
conducted	O
in	O
three	O
districts	O
In	O
two	O
intervention	O
districts	O
85	O
000	O
children	O
aged	O
3	O
59	O
months	O
were	O
targeted	O
to	O
receive	O
monthly	O
courses	O
of	O
SMC	O
using	O
SPAQ	O
during	O
the	O
peak	O
transmission	O
season	O
May	O
to	O
September	O
2021	O
A	O
third	O
district	O
served	O
as	O
a	O
control	O
where	O
SMC	O
was	O
not	O
implemented	O
Communities	O
with	O
comparable	O
malaria	O
attack	O
rates	O
were	O
selected	O
from	O
the	O
three	O
districts	O
and	O
households	O
with	O
at	O
least	O
one	O
SMC	O
eligible	O
child	O
were	O
purposively	O
selected	O
A	O
total	O
cohort	O
of	O
600	O
children	O
200	O
children	O
per	O
district	O
were	O
selected	O
and	O
followed	O
using	O
passive	O
surveillance	O
for	O
breakthrough	O
confirmed	O
malaria	O
episodes	O
during	O
the	O
five	O
month	O
peak	O
transmission	O
season	O
Malaria	O
incidence	O
rate	O
per	O
person	O
months	O
and	O
number	O
of	O
malaria	O
episodes	O
among	O
children	O
in	O
the	O
two	O
arms	O
were	O
compared	O
Kaplan	O
Meier	O
failure	O
estimates	O
were	O
used	O
to	O
compare	O
the	O
probability	O
of	O
a	O
positive	O
malaria	O
test	O
Other	O
factors	O
that	O
may	O
influence	O
malaria	O
transmission	O
and	O
infection	O
among	O
children	O
in	O
the	O
two	O
arms	O
were	O
also	O
assessed	O
using	O
multivariable	O
cox	O
proportional	O
hazards	O
regression	O
model	O
nThe	O
malaria	O
incidence	O
rate	O
was	O
3	O
0	O
and	O
38	O
8	O
per	O
100	O
person	O
months	O
in	O
the	O
intervention	O
and	O
control	O
groups	O
respectively	O
In	O
the	O
intervention	O
areas	O
90	O
0	O
361	O
400	O
of	O
children	O
did	O
not	O
experience	O
any	O
malaria	O
episodes	O
during	O
the	O
study	O
period	O
compared	O
to	O
15	O
29	O
200	O
in	O
the	O
control	O
area	O
The	O
incidence	O
rate	O
ratio	O
was	O
0	O
078	O
95	O
CI	O
0	O
063	O
0	O
096	O
which	O
corresponds	O
to	O
a	O
protective	O
effectiveness	O
of	O
92	O
95	O
CI	O
90	O
0	O
94	O
0	O
among	O
children	O
in	O
the	O
intervention	O
area	O
nSMC	O
using	O
SPAQ	O
provided	O
high	O
protective	O
effect	O
against	O
malaria	O
during	O
the	O
peak	O
transmission	O
season	O
in	O
children	O
aged	O
3	O
59	O
months	O
in	O
the	O
Karamoja	O
sub	O
region	O
of	O
Uganda	O
Despite	O
notable	O
progress	O
in	O
the	O
control	O
and	O
prevention	O
of	O
 malaria	S-Disease
in	O
the	O
Horn	O
of	O
Africa	O
the	O
disease	O
continues	O
to	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
various	O
regions	O
of	O
Ethiopia	O
and	O
elsewhere	O
in	O
the	O
region	O
The	O
transmission	O
of	O
 malaria	S-Disease
is	O
affected	O
by	O
genetic	O
sociocultural	O
and	O
ecological	O
factors	O
Lare	O
is	O
an	O
Ethiopian	O
district	O
adjacent	O
to	O
the	O
Ethio	O
South	O
Sudan	O
border	O
in	O
Gambella	O
region	O
The	O
region	O
currently	O
has	O
the	O
highest	O
prevalence	O
of	O
malaria 	S-Disease
n	O
Ethiopia	O
This	O
study	O
assesses	O
the	O
burden	O
and	O
spatiotemporal	O
patterns	O
of	O
disease	O
transmission	O
including	O
the	O
effect	O
of	O
climatic	O
factors	O
on	O
the	O
occurrence	O
of	O
 malaria	S-Disease
across	O
an	O
international	O
border	O
crossing	O
This	O
understanding	O
can	O
assist	O
in	O
crafting	O
informed	O
programmatic	O
and	O
policy	O
decisions	O
for	O
interventions	O
nThis	O
study	O
was	O
conducted	O
in	O
Lare	O
district	O
Southwest	O
Ethiopia	O
a	O
temperate	O
zone	O
A	O
retrospective	O
descriptive	O
analysis	O
was	O
conducted	O
using	O
clinical	O
service	O
data	O
collected	O
between	O
2011	O
and	O
2021	O
from	O
the	O
9	O
health	O
facilities	O
of	O
the	O
district	O
Both	O
clinically	O
diagnosed	O
patients	O
and	O
those	O
identified	O
using	O
microscopy	O
and	O
rapid	O
diagnostic	O
testing	O
RDT	O
were	O
included	O
in	O
the	O
study	O
Additionally	O
climate	O
data	O
was	O
incorporated	O
into	O
analyses	O
Examples	O
of	O
analyses	O
include	O
malaria	O
burden	O
positivity	O
rate	O
incidence	O
species	O
frequency	O
and	O
an	O
ANOVA	O
to	O
assess	O
inter	O
annual	O
case	O
number	O
and	O
meteorological	O
factor	O
variation	O
Between	O
2011	O
and	O
2021	O
a	O
total	O
of	O
96	O
616	O
suspected	O
malaria	S-Disease
cases	O
were	O
tested	O
by	O
microscopy	O
or	O
RDT	O
and	O
39	O
428	O
40	O
8	O
of	O
these	O
cases	O
were	O
reported	O
as	O
positive	O
There	O
were	O
1276	O
patients	O
admitted	O
with	O
22	O
deaths	O
recorded	O
There	O
were	O
further	O
more	O
significant	O
fluctuations	O
in	O
positivity	O
rates	O
across	O
years	O
the	O
highest	O
being	O
74	O
5	O
in	O
2021	O
Incidence	O
varied	O
from	O
18	O
0	O
in	O
2011	O
to	O
151	O
6	O
in	O
2016	O
The	O
malaria parasite	B-Organism
Plasmodium	B-Organism
falciparum	I-Organism
species	O
most	O
detected	O
was	O
followed	O
by	O
a	O
smaller	O
proportion	O
of	O
Plasmodium	B-Organism
vivax.	I-Organism
The	O
greatest	O
proportions	O
of	O
 P. falciparum	B-Organism
cases	O
were	O
observed	O
in	O
2018	O
and	O
2019	O
at	O
97	O
4	O
and	O
97	O
0	O
prevalence	O
respectively	O
There	O
was	O
significant	O
seasonal	O
variation	O
in	O
case	O
number	O
the	O
highest	O
observed	O
in	O
July	O
through	O
September	O
of	O
each	O
year	O
Climatic	O
conditions	O
of	O
annual	O
rainfall	O
temperature	O
and	O
humidity	O
favored	O
the	O
increment	O
o	O
 malaria	S-Disease
cases	O
from	O
June	O
until	O
October	O
nThe	O
study	O
shows	O
that	O
the	O
burden	O
i	O
e	O
morbidity	O
and	O
mortality	O
with	O
fluctuating	O
patterns	O
of	O
malaria	O
are	O
still	O
significant	O
public	O
health	O
problems	O
and	O
can	O
pose	O
serious	O
consequences	O
in	O
the	O
district	O
This	O
has	O
implication	O
for	O
cross	O
border	O
malaria	O
transmission	O
risk	O
due	O
to	O
considerable	O
border	O
crossings	O
The	O
predominant	O
cause	O
of	O
the	O
disease	O
is	O
P. falciparum,	B-Organism
which	O
causes	O
severe	O
complications	O
in	O
patients	O
The	O
district	O
has	O
to	O
prepare	O
to	O
deal	O
with	O
such	O
complications	O
for	O
better	O
patient	O
care	O
and	O
outcomes	O
Mobile	O
phones	O
are	O
increasingly	O
used	O
in	O
community	O
health	O
programmes	O
but	O
the	O
use	O
of	O
video	O
job	O
aids	O
that	O
can	O
be	O
displayed	O
on	O
smart	O
phones	O
has	O
not	O
been	O
widely	O
exploited	O
We	O
investigated	O
the	O
use	O
of	O
video	O
job	O
aids	O
to	O
support	O
the	O
delivery	O
of	O
seasonal	O
malaria	O
chemoprevention	O
SMC	O
in	O
countries	O
in	O
West	O
and	O
Central	O
Africa	O
The	O
study	O
was	O
prompted	O
by	O
the	O
need	O
for	O
training	O
tools	O
that	O
could	O
be	O
used	O
in	O
a	O
socially	O
distanced	O
manner	O
during	O
the	O
COVID	O
19	O
pandemic	O
Animated	O
videos	O
were	O
developed	O
in	O
English	O
French	O
Portuguese	O
Fula	O
and	O
Hausa	O
illustrating	O
key	O
steps	O
for	O
administering	O
SMC	O
safely	O
including	O
wearing	O
masks	O
washing	O
hands	O
and	O
social	O
distancing	O
Through	O
a	O
consultative	O
process	O
with	O
the	O
national	O
malaria	O
programmes	O
of	O
countries	O
using	O
SMC	O
successive	O
versions	O
of	O
the	O
script	O
and	O
videos	O
were	O
reviewed	O
to	O
ensure	O
accurate	O
and	O
relevant	O
content	O
Online	O
workshops	O
were	O
held	O
with	O
programme	O
managers	O
to	O
plan	O
how	O
to	O
use	O
the	O
videos	O
in	O
SMC	O
staff	O
training	O
and	O
supervision	O
and	O
the	O
use	O
of	O
the	O
videos	O
was	O
evaluated	O
in	O
Guinea	O
through	O
focus	O
groups	O
and	O
in	O
depth	O
interviews	O
with	O
drug	O
distributors	O
and	O
other	O
staff	O
involved	O
in	O
SMC	O
delivery	O
and	O
through	O
direct	O
observations	O
of	O
SMC	O
administration	O
Programme	O
managers	O
found	O
the	O
videos	O
useful	O
as	O
they	O
reinforce	O
messages	O
can	O
be	O
viewed	O
at	O
any	O
time	O
and	O
repeatedly	O
and	O
when	O
used	O
during	O
training	O
sessions	O
provide	O
a	O
focus	O
of	O
discussion	O
and	O
support	O
for	O
trainers	O
and	O
help	O
retain	O
messages	O
Managers	O
requested	O
that	O
local	O
specificities	O
of	O
SMC	O
delivery	O
in	O
their	O
setting	O
be	O
included	O
in	O
tailored	O
versions	O
of	O
the	O
video	O
for	O
their	O
country	O
and	O
videos	O
were	O
required	O
to	O
be	O
narrated	O
in	O
a	O
variety	O
of	O
local	O
languages	O
In	O
Guinea	O
SMC	O
drug	O
distributors	O
found	O
the	O
video	O
covered	O
the	O
all	O
the	O
essential	O
steps	O
and	O
found	O
the	O
video	O
easy	O
to	O
understand	O
However	O
not	O
all	O
key	O
messages	O
were	O
followed	O
as	O
some	O
of	O
the	O
safety	O
measures	O
social	O
distancing	O
and	O
wearing	O
masks	O
were	O
perceived	O
by	O
some	O
as	O
creating	O
mistrust	O
amongst	O
communities	O
Video	O
job	O
aids	O
can	O
potentially	O
provide	O
an	O
efficient	O
means	O
of	O
reaching	O
large	O
numbers	O
of	O
drug	O
distributors	O
with	O
guidance	O
for	O
safe	O
and	O
effective	O
distribution	O
of	O
SMC	O
Not	O
all	O
distributors	O
use	O
android	O
phones	O
but	O
SMC	O
programmes	O
are	O
increasingly	O
providing	O
drug	O
distributors	O
with	O
android	O
devices	O
to	O
track	O
delivery	O
and	O
personal	O
ownership	O
of	O
smartphones	O
in	O
sub	O
Saharan	O
Africa	O
is	O
growing	O
The	O
use	O
of	O
video	O
job	O
aids	O
for	O
community	O
health	O
workers	O
to	O
improve	O
the	O
quality	O
delivery	O
of	O
SMC	O
or	O
of	O
other	O
primary	O
health	O
care	O
interventions	O
should	O
be	O
more	O
widely	O
evaluated	O
There	O
is	O
a	O
large	O
gap	O
between	O
diagnostic	O
needs	O
and	O
diagnostic	O
access	O
across	O
much	O
of	O
sub	O
Saharan	O
Africa	O
SSA	O
particularly	O
for	O
infectious	O
diseases	O
that	O
inflict	O
a	O
substantial	O
burden	O
of	O
morbidity	O
and	O
mortality	O
Accurate	O
diagnostics	O
are	O
essential	O
for	O
the	O
correct	O
treatment	O
of	O
individuals	O
and	O
provide	O
vital	O
information	O
underpinning	O
disease	O
surveillance	O
prevention	O
and	O
control	O
strategies	O
Digital	O
molecular	O
diagnostics	O
combine	O
the	O
high	O
sensitivity	O
and	O
specificity	O
of	O
molecular	O
detection	O
with	O
point	O
of	O
care	O
format	O
and	O
mobile	O
connectivity	O
Recent	O
developments	O
in	O
these	O
technologies	O
create	O
an	O
opportunity	O
for	O
a	O
radical	O
transformation	O
of	O
the	O
diagnostic	O
ecosystem	O
Rather	O
than	O
trying	O
to	O
emulate	O
diagnostic	O
laboratory	O
models	O
in	O
resource	O
rich	O
settings	O
African	O
countries	O
have	O
the	O
potential	O
to	O
pioneer	O
new	O
models	O
of	O
healthcare	O
designed	O
around	O
digital	O
diagnostics	O
This	O
article	O
describes	O
the	O
need	O
for	O
new	O
diagnostic	O
approaches	O
highlights	O
advances	O
in	O
digital	O
molecular	O
diagnostic	O
technology	O
and	O
outlines	O
their	O
potential	O
for	O
tackling	O
infectious	O
diseases	O
in	O
SSA	O
It	O
then	O
addresses	O
the	O
steps	O
that	O
will	O
be	O
necessary	O
for	O
the	O
development	O
and	O
implementation	O
of	O
digital	O
molecular	O
diagnostics	O
Although	O
the	O
focus	O
is	O
on	O
infectious	O
diseases	O
in	O
SSA	O
many	O
of	O
the	O
principles	O
apply	O
to	O
other	O
resource	O
limited	O
settings	O
and	O
to	O
noncommunicable	O
diseases	O
Public	O
health	O
interventions	O
require	O
evidence	O
based	O
decision	O
making	O
to	O
maximize	O
impact	O
Spatial	O
decision	O
support	O
systems	O
SDSS	O
are	O
designed	O
to	O
collect	O
store	O
process	O
and	O
analyze	O
data	O
to	O
generate	O
knowledge	O
and	O
inform	O
decisions	O
This	O
paper	O
discusses	O
how	O
the	O
use	O
of	O
a	O
SDSS	O
the	O
Campaign	O
Information	O
Management	O
System	O
CIMS	O
to	O
support	O
malaria	S-Disease
control	O
operations	O
on	O
Bioko	O
Island	O
has	O
impacted	O
key	O
process	O
indicators	O
of	O
indoor	O
residual	O
spraying	O
IRS	O
coverage	O
operational	O
efficiency	O
and	O
productivity	O
We	O
used	O
data	O
from	O
the	O
last	O
five	O
annual	O
IRS	O
rounds	O
2017	O
to	O
2021	O
to	O
estimate	O
these	O
indicators	O
IRS	O
coverage	O
was	O
calculated	O
as	O
the	O
percentage	O
of	O
houses	O
sprayed	O
per	O
unit	O
area	O
represented	O
by	O
100x100	O
m	O
map	O
sectors	O
Optimal	O
coverage	O
was	O
defined	O
as	O
between	O
80	O
and	O
85	O
and	O
under	O
and	O
overspraying	O
as	O
coverage	O
below	O
80	O
and	O
above	O
85	O
respectively	O
Operational	O
efficiency	O
was	O
defined	O
as	O
the	O
fraction	O
of	O
map	O
sectors	O
that	O
achieved	O
optimal	O
coverage	O
Daily	O
productivity	O
was	O
expressed	O
as	O
the	O
number	O
of	O
houses	O
sprayed	O
per	O
sprayer	O
per	O
day	O
h	O
s	O
d	O
These	O
indicators	O
were	O
compared	O
across	O
the	O
five	O
rounds	O
Overall	O
IRS	O
coverage	O
i	O
e	O
percent	O
of	O
total	O
houses	O
sprayed	O
against	O
the	O
overall	O
denominator	O
by	O
round	O
was	O
highest	O
in	O
2017	O
80	O
2	O
yet	O
this	O
round	O
showed	O
the	O
largest	O
proportion	O
of	O
oversprayed	O
map	O
sectors	O
36	O
0	O
Conversely	O
despite	O
producing	O
a	O
lower	O
overall	O
coverage	O
77	O
5	O
the	O
2021	O
round	O
showed	O
the	O
highest	O
operational	O
efficiency	O
37	O
7	O
and	O
the	O
lowest	O
proportion	O
of	O
oversprayed	O
map	O
sectors	O
18	O
7	O
In	O
2021	O
higher	O
operational	O
efficiency	O
was	O
also	O
accompanied	O
by	O
marginally	O
higher	O
productivity	O
Productivity	O
ranged	O
from	O
3	O
3	O
h	O
s	O
d	O
in	O
2020	O
to	O
3	O
9	O
h	O
s	O
d	O
in	O
2021	O
median	O
3	O
6	O
h	O
s	O
d	O
Our	O
findings	O
showed	O
that	O
the	O
novel	O
approach	O
to	O
data	O
collection	O
and	O
processing	O
proposed	O
by	O
the	O
CIMS	O
has	O
significantly	O
improved	O
the	O
operational	O
efficiency	O
of	O
IRS	O
on	O
Bioko	O
High	O
spatial	O
granularity	O
during	O
planning	O
and	O
deployment	O
together	O
with	O
closer	O
follow	O
up	O
of	O
field	O
teams	O
using	O
real	O
time	O
data	O
supported	O
more	O
homogeneous	O
delivery	O
of	O
optimal	O
coverage	O
while	O
sustaining	O
high	O
productivity	O
 antimalarial 	B-Medication
chemotypes	I-Medication
antimalarials	S-Medication
There	O
is	O
an	O
urgent	O
need	O
to	O
populate	O
the	O
antimalarial	O
clinical	O
portfolio	O
with	O
new	O
candidates	O
because	O
of	O
resistance	O
against	O
frontline	O
we	O
performed	O
a	O
high	O
throughput	O
screen	O
of	O
the	O
Janssen	O
Jumpstarter	O
library	O
against	O
the	O
discover	O
new	O
artemisinin	S-Medication
The	O
emergence	O
of	O
resistance	O
by	O
malaria	B-Organism
parasites	I-Organism
is	O
a	O
major	O
challenge	O
in	O
the	O
fight	O
against	O
malaria	S-Disease
thus	O
posing	O
serious	O
threat	O
to	O
the	O
public	O
health	O
across	O
the	O
world	O
To	O
tackle	O
this	O
 antimalarial	B-Medication
 drugs	I-Medication
with	O
unconventional	O
mechanisms	O
are	O
therefore	O
urgently	O
needed	O
It	O
has	O
been	O
reported	O
that	O
selective	O
starvation	O
of	O
 Plasmodium 	B-Organism
falciparum 	I-Organism
 IgG 	S-Protien
The	O
in	O
utero	O
transfer	O
malaria	S-Disease
specific	O
to	O
the	O
fetus	O
in	O
infected	O
pregnant	O
women	O
potentially	O
plays	O
a	O
role	O
in	O
provision	O
of	O
immune	O
protection	O
agains	O
malaria	S-Disease
in	O
the	O
first	O
birth	O
year	O
However	O
the	O
effect	O
of	O
 Intermittent 	B-Medication
Prophylactic 	I-Medication
Treatment in Pregnancy 	E-Medication
IPTp	O
and	O
placental malaria	B-Disease
on	O
the	O
extent	O
of	O
in	O
utero	O
antibody	O
transfer	O
in	O
malaria	S-Disease
endemic	O
regions	O
like	O
Uganda	O
remain	O
unknown	O
The	O
aim	O
of	O
this	O
study	O
was	O
thus	O
to	O
establish	O
the	O
effect	O
of	O
IPTp	O
on	O
in	O
utero	O
transfer	O
of	O
malaria	O
specific	O
IgG	S-Protien
to	O
the	O
fetus	O
and	O
the	O
associated	O
immune	O
protection	O
against	O
malaria	O
in	O
the	O
first	O
birth	O
year	O
of	O
children	O
born	O
to	O
mothers	O
who	O
had	O
P. falciparum 	B-Disease
infection	I-Disease
during	O
pregnancy	O
in	O
Uganda	O
We	O
screened	O
a	O
total	O
of	O
637	O
cord	O
blood	O
samples	O
from	O
a	O
double	O
blinded	O
randomized	O
clinical	O
trial	O
on	O
Sulfadoxine-Pyrimethamine	S-Medication
SP	O
and	O
Dihydroartemisinin-Piperaquine	S-Medication
DP	O
IPTp	O
in	O
a	O
Ugandan	O
birth	O
cohort	O
study	O
conducted	O
from	O
Busia	O
Eastern	O
Uganda	O
Luminex	O
assay	O
was	O
used	O
to	O
measure	O
the	O
cord	O
levels	O
of	O
IgG	S-Protien
sub	O
types	O
IgG1, IgG2, IgG3 and IgG4	S-Protien
 P. falciparum 	S-Organism
specific	O
antigens	O
with	O
tetanus	O
toxoid	O
t	O
t	O
as	O
a	O
control	O
antigen	O
Man	O
Whitney	O
U	O
test	O
non	O
parametric	O
in	O
STATA	O
ver15	O
was	O
used	O
in	O
statistical	O
analysis	O
of	O
the	O
samples	O
In	O
addition	O
Multivariate	O
cox	O
regression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
effect	O
of	O
maternal	O
transfer	O
of	O
IgG	O
on	O
the	O
incidence	O
of	O
malaria	O
in	O
the	O
first	O
birth	O
year	O
of	O
children	O
under	O
study	O
P. falciparum	S-Organism
 P. falciparum 	S-Organism
P. falciparum	S-Organism
malaria infections 	S-Disease
parasitemia	S-Disease
malaria infections 	S-Disease
cord IgG4 	S-Protien
against	O
15	O
different	O
Mothers	O
on	O
SP	O
expressed	O
higher	O
levels	O
of	O
erythrocyte	B-Anatomical_Substances
binding 	I-Anatomical_Substances
antigens	E-Anatomical_Substances
EBA140, EBA175 and EBA181	S_Anatomical_Substances
Placental	B-Disease
malaria	I-Disease
did	O
not	O
affect	O
cord	O
levels	O
of	O
 IgG 	S-Protien
 P. falciparum	S-Organism
IgG	S-Protien
sub	O
types	O
against	O
selected	O
specific	O
antigens	O
p	O
0	O
05	O
Children	O
who	O
expressed	O
higher	O
levels	O
75th	O
percentile	O
of	O
total	O
against	O
the	O
six	O
key	O
antigens	O
in	O
the	O
first	O
birth	O
year	O
of	O
children	O
infections	O
during	O
gestation	O
had	O
higher	O
risk	O
of	O
getting	O
Malaria	B-Disease
prophylaxis 	I-Disease
Pf SEA	S-Protien
Rh4.2	S-Protien
AMA1	S-Protien
GLURP	S-Protien
Etramp5Ag1	S-Protien
 EBA 175	S-Protien
AMA1	S-Protien
GLURP	S-Protien
GLURP	S-Protien
EBA175	S-Protien
 malaria	B-Disease
 infections 	I-Disease
had	O
higher	O
risk	O
of	O
malaria	O
in	O
the	O
first	O
birth	O
year	O
AHRs	O
1	O
092	O
95	O
CI	O
1	O
02	O
1	O
17	O
Rh4.2	S-Protien
PfSEA	S-Protien
Etramp5Ag1	S-Protien
malaria	B-Disease
infections	I-Disease
in	O
pregnant	O
mothers	O
using	O
either	O
DP	O
or	O
SP	O
does	O
not	O
affect	O
expression	O
of	O
antibodies	O
against	O
poorest	O
had	O
the	O
highest	O
risk	O
of	O
in	O
the	O
first	O
birth	O
year	O
AHR	O
1	O
79	O
95	O
CI	O
1	O
31	O
2	O
4	O
Children	O
born	O
to	O
mothers	O
who	O
had	O
malaria	O
g	O
malaria	O
in	O
the	O
first	O
birth	O
year	O
AHR	O
1	O
30	O
95	O
CI	O
0	O
97	O
1	O
7	O
and	O
1	O
35	O
95	O
CI	O
1	O
03	O
1	O
78	O
1	O
32	O
95	O
CI	O
1	O
00	O
1	O
74	O
1	O
21	O
95	O
CI	O
0	O
97	O
1	O
52	O
Children	O
born	O
to	O
mothers	O
1	O
25	O
95	O
CI	O
0	O
98	O
1	O
60	O
1	O
83	O
95	O
CI	O
1	O
15	O
2	O
93	O
categorized	O
as	O
the	O
cord	O
blood	O
Poverty	O
and	O
during	O
pregnancy	O
are	O
key	O
risk	O
factors	O
o	O
born	O
in	O
malaria	O
endemic	O
areas	O
pecific	O
antigens	O
does	O
not	O
protect	O
against	O
in	O
the	O
first	O
birth	O
year	O
of	O
growth	O
of	O
specific	O
antigens	O
in	O
children	O
Antibodies	O
against	O
 malaria	S-Disease
malaria	S-Disease
Delayed	O
treatment	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
severe	O
endemic	O
areas	O
the	O
main	O
factors	O
associated	O
with	O
delay	O
in	O
seeking	O
healthcare	O
are	O
low	O
educational	O
level	O
and	O
traditional	O
beliefs	O
In	O
imported	O
 malaria	S-Disease
determinants	O
of	O
delay	O
in	O
seeking	O
healthcare	O
are	O
currently	O
unknown	O
nWe	O
studied	O
all	O
patients	O
presenting	O
with	O
malaria	O
from	O
January	O
1st	O
2017	O
to	O
February	O
14	O
2022	O
in	O
the	O
hospital	O
of	O
Melun	O
France	O
Demographic	O
and	O
medical	O
data	O
were	O
recorded	O
for	O
all	O
patients	O
and	O
socio	O
professional	O
data	O
in	O
a	O
subgroup	O
of	O
hospitalized	O
adults	O
Relative	O
risks	O
and	O
95	O
confidence	O
intervals	O
were	O
determined	O
using	O
univariate	O
analysis	O
by	O
cross	O
tabulation	O
234	O
patients	O
were	O
included	O
all	O
travelling	O
from	O
Africa	O
Among	O
them	O
218	O
93	O
were	O
infected	O
with	O
P. falciparum,	S-Organism
severe malaria	S-Disease
77	O
33	O
had	O
26	O
11	O
were	O
younger	O
than	O
18	O
years	O
old	O
and	O
81	O
were	O
included	O
during	O
the	O
 SARS-CoV-2	S-Disease
pandemic	O
There	O
were	O
135	O
hospitalized	O
adults	O
58	O
of	O
all	O
patients	O
The	O
median	O
time	O
to	O
first	O
medical	O
consultation	O
TFMC	O
defined	O
by	O
the	O
period	O
from	O
onset	O
of	O
symptoms	O
to	O
first	O
medical	O
advice	O
was	O
3	O
days	O
IQR	O
1	O
5	O
A	O
TFMC	O
3	O
days	O
tended	O
to	O
be	O
more	O
frequent	O
in	O
travellers	O
visiting	O
friends	O
and	O
relatives	O
VFR	O
RR	O
1	O
44	O
95	O
CI	O
1	O
0	O
2	O
05	O
p	O
0	O
06	O
while	O
it	O
was	O
less	O
frequent	O
in	O
children	O
and	O
teenagers	O
RR	O
0	O
58	O
95	O
CI	O
0	O
39	O
0	O
84	O
p	O
0	O
01	O
Gender	O
African	O
background	O
unemployment	O
living	O
alone	O
and	O
absence	O
of	O
referring	O
physician	O
were	O
not	O
associated	O
with	O
delay	O
in	O
seeking	O
healthcare	O
Consulting	O
during	O
the	O
SARS	O
CoV	O
2	O
pandemic	O
was	O
not	O
associated	O
with	O
a	O
longer	O
TFMC	O
nor	O
with	O
a	O
higher	O
rate	O
of	O
severe	O
malaria	O
nIn	O
contrast	O
to	O
an	O
endemic	O
area	O
socio	O
economic	O
factors	O
did	O
not	O
impact	O
on	O
delay	O
in	O
seeking	O
healthcare	O
in	O
imported	O
malaria	O
Prevention	O
should	O
focus	O
on	O
VFR	O
subjects	O
who	O
tend	O
to	O
consult	O
later	O
than	O
other	O
travellers	O
Adult 	B-Organism
mosquito	I-Organism
females	E-Organism
through	O
their	O
bites	O
are	O
responsible	O
for	O
the	O
transmission	O
of	O
different	O
zoonotic 	B-Organism
pathogens	I-Organism
Although	O
adult	O
control	O
represents	O
a	O
pillar	O
for	O
the	O
prevention	O
of	O
disease	O
spread	O
larval	O
control	O
is	O
also	O
crucial	O
Herein	O
we	O
characterized	O
the	O
effectiveness	O
of	O
a	O
suitable	O
tool	O
named	O
MosChito	O
raft	O
for	O
the	O
aquatic	O
delivery	O
of	O
a	O
Bacillus 	B-Organism
thuringiensis	I-Organism
var. israelensis	E-Organism
Bti	O
formulate	O
a	O
bioinsecticide	O
active	O
by	O
ingestion	O
against	O
mosquito	O
larvae	O
MosChito	O
raft	O
is	O
a	O
floating	O
tool	O
composed	O
by	O
chitosan	O
cross	O
linked	O
with	O
genipin	O
in	O
which	O
a	O
Bti	O
based	O
formulate	O
and	O
an	O
attractant	O
have	O
been	O
included	O
MosChito	O
rafts	O
i	O
resulted	O
attractive	O
for	O
the	O
larvae	O
of	O
the	O
Asian	O
tiger	O
mosquito	O
Aedes	O
albopictus	O
ii	O
induced	O
larval	O
mortality	O
within	O
a	O
few	O
hours	O
of	O
exposure	O
and	O
more	O
importantly	O
iii	O
protected	O
the	O
Bti	O
based	O
formulate	O
whose	O
insecticidal	O
activity	O
was	O
maintained	O
for	O
more	O
than	O
one	O
month	O
in	O
comparison	O
to	O
the	O
few	O
days	O
residual	O
activity	O
of	O
the	O
commercial	O
product	O
The	O
delivery	O
method	O
was	O
effective	O
in	O
both	O
laboratory	O
and	O
semi	O
field	O
conditions	O
demonstrating	O
that	O
MosChito	O
rafts	O
may	O
represent	O
an	O
original	O
eco	O
based	O
and	O
user	O
friendly	O
solution	O
for	O
larval	O
control	O
in	O
domestic	O
and	O
peri	O
domestic	O
aquatic	O
habitats	O
such	O
as	O
saucers	O
and	O
artificial	O
containers	O
in	O
residential	O
or	O
urban	O
environments	O
Eukaryotes	S_Anatomical_Substances
have	O
canonical	O
pathways	O
for	O
responding	O
to	O
amino acid 	S-Protien
AA	O
availability	O
Under	O
AA	O
limiting	O
conditions	O
the	O
TOR	O
complex	O
is	O
repressed	O
whereas	O
the	O
 sensor	B-Anatomical_Substances
kinase 	I-Anatomical_Substances
GCN2 i	E-Anatomical_Substances
activated	O
While	O
these	O
pathways	O
have	O
been	O
highly	O
conserved	O
throughout	O
evolution	O
malaria	B-Organism
parasites 	I-Organism
are	O
a	O
rare	O
exception	O
Despite	O
auxotrophic	O
for	O
most	O
AA	O
Plasmodium	S-Organism
does	O
not	O
have	O
either	O
a	O
TOR	O
complex	O
nor	O
the	O
GCN2	O
downstream	O
transcription	O
factors	O
While	O
Ile	O
starvation	O
has	O
been	O
shown	O
to	O
trigger	O
growth	O
and	O
survival	O
parasite	S-Organism
Collectively	O
our	O
data	O
disclose	O
a	O
set	O
of	O
heterogeneous	O
responses	O
to	O
AA	O
depletion	O
in	O
malaria 	B-Organism
parasites	I-Organism
mediated	O
by	O
a	O
complex	O
mechanism	O
that	O
is	O
critical	O
for	O
modulating	O
eIF2α	B-Protien
phosphorylation	I-Protien
and	O
a	O
hibernation	O
like	O
response	O
the	O
overall	O
mechanisms	O
mediating	O
detection	O
and	O
response	O
to	O
AA	O
fluctuation	O
in	O
the	O
absence	O
of	O
such	O
pathways	O
has	O
remained	O
elusive	O
Here	O
we	O
show	O
that	O
Plasmodium 	B-Organism
parasites	I-Organism
rely	O
on	O
an	O
efficient	O
sensing	O
pathway	O
to	O
respond	O
to	O
AA	O
fluctuations	O
A	O
phenotypic	O
screen	O
of	O
kinase	O
knockout	O
mutant	O
parasites	O
identified	O
nek4	S-Protien
eIK1	S-Protien
eIK2	S-Protien
the	O
last	O
two	O
clustering	O
with	O
the	O
 eukaryotic	B-Protien
eIF2α	I-Protien
kinases	E-Protien
as	O
critical	O
for	O
Plasmodium	S-Organism
to	O
sense	O
and	O
respond	O
to	O
distinct	O
AA	O
limiting	O
conditions	O
Such	O
AA	O
sensing	O
pathway	O
is	O
temporally	O
regulated	O
at	O
distinct	O
life	O
cycle	O
stages	O
allowing	O
parasites	O
to	O
actively	O
fine	O
tune	O
replication	O
and	O
development	O
in	O
response	O
to	O
AA	O
availability	O
 malaria	S-Disease
Residual	O
transmission	O
is	O
the	O
result	O
of	O
adaptive	O
mosquito	S-Organism
behavior	O
that	O
allows	O
malaria vectors 	S-Disease
to	O
thrive	O
and	O
sustain	O
transmission	O
in	O
the	O
presence	O
of	O
good	O
access	O
to	O
bed	O
nets	O
or	O
insecticide	O
residual	O
spraying	O
These	O
behaviors	O
include	O
crepuscular	O
and	O
outdoor	O
feeding	O
as	O
well	O
as	O
intermittent	O
feeding	O
upon	O
livestock	O
 Ivermectin	S-Medication
antiparasitic 	B-Medication
drug	I-Medication
is	O
a	O
broadly	O
used	O
that	O
kills	O
mosquitoes	S-Organism
feeding	O
on	O
a	O
treated	O
subject	O
for	O
a	O
dose	O
dependent	O
period	O
Mass	O
drug	O
administration	O
with	O
ivermectin	O
has	O
been	O
proposed	O
as	O
a	O
complementary	O
strategy	O
to	O
reduce	O
 malaria	S-Disease
transmission	O
A	O
cluster	O
randomized	O
parallel	O
arm	O
superiority	O
trial	O
conducted	O
in	O
two	O
settings	O
with	O
distinct	O
eco	O
epidemiological	O
conditions	O
in	O
East	O
and	O
Southern	O
Africa	O
There	O
will	O
be	O
three	O
groups	O
human	S-Organism
intervention	O
consisting	O
of	O
a	O
dose	O
of	O
ivermectin 	S-Medication
400	O
mcg	O
kg	O
administered	O
monthly	O
for	O
3	O
months	O
to	O
all	O
the	O
eligible	O
population	O
in	O
the	O
cluster	O
15	O
kg	O
non	O
pregnant	O
and	O
no	O
medical	O
contraindication	O
human	O
and	O
livestock	O
intervention	O
consisting	O
human	O
treatment	O
as	O
above	O
plus	O
treatment	O
of	O
livestock	O
in	O
the	O
area	O
with	O
a	O
single	O
dose	O
of	O
injectable	O
ivermectin	O
200	O
mcg	O
kg	O
monthly	O
for	O
3	O
months	O
and	O
controls	O
consisting	O
of	O
a	O
dose	O
of	O
albendazole	O
400	O
mg	O
monthly	O
for	O
3	O
months	O
The	O
main	O
outcome	O
measure	O
will	O
be	O
malaria	S-Disease
incidence	O
in	O
a	O
cohort	O
of	O
children	O
under	O
five	O
living	O
in	O
the	O
core	O
of	O
each	O
cluster	O
followed	O
prospectively	O
with	O
monthly	O
RDTs	O
DISCUSSION	O
The	O
second	O
site	O
for	O
the	O
implementation	O
of	O
this	O
protocol	O
has	O
changed	O
from	O
Tanzania	O
to	O
Kenya	O
This	O
summary	O
presents	O
the	O
Mozambique	O
specific	O
protocol	O
while	O
the	O
updated	O
master	O
protocol	O
and	O
the	O
adapted	O
Kenya	O
specific	O
protocol	O
undergo	O
national	O
approval	O
in	O
Kenya	O
BOHEMIA	O
will	O
be	O
the	O
first	O
large	O
scale	O
trial	O
evaluating	O
the	O
impact	O
of	O
ivermectin	O
only	O
mass	O
drug	O
administration	O
to	O
humans	O
or	O
humans	O
and	O
cattle	O
on	O
local	O
malaria	O
transmission	O
TRIAL	O
REGISTRATION	O
ClinicalTrials	O
gov	O
NCT04966702	O
Registered	O
on	O
July	O
19	O
2021	O
Pan	O
African	O
Clinical	O
Trials	O
Registry	O
PACTR202106695877303	O
malaria	S-Disease
Global	O
cases	O
rose	O
by	O
14	O
million	O
and	O
deaths	O
by	O
69	O
000	O
in	O
2020	O
In	O
India	O
a	O
46	O
decline	O
has	O
been	O
reported	O
between	O
2020	O
and	O
2019	O
In	O
2017	O
the	O
Malaria	S-Disease
Elimination	O
Demonstration	O
Project	O
conducted	O
a	O
needs	O
assessment	O
of	O
the	O
Accredited	O
Social	O
Health	O
Activists	O
ASHAs	O
of	O
Mandla	O
district	O
This	O
survey	O
revealed	O
the	O
inadequate	O
level	O
of	O
knowledge	O
in	O
malaria	O
diagnosis	O
and	O
treatment	O
Subsequently	O
a	O
training	O
programme	O
was	O
launched	O
for	O
enhancing	O
malaria-	S-Disease
related	O
knowledge	O
of	O
ASHAs	O
The	O
present	O
study	O
was	O
conducted	O
in	O
2021	O
to	O
evaluate	O
the	O
impact	O
of	O
training	O
on	O
malaria	O
related	O
knowledge	O
and	O
practices	O
of	O
ASHAs	O
in	O
Mandla	O
This	O
assessment	O
was	O
also	O
done	O
in	O
two	O
adjoining	O
districts	O
Balaghat	O
and	O
Dindori	O
nA	O
cross	O
sectional	O
survey	O
using	O
a	O
structured	O
questionnaire	O
was	O
administered	O
to	O
ASHAs	O
to	O
measure	O
their	O
knowledge	O
and	O
practices	O
related	O
to	O
malaria	O
etiology	O
prevention	O
diagnosis	O
and	O
treatment	O
A	O
comparison	O
of	O
information	O
collected	O
from	O
these	O
three	O
districts	O
was	O
performed	O
using	O
simple	O
descriptive	O
statistics	O
comparison	O
of	O
means	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
nSignificant	O
improvement	O
was	O
noted	O
amongst	O
ASHAs	O
of	O
district	O
Mandla	O
between	O
2017	O
baseline	O
and	O
2021	O
endline	O
in	O
knowledge	O
related	O
to	O
malaria	O
transmission	O
preventive	O
measures	O
adherence	O
to	O
the	O
national	O
drug	O
policy	O
diagnosis	O
using	O
rapid	O
diagnostic	O
tests	O
and	O
identification	O
of	O
age	O
group	O
specific	O
colour	O
coded	O
artemisinin	O
combination	O
therapy	O
blister	O
packs	O
p	O
0	O
05	O
The	O
multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
odds	O
of	O
Mandla	O
baseline	O
was	O
0	O
39	O
0	O
48	O
0	O
34	O
and	O
0	O
07	O
times	O
lower	O
for	O
malaria	O
related	O
knowledge	O
on	O
disease	O
etiology	O
prevention	O
diagnosis	O
and	O
treatment	O
respectively	O
p	O
0	O
001	O
Further	O
participants	O
in	O
districts	O
Balaghat	O
and	O
Dindori	O
showed	O
significantly	O
lower	O
odds	O
for	O
knowledge	O
p	O
0	O
001	O
and	O
treatment	O
practices	O
p	O
0	O
01	O
compared	O
to	O
Mandla	O
endline	O
Education	O
attended	O
training	O
having	O
a	O
malaria	O
learner	O
s	O
guide	O
and	O
minimum	O
10	O
years	O
work	O
experience	O
were	O
potential	O
predictors	O
for	O
good	O
treatment	O
practices	O
nThe	O
findings	O
of	O
the	O
study	O
unequivocally	O
establishes	O
significant	O
improvement	O
in	O
overall	O
malaria	O
related	O
knowledge	O
and	O
practices	O
of	O
ASHAs	O
in	O
Mandla	O
as	O
a	O
result	O
of	O
periodic	O
training	O
and	O
capacity	O
building	O
efforts	O
The	O
study	O
suggests	O
that	O
learnings	O
from	O
Mandla	O
district	O
could	O
be	O
helpful	O
in	O
improving	O
level	O
of	O
knowledge	O
and	O
practices	O
among	O
frontline	O
health	O
workers	O
Insecticide	S-Chemical_Substance
treated	O
nets	O
ITN	O
are	O
the	O
cornerstone	O
of	O
modern	O
malaria vector	B-Organism
control	O
with	O
nearly	O
3	O
billion	O
ITNs	O
delivered	O
to	O
households	O
in	O
endemic	O
areas	O
since	O
2000	O
ITN	O
access	O
i	O
e	O
availability	O
within	O
the	O
household	O
based	O
on	O
the	O
number	O
of	O
ITNs	O
and	O
number	O
of	O
household	O
members	O
is	O
a	O
pre	O
requisite	O
for	O
ITN	O
use	O
Factors	O
determining	O
ITN	O
use	O
are	O
frequently	O
examined	O
in	O
published	O
literature	O
but	O
to	O
date	O
large	O
household	O
survey	O
data	O
on	O
reasons	O
given	O
for	O
non	O
use	O
of	O
nets	O
have	O
not	O
been	O
explored	O
A	O
total	O
of	O
156	O
DHS	O
MIS	O
and	O
MICS	O
surveys	O
conducted	O
between	O
2003	O
and	O
2021	O
were	O
reviewed	O
for	O
questions	O
on	O
reasons	O
why	O
nets	O
were	O
not	O
used	O
the	O
previous	O
night	O
identifying	O
twenty	O
seven	O
surveys	O
The	O
percent	O
of	O
nets	O
that	O
were	O
reported	O
used	O
the	O
previous	O
night	O
was	O
calculated	O
for	O
the	O
156	O
surveys	O
and	O
frequencies	O
and	O
proportions	O
of	O
reasons	O
for	O
non	O
use	O
were	O
calculated	O
within	O
the	O
twenty	O
seven	O
surveys	O
Results	O
were	O
stratified	O
by	O
household	O
supply	O
of	O
ITNs	O
in	O
three	O
categories	O
not	O
enough	O
enough	O
and	O
more	O
than	O
enough	O
and	O
by	O
residence	O
urban	O
rural	O
The	O
proportion	O
of	O
nets	O
used	O
the	O
previous	O
night	O
averaged	O
over	O
70	O
between	O
2003	O
and	O
2021	O
with	O
no	O
discernible	O
change	O
over	O
this	O
period	O
Reported	O
reasons	O
for	O
why	O
a	O
net	O
goes	O
unused	O
fell	O
largely	O
into	O
three	O
categories	O
nets	O
that	O
are	O
extra	O
being	O
saved	O
for	O
future	O
use	O
the	O
perception	O
that	O
there	O
is	O
little	O
risk	O
of	O
malaria	O
particularly	O
in	O
dry	O
season	O
and	O
other	O
responses	O
Net	O
attributes	O
such	O
as	O
colour	O
size	O
shape	O
and	O
texture	O
and	O
concerns	O
related	O
to	O
chemicals	O
were	O
the	O
least	O
frequent	O
reasons	O
given	O
Reasons	O
for	O
non	O
use	O
of	O
nets	O
varied	O
by	O
household	O
net	O
supply	O
and	O
in	O
some	O
surveys	O
by	O
residence	O
In	O
Senegal	O
s	O
continuous	O
DHS	O
the	O
proportion	O
of	O
nets	O
used	O
peaked	O
during	O
high	O
transmission	O
season	O
and	O
the	O
proportion	O
of	O
nets	O
that	O
went	O
unused	O
due	O
to	O
no	O
few	O
mosquitoes	O
peaked	O
during	O
the	O
dry	O
season	O
nUnused	O
nets	O
were	O
primarily	O
those	O
being	O
saved	O
for	O
later	O
use	O
or	O
were	O
not	O
used	O
due	O
to	O
perceived	O
low	O
risk	O
of	O
malaria	O
Classifying	O
reasons	O
for	O
non	O
use	O
into	O
broader	O
categories	O
facilitates	O
the	O
design	O
of	O
appropriate	O
social	O
and	O
behaviour	O
change	O
interventions	O
to	O
address	O
the	O
major	O
underlying	O
reasons	O
for	O
non	O
use	O
where	O
this	O
is	O
feasible	O
Xanthones	S-Chemical_Substance
are	O
widely	O
distributed	O
polyphenols	S-Chemical_Substance
present	O
commonly	O
in	O
higher	O
plants	O
 Garcinia	S-Organism
Calophyllum	S-Organism
Hypericum	S-Organism
Platonia	S-Organism
Mangifera	S-Organism
Gentiana 	S-Organism
Xanthone 	B-Chemical_Substance
 Swertia	S-Organism
tricyclic	I-Chemical_Substance
 scaffold	E-Chemical_Substance
is	O
able	O
to	O
interact	O
with	O
different	O
biological	O
targets	O
showing	O
antibacterial	O
and	O
cytotoxic	O
effects	O
as	O
well	O
as	O
potent	O
effects	O
against	O
osteoarthritis	S-Disease
malaria	S-Disease
cardiovascular	B-Disease
diseases	I-Disease
Thus	O
in	O
this	O
article	O
we	O
focused	O
on	O
pharmacological	O
effects	O
applications	O
and	O
preclinical	O
studies	O
with	O
the	O
recent	O
updates	O
of	O
xanthon	S-Chemical_Substance
isolated	O
compounds	O
from	O
2017	O
2020	O
We	O
found	O
that	O
only	O
 α-mangostin	S-Chemical_Substance
gambogic acid	S-Chemical_Substance
mangiferin	S-Chemical_Substance
have	O
been	O
subjected	O
to	O
preclinical	O
studies	O
with	O
particular	O
emphasis	O
on	O
the	O
development	O
of	O
diabetes	S-Disease
antimicrobial	O
and	O
hepatoprotective	O
therapeutics	O
Molecular	O
docking	O
calculations	O
were	O
performed	O
to	O
predict	O
the	O
binding	O
affinities	O
of	O
xanthone	S-Chemical_Substance
derived	O
compounds	O
against	O
 SARS-CoV-2 	S-Disease
Mpro	O
According	O
to	O
the	O
results	O
cratoxanthone E 	S-Chemical_Substance
morellic acid	S-Chemical_Substance
demonstrated	O
promising	O
binding	O
affinities	O
towards	O
SARS-CoV-2 Mpro	S-Disease
with	O
docking	O
scores	O
of	O
11	O
2	O
and	O
11	O
0	O
kcal	O
mol	O
respectively	O
Binding	O
features	O
manifested	O
the	O
capability	O
of	O
cratoxanthone E	S-Chemical_Substance
morellic acid	S-Chemical_Substance
to	O
exhibit	O
nine	O
and	O
five	O
hydrogen	O
bonds	O
respectively	O
with	O
the	O
key	O
amino	O
acids	O
of	O
the	O
Mpro	O
active	O
site	O
In	O
conclusion	O
cratoxanthone E	S-Chemical_Substance
morellic acid 	S-Chemical_Substance
are	O
promising	O
anti	O
COVID	O
19	O
drug	O
candidates	O
that	O
warrant	O
further	O
detailed	O
in	O
vivo	O
experimental	O
estimation	O
and	O
clinical	O
assessment	O
For	O
a	O
full	O
treatment	O
course	O
of	O
severe	O
malaria	S-Disease
community	O
administered	O
 pre-referral	B-Medication
 rectal	I-Medication
artesunate (	E-Medication
should	O
be	O
completed	O
by	O
post	O
referral	O
treatment	O
consisting	O
of	O
an	O
 injectable antimalarial	B-Medication
oral artemisinin-based 	I-Medication
combination therapy	E-Medication
This	O
study	O
aimed	O
to	O
assess	O
compliance	O
with	O
this	O
treatment	O
recommendation	O
in	O
children	O
under	O
5	O
years	O
This	O
observational	O
study	O
accompanied	O
the	O
implementation	O
of	O
RAS	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
DRC	O
Nigeria	O
and	O
Uganda	O
between	O
2018	O
and	O
2020	O
Antimalarial	O
treatment	O
was	O
assessed	O
during	O
admission	O
in	O
included	O
referral	O
health	O
facilities	O
RHFs	O
in	O
children	O
under	O
5	O
with	O
a	O
diagnosis	O
of	O
severe	O
malaria	S-Disease
Children	O
were	O
either	O
referred	O
from	O
a	O
community	O
based	O
provider	O
or	O
directly	O
attending	O
the	O
RHF	O
RHF	O
data	O
of	O
7	O
983	O
children	O
was	O
analysed	O
for	O
appropriateness	O
of	O
antimalarials	O
a	O
subsample	O
of	O
3	O
449	O
children	O
was	O
assessed	O
additionally	O
for	O
dosage	O
and	O
method	O
of	O
ACT	O
provision	O
treatment	O
compliance	O
A	O
parenteral	O
antimalarial	O
and	O
an	O
ACT	O
were	O
administered	O
to	O
2	O
7	O
28	O
1	O
051	O
of	O
admitted	O
children	O
in	O
Nigeria	O
44	O
5	O
1	O
211	O
2	O
724	O
in	O
Uganda	O
and	O
50	O
3	O
2	O
117	O
4	O
208	O
in	O
DRC	O
Children	O
receiving	O
RAS	O
from	O
a	O
community	O
based	O
provider	O
were	O
more	O
likely	O
to	O
be	O
administered	O
post	O
referral	O
medication	O
according	O
to	O
the	O
guidelines	O
in	O
DRC	O
adjusted	O
odds	O
ratio	O
aOR	O
2	O
13	O
95	O
CI	O
1	O
55	O
to	O
2	O
92	O
P	O
0	O
001	O
but	O
less	O
likely	O
in	O
Uganda	O
aOR	O
0	O
37	O
95	O
CI	O
0	O
14	O
to	O
0	O
96	O
P	O
0	O
04	O
adjusting	O
for	O
patient	O
provider	O
caregiver	O
and	O
other	O
contextual	O
factors	O
While	O
in	O
DRC	O
inpatient	O
ACT	O
administration	O
was	O
common	O
ACTs	O
were	O
often	O
prescribed	O
at	O
discharge	O
in	O
Nigeria	O
54	O
4	O
229	O
421	O
and	O
Uganda	O
53	O
0	O
715	O
1	O
349	O
Study	O
limitations	O
include	O
the	O
unfeasibility	O
to	O
independently	O
confirm	O
the	O
diagnosis	O
of	O
severe	O
malaria	O
due	O
to	O
the	O
observational	O
nature	O
of	O
the	O
study	O
nDirectly	O
observed	O
treatment	O
was	O
often	O
incomplete	O
bearing	O
a	O
high	O
risk	O
for	O
partial	O
parasite	O
clearance	O
and	O
disease	O
recrudescence	O
Parenteral	O
artesunate	O
not	O
followed	O
up	O
with	O
oral	O
ACT	O
constitutes	O
an	O
artemisinin	O
monotherapy	O
and	O
may	O
favour	O
the	O
selection	O
of	O
resistant	O
parasites	O
In	O
connection	O
with	O
the	O
finding	O
that	O
pre	O
referral	O
RAS	O
had	O
no	O
beneficial	O
effect	O
on	O
child	O
survival	O
in	O
the	O
3	O
study	O
countries	O
concerns	O
about	O
an	O
effective	O
continuum	O
of	O
care	O
for	O
children	O
with	O
severe	O
malaria	O
seem	O
justified	O
Stricter	O
compliance	O
with	O
the	O
WHO	O
severe	O
malaria	O
treatment	O
guidelines	O
is	O
critical	O
to	O
effectively	O
manage	O
this	O
disease	O
and	O
further	O
reduce	O
child	O
mortality	O
nClinicalTrials	O
gov	O
NCT03568344	O
The malaria	S-Disease
parasite	B-Organism
Plasmodium	I-Organism
falciparum	E-Organism
replicates	O
via	O
schizogony	O
an	O
unusual	O
type	O
of	O
cell	O
cycle	O
involving	O
asynchronous	O
replication	O
of	O
multiple	O
nuclei	O
within	O
the	O
same	O
cytoplasm	B-Anatomical_Substances
Here	O
we	O
present	O
the	O
first	O
comprehensive	O
study	O
of	O
DNA	O
replication	O
origin	O
specification	O
and	O
activation	O
during	O
Plasmodium	S-Organism
schizogony	O
Potential	O
replication	O
origins	O
were	O
abundant	O
with	O
ORC1	S-Protien
binding	O
sites	O
detected	O
every	O
800	O
bp	O
In	O
this	O
extremely	O
A	O
T	O
biased	O
genome	O
the	O
sites	O
were	O
biased	O
towards	O
areas	O
of	O
higher	O
G	O
C	O
content	O
and	O
contained	O
no	O
specific	O
sequence	O
motif	O
Origin	O
activation	O
was	O
then	O
measured	O
at	O
single	O
molecule	O
resolution	O
using	O
newly	O
developed	O
DNAscent	O
technology	O
a	O
powerful	O
method	O
of	O
detecting	O
replication	O
fork	O
movement	O
via	O
base	O
analogues	O
in	O
DNA	O
sequenced	O
on	O
the	O
Oxford	O
Nanopore	O
platform	O
Unusually	O
origins	O
were	O
preferentially	O
activated	O
in	O
areas	O
of	O
low	O
transcriptional	O
activity	O
and	O
replication	O
forks	O
also	O
moved	O
fastest	O
through	O
lowly	O
transcribed	O
genes	O
This	O
contrasts	O
with	O
the	O
way	O
that	O
origin	O
activation	O
is	O
organised	O
in	O
other	O
systems	O
such	O
as	O
human	O
cells	O
and	O
suggests	O
that	O
P	O
falciparum	O
has	O
evolved	O
its	O
S	O
phase	O
specifically	O
to	O
minimise	O
conflicts	O
between	O
transcription	O
and	O
origin	O
firing	O
This	O
may	O
be	O
particularly	O
important	O
to	O
maximise	O
the	O
efficiency	O
and	O
accuracy	O
of	O
schizogony	O
with	O
its	O
multiple	O
rounds	O
of	O
DNA	O
replication	O
and	O
its	O
absence	O
of	O
canonical	O
cell	O
cycle	O
checkpoints	O
malaria vaccine	S-Medication
that	O
blocks	O
parasite	S-Organism
transmission	O
from	O
human	S-Organism
mosquito 	S-Organism
would	O
be	O
a	O
powerful	O
method	O
of	O
disrupting	O
the	O
parasite	S-Organism
lifecycle	O
and	O
reducing	O
the	O
incidence	O
of	O
disease	O
in	O
humans	S-Organism
 malaria	S-Disease
parasite	B-Organism
Plasmodium 	I-Organism
falciparum	I-Organism
 Pfs48/45	S-Protien
 Pfs48/45	S-Protien
is	O
a	O
promising	O
antigen	O
in	O
development	O
as	O
a	O
transmission	O
blocking	O
vaccine	O
TBV	O
against	O
the	O
deadliest	O
The	O
third	O
domain	O
of	O
D3	O
is	O
an	O
established	O
TBV	O
candidate	O
but	O
production	O
challenges	O
have	O
hampered	O
development	O
For	O
example	O
to	O
date	O
a	O
non	O
native	O
N-glycan	S-Chemical_Substance
is	O
required	O
to	O
stabilize	O
the	O
domain	O
when	O
produced	O
in	O
eukaryotic	O
systems	O
Here	O
we	O
implement	O
a	O
SPEEDesign	O
computational	O
design	O
and	O
in	O
vitro	O
screening	O
pipeline	O
that	O
retains	O
the	O
potent	O
transmission	O
blocking	O
epitope	O
in	O
Pfs48/45 	S-Protien
while	O
creating	O
a	O
stabilized 	B-Protien
non-glycosylated 	I-Protien
Pfs48/45 D3 	E-Protien
antigen	O
with	O
improved	O
characteristics	O
for	O
vaccine	O
manufacture	O
This	O
antigen	O
can	O
be	O
genetically	O
fused	O
to	O
a	O
self	O
assembling	O
single	O
component	O
nanoparticle	O
resulting	O
in	O
a	O
vaccine	O
that	O
elicits	O
potent	O
transmission	O
reducing	O
activity	O
in	O
rodents	O
at	O
low	O
doses	O
The	O
enhanced	O
Pfs48/45	S-Protien
antigen	O
enables	O
many	O
new	O
and	O
powerful	O
approaches	O
to	O
TBV	O
development	O
and	O
this	O
antigen	O
design	O
method	O
can	O
be	O
broadly	O
applied	O
towards	O
the	O
design	O
of	O
other	O
vaccine	O
antigens	O
and	O
therapeutics	O
without	O
interfering	O
glycans	O
Four	O
types	O
of	O
cells	O
were	O
engineered	O
from	O
Artemisia	B-Organism
annua	I-Organism
to	O
produce	O
approximately	O
17	O
anthocyanins	S-Chemical_Substance
four	O
of	O
which	O
were	O
elucidated	O
structurally	O
All	O
of	O
them	O
expressed	O
the	O
artemisinin	S-Medication
Artemisia	B-Organism
annua	I-Organism
is	O
the	O
only	O
medicinal	O
crop	O
to	O
produce	O
artemisinin 	S-Medication
 malignant	B-Disease
malaria	I-Disease
or	O
the	O
treatment	O
of	O
Unfortunately	O
hundreds	O
of	O
thousands	O
of	O
people	O
still	O
lose	O
their	O
life	O
every	O
year	O
due	O
to	O
the	O
lack	O
of	O
sufficient	O
artemisinin	S-Medication
 Artemisinin	S-Medication
considered	O
to	O
result	O
from	O
the	O
spontaneous	O
autoxidation	O
of	O
dihydroartemisinic	B-Chemical_Substance
acid	I-Chemical_Substance
in	O
the	O
presence	O
of	O
 reactive oxygen species 	S-Chemical_Substance
in	O
an	O
oxidative	O
condition	O
of	O
glandular t	B-Chemical_Substance
trichomes	E-Chemical_Substance
however	O
whether	O
increasing	O
antioxidative	O
compounds	O
can	O
inhibit	O
artemisinin 	S-Medication
biosynthesis	O
in	O
plant	O
cells	O
is	O
unknown	O
Anthocyanins	S-Chemical_Substance
are	O
potent	O
antioxidants	O
that	O
can	O
remove	O
ROS	O
in	O
plant	O
cells	O
To	O
date	O
no	O
anthocyanins	S-Chemical_Substance
have	O
been	O
structurally	O
elucidated	O
from	O
A. annua	S-Organism
A. annua	S-Organism
 anthocyanins	S-Chemical_Substance
In	O
this	O
study	O
we	O
had	O
two	O
goals	O
1	O
to	O
engineer	O
cells	O
and	O
2	O
to	O
understand	O
the	O
 artemisinin	S-Medication
 anthocyanin	S-Chemical_Substance
biosynthesis	O
in	O
producing	O
cells	O
Arabidopsis	O
Production	O
of	O
Anthocyanin 	S-Chemical_Substance
Pigment	O
1	O
was	O
used	O
to	O
engineer	O
four	O
types	O
of	O
transgenic	O
anthocyanin	S-Chemical_Substance
A. annua (TAPA1-4)	S-Organism
cells	O
Three	O
wild	O
type	O
cell	O
types	O
were	O
developed	O
as	O
controls	O
 anthocyanins	S-Chemical_Substance
TAPA1	O
cells	O
produced	O
the	O
highest	O
contents	O
of	O
tota	O
LC	O
MS	O
analysis	O
detected	O
17	O
anthocyanin	S-Chemical_Substance
anthocyanidin	S-Chemical_Substance
compounds	O
Crystallization	O
LC	O
MS	O
MS	O
and	O
NMR	O
analyses	O
identified	O
An	O
integrative	O
analysis	O
characterized	O
that	O
four	O
types	O
of	O
TAPA	O
cells	O
expressed	O
the	O
artemisinin 	S-Medication
pathway	O
and	O
TAPA1	O
cells	O
produced	O
the	O
highest	O
artemisinin 	S-Medication
artemisinic acid	S-Chemical_Substance
cyanidin	S-Chemical_Substance
 pelargonidin	S-Chemical_Substance
 one cyanin	S-Chemical_Substance
 one pelargonin	S-Chemical_Substance
The	O
contents	O
of	O
arteannuin	O
B	O
were	O
similar	O
in	O
seven	O
cell	O
types	O
These	O
data	O
showed	O
that	O
the	O
engineering	O
of	O
anthocyanins	O
does	O
not	O
eliminate	O
the	O
biosynthesis	O
of	O
artemisinin	O
in	O
cells	O
These	O
data	O
allow	O
us	O
to	O
propose	O
a	O
new	O
hypothesis	O
that	O
enzymes	O
catalyze	O
the	O
formation	O
of	O
artemisinin	O
from	O
dihydroartemisinic	O
acid	O
in	O
non	O
GT	O
cells	O
These	O
findings	O
show	O
a	O
new	O
platform	O
to	O
increase	O
artemisinin	O
production	O
via	O
non	O
GT	O
cells	O
of	O
A	O
annua	O
This	O
study	O
aimed	O
to	O
evaluate	O
at	O
a	O
temporospatial	O
scale	O
the	O
influence	O
of	O
anthropogenic	O
land	O
cover	O
changes	O
in	O
the	O
 Anopheles	S-Organism
species	O
community	O
composition	O
and	O
diversity	O
in	O
two	O
Colombian	O
malaria	S-Disease
endemic	O
regions	O
Bajo	O
Cauca	O
and	O
Pacific	O
To	O
determine	O
variations	O
over	O
time	O
mosquitoes	S-Organism
were	O
collected	O
in	O
two	O
time	O
periods	O
land	O
cover	O
types	O
were	O
characterized	O
on	O
orthorectified	O
aerial	O
photographs	O
and	O
landscape	O
metrics	O
were	O
estimated	O
for	O
each	O
locality	O
and	O
period	O
A	O
temporal	O
dissimilarity	O
analysis	O
to	O
evaluated	O
species	O
replacement	O
and	O
the	O
nestedness	O
species	O
loss	O
gain	O
showed	O
the	O
influence	O
of	O
the	O
species	O
loss	O
or	O
gain	O
component	O
on	O
 Anopheles	S-Organism
species	O
assemblage	O
23	O
The	O
relationship	O
between	O
land	O
cover	O
variation	O
and	O
Anopheles beta	S-Organism
diversity	O
evaluated	O
by	O
regression	O
analysis	O
showed	O
the	O
effect	O
of	O
forest	O
variation	O
in	O
the	O
Anopheles	S-Organism
community	O
βsim	O
and	O
forest	O
r2	O
0	O
9323	O
βsne	O
and	O
forest	O
r2	O
0	O
9425	O
Furthermore	O
a	O
canonical	O
correspondence	O
analysis	O
showed	O
that	O
the	O
land	O
cover	O
types	O
associated	O
with	O
Anopheles	S-Organism
species	O
presence	O
were	O
bare	O
soil	O
shrub	O
wet	O
areas	O
and	O
forest	O
Results	O
demonstrated	O
the	O
impact	O
of	O
land	O
cover	O
changes	O
attributed	O
to	O
human	O
activities	O
on	O
Anopheles	S-Organism
population	O
dynamics	O
over	O
time	O
this	O
was	O
evidenced	O
as	O
species	O
loss	O
or	O
gain	O
which	O
was	O
specific	O
to	O
each	O
locality	O
Notably	O
the	O
main	O
malaria	S-Disease
vectors	O
were	O
dominant	O
in	O
most	O
localities	O
over	O
time	O
suggesting	O
their	O
tolerance	O
to	O
anthropogenic	O
transformations	O
alternatively	O
the	O
environmental	O
changes	O
are	O
providing	O
adequate	O
ecological	O
conditions	O
for	O
their	O
persistence	O
Finally	O
the	O
data	O
generated	O
are	O
relevant	O
for	O
understanding	O
the	O
impact	O
that	O
environmental	O
change	O
may	O
have	O
on	O
the	O
dynamics	O
of	O
the	O
neotropical	O
malaria	O
vectors	O
Thus	O
this	O
research	O
has	O
potential	O
implications	O
for	O
vector	O
control	O
interventions	O
Zambia	O
experienced	O
a	O
major	O
decline	O
in	O
under	O
five	O
mortality	O
rates	O
U5MR	O
with	O
one	O
of	O
the	O
fastest	O
declines	O
in	O
socio	O
economic	O
disparities	O
in	O
sub	O
Saharan	O
Africa	O
in	O
the	O
last	O
two	O
decades	O
We	O
aimed	O
to	O
understand	O
the	O
extent	O
to	O
which	O
and	O
how	O
Zambia	O
has	O
reduced	O
socio	O
economic	O
inequalities	O
in	O
U5MR	O
since	O
2000	O
Using	O
nationally	O
representative	O
data	O
from	O
Zambia	O
Demographic	O
Health	O
Surveys	O
2001	O
2	O
2007	O
2013	O
14	O
and	O
2018	O
we	O
examined	O
trends	O
and	O
levels	O
of	O
inequalities	O
in	O
under	O
five	O
mortality	O
intervention	O
coverage	O
household	O
water	O
and	O
sanitation	O
and	O
fertility	O
This	O
analysis	O
was	O
integrated	O
with	O
an	O
in	O
depth	O
review	O
of	O
key	O
policy	O
and	O
program	O
documents	O
relevant	O
to	O
improving	O
child	O
survival	O
in	O
Zambia	O
between	O
1990	O
and	O
2020	O
nThe	O
under	O
five	O
mortality	O
rate	O
U5MR	O
declined	O
from	O
168	O
to	O
64	O
deaths	O
per	O
1000	O
live	O
births	O
between	O
2001	O
2	O
and	O
2018	O
ZDHS	O
rounds	O
particularly	O
in	O
the	O
post	O
neonatal	O
period	O
There	O
were	O
major	O
reductions	O
in	O
U5MR	O
inequalities	O
between	O
wealth	O
education	O
and	O
urban	O
rural	O
residence	O
groups	O
Yet	O
reduced	O
gaps	O
between	O
wealth	O
groups	O
in	O
estimated	O
absolute	O
income	O
or	O
education	O
levels	O
did	O
not	O
simultaneously	O
occur	O
Inequalities	O
reduced	O
markedly	O
for	O
coverage	O
of	O
reproductive	O
maternal	O
newborn	O
and	O
child	O
health	O
RMNCH	O
malaria	O
and	O
human	O
immunodeficiency	O
virus	O
interventions	O
but	O
less	O
so	O
for	O
water	O
or	O
sanitation	O
and	O
fertility	O
levels	O
Several	O
policy	O
and	O
health	O
systems	O
drivers	O
were	O
identified	O
for	O
reducing	O
RMNCH	O
inequalities	O
policy	O
commitment	O
to	O
equity	O
in	O
RMNCH	O
financing	O
with	O
a	O
focus	O
on	O
disadvantaged	O
groups	O
multisectoral	O
partnerships	O
and	O
horizontal	O
programming	O
expansion	O
of	O
infrastructure	O
and	O
human	O
resources	O
for	O
health	O
and	O
involvement	O
of	O
community	O
stakeholders	O
and	O
service	O
providers	O
nZambia	O
s	O
major	O
progress	O
in	O
reducing	O
inequalities	O
in	O
child	O
survival	O
between	O
the	O
poorest	O
and	O
richest	O
people	O
appeared	O
to	O
be	O
notably	O
driven	O
by	O
government	O
policies	O
and	O
programs	O
that	O
centrally	O
valued	O
equity	O
despite	O
ongoing	O
gaps	O
in	O
absolute	O
income	O
and	O
education	O
levels	O
Future	O
work	O
should	O
focus	O
on	O
sustaining	O
these	O
gains	O
while	O
targeting	O
families	O
that	O
have	O
been	O
left	O
behind	O
to	O
achieve	O
the	O
sustainable	O
development	O
goal	O
targets	O
Vector	O
populations	O
are	O
a	O
key	O
target	O
for	O
malaria	S-Disease
control	O
and	O
elimination	O
In	O
Honduras	O
there	O
are	O
at	O
least	O
12	O
reported	O
anopheline	S-Organism
species	O
however	O
the	O
definitive	O
number	O
of	O
species	O
remains	O
uncertain	O
Due	O
to	O
the	O
inherent	O
limitations	O
of	O
morphological	O
identification	O
of	O
Anopheles species	S-Organism
molecular	O
approaches	O
have	O
been	O
developed	O
to	O
provide	O
accurate	O
identification	O
and	O
robust	O
surveillance	O
of	O
local	O
malaria vectors	S-Organism
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
design	O
and	O
assess	O
three	O
PCR	O
RFLP	O
assays	O
to	O
identify	O
anopheline	O
species	O
known	O
to	O
presently	O
occur	O
in	O
Honduras	O
Mosquitoes	S-Organism
captured	O
between	O
2018	O
and	O
2022	O
in	O
seven	O
malaria	O
endemic	O
and	O
non	O
endemic	O
departments	O
in	O
Honduras	O
were	O
analysed	O
The	O
ITS2	O
ribosomal	O
region	O
and	O
three	O
restriction	O
enzyme	O
based	O
assays	O
were	O
evaluated	O
in	O
silico	O
and	O
experimentally	O
nA	O
total	O
of	O
132	O
sequences	O
from	O
12	O
anopheline	S-Organism
species	O
were	O
analysed	O
The	O
ITS2	O
marker	O
showed	O
length	O
polymorphisms	O
that	O
generated	O
products	O
between	O
388	O
and	O
592	O
bp	O
and	O
no	O
relevant	O
intraspecies	O
polymorphisms	O
were	O
found	O
Furthermore	O
the	O
three	O
PCR	O
RFLP	O
assays	O
were	O
able	O
to	O
differentiate	O
11	O
species	O
with	O
sufficient	O
precision	O
and	O
resolution	O
nThe	O
ITS2	O
region	O
was	O
shown	O
to	O
be	O
a	O
useful	O
molecular	O
marker	O
for	O
identifying	O
local	O
Anopheles	O
species	O
In	O
addition	O
the	O
PCR	O
RFLP	O
assays	O
evaluated	O
here	O
proved	O
to	O
be	O
capable	O
of	O
discriminating	O
most	O
of	O
the	O
anopheline	O
species	O
present	O
in	O
Honduras	O
These	O
methods	O
provide	O
alternatives	O
to	O
improve	O
entomological	O
surveillance	O
of	O
 Anopheles	S-Organism
in	O
Honduras	O
and	O
other	O
Mesoamerican	O
countries	O
 COVID-19	S-Disease
Management	O
of	O
the	O
pandemic	O
relies	O
on	O
molecular	O
diagnostic	O
methods	O
supported	O
by	O
serological	O
tools	O
Herein	O
we	O
developed	O
 SARS-CoV-2	S-Organism
COVID-19 	S-Disease
S	O
RBD	O
and	O
N	O
based	O
ELISA	O
assays	O
useful	O
for	O
infection	O
rate	O
surveillance	O
as	O
well	O
as	O
the	O
follow	O
up	O
of	O
acquired	O
protective	O
immunity	O
against	O
ELISA	O
assays	O
were	O
optimized	O
using	O
Tunisian	O
patients	O
sera	O
and	O
prepandemic	O
controls	O
Assays	O
were	O
further	O
validated	O
in	O
3	O
African	O
countries	O
with	O
variable	O
endemic	O
settings	O
The	O
receiver	O
operating	O
curve	O
was	O
used	O
to	O
evaluate	O
the	O
assay	O
performances	O
The	O
N	O
and	O
S	O
RBD	O
based	O
ELISA	O
assays	O
performances	O
in	O
Tunisia	O
were	O
very	O
high	O
AUC	O
0	O
966	O
and	O
0	O
98	O
respectively	O
p	O
0	O
0001	O
Cross	O
validation	O
analysis	O
showed	O
similar	O
performances	O
in	O
different	O
settings	O
Cross	O
reactivity	O
with	O
malaria	O
infection	O
against	O
viral	O
antigens	O
was	O
noticed	O
In	O
head	O
to	O
head	O
comparisons	O
with	O
different	O
commercial	O
assays	O
the	O
developed	O
assays	O
showed	O
high	O
agreement	O
This	O
study	O
demonstrates	O
the	O
added	O
value	O
of	O
the	O
developed	O
serological	O
assays	O
in	O
low	O
income	O
countries	O
particularly	O
in	O
ethnically	O
diverse	O
populations	O
with	O
variable	O
exposure	O
to	O
local	O
endemic	O
infectious	O
diseases	O
 pediatric 	B-Disease
pneumonia	I-Disease
pneumonia 	S-Disease
pneumonia	S-Disease
Pneumonia	S-Disease
pneumonia	S-Disease
We	O
determined	O
pulse	O
oximetry	O
benefit	O
in	O
mortality	O
risk	O
stratification	O
and	O
chest	O
indrawing	O
in	O
hospital	O
mortality	O
risk	O
factors	O
nWe	O
report	O
characteristics	O
and	O
in	O
hospital	O
related	O
mortality	O
of	O
children	O
2	O
59	O
months	O
old	O
included	O
in	O
the	O
Research	O
Partnership	O
to	O
Assess	O
WHO	O
Recommendations	O
dataset	O
We	O
developed	O
multivariable	O
logistic	O
regression	O
models	O
of	O
chest	O
indrawing	O
to	O
identify	O
mortality	O
risk	O
factors	O
nAmong	O
285	O
839	O
children	O
164	O
244	O
57	O
5	O
from	O
hospital	O
based	O
studies	O
were	O
included	O
 Pneumonia	S-Disease
case	O
fatality	O
risk	O
CFR	O
without	O
pulse	O
oximetry	O
measurement	O
was	O
higher	O
than	O
with	O
measurement	O
5	O
8	O
95	O
CI	O
5	O
6	O
5	O
9	O
vs	O
2	O
1	O
95	O
CI	O
1	O
9	O
2	O
4	O
One	O
in	O
five	O
children	O
with	O
chest	O
indrawing	O
pneumonia	O
was	O
hypoxemic	O
19	O
7	O
95	O
CI	O
19	O
0	O
20	O
4	O
and	O
the	O
hypoxemic	O
CFR	O
was	O
10	O
3	O
95	O
CI	O
9	O
1	O
11	O
5	O
Other	O
mortality	O
risk	O
factors	O
were	O
younger	O
age	O
either	O
2	O
5	O
months	O
aOR	O
9	O
94	O
95	O
CI	O
6	O
67	O
14	O
84	O
or	O
6	O
11	O
months	O
aOR	O
2	O
67	O
95	O
CI	O
1	O
71	O
4	O
16	O
moderate	O
malnutrition	O
aOR	O
2	O
41	O
95	O
CI	O
1	O
87	O
3	O
09	O
and	O
female	O
sex	O
aOR	O
1	O
82	O
95	O
CI	O
1	O
43	O
2	O
32	O
nChildren	O
with	O
a	O
pulse	O
oximetry	O
measurement	O
had	O
a	O
lower	O
CFR	O
Many	O
children	O
hospitalized	O
with	O
chest	O
indrawing	O
pneumonia	O
were	O
hypoxemic	O
and	O
one	O
in	O
ten	O
died	O
Young	O
age	O
and	O
moderate	O
malnutrition	O
were	O
risk	O
factors	O
for	O
in	O
hospital	O
chest	O
indrawing	O
pneumonia	O
related	O
mortality	O
Pulse	O
oximetry	O
should	O
be	O
integrated	O
in	O
under	O
five	O
pneumonia	O
hospital	O
care	O
Plasmodium	S-Organism
replicates	O
within	O
the	O
liver	O
prior	O
to	O
reaching	O
the	O
bloodstream	O
and	O
infecting	O
red blood cells	S_Anatomical_Substances
Because	O
clinical	O
manifestations	O
of	O
malaria	S-Disease
only	O
arise	O
during	O
the	O
blood	O
stage	O
of	O
infection	O
a	O
perception	O
exists	O
that	O
liver	S_Anatomical_Substances
infection	O
does	O
not	O
impact	O
disease	O
pathology	O
By	O
developing	O
a	O
murine	O
model	O
where	O
the	O
liver	S_Anatomical_Substances
 blood	S_Anatomical_Substances
tages	O
of	O
infection	O
are	O
uncoupled	O
we	O
showed	O
that	O
the	O
integration	O
of	O
signals	O
from	O
both	O
stages	O
dictated	O
mortality	O
outcomes	O
This	O
dichotomy	O
relied	O
on	O
liver	O
stage	O
dependent	O
activation	O
of	O
Vγ4	O
Malaria 	B-Disease
n pregnancy 	I-Disease
increases	O
the	O
risk	O
of	O
poor	O
maternal	O
and	O
infant	O
outcomes	O
To	O
reduce	O
these	O
risks	O
WHO	O
recommends	O
insecticide	O
treated	O
net	O
ITN	O
use	O
intermittent	O
preventive	O
treatment	O
during	O
pregnancy	O
IPTp	O
with	O
sulfadoxine	B-Medication
pyrimethamine	I-Medication
and	O
prompt	O
case	O
management	O
However	O
uptake	O
of	O
these	O
interventions	O
remains	O
sub	O
optimal	O
in	O
Madagascar	O
A	O
scoping	O
review	O
was	O
conducted	O
to	O
determine	O
the	O
breadth	O
and	O
depth	O
of	O
information	O
available	O
during	O
2010	O
2021	O
about	O
Madagascar	O
s	O
MIP	O
activities	O
and	O
to	O
identify	O
barriers	O
and	O
facilitators	O
to	O
MIP	O
interventions	O
uptake	O
nPubMed	O
Google	O
Scholar	O
and	O
USAID	O
s	O
files	O
Development	O
Experience	O
Catalog	O
were	O
searched	O
using	O
the	O
terms	O
Madagascar	O
AND	O
pregnancy	O
AND	O
malaria	O
and	O
reports	O
and	O
materials	O
from	O
stakeholders	O
were	O
collected	O
Documents	O
in	O
English	O
and	O
French	O
from	O
2010	O
to	O
2021	O
with	O
data	O
regarding	O
MIP	O
were	O
included	O
Documents	O
were	O
systematically	O
reviewed	O
and	O
summarized	O
results	O
were	O
captured	O
in	O
an	O
Excel	O
database	O
Of	O
91	O
project	O
reports	O
surveys	O
and	O
published	O
articles	O
23	O
25	O
fell	O
within	O
the	O
stated	O
time	O
period	O
and	O
contained	O
relevant	O
data	O
on	O
MIP	O
activities	O
in	O
Madagascar	O
and	O
were	O
categorized	O
accordingly	O
eight	O
35	O
quality	O
of	O
care	O
including	O
health	O
facility	O
readiness	O
provider	O
knowledge	O
and	O
commodity	O
availability	O
nine	O
39	O
care	O
seeking	O
behaviour	O
and	O
six	O
26	O
prevention	O
of	O
MIP	O
Key	O
barriers	O
were	O
identified	O
nine	O
articles	O
mentioned	O
SP	O
stockouts	O
seven	O
found	O
limitations	O
of	O
provider	O
knowledge	O
attitudes	O
and	O
behaviours	O
KAB	O
regarding	O
MIP	O
treatment	O
and	O
prevention	O
and	O
one	O
reported	O
limited	O
supervision	O
MIP	O
care	O
seeking	O
and	O
prevention	O
barriers	O
and	O
facilitators	O
included	O
women	O
s	O
KAB	O
regarding	O
MIP	O
treatment	O
and	O
prevention	O
distance	O
wait	O
times	O
poor	O
service	O
quality	O
cost	O
and	O
or	O
unwelcoming	O
providers	O
A	O
2015	O
survey	O
of	O
52	O
health	O
facilities	O
revealed	O
limited	O
client	O
access	O
to	O
antenatal	O
care	O
due	O
to	O
financial	O
and	O
geographic	O
barriers	O
two	O
2018	O
surveys	O
revealed	O
similar	O
findings	O
Self	O
treatment	O
and	O
care	O
seeking	O
delays	O
were	O
reported	O
even	O
when	O
distance	O
was	O
not	O
a	O
barrier	O
nAmong	O
the	O
studies	O
and	O
reports	O
on	O
MIP	O
in	O
Madagascar	O
the	O
scoping	O
review	O
frequently	O
noted	O
barriers	O
that	O
could	O
be	O
mitigated	O
by	O
reducing	O
stockouts	O
improving	O
provider	O
knowledge	O
and	O
attitudes	O
refining	O
MIP	O
communication	O
and	O
improving	O
service	O
access	O
There	O
is	O
a	O
need	O
for	O
coordinated	O
efforts	O
to	O
address	O
the	O
identified	O
barriers	O
is	O
the	O
key	O
implication	O
of	O
the	O
findings	O
The	O
2021	O
Global	O
Vaccine	O
and	O
Immunization	O
Research	O
Forum	O
highlighted	O
the	O
considerable	O
advances	O
and	O
recent	O
progress	O
in	O
research	O
and	O
development	O
for	O
vaccines	O
and	O
immunization	O
critically	O
reviewed	O
lessons	O
learned	O
from	O
COVID-19 	S-Disease
vaccine	O
programs	O
and	O
looked	O
ahead	O
to	O
opportunities	O
for	O
this	O
decade	O
For	O
COVID-19,	S-Disease
decades	O
of	O
investments	O
in	O
basic	O
and	O
translational	O
research	O
new	O
technology	O
platforms	O
and	O
vaccines	O
targeting	O
prototype	O
pathogens	O
enabled	O
a	O
rapid	O
global	O
response	O
Unprecedented	O
global	O
coordination	O
and	O
partnership	O
have	O
played	O
an	O
essential	O
role	O
in	O
creating	O
and	O
delivering	O
COVID-19 vaccines	S-Disease
More	O
improvement	O
is	O
needed	O
in	O
product	O
attributes	O
such	O
as	O
deliverability	O
and	O
in	O
equitable	O
access	O
to	O
vaccines	O
Developments	O
in	O
other	O
priority	O
areas	O
included	O
the	O
halting	O
of	O
two	O
human	O
immunodeficiency	O
virus	O
vaccine	O
trials	O
due	O
to	O
lack	O
of	O
efficacy	O
in	O
preventing	O
infection	O
promising	O
efficacy	O
results	O
in	O
Phase	O
2	O
trials	O
of	O
two	O
tuberculosis	S-Disease
vaccines	O
pilot	O
implementation	O
of	O
the	O
most	O
advanced	O
malaria	O
vaccine	O
candidate	O
in	O
three	O
countries	O
trials	O
of	O
human	B-Medication
papillomavirus	I-Medication
vaccines 	E-Medication
given	O
in	O
single	O
dose	O
regimens	O
and	O
emergency	O
use	O
listing	O
of	O
a	O
novel	O
oral	O
poliomyelitis	O
type	O
2	O
vaccine	O
More	O
systematic	O
proactive	O
approaches	O
are	O
being	O
developed	O
for	O
fostering	O
vaccine	O
uptake	O
and	O
demand	O
aligning	O
on	O
priorities	O
for	O
investment	O
by	O
the	O
public	O
and	O
private	O
sectors	O
and	O
accelerating	O
policy	O
making	O
Participants	O
emphasized	O
that	O
addressing	O
endemic	O
disease	O
is	O
intertwined	O
with	O
emergency	O
preparedness	O
and	O
pandemic	O
response	O
so	O
that	O
advances	O
in	O
one	O
area	O
create	O
opportunities	O
in	O
the	O
other	O
In	O
this	O
decade	O
advances	O
made	O
in	O
response	O
to	O
the	O
COVID-19	S-Disease
pandemic	O
should	O
accelerate	O
availability	O
of	O
vaccines	O
for	O
other	O
diseases	O
contribute	O
to	O
preparedness	O
for	O
future	O
pandemics	O
and	O
help	O
to	O
achieve	O
impact	O
and	O
equity	O
under	O
Immunization	O
Agenda	O
2030	O
Multidose	O
presentation	O
of	O
vaccines	O
is	O
the	O
most	O
preferred	O
choice	O
for	O
mass	O
immunization	O
particularly	O
during	O
pandemics	O
WHO	O
also	O
recommends	O
multidose	O
containers	O
of	O
fill	O
finished	O
vaccines	O
for	O
programmatic	O
suitability	O
and	O
global	O
immunizations	O
programmes	O
However	O
multidose	O
vaccine	O
presentations	O
requires	O
inclusion	O
of	O
preservatives	O
to	O
prevent	O
contaminations	O
2-Phenoxy ethanol	S-Chemical_Substance
is	O
one	O
such	O
preservative	O
which	O
is	O
being	O
used	O
in	O
numerous	O
cosmetics	O
and	O
many	O
vaccines	O
recently	O
Estimation	O
of	O
2	O
PE	O
content	O
in	O
multidose	O
vials	O
is	O
a	O
crucial	O
quality	O
control	O
parameter	O
to	O
ensure	O
in	O
use	O
stability	O
of	O
the	O
vaccines	O
Presently	O
available	O
conventional	O
methods	O
have	O
their	O
own	O
limitation	O
in	O
terms	O
of	O
being	O
time	O
consuming	O
requiring	O
sample	O
extraction	O
large	O
sample	O
volume	O
requirement	O
etc	O
Therefore	O
a	O
robust	O
simple	O
high	O
throughput	O
method	O
with	O
a	O
low	O
turnaround	O
time	O
was	O
required	O
which	O
can	O
quantitate	O
2	O
PE	O
content	O
in	O
the	O
conventional	O
combination	O
vaccines	O
as	O
well	O
as	O
new	O
generation	O
complex	O
VLP	O
based	O
vaccines	O
In	O
order	O
to	O
address	O
this	O
issue	O
a	O
novel	O
absorbance	O
based	O
method	O
has	O
been	O
developed	O
This	O
novel	O
method	O
specifically	O
detects	O
2	O
PE	O
content	O
in	O
Matrix	O
M1	O
adjuvanted	O
R21	O
malaria	O
vaccine	O
nano	O
particle	O
and	O
viral	O
vector	O
based	O
covid	O
vaccines	O
and	O
combination	O
vaccines	O
like	O
Hexavalent	O
vaccine	O
The	O
method	O
has	O
been	O
validated	O
for	O
parameters	O
such	O
as	O
linearity	O
accuracy	O
and	O
precision	O
Importantly	O
this	O
method	O
works	O
even	O
in	O
presence	O
of	O
high	O
amounts	O
of	O
proteins	O
and	O
residual	O
DNA	O
Considering	O
the	O
advantages	O
associated	O
with	O
method	O
under	O
study	O
this	O
method	O
can	O
be	O
used	O
as	O
an	O
important	O
in	O
process	O
or	O
release	O
quality	O
parameter	O
to	O
estimate	O
the	O
2	O
PE	O
content	O
in	O
various	O
vaccines	O
containing	O
2	O
PE	O
in	O
multidose	O
presentations	O
Rapid	O
diagnostic	O
tests	O
RDTs	O
are	O
effective	O
tools	O
to	O
diagnose	O
and	O
inform	O
the	O
treatment	O
of	O
malaria	S-Disease
in	O
adults	O
and	O
children	O
The	O
recent	O
development	O
of	O
a	O
highly	O
sensitive	O
rapid	O
diagnostic	O
test	O
HS	O
RDT	O
for	O
Plasmodium	B-Organism
falciparum	I-Organism
has	O
prompted	O
questions	O
over	O
whether	O
it	O
could	O
improve	O
the	O
diagnosis	O
of	O
malaria	O
in	O
pregnancy	O
and	O
pregnancy	O
outcomes	O
in	O
malaria	S-Disease
endemic	O
areas	O
This	O
landscape	O
review	O
collates	O
studies	O
addressing	O
the	O
clinical	O
performance	O
of	O
the	O
HS	O
RDT	O
Thirteen	O
studies	O
were	O
identified	O
comparing	O
the	O
HS	O
RDT	O
and	O
conventional	O
RDT	O
co	O
RDT	O
to	O
molecular	O
methods	O
to	O
detect	O
malaria	O
in	O
pregnancy	O
Using	O
data	O
from	O
five	O
completed	O
studies	O
the	O
association	O
of	O
epidemiological	O
and	O
pregnancy	O
related	O
factors	O
on	O
the	O
sensitivity	O
of	O
HS	O
RDT	O
and	O
comparisons	O
with	O
co	O
RDT	O
were	O
investigated	O
The	O
studies	O
were	O
conducted	O
in	O
4	O
countries	O
over	O
a	O
range	O
of	O
transmission	O
intensities	O
in	O
largely	O
asymptomatic	O
women	O
Sensitivity	O
of	O
both	O
RDTs	O
varied	O
widely	O
HS	O
RDT	O
range	O
19	O
6	O
to	O
85	O
7	O
co	O
RDT	O
range	O
22	O
8	O
to	O
82	O
8	O
compared	O
to	O
molecular	O
testing	O
yet	O
HS	O
RDT	O
detected	O
individuals	O
with	O
similar	O
parasite	O
densities	O
across	O
all	O
the	O
studies	O
including	O
different	O
geographies	O
and	O
transmission	O
areas	O
geometric	O
mean	O
parasitaemia	O
around	O
100	O
parasites	O
per	O
µL	O
p	O
µL	O
HS	O
RDTs	O
were	O
capable	O
of	O
detecting	O
low	O
density	O
parasitaemias	O
and	O
in	O
one	O
study	O
detected	O
around	O
30	O
of	O
infections	O
with	O
parasite	O
densities	O
of	O
0	O
2	O
p	O
µL	O
compared	O
to	O
the	O
co	O
RDT	O
in	O
the	O
same	O
study	O
which	O
detected	O
around	O
15	O
nThe	O
HS	O
RDT	O
has	O
a	O
slightly	O
higher	O
analytical	O
sensitivity	O
to	O
detect	O
malaria	O
infections	O
in	O
pregnancy	O
than	O
co	O
RDT	O
but	O
this	O
mostly	O
translates	O
to	O
only	O
fractional	O
and	O
not	O
statistically	O
significant	O
improvement	O
in	O
clinical	O
performance	O
by	O
gravidity	O
trimester	O
geography	O
or	O
transmission	O
intensity	O
The	O
analysis	O
presented	O
here	O
highlights	O
the	O
need	O
for	O
larger	O
and	O
more	O
studies	O
to	O
evaluate	O
incremental	O
improvements	O
in	O
RDTs	O
The	O
HS	O
RDT	O
could	O
be	O
used	O
in	O
any	O
situation	O
where	O
co	O
RDT	O
are	O
currently	O
used	O
for	O
P	O
falciparum	O
diagnosis	O
if	O
storage	O
conditions	O
can	O
be	O
adhered	O
to	O
 armamentarium	S-Medication
While	O
prevention	O
is	O
a	O
bedrock	O
of	O
public	O
health	O
innovative	O
therapeutics	O
are	O
needed	O
to	O
complement	O
the	O
of	O
interventions	O
required	O
to	O
achieve	O
disease	O
control	O
and	O
elimination	O
targets	O
for	O
neglected	O
diseases	O
Extraordinary	O
advances	O
in	O
drug	O
discovery	O
technologies	O
have	O
occurred	O
over	O
the	O
past	O
decades	O
along	O
with	O
accumulation	O
of	O
scientific	O
knowledge	O
and	O
experience	O
in	O
pharmacological	O
and	O
clinical	O
sciences	O
that	O
are	O
transforming	O
many	O
aspects	O
of	O
drug	O
R	O
D	O
across	O
disciplines	O
We	O
reflect	O
on	O
how	O
these	O
advances	O
have	O
propelled	O
drug	O
discovery	O
for	O
parasitic infections,	S-Disease
malaria,	S-Disease
kinetoplastid diseases	S-Disease
 cryptosporidiosis	S-Disease
antiparasitic drugs	S-Medication
We	O
also	O
discuss	O
challenges	O
and	O
research	O
priorities	O
to	O
accelerate	O
discovery	O
and	O
development	O
of	O
urgently	O
needed	O
nove	O
Artemisinin	B-Medication
-based 	I-Medication
combination therapy	E-Medication
(ACT)	S-Medication
malaria in	S-Disease
Artemisinin	S-Medication
s	O
the	O
first	O
line	O
treatment	O
for	O
uncomplicated	O
malaria	O
in	O
Ghana	O
ART	O
tolerance	O
in	O
Plasmodium	B-Organism
falciparum	I-Organism
has	O
arisen	O
in	O
Southeast	O
Asia	O
and	O
recently	O
in	O
parts	O
of	O
East	O
Africa	O
This	O
is	O
ascribed	O
to	O
the	O
survival	O
of	O
ring	O
stage	O
parasites	O
post	O
treatment	O
The	O
present	O
study	O
sought	O
to	O
assess	O
and	O
characterize	O
correlates	O
of	O
potential	O
ART	O
tolerance	O
based	O
on	O
post	O
treatment	O
parasite	O
clearance	O
ex	O
vivo	O
and	O
in	O
vitro	O
drug	O
sensitivity	O
and	O
molecular	O
markers	O
of	O
drug	O
resistance	O
in	O
P	O
falciparum	O
isolates	O
from	O
children	O
with	O
uncomplicated	O
malaria	O
in	O
Ghana	O
Six	O
months	O
to	O
fourteen	O
years	O
old	O
children	O
presenting	O
with	O
acute	O
uncomplicated	O
malaria	O
n	O
115	O
were	O
enrolled	O
in	O
two	O
hospitals	O
and	O
a	O
Health	O
Centre	O
in	O
Ghana	O
s	O
Greater	O
Accra	O
region	O
and	O
treated	O
with	O
artemether	O
lumefantrine	O
AL	O
according	O
to	O
body	O
weight	O
Pre	O
and	O
post	O
treatment	O
parasitaemia	O
day	O
0	O
and	O
day	O
3	O
was	O
confirmed	O
by	O
microscopy	O
The	O
ex	O
vivo	O
ring	O
stage	O
survival	O
assay	O
RSA	O
was	O
used	O
to	O
detect	O
percent	O
ring	O
survival	O
while	O
the	O
72	O
h	O
SYBR	O
Green	O
I	O
assay	O
was	O
used	O
to	O
measure	O
the	O
50	O
inhibition	O
concentration	O
IC	O
nOf	O
the	O
total	O
of	O
115	O
participants	O
85	O
were	O
successfully	O
followed	O
up	O
on	O
day	O
3	O
post	O
treatment	O
and	O
2	O
85	O
2	O
4	O
had	O
parasitaemia	O
The	O
IC	O
nThe	O
observed	O
low	O
proportion	O
of	O
participants	O
with	O
day	O
3	O
post	O
treatment	O
parasitaemia	O
is	O
consistent	O
with	O
rapid	O
ART	O
clearance	O
However	O
the	O
increased	O
rates	O
of	O
survival	O
observed	O
in	O
the	O
ex	O
vivo	O
RSA	O
against	O
DHA	O
maybe	O
a	O
pointer	O
of	O
an	O
early	O
start	O
of	O
ART	O
tolerance	O
Furthermore	O
the	O
role	O
of	O
two	O
novel	O
mutations	O
in	O
PfK13	O
and	O
Pfcoronin	O
genes	O
harboured	O
by	O
the	O
two	O
RSA	O
positive	O
isolates	O
that	O
had	O
high	O
ring	O
survival	O
in	O
the	O
present	O
study	O
remains	O
to	O
be	O
elucidated	O
 acute diarrhoea	S-Disease
 Malaria 	S-Disease
influenza	S-Disease
, rickettsiosi	S-Disease
dengue	S-Disease
enteric fever	S-Disease
chikungunya	S-Disease
 leptospirosis	S-Disease
malaria	S-Disease
We	O
aimed	O
to	O
investigate	O
the	O
aetiology	O
and	O
outcomes	O
of	O
illnesses	O
in	O
patients	O
presenting	O
to	O
an	O
emergency	O
department	O
after	O
travelling	O
to	O
a	O
malaria	O
endemic	O
country	O
in	O
order	O
to	O
raise	O
awareness	O
of	O
both	O
tropical	O
and	O
cosmopolitan	O
diseases	O
nA	O
retrospective	O
chart	O
review	O
was	O
performed	O
for	O
all	O
patients	O
who	O
underwent	O
blood	O
smear	O
testing	O
for	O
malaria	O
at	O
the	O
Emergency	O
Department	O
of	O
the	O
University	O
Hospitals	O
Leuven	O
from	O
2017	O
to	O
2020	O
Patient	O
characteristics	O
results	O
of	O
laboratory	O
and	O
radiological	O
examinations	O
diagnoses	O
disease	O
course	O
and	O
outcome	O
were	O
collected	O
and	O
analysed	O
nA	O
total	O
of	O
253	O
patients	O
were	O
included	O
in	O
the	O
study	O
The	O
majority	O
of	O
ill	O
travellers	O
returned	O
from	O
Sub	O
Saharan	O
Africa	O
68	O
4	O
and	O
Southeast	O
Asia	O
19	O
4	O
Their	O
diagnoses	O
fell	O
into	O
three	O
major	O
syndrome	O
categories	O
systemic	O
 febrile illness	S-Disease
inflammatory	O
syndrome	O
of	O
unknown	O
origin	O
23	O
3	O
and	O
15	O
8	O
was	O
the	O
most	O
common	O
specific	O
diagnosis	O
in	O
patients	O
with	O
systemic	O
febrile illness	S-Disease
The	O
presence	O
of	O
hyperbilirubinemia	S-Disease
 thrombocytopenia	S-Disease
increased	O
the	O
probability	O
of	O
with	O
a	O
likelihood	O
ratio	O
of	O
4	O
01	O
and	O
6	O
03	O
respectively	O
Seven	O
patients	O
2	O
8	O
were	O
treated	O
in	O
the	O
intensive	O
care	O
unit	O
and	O
none	O
died	O
nSystemic	O
febrile	O
illness	O
inflammatory	O
syndrome	O
of	O
unknown	O
origin	O
and	O
acute	O
diarrhoea	O
were	O
the	O
three	O
major	O
syndromic	O
categories	O
in	O
returning	O
travellers	O
presenting	O
to	O
our	O
emergency	O
department	O
after	O
a	O
stay	O
in	O
a	O
malaria	O
endemic	O
country	O
Malaria	O
was	O
the	O
most	O
common	O
specific	O
diagnosis	O
in	O
patients	O
with	O
systemic	O
febrile	O
illness	O
None	O
of	O
the	O
patients	O
died	O
Glucose	B-Protien
6 Phosphate 	I-Protien
Dehydrogenase	E-Protien
enzyme	O
activity	O
estimation	O
in	O
a	O
freshly	O
collected	O
blood	O
sample	O
is	O
the	O
most	O
widely	O
used	O
diagnostic	O
method	O
for	O
the	O
diagnosis	O
of	O
(G6PD	S-Protien
 G6PD 	S-Protien
eficiency	O
The	O
objective	O
is	O
to	O
evaluate	O
the	O
need	O
for	O
newborn	O
screening	O
for	O
G6PD 	S-Protien
deficiency	O
over	O
post	O
malarial	O
diagnosis	O
and	O
the	O
feasibility	O
and	O
reliability	O
of	O
using	O
dried	O
blood	O
spots	O
DBS	O
as	O
samples	O
for	O
screening	O
A	O
total	O
of	O
562	O
samples	O
were	O
analyzed	O
for	O
G6PD	O
and	O
parallel	O
measurement	O
of	O
G6PD 	S-Protien
activity	O
by	O
the	O
colorimetric	O
method	O
in	O
whole	O
blood	O
and	O
DBS	O
was	O
carried	O
out	O
in	O
the	O
neonatal	O
subset	O
Among	O
466	O
adults	O
27	O
5	O
7	O
showed	O
G6PD 	S-Protien
G6PD 	S-Protien
G6PD	S-Protien
deficiency	O
out	O
of	O
whom	O
22	O
81	O
48	O
were	O
diagnosed	O
after	O
the	O
malarial	O
encounter	O
In	O
the	O
pediatric	O
group	O
8	O
neonates	O
showed	O
G6PD	O
deficiency	O
activity	O
estimated	O
from	O
DBS	O
samples	O
agreed	O
with	O
whole	O
blood	O
with	O
a	O
statistically	O
significant	O
strong	O
positive	O
correlation	O
Screening	O
of	O
deficiency	O
at	O
birth	O
to	O
prevent	O
future	O
unwarranted	O
complications	O
using	O
DBS	O
is	O
feasible	O
test, treat, and track 	S-Medication
T3	O
strategy	O
is	O
directed	O
at	O
ensuring	O
diagnosis	O
and	O
prompt	O
treatment	O
of	O
uncomplicated	O
 malaria	S-Disease
cases	O
Adherence	O
to	O
T3	O
strategy	O
reduces	O
wrong	O
treatment	O
and	O
prevents	O
delays	O
in	O
treating	O
the	O
actual	O
cause	O
of	O
fever	O
that	O
may	O
otherwise	O
lead	O
to	O
complications	O
or	O
death	O
Data	O
on	O
adherence	O
to	O
all	O
three	O
aspects	O
of	O
the	O
T3	O
strategy	O
is	O
sparse	O
with	O
previous	O
studies	O
focusing	O
on	O
the	O
testing	O
and	O
treatment	O
aspects	O
We	O
determined	O
adherence	O
to	O
the	O
T3	O
strategy	O
and	O
associated	O
factors	O
in	O
the	O
Mfantseman	O
Municipality	O
of	O
Ghana	O
nWe	O
conducted	O
a	O
health	O
facility	O
based	O
cross	O
sectional	O
survey	O
in	O
Saltpond	O
Municipal	O
Hospital	O
and	O
Mercy	O
Women	O
s	O
Catholic	O
Hospitals	O
in	O
Mfantseman	O
Municipality	O
of	O
the	O
Central	O
Region	O
Ghana	O
in	O
2020	O
We	O
retrieved	O
electronic	O
records	O
of	O
febrile	O
outpatients	O
and	O
extracted	O
the	O
testing	O
treatment	O
and	O
tracking	O
variables	O
Prescribers	O
were	O
interviewed	O
on	O
factors	O
associated	O
with	O
adherence	O
using	O
a	O
semi	O
structured	O
questionnaire	O
Data	O
analyses	O
was	O
done	O
using	O
descriptive	O
statistics	O
bivariate	O
and	O
multiple	O
logistic	O
regression	O
nOf	O
414	O
febrile	O
outpatient	O
records	O
analyzed	O
47	O
11	O
3	O
were	O
under	O
five	O
years	O
old	O
About	O
180	O
43	O
5	O
were	O
tested	O
with	O
138	O
76	O
7	O
testing	O
positive	O
All	O
positive	O
cases	O
received	O
antimalarials	O
and	O
127	O
92	O
0	O
were	O
reviewed	O
after	O
treatment	O
Of	O
414	O
febrile	O
patients	O
127	O
30	O
7	O
were	O
treated	O
according	O
to	O
the	O
T3	O
strategy	O
Higher	O
odds	O
of	O
adherence	O
to	O
T3	O
were	O
observed	O
for	O
patients	O
aged	O
5	O
25	O
years	O
compared	O
to	O
older	O
patients	O
AOR	O
2	O
5	O
95	O
CI	O
1	O
27	O
4	O
87	O
p	O
0	O
008	O
Adherence	O
was	O
low	O
among	O
physician	O
assistants	O
compared	O
to	O
medical	O
officers	O
AOR	O
0	O
004	O
95	O
CI	O
0	O
004	O
0	O
02	O
p	O
0	O
001	O
Prescribers	O
trained	O
on	O
T3	O
had	O
higher	O
adherence	O
AOR	O
99	O
33	O
95	O
CI	O
19	O
53	O
505	O
13	O
p	O
0	O
000	O
nAdherence	O
to	O
T3	O
strategy	O
is	O
low	O
in	O
Mfantseman	O
Municipality	O
of	O
the	O
Central	O
Region	O
of	O
Ghana	O
Health	O
facilities	O
should	O
perform	O
RDTs	O
for	O
febrile	O
patients	O
at	O
the	O
OPD	O
with	O
priority	O
on	O
low	O
cadre	O
prescribers	O
during	O
the	O
planning	O
and	O
implementation	O
of	O
interventions	O
to	O
improve	O
T3	O
adherence	O
at	O
the	O
facility	O
level	O
Plasmodium	B-Protien
falciparum	I-Protien
 hrp2	E-Protien
pfhrp2)	S-Protien
 pfhrp2	S-Protien
pfhrp2	S-Protien
pfhrp2	S-Protien
 Pfhrp2	S-Protien
pfhrp2	S-Protien
deleted	O
parasites	S-Organism
threatens	O
the	O
efficacy	O
of	O
the	O
most	O
used	O
and	O
sensitive	O
malaria 	S-Disease
rapid	O
diagnostic	O
tests	O
and	O
highlights	O
the	O
need	O
for	O
continued	O
surveillance	O
for	O
this	O
gene	O
deletion	O
While	O
PCR	O
methods	O
are	O
adequate	O
for	O
determining	O
presence	O
or	O
absence	O
they	O
offer	O
a	O
limited	O
view	O
of	O
its	O
genetic	O
diversity	O
Here	O
we	O
present	O
a	O
portable	O
sequencing	O
method	O
using	O
the	O
MinION	O
The	O
prevalence	O
of	O
amplicons	O
were	O
generated	O
from	O
individual	O
samples	O
barcoded	O
and	O
pooled	O
for	O
sequencing	O
To	O
overcome	O
potential	O
crosstalk	O
between	O
barcodes	O
we	O
implemented	O
a	O
coverage	O
based	O
threshold	O
for	O
deletion	O
confirmation	O
Amino	O
acid	O
repeat	O
types	O
were	O
then	O
counted	O
and	O
visualized	O
with	O
custom	O
Python	O
scripts	O
following	O
de	O
novo	O
assembly	O
We	O
evaluated	O
this	O
assay	O
using	O
well	O
characterized	O
reference	O
strains	O
and	O
152	O
field	O
isolates	O
with	O
and	O
withou	O
deletions	O
of	O
which	O
38	O
were	O
also	O
sequenced	O
on	O
the	O
PacBio	O
platform	O
to	O
provide	O
a	O
standard	O
for	O
comparison	O
Of	O
152	O
field	O
samples	O
93	O
surpassed	O
the	O
positivity	O
threshold	O
and	O
of	O
those	O
samples	O
62	O
93	O
had	O
a	O
dominant	O
pfhrp2 	S-Protien
repeat	O
type	O
PacBio	O
sequenced	O
samples	O
with	O
a	O
dominant	O
repeat	O
type	O
profile	O
from	O
the	O
MinION	O
sequencing	O
data	O
matched	O
the	O
PacBio	O
profile	O
This	O
field	O
deployable	O
assay	O
can	O
be	O
used	O
alone	O
for	O
surveilling	O
diversity	O
or	O
as	O
a	O
sequencing	O
based	O
addition	O
to	O
the	O
World	O
Health	O
Organization	O
s	O
existing	O
deletion	O
surveillance	O
protocol	O
Severe malaria	S-Disease
remains	O
a	O
deadly	O
disease	O
for	O
many	O
young	O
children	O
in	O
low	O
and	O
middle	O
income	O
countries	O
Levels	O
of	O
Interleukin-6	S-Protien
have	O
been	O
shown	O
to	O
identify	O
cases	O
of	O
severe malaria	S-Disease
and	O
associate	O
with	O
severity	O
but	O
it	O
is	O
unknown	O
if	O
this	O
association	O
is	O
causal	O
A	O
single	O
 malari	S-Disease
 malaria 	S-Disease
 malaria	S-Disease
nucleotide	O
polymorphism	O
SNP	O
rs2228145	O
in	O
the	O
IL	O
6	O
receptor	O
IL6R	O
was	O
chosen	O
as	O
a	O
genetic	O
variant	O
that	O
is	O
known	O
to	O
alter	O
IL	O
6	O
signalling	O
We	O
tested	O
this	O
then	O
took	O
this	O
forward	O
as	O
an	O
instrument	O
to	O
perform	O
Mendelian	O
randomisation	O
MR	O
in	O
MalariaGEN	O
a	O
large	O
cohort	O
study	O
of	O
patients	O
with	O
severe	O
at	O
eleven	O
worldwide	O
sites	O
nIn	O
MR	O
analyses	O
using	O
rs2228145	O
we	O
did	O
not	O
identify	O
an	O
effect	O
of	O
decreased	O
IL	O
6	O
signalling	O
on	O
severe	O
malaria	O
Odds	O
ratio	O
1	O
14	O
95	O
CI	O
0	O
56	O
2	O
34	O
p	O
0	O
713	O
Estimates	O
of	O
the	O
association	O
with	O
any	O
severe	O
malaria	O
sub	O
phenotype	O
were	O
similarly	O
null	O
although	O
with	O
some	O
imprecision	O
Further	O
analyses	O
using	O
other	O
MR	O
approaches	O
had	O
similar	O
results	O
nMendelian	O
randomisation	O
analyses	O
do	O
not	O
support	O
a	O
causal	O
role	O
for	O
IL	O
6	O
signalling	O
in	O
the	O
development	O
of	O
severe	O
malaria	O
This	O
result	O
suggests	O
IL	O
6	O
may	O
not	O
be	O
causal	O
for	O
severe	O
outcomes	O
in	O
and	O
that	O
therapeutic	O
manipulation	O
of	O
IL	O
6	O
is	O
unlikely	O
to	O
be	O
a	O
suitable	O
treatment	O
for	O
severe	O
malaria	O
Africa	O
has	O
a	O
higher	O
burden	O
of	O
malaria	S-Disease
related	O
cases	O
and	O
deaths	O
globally	O
Children	O
under	O
five	O
accounted	O
for	O
over	O
two	O
thirds	O
of	O
all	O
malaria	S-Disease
deaths	O
in	O
sub	O
Saharan	O
Africa	O
SSA	O
This	O
scoping	O
review	O
aims	O
to	O
map	O
evidence	O
of	O
the	O
prevalence	O
contextual	O
factors	O
and	O
health	O
education	O
interventions	O
of	O
malaria	O
amongst	O
children	O
under	O
5	O
years	O
UN5	O
in	O
SSA	O
nFour	O
main	O
databases	O
PubMed	O
Central	O
Dimensions	O
and	O
JSTOR	O
produced	O
27	O
841	O
records	O
of	O
literature	O
Additional	O
searches	O
in	O
Google	O
Google	O
Scholar	O
and	O
institutional	O
repositories	O
produced	O
37	O
records	O
Finally	O
255	O
full	O
text	O
records	O
were	O
further	O
screened	O
and	O
100	O
records	O
were	O
used	O
for	O
this	O
review	O
nLow	O
or	O
no	O
formal	O
education	O
poverty	O
or	O
low	O
income	O
and	O
rural	O
areas	O
are	O
risk	O
factors	O
fo	O
malaria	S-Disease
amongst	O
UN5	O
Evidence	O
on	O
age	O
and	O
malnutrition	O
as	O
risk	O
factors	O
for	O
malaria	O
in	O
UN5	O
is	O
inconsistent	O
and	O
inconclusive	O
Furthermore	O
the	O
poor	O
housing	O
system	O
in	O
SSA	O
and	O
the	O
unavailability	O
of	O
electricity	O
in	O
rural	O
areas	O
and	O
unclean	O
water	O
make	O
UN5	O
more	O
susceptible	O
to	O
malaria	O
Health	O
education	O
and	O
promotion	O
interventions	O
have	O
significantly	O
reduced	O
the	O
malaria	O
burden	O
on	O
UN5	O
in	O
SSA	O
nWell	O
planned	O
and	O
resourced	O
health	O
education	O
and	O
promotion	O
interventions	O
that	O
focus	O
on	O
prevention	O
testing	O
and	O
treatment	O
of	O
malaria	O
could	O
reduce	O
malaria	O
burden	O
amongst	O
UN5	O
in	O
SSA	O
malaria	S-Disease
HIV	B-Disease
 prophylaxis	I-Disease
" malaria """	S-Disease
 atovaquone	S-Chemical_Substance
atovaquone	S-Chemical_Substance
cases	O
and	O
deaths	O
underscore	O
the	O
need	O
for	O
new	O
interventions	O
Long	O
acting	O
injectable	O
medications	O
such	O
as	O
those	O
now	O
in	O
use	O
for	O
offer	O
the	O
prospect	O
of	O
a	O
chemical	O
vaccine	O
combining	O
the	O
efficacy	O
of	O
a	O
drug	O
like	O
with	O
the	O
durability	O
of	O
a	O
biological	O
vaccine	O
Of	O
concern	O
however	O
is	O
the	O
possible	O
selection	O
and	O
transmission	O
of	O
drug	O
resistant	O
parasites	O
We	O
addressed	O
this	O
question	O
by	O
generating	O
clinically	O
relevant	O
highly	O
resistant	O
Rising	O
numbers	O
of	O
New	O
tools	O
are	O
needed	O
to	O
protect	O
individuals	O
from	O
malaria	O
and	O
to	O
control	O
malaria	S-Disease
n	O
the	O
field	O
Atovaquone	S-Chemical_Substance
proguanil	S-Chemical_Substance
s	O
a	O
commonly	O
used	O
and	O
well	O
tolerated	O
medicine	O
to	O
prevent	O
malaria	O
No	O
drug	O
resistance	O
has	O
been	O
reported	O
from	O
its	O
prophylactic	O
use	O
but	O
tablets	O
must	O
be	O
taken	O
daily	O
Giving	O
atovaquone	O
as	O
a	O
single	O
injection	O
may	O
provide	O
much	O
longer	O
lasting	O
protection	O
against	O
both	O
falciparum	O
and	O
vivax	O
malaria	O
but	O
there	O
is	O
concern	O
this	O
may	O
create	O
drug	O
resistance	O
In	O
this	O
study	O
we	O
showed	O
that	O
clinically	O
relevant	O
atovaquone	S-Chemical_Substance
mosquitoes	S-Organism
 mosquitoes	S-Organism
 parasites	S-Organism
atovaquone	B-Medication
"""chemical vaccine"	I-Medication
would	O
lead	O
to	O
the	O
spread	O
of	O
atovaquone	O
resistance	O
to	O
humanized	O
mice	O
These	O
findings	O
lessen	O
the	O
likelihood	O
that	O
an	O
resistant	O
malaria	O
parasites	O
survive	O
poorly	O
if	O
at	O
all	O
in	O
do	O
not	O
transmit	O
drug	O
resistan	O
and	O
that	O
Malaria 	S-Disease
control	O
is	O
highly	O
dependent	O
on	O
the	O
effectiveness	O
of	O
artemisinin-based	B-Medication
combination	I-Medication
 therapies	E-Medication
the	O
current	O
frontline	O
malaria	O
curative	O
treatments	O
Unfortunately	O
the	O
emergence	O
and	O
spread	O
of	O
parasites	O
resistant	O
to	O
artemisinin	O
ART	O
derivatives	O
in	O
Southeast	O
Asia	O
and	O
South	O
America	O
and	O
more	O
recently	O
in	O
Rwanda	O
and	O
Uganda	O
East	O
Africa	O
compromise	O
their	O
long	O
term	O
use	O
in	O
Sub	O
Saharan	O
Africa	O
where	O
most	O
malaria	O
deaths	O
occur	O
nHere	O
we	O
evaluated	O
nAll	O
samples	O
tested	O
in	O
the	O
nAltogether	O
investigations	O
combining	O
Mechanisms	O
of	O
cell	O
division	O
are	O
remarkably	O
diverse	O
suggesting	O
the	O
underlying	O
molecular	O
networks	O
among	O
eukaryotes	O
differ	O
extensively	O
The	O
Aurora	O
family	O
of	O
 kinases 	B-Protien
orchestrates	I-Protien
the	O
process	O
of	O
chromosome	O
segregation	O
and	O
cytokinesis	O
during	O
cell	O
division	O
through	O
precise	O
spatiotemporal	O
regulation	O
of	O
their	O
catalytic	O
activities	O
by	O
distinct	O
scaffolds	O
Plasmodium spp	S-Organism
the	O
causative	O
agents	O
of	O
malaria	S-Disease
are	O
unicellular	B-Organism
eukaryotes 	I-Organism
hat	O
have	O
three	O
divergent	O
 aurora-related	B-Protien
kinases	I-Protien
and	O
lack	O
most	O
canonical	O
scaffolds	O
activators	O
Th	O
parasite	S-Organism
uses	O
unconventional	O
modes	O
of	O
chromosome	O
segregation	O
during	O
endomitosis	O
and	O
meiosis	O
in	O
sexual	O
transmission	O
stages	O
within	O
mosquito 	S-Organism
host	O
This	O
includes	O
a	O
rapid	O
threefold	O
genome	O
replication	O
from	O
1N	O
to	O
8N	O
with	O
successive	O
cycles	O
of	O
closed	O
mitosis	O
spindle	O
formation	O
and	O
chromosome	O
segregation	O
within	O
eight	O
minutes	O
termed	O
male	O
gametogony	O
Kinome	O
studies	O
had	O
previously	O
suggested	O
likely	O
essential	O
functions	O
for	O
all	O
three	O
Plasmodium 	S-Organism
ARKs	O
during	O
asexual	O
mitotic	O
cycles	O
however	O
little	O
is	O
known	O
about	O
their	O
location	O
function	O
or	O
their	O
scaffolding	O
molecules	O
during	O
unconventional	O
sexual	O
proliferative	O
stages	O
Using	O
a	O
combination	O
of	O
super	O
resolution	O
microscopy	O
mass	O
spectrometry	O
omics	O
and	O
live	O
cell	O
fluorescence	O
imaging	O
we	O
set	O
out	O
to	O
investigate	O
the	O
contribution	O
of	O
the	O
atypical	O
Aurora	O
paralog	O
ARK2	O
to	O
proliferative	O
sexual	O
stages	O
using	O
rodent	O
malaria	O
model	O
Plasmodium	O
berghei	O
We	O
find	O
that	O
ARK2	O
primarily	O
localises	O
to	O
the	O
spindle	O
apparatus	O
associated	O
with	O
kinetochores	O
during	O
both	O
mitosis	O
and	O
meiosis	O
Interactomics	O
and	O
co	O
localisation	O
studies	O
reveal	O
a	O
unique	O
ARK2	O
scaffold	O
at	O
the	O
spindle	O
including	O
the	O
microtubule	O
plus	O
end	O
binding	O
protein	O
EB1	O
and	O
lacking	O
some	O
other	O
conserved	O
molecules	O
Gene	O
function	O
studies	O
indicate	O
complementary	O
functions	O
of	O
ARK2	O
and	O
EB1	O
in	O
driving	O
endomitotic	O
divisions	O
and	O
thereby	O
parasite	O
transmission	O
Our	O
discovery	O
of	O
a	O
novel	O
Aurora	O
spindle	O
scaffold	O
underlines	O
the	O
emerging	O
flexibility	O
of	O
molecular	O
networks	O
to	O
rewire	O
and	O
drive	O
unconventional	O
mechanisms	O
of	O
chromosome	O
segregation	O
in	O
the	O
malaria 	B-Organism
parasite	I-Organism
Plasmodium.	E-Organism
Female	B-Organism
mosquitoes	I-Organism
nject	O
saliva	O
into	O
vertebrate	O
hosts	O
during	O
blood	S_Anatomical_Substances
feeding	O
This	O
process	O
transmits	O
mosquito-borne	B-Organism
 human	I-Organism
pathogens	E-Organism
that	O
collectively	O
cause	O
1	O
000	O
000	O
deaths	O
year	O
Among	O
the	O
most	O
abundant	O
and	O
conserved	O
proteins	O
secreted	O
by	O
female	O
salivary	O
glands	O
is	O
a	O
high	O
molecular	O
weight	O
protein	O
called	O
salivary gland	B-Protien
surface protein 1	I-Protien
SGS1	S-Protien
that	O
facilitates	O
pathogen 	S-Organism
ransmission	O
but	O
its	O
mechanism	O
remains	O
elusive	O
Here	O
we	O
determine	O
the	O
native	O
structure	O
of	O
SGS1	S-Protien
by	O
the	O
cryoID	O
approach	O
showing	O
that	O
the	O
3364	O
 amino-acid	B-Protien
 protein	I-Protien
has	O
a	O
Tc	O
toxin	O
like	O
Rhs	O
YD	O
shell	O
four	O
receptor	O
domains	O
and	O
a	O
set	O
of	O
C	O
terminal	O
daisy	O
chained	O
helices	O
These	O
helices	O
are	O
partially	O
shielded	O
inside	O
the	O
Rhs	O
YD	O
shell	O
and	O
poised	O
to	O
transform	O
into	O
predicted	O
transmembrane	O
helices	O
This	O
transformation	O
and	O
the	O
numerous	O
receptor	O
domains	O
on	O
the	O
surface	O
of	O
SGS1	S-Protien
are	O
likely	O
key	O
in	O
facilitating	O
sporozoite/arbovirus	S-Organism
invasion	O
into	O
the	O
salivary	O
glands	O
and	O
manipulating	O
the	O
host	O
s	O
immune	O
response	O
BackgroundTravellers	O
are	O
generally	O
considered	O
good	O
sentinels	O
for	O
infectious	O
disease	O
surveillance	O
AimTo	O
investigate	O
whether	O
health	O
data	O
from	O
travellers	O
arriving	O
from	O
Africa	O
to	O
Europe	O
could	O
provide	O
evidence	O
to	O
support	O
surveillance	O
systems	O
in	O
Africa	O
MethodsWe	O
examined	O
disease	O
occurrence	O
and	O
estimated	O
risk	O
of	O
infection	O
among	O
travellers	O
arriving	O
from	O
Africa	O
to	O
Europe	O
from	O
2015	O
to	O
2019	O
using	O
surveillance	O
data	O
of	O
 arthropod-borne	B-Disease
disease 	I-Disease
cases	O
collected	O
through	O
The	O
European	O
Surveillance	O
System	O
TESSy	O
and	O
flight	O
passenger	O
volumes	O
from	O
the	O
International	O
Air	O
Transport	O
Association	O
Results	O
Malaria	S-Disease
was	O
the	O
most	O
common	O
arthropod-borne	B-Disease
disease 	I-Disease
reported	O
among	O
travellers	O
from	O
Africa	O
with	O
34	O
235	O
cases	O
The	O
malaria	S-Disease
travellers	O
infection	O
rate	O
TIR	O
was	O
28	O
8	O
cases	O
per	O
100	O
000	O
travellers	O
which	O
is	O
36	O
and	O
144	O
times	O
higher	O
than	O
the	O
TIR	O
for	O
dengue 	S-Disease
and	O
chikungunya	S-Disease
respectively	O
The	O
 malaria 	S-Disease
TIR	O
was	O
highest	O
among	O
travellers	O
arriving	O
from	O
Central	O
and	O
Western	O
Africa	O
There	O
were	O
956	O
and	O
161	O
diagnosed	O
imported	O
cases	O
of	O
dengue 	S-Disease
chikungunya	S-Disease
respectively	O
The	O
highest	O
TIR	O
was	O
among	O
travellers	O
arriving	O
from	O
Central	O
Eastern	O
and	O
Western	O
Africa	O
for	O
dengue	S-Disease
and	O
from	O
Central	O
Africa	O
for	O
chikungunya	S-Disease
in	O
this	O
period	O
Limited	O
numbers	O
of	O
cases	O
of	O
Zika	B-Disease
 virus	I-Disease
disease	E-Disease
West Nile	B-Disease
virus	I-Disease
infection	E-Disease
Rift 	B-Disease
Valley 	I-Disease
fever	E-Disease
yellow	B-Disease
fever	I-Disease
were	O
reported	O
ConclusionsDespite	O
some	O
limitations	O
travellers	O
health	O
data	O
can	O
efficiently	O
complement	O
local	O
surveillance	O
data	O
in	O
Africa	O
particularly	O
when	O
the	O
country	O
or	O
region	O
has	O
a	O
sub	O
optimal	O
surveillance	O
system	O
The	O
sharing	O
of	O
anonymised	O
traveller	O
health	O
data	O
between	O
regions	O
continents	O
should	O
be	O
encouraged	O
8-aminoquinoline 	B-Medication
tafenoquine	I-Medication
The	O
long	O
acting	O
may	O
be	O
a	O
good	O
candidate	O
for	O
mass	O
drug	O
administration	O
if	O
it	O
exhibits	O
sufficient	O
blood	O
stage	O
antimalarial	O
activity	O
at	O
doses	O
low	O
enough	O
to	O
be	O
tolerated	O
by	O
 glucose	B-Protien
6-phosphate	I-Protien
dehydrogenase	E-Protien
G6PD	S-Protien
deficient	O
individuals	O
Healthy	O
G6PD	S-Protien
normal	O
adults	O
were	O
inoculated	O
with	O
Plasmodium	B-Organism
falciparum	I-Organism
3D7	E-Organism
infected	O
erythrocytes	S_Anatomical_Substances
on	O
day	O
0	O
Different	O
single	O
oral	O
doses	O
of	O
tafenoquine 	S-Medication
were	O
administered	O
on	O
day	O
8	O
Parasitemia	O
and	O
concentrations	O
of	O
tafenoquine	S-Medication
and	O
the	O
 5,6-orthoquinone	B-Chemical_Substance
metabolite 	I-Chemical_Substance
plasma	S_Anatomical_Substances
blood	S_Anatomical_Substances
urine	S_Anatomical_Substances
were	O
measured	O
and	O
standard	O
safety	O
assessments	O
performed	O
Curative	B-Medication
 artemether-lumefantrine	I-Medication
 therapy	E-Medication
was	O
administered	O
if	O
parasite	S-Organism
regrowth	O
occurred	O
or	O
on	O
day	O
48	O
2	O
Outcomes	O
were	O
parasite 	S-Organism
pharmacokinetic	O
pharmacodynamic	O
clearance	O
kinetics	O
pharmacokinetic	O
and	O
PK	O
PD	O
parameters	O
from	O
modelling	O
and	O
dose	O
simulations	O
in	O
a	O
theoretical	O
endemic	O
population	O
Twelve	O
participants	O
were	O
inoculated	O
and	O
administered	O
200	O
mg	O
n	O
3	O
300	O
mg	O
n	O
4	O
400	O
mg	O
n	O
2	O
or	O
600	O
mg	O
n	O
3	O
tafenoquine	S-Medication
The	O
parasite	S-Organism
clearance	O
half	O
life	O
with	O
400	O
mg	O
or	O
600	O
mg	O
5	O
4	O
h	O
and	O
4	O
2	O
h	O
respectively	O
was	O
faster	O
than	O
with	O
200	O
mg	O
or	O
300	O
mg	O
11	O
8	O
h	O
and	O
9	O
6	O
h	O
respectively	O
Parasite	S-Disease
regrowth	O
occurred	O
after	O
dosing	O
with	O
200	O
mg	O
3	O
3	O
participants	O
and	O
300	O
mg	O
3	O
4	O
participants	O
but	O
not	O
after	O
400	O
mg	O
or	O
600	O
mg	O
Simulations	O
using	O
the	O
PK	O
PD	O
model	O
predicted	O
that	O
460	O
mg	O
and	O
540	O
mg	O
would	O
clear	O
parasitaemia	O
by	O
a	O
factor	O
of	O
106	O
and	O
109	O
respectively	O
in	O
a	O
60	O
kg	O
adult	O
nAlthough	O
a	O
single	O
dose	O
of	O
tafenoquine	O
exhibits	O
potent	O
 P. falciparum	S-Organism
blood	S_Anatomical_Substances
stage	O
antimalarial	O
activity	O
the	O
estimated	O
doses	O
to	O
effectively	O
clear	O
asexual	O
parasitemia	O
will	O
require	O
prior	O
screening	O
to	O
exclude	O
 G6PD 	S-Protien
deficiency	O
Malaria	S-Disease
remains	O
one	O
of	O
the	O
major	O
health	O
problems	O
in	O
the	O
world	O
In	O
this	O
work	O
a	O
series	O
of	O
squaramide	B-Medication
 tethered	I-Medication
chloroquine	E-Medication
clindamycin	S-Medication
mortiamide	B-Medication
D hybrids	I-Medication
have	O
been	O
synthesized	O
to	O
assess	O
their	O
Cancer 	S-Disease
remains	O
a	O
global	O
health	O
concern	O
and	O
constitutes	O
an	O
important	O
barrier	O
to	O
increasing	O
life	O
expectancy	O
 Malignant	B-Anatomical_Substances
 cells 	I-Anatomical_Substances
rapidly	O
develop	O
drug	O
resistance	O
leading	O
to	O
many	O
clinical	O
therapeutic	O
failures	O
The	O
importance	O
of	O
medicinal	B-Medication
plants	I-Medication
as	O
an	O
alternative	O
to	O
classical	O
drug	O
discovery	O
to	O
fight	O
cancer	S-Disease
is	O
well	O
known	O
Brucea 	B-Medication
antidysenterica	I-Medication
is	O
an	O
African	O
medicinal	O
plant	O
traditionally	O
used	O
to	O
treat	O
cancer	S-Disease
dysentery	S-Disease
 malaria,	S-Disease
 diarrhea	S-Disease
stomach aches	S-Disease
 helminthic	B-Disease
infections	I-Disease
fever	S-Disease
asthma	S-Disease
Brucea	B-Medication
 antidysenterica	I-Medication
 cancer	S-Disease
The	O
present	O
work	O
was	O
designed	O
to	O
identify	O
the	O
cytotoxic	O
constituents	O
of	O
and	O
on	O
a	O
broad	O
range	O
of	O
cell	O
lines	O
and	O
to	O
demonstrate	O
the	O
mode	O
of	O
induction	O
of	O
apoptosis	O
of	O
the	O
most	O
active	O
samples	O
Seven	O
phytochemicals	S-Chemical_Substance
were	O
isolated	O
from	O
the	O
leaves	O
BAL	O
and	O
stem	O
BAS	O
extract	O
of	O
Brucea	B-Medication
antidysenterica	I-Medication
by	O
column	O
chromatography	O
and	O
structurally	O
elucidated	O
using	O
spectroscopic	O
techniques	O
The	O
antiproliferative	O
effects	O
of	O
the	O
crude	O
extracts	O
and	O
compounds	O
against	O
9	O
human	S-Organism
cancer	S-Disease
cell	O
lines	O
were	O
evaluated	O
by	O
the	O
resazurin	O
reduction	O
assay	O
RRA	O
The	O
activity	O
in	O
cell	O
lines	O
was	O
assessed	O
by	O
the	O
Caspase	O
Glo	O
assay	O
The	O
cell	O
cycle	O
distribution	O
apoptosis	O
via	O
 propidium	B-Chemical_Substance
iodide	I-Chemical_Substance
staining	E-Chemical_Substance
 mitochondrial	B-Anatomical_Substances
membrane 	I-Anatomical_Substances
potential	O
MMP	O
through	O
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine 	B-Chemical_Substance
iodide	I-Chemical_Substance
staining	O
and	O
the	O
reactive	O
oxygen	O
species	O
ROS	O
via	O
2´,7´-dichlorodihydrofluoresceine	B-Chemical_Substance
diacetate	I-Chemical_Substance
H2DCFH-DA	S-Chemical_Substance
staining	O
were	O
investigated	O
by	O
flow	O
cytometry	O
Phytochemical	O
studies	O
of	O
the	O
botanicals	O
BAL	O
and	O
BAS	O
led	O
to	O
the	O
isolation	O
of	O
seven	O
compounds	O
BAL	O
and	O
its	O
constituents	O
3, (3-(3-Methyl-1-oxo-2-butenyl))1H indole	S-Chemical_Substance
hydnocarpin	S-Chemical_Substance
2	O
as	O
well	O
as	O
the	O
reference	O
compound	O
doxorubicin	S-Chemical_Substance
had	O
antiproliferative	O
activity	O
against	O
9	O
cancer	S-Disease
cell	O
lines	O
The	O
IC	O
 Brucea	B-Medication
antidysenterica	I-Medication
BAL	O
and	O
its	O
constituents	O
mostly	O
compound	O
2	O
are	O
potential	O
antiproliferative	O
products	O
from	O
Other	O
studies	O
will	O
be	O
necessary	O
in	O
the	O
perspective	O
of	O
the	O
discovery	O
of	O
new	O
antiproliferative	O
agents	O
to	O
fight	O
against	O
resistance	O
to	O
anticancer	O
drugs	O
An. stephensi	B-Organism
mosquitoes	I-Organism
The	O
invasion	O
and	O
establishment	O
of	O
in	O
the	O
Horn	O
of	O
Africa	O
represents	O
a	O
significant	O
regional	O
threat	O
which	O
may	O
jeopardise	O
malaria	S-Disease
control	O
particularly	O
in	O
urban	O
areas	O
which	O
were	O
formally	O
free	O
from	O
disease	O
transmission	O
Novel	O
vector	O
surveillance	O
methods	O
are	O
urgently	O
needed	O
both	O
agnostic	O
to	O
mosquito	S-Organism
larval	O
morphology	O
and	O
simple	O
to	O
implement	O
at	O
the	O
sampling	O
stage	O
Using	O
new	O
multiplex	O
TaqMan	O
assays	O
specifically	O
targeting	O
An. stephensi	S-Organism
Ae. aegypti	S-Organism
we	O
validated	O
the	O
use	O
of	O
environmental DNA	S_Anatomical_Substances
for	O
simultaneous	O
vector	O
detection	O
in	O
shared	O
artificial	O
breeding	O
sites	O
Study	O
findings	O
demonstrated	O
that	O
An. stephensi	S-Organism
Ae. aegypti	S-Organism
eDNA	S_Anatomical_Substances
eDNA	S_Anatomical_Substances
deposited	O
by	O
as	O
few	O
as	O
one	O
second	O
instar	O
larva	O
in	O
1L	O
of	O
water	O
was	O
detectable	O
Characterization	O
of	O
molecular	O
insecticide	O
resistance	O
mechanisms	O
using	O
novel	O
amplicon	O
sequencing	O
panels	O
for	O
both	O
vector	O
species	O
was	O
possible	O
from	O
eDNA	O
shed	O
by	O
as	O
few	O
as	O
16	O
32	O
s	O
instar	O
larvae	O
in	O
50	O
ml	O
of	O
water	O
An. stephensi	S-Organism
eDNA	S_Anatomical_Substances
derived	O
from	O
emergent	O
pupae	O
for	O
24	O
h	O
was	O
remarkably	O
stable	O
and	O
still	O
detectable	O
2	O
weeks	O
later	O
eDNA	S_Anatomical_Substances
surveillance	O
has	O
the	O
potential	O
to	O
be	O
implemented	O
in	O
local	O
endemic	O
communities	O
and	O
at	O
points	O
of	O
country	O
entry	O
to	O
monitor	O
the	O
spread	O
of	O
invasive	O
vector	O
species	O
Further	O
studies	O
are	O
required	O
to	O
validate	O
the	O
feasibility	O
of	O
this	O
technique	O
under	O
field	O
conditions	O
Pfs230	B-Protien
domain 1	I-Protien
Pfs230D1	S-Protien
is	O
an	O
advanced	O
malaria 	S-Disease
transmission-blocking	B-Medication
vaccine	I-Medication
antigen	E-Medication
demonstrating	O
high	O
functional	O
activity	O
in	O
clinical	O
trials	O
However	O
the	O
structural	O
and	O
functional	O
correlates	O
of	O
transmission	O
blocking	O
activity	O
are	O
not	O
defined	O
Here	O
we	O
characterized	O
a	O
panel	O
of	O
 human	B-Protien
monoclona	I-Protien
antibodies	E-Protien
hmAbs	S-Protien
elicited	O
in	O
vaccinees	O
immunized	O
with	O
 Pfs230D1	S-Protien
These	O
hmAbs	S-Protien
exhibited	O
diverse	O
transmission	O
reducing	O
activity	O
yet	O
all	O
bound	O
to	O
Pfs230D1	S-Protien
with	O
nanomolar	O
affinity	O
We	O
compiled	O
epitope	O
binning	O
data	O
for	O
seventeen	O
hmAbs	S-Protien
and	O
structures	O
of	O
nine	O
hmAbs	S-Protien
complexes	O
to	O
construct	O
a	O
high	O
resolution	O
epitope	O
map	O
and	O
revealed	O
that	O
potent	O
transmission	O
reducing	O
hmAbs	S-Protien
bound	O
to	O
one	O
face	O
of	O
Pfs230D1	S-Protien
while	O
non	O
potent	O
hmAbs 	S-Protien
bound	O
to	O
the	O
opposing	O
side	O
The	O
structure	O
of	O
Pfs230D1D2	S-Protien
epitope	O
map	O
delineated	O
binary	O
hmAb	O
combinations	O
that	O
synergized	O
for	O
extremely	O
high	O
potency	O
transmission	O
reducing	O
activity	O
This	O
work	O
provides	O
a	O
high	O
resolution	O
guide	O
for	O
structure	O
based	O
design	O
of	O
enhanced	O
immunogens	O
and	O
informs	O
diagnostics	O
that	O
measure	O
the	O
transmission	O
reducing	O
response	O
 hmAb	S-Protien
revealed	O
that	O
non	O
potent	O
transmission	O
reducing	O
epitopes	O
were	O
occluded	O
by	O
the	O
second	O
domain	O
The	O
Pfs230	S-Protien
is	O
essential	O
for	O
Plasmodium	B-Organism
 falciparum	I-Organism
transmission	O
to	O
mosquitoes	S-Organism
and	O
is	O
the	O
protein	O
targeted	O
by	O
the	O
most	O
advanced	O
malaria	O
transmission	O
blocking	O
vaccine	O
candidate	O
Prior	O
understanding	O
of	O
functional	O
epitopes	O
on	O
Pfs230	S-Protien
is	O
based	O
on	O
two	O
monoclonal	B-Protien
antibodies 	I-Protien
mAbs	S-Protien
with	O
moderate	O
transmission	O
reducing	O
activity	O
TRA	O
elicited	O
from	O
subunit	O
immunization	O
Here	O
we	O
screened	O
the	O
B cell 	B-Anatomical_Substances
repertoire 	I-Anatomical_Substances
of	O
two	O
naturally	O
exposed	O
individuals	O
possessing	O
serum	O
TRA	O
and	O
identified	O
five	O
potent	O
mAbs	S-Protien
from	O
sixteen	O
 Pfs230 	B-Protien
domain-1-specific 	I-Protien
mAbs	E-Protien
Structures	O
of	O
three	O
potent	O
and	O
three	O
low	O
activity	O
antibodies	O
bound	O
to	O
 Pfs230 domain 1	S-Protien
revealed	O
four	O
distinct	O
epitopes	O
Highly	O
potent	O
 mAbs	S-Protien
from	O
natural	O
infection	O
recognized	O
a	O
common	O
conformational	O
epitope	O
that	O
is	O
highly	O
conserved	O
across	O
P. falciparum	S-Organism
field	O
isolates	O
while	O
antibodies	O
with	O
negligible	O
TRA	O
derived	O
from	O
natural	O
infection	O
or	O
immunization	O
recognized	O
three	O
distinct	O
sites	O
Our	O
study	O
provides	O
molecular	O
blueprints	O
describing	O
P. falciparum	S-Organism
TRA	O
informed	O
by	O
contrasting	O
potent	O
and	O
non	O
functional	O
epitopes	O
elicited	O
by	O
natural	O
exposure	O
and	O
vaccination	O
Malaria	B-Medication
transmission-blocking	I-Medication
vaccines	E-Medication
TBVs	S-Medication
aim	O
to	O
induce	O
antibodies	O
that	O
interrupt	O
malaria	B-Organism
parasite	I-Organism
mosquito	S-Organism
development	O
in	O
the	O
thereby	O
blocking	O
onward	O
transmission	O
and	O
provide	O
a	O
much	O
needed	O
tool	O
for	O
malaria	S-Disease
control	O
and	O
elimination	O
The	O
 parasite	S-Organism
 surface protein	B-Protien
Pfs48/45	I-Protien
is	O
a	O
leading	O
TBV	S-Medication
candidate	O
Here	O
we	O
isolated	O
and	O
characterized	O
a	O
panel	O
of	O
81	O
human	S-Organism
Pfs48/45-specific	B-Protien
monoclonal	I-Protien
antibodies	E-Protien
mAbs)	S-Protien
from	O
donors	O
naturally	O
exposed	O
to	O
Plasmodium	B-Organism
parasites	I-Organism
Genetically	O
diverse	O
mAbs	S-Protien
against	O
each	O
of	O
the	O
three	O
domains	O
 (D1-D3) of 	B-Protien
Pfs48/45	I-Protien
were	O
identified	O
The	O
most	O
potent	O
mAbs targeted	B-Protien
 D1 and D3 	I-Protien
and	O
achieved	O
80	O
transmission	O
reducing	O
activity	O
in	O
standard	O
membrane	O
feeding	O
assays	O
at	O
10	O
and	O
2	O
μg	O
mL	O
respectively	O
Co	O
crystal	O
structures	O
of	O
D3	O
in	O
complex	O
with	O
four	O
different	O
mAbs	S-Protien
delineated	O
two	O
conserved	O
protective	O
epitopes	O
Altogether	O
these	O
Pfs48/45-specific	B-Protien
human mAbs	I-Protien
provide	O
important	O
insight	O
into	O
protective	O
and	O
non	O
protective	O
epitopes	O
that	O
can	O
further	O
our	O
understanding	O
of	O
transmission	O
and	O
inform	O
the	O
design	O
of	O
refined	O
malaria	O
transmission	O
blocking	O
vaccine	O
candidates	O
transmission-blocking	B-Medication
vaccine	I-Medication
TBV	S-Medication
The	O
development	O
of	O
a	O
against	O
malaria	S-Disease
is	O
hampered	O
by	O
poor	O
understanding	O
of	O
functional	O
antibody	O
responses	O
In	O
this	O
issue	O
of	O
Immunity	O
 human	B-Protien
monoclonal	I-Protien
 antibodies 	E-Protien
Pfs48/45	S-Protien
 Pfs230	S-Protien
Fabra	O
Garcia	O
et	O
al	O
Ivanochko	O
et	O
al	O
and	O
Tang	O
et	O
al	O
isolate	O
against	O
the	O
two	O
most	O
promising	O
TBV	O
candidates	O
and	O
and	O
map	O
the	O
epitopes	O
responsible	O
for	O
potent	O
transmission	O
reducing	O
activity	O
The	O
Biomarkers	O
Reflecting	O
Inflammation	O
and	O
Nutritional	O
Determinants	O
of	O
Anemia	O
BRINDA	O
research	O
group	O
was	O
formed	O
over	O
a	O
decade	O
ago	O
to	O
improve	O
the	O
interpretation	O
of	O
micronutrient	O
biomarkers	O
in	O
settings	O
with	O
inflammation	O
The	O
BRINDA	O
inflammation	O
adjustment	O
method	O
uses	O
regression	O
correction	O
to	O
adjust	O
for	O
the	O
confounding	O
effects	O
of	O
inflammation	O
on	O
select	O
micronutrient	O
biomarkers	O
and	O
has	O
provided	O
important	O
insights	O
to	O
micronutrient	O
research	O
policy	O
and	O
programming	O
However	O
users	O
may	O
face	O
challenges	O
when	O
applying	O
the	O
BRINDA	O
inflammation	O
adjustment	O
methods	O
to	O
their	O
own	O
data	O
due	O
to	O
varying	O
guidance	O
on	O
the	O
adjustment	O
approach	O
for	O
different	O
biomarkers	O
and	O
the	O
need	O
to	O
develop	O
statistical	O
programming	O
to	O
conduct	O
these	O
analyses	O
This	O
may	O
result	O
in	O
lost	O
opportunities	O
to	O
have	O
results	O
of	O
micronutrient	O
data	O
readily	O
available	O
during	O
critical	O
decision	O
making	O
periods	O
Our	O
research	O
objectives	O
are	O
to	O
1	O
provide	O
an	O
all	O
in	O
one	O
summary	O
of	O
the	O
BRINDA	O
method	O
in	O
adjusting	O
multiple	O
micronutrient	O
biomarkers	O
for	O
inflammation	O
2	O
evaluate	O
whether	O
malaria	O
as	O
a	O
binary	O
variable	O
should	O
be	O
included	O
in	O
the	O
BRINDA	O
inflammation	O
adjustment	O
method	O
and	O
3	O
present	O
standardized	O
and	O
user	O
friendly	O
BRINDA	O
adjustment	O
R	O
package	O
and	O
SAS	O
macro	O
This	O
paper	O
serves	O
as	O
a	O
practical	O
guidebook	O
for	O
the	O
BRINDA	O
inflammation	O
adjustment	O
approach	O
and	O
aids	O
users	O
to	O
use	O
the	O
BRINDA	O
R	O
package	O
and	O
SAS	O
to	O
streamline	O
their	O
analyses	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
rates	O
of	O
parasitaemia	O
clearance	O
and	O
the	O
prevalence	O
of	O
treatment	O
failure	O
in	O
patients	O
with	O
uncomplicated	O
Plasmodium	B-Organism
 falciparum	I-Organism
malaria	S-Disease
 artemether-lumefantrine 	S-Medication
mefloquine	S-Medication
atovaquone-proguanil	S-Medication
treated	O
with	O
MQ	O
and	O
AP	O
AL	O
The	O
retrospective	O
descriptive	O
study	O
included	O
adult	O
patients	O
with	O
uncomplicated	O
P. falciparum	S-Organism
malaria	S-Disease
treated	O
at	O
the	O
University	O
Hospital	O
Bulovka	O
in	O
Prague	O
from	O
2006	O
to	O
2019	O
Parasitaemia	O
clearance	O
was	O
estimated	O
using	O
a	O
linear	O
regression	O
model	O
The	O
study	O
included	O
72	O
patients	O
with	O
a	O
median	O
age	O
of	O
33	O
years	O
IQR	O
27	O
45	O
and	O
a	O
male	O
to	O
female	O
ratio	O
of	O
3	O
2	O
1	O
Thirty	O
six	O
patients	O
50	O
0	O
were	O
treated	O
with	O
AL	O
27	O
37	O
5	O
with	O
MQ	O
and	O
9	O
12	O
5	O
with	O
AP	O
The	O
proportion	O
of	O
VFR	O
and	O
migrants	O
was	O
22	O
2	O
with	O
no	O
significant	O
differences	O
among	O
the	O
three	O
groups	O
The	O
median	O
time	O
to	O
the	O
parasitaemia	O
clearance	O
was	O
two	O
days	O
IQR	O
2	O
3	O
in	O
patients	O
treated	O
with	O
AL	O
versus	O
four	O
days	O
in	O
the	O
MQ	O
IQR	O
3	O
4	O
and	O
AP	O
IQR	O
3	O
4	O
groups	O
p	O
0	O
001	O
The	O
clearance	O
rate	O
constant	O
was	O
3	O
3	O
hour	O
IQR	O
2	O
5	O
4	O
0	O
for	O
AL	O
1	O
6	O
hour	O
IQR	O
1	O
3	O
1	O
9	O
for	O
MQ	O
and	O
1	O
9	O
hour	O
IQR	O
1	O
3	O
2	O
4	O
for	O
AP	O
p	O
0	O
001	O
Malaria	B-Disease
 recrudescence	I-Disease
occurred	O
in	O
5	O
36	O
13	O
9	O
patients	O
treated	O
with	O
AL	O
and	O
in	O
no	O
patients	O
treated	O
with	O
MQ	O
or	O
AP	O
nThe	O
findings	O
demonstrate	O
the	O
superior	O
efficacy	O
of	O
AL	O
compared	O
to	O
other	O
oral	O
antimalarials	O
in	O
early	O
malaria	O
treatment	O
However	O
we	O
observed	O
a	O
higher	O
rate	O
of	O
late	O
treatment	O
failure	O
in	O
patients	O
treated	O
with	O
AL	O
than	O
previously	O
reported	O
This	O
issue	O
warrants	O
further	O
investigation	O
of	O
possible	O
dose	O
adjustments	O
extended	O
regimens	O
or	O
alternative	O
artemisinin	S-Medication
based	O
combinations	O
Specification	O
of	O
migratory	O
cell	O
fate	O
from	O
a	O
stationary	O
population	O
is	O
complex	O
and	O
indispensable	O
both	O
for	O
metazoan	S-Organism
development	O
as	O
well	O
for	O
the	O
progression	O
of	O
the	O
pathological condition	B-Disease
tumor metastasis	I-Disease
Though	O
this	O
cell	O
fate	O
transformation	O
is	O
widely	O
prevalent	O
the	O
molecular	O
understanding	O
of	O
this	O
phenomenon	O
remains	O
largely	O
elusive	O
We	O
have	O
employed	O
the	O
model	O
of	O
border cells	B-Anatomical_Substances
BC	O
in	O
Drosophila	O
oogenesis	O
and	O
identified	O
germline	O
activity	O
of	O
an	O
RNA	O
binding	O
protein	O
Cup	O
that	O
limits	O
acquisition	O
of	O
migratory	O
cell	O
fate	O
from	O
the	O
neighbouring	O
follicle	B-Anatomical_Substances
 epithelial	I-Anatomical_Substances
cells	E-Anatomical_Substances
As	O
activation	O
of	O
JAK	O
STAT	O
in	O
the	O
follicle	B-Anatomical_Substances
cells	I-Anatomical_Substances
is	O
critical	O
for	O
BC	O
specification	O
our	O
data	O
suggest	O
that	O
Cup	O
non	O
cell	O
autonomously	O
restricts	O
the	O
domain	O
of	O
JAK	O
STAT	O
by	O
activating	O
Notch	O
in	O
the	O
follicle	B-Anatomical_Substances
cells	I-Anatomical_Substances
Employing	O
genetics	O
and	O
Delta	O
endocytosis	O
assay	O
we	O
demonstrate	O
that	O
Cup	O
regulates	O
Delta	O
recycling	O
in	O
the	O
nurse	O
cells	O
through	O
Rab11GTPase	S-Protien
thus	O
facilitating	O
Notch	O
activation	O
in	O
the	O
adjacent	O
follicle	B-Anatomical_Substances
cells	I-Anatomical_Substances
Since	O
Notch	O
and	O
JAK	O
STAT	O
are	O
antagonistic	O
we	O
propose	O
that	O
germline	O
Cup	O
functions	O
through	O
Notch	O
and	O
JAK	O
STAT	O
to	O
modulate	O
BC	O
fate	O
specification	O
from	O
their	O
static	O
epithelial	O
progenitors	O
 malaria	S-Disease
Invasion	O
of	O
the	O
vector	O
A	O
minimum	O
of	O
one	O
ultrasound	O
scan	O
is	O
recommended	O
for	O
all	O
pregnant	O
women	O
before	O
the	O
24th	O
week	O
of	O
gestation	O
In	O
Ethiopia	O
there	O
is	O
a	O
shortage	O
of	O
skilled	O
manpower	O
to	O
provide	O
these	O
services	O
Currently	O
trained	O
mid	O
level	O
providers	O
are	O
providing	O
the	O
services	O
at	O
the	O
primary	O
healthcare	O
level	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
compare	O
antenatal care 1	S-Medication
antenatal care 4	S-Medication
postnatal care	S-Medication
skilled birth attendance 	S-Medication
service	O
utilization	O
before	O
and	O
after	O
institutionalizing	O
Vscan	O
limited	O
obstetric	O
ultrasounds	O
at	O
semi	O
urban	O
health	O
centers	O
in	O
Ethiopia	O
nA	O
pre	O
and	O
post	O
intervention	O
observational	O
study	O
was	O
conducted	O
to	O
investigate	O
maternal	O
and	O
neonatal	O
health	O
service	O
utilization	O
rates	O
before	O
and	O
after	O
institutionalizing	O
Vscan	O
limited	O
obstetric	O
ultrasound	O
services	O
between	O
July	O
2016	O
and	O
June	O
2020	O
The	O
data	O
were	O
extracted	O
from	O
1st	O
August	O
31st	O
December	O
2020	O
The	O
observed	O
monthly	O
increase	O
on	O
the	O
mean	O
rank	O
of	O
first	O
ANC	O
visits	O
after	O
the	O
introduction	O
of	O
Vscan	O
limited	O
obstetric	O
ultrasound	O
services	O
showed	O
a	O
statistically	O
significant	O
difference	O
at	O
KW	O
ANOVA	O
H	O
3	O
17	O
09	O
P	O
0	O
001	O
The	O
mean	O
rank	O
of	O
fourth	O
ANC	O
utilization	O
showed	O
a	O
statistically	O
significant	O
difference	O
at	O
KW	O
ANOVA	O
H	O
3	O
16	O
24	O
P	O
0	O
001	O
The	O
observed	O
mean	O
rank	O
in	O
skilled	O
birth	O
attendance	O
SBA	O
showed	O
a	O
statistically	O
significant	O
positive	O
difference	O
using	O
KW	O
ANOVA	O
H	O
3	O
23	O
6	O
P	O
0	O
001	O
The	O
mean	O
rank	O
of	O
increased	O
utilization	O
in	O
postnatal	O
care	O
showed	O
a	O
statistically	O
significant	O
difference	O
using	O
KW	O
ANOVA	O
H	O
3	O
17	O
79	O
P	O
0	O
001	O
nThe	O
introduction	O
of	O
limited	O
obstetric	O
ultrasound	O
services	O
by	O
trained	O
mid	O
level	O
providers	O
at	O
the	O
primary	O
healthcare	O
level	O
was	O
found	O
to	O
have	O
improved	O
the	O
utilization	O
of	O
ANC	O
SBA	O
and	O
postnatal	O
care	O
PNC	O
services	O
It	O
is	O
recommended	O
that	O
the	O
institutionalization	O
of	O
limited	O
obstetric	O
ultrasound	O
services	O
be	O
scaled	O
up	O
and	O
a	O
further	O
comparative	O
study	O
between	O
facilities	O
with	O
and	O
without	O
ultrasound	O
services	O
be	O
conducted	O
to	O
confirm	O
causality	O
and	O
assess	O
effects	O
on	O
maternal	O
and	O
perinatal	O
outcomes	O
SARS-CoV-2 	S-Organism
infection	S-Disease
Estimating	O
the	O
true	O
burden	O
of	O
has	O
been	O
difficult	O
in	O
sub	O
Saharan	O
Africa	O
owing	O
to	O
asymptomatic	O
infections	O
and	O
inadequate	O
testing	O
capacity	O
Antibody	O
responses	O
from	O
serologic	O
surveys	O
can	O
provide	O
an	O
estimate	O
of	O
SARS-CoV-2	S-Organism
exposure	O
at	O
the	O
population	O
level	O
To	O
estimate	O
SARS-CoV-2	S-Organism
seroprevalence	O
attack	O
rates	O
and	O
reinfection	O
in	O
eastern	O
Uganda	O
using	O
serologic	O
surveillance	O
from	O
2020	O
to	O
early	O
2022	O
nThis	O
cohort	O
study	O
was	O
conducted	O
in	O
the	O
Tororo	O
and	O
Busia	O
districts	O
of	O
eastern	O
Uganda	O
 Plasma 	B-Anatomical_Substances
samples	O
from	O
participants	O
in	O
the	O
Program	O
for	O
Resistance	O
Immunology	O
Surveillance	O
and	O
Modeling	O
of	O
Malaria	S-Disease
in	O
Uganda	O
Border	O
Cohort	O
were	O
obtained	O
at	O
4	O
sampling	O
intervals	O
October	O
to	O
November	O
2020	O
March	O
to	O
April	O
2021	O
August	O
to	O
September	O
2021	O
and	O
February	O
to	O
March	O
2022	O
Each	O
participant	O
contributed	O
up	O
to	O
4	O
time	O
points	O
for	O
SARS-CoV-2	S-Organism
serology	O
with	O
almost	O
half	O
of	O
all	O
participants	O
contributing	O
at	O
all	O
4	O
time	O
points	O
and	O
almost	O
90	O
contributing	O
at	O
3	O
or	O
4	O
time	O
points	O
Information	O
on	O
SARS-CoV-2	S-Organism
vaccination	O
status	O
was	O
collected	O
from	O
participants	O
with	O
the	O
earliest	O
reported	O
vaccinations	O
in	O
the	O
cohort	O
occurring	O
in	O
May	O
2021	O
SARS-CoV-2 spike protein	S-Protien
The	O
main	O
outcomes	O
of	O
this	O
study	O
were	O
antibody	O
responses	O
to	O
the	O
as	O
measured	O
with	O
a	O
bead	O
based	O
serologic	O
assay	O
Individual	O
level	O
outcomes	O
were	O
aggregated	O
to	O
population	O
level	O
SARS-CoV-2	S-Organism
seroprevalence	O
attack	O
rates	O
and	O
boosting	O
rates	O
Estimates	O
were	O
weighted	O
by	O
the	O
local	O
age	O
distribution	O
according	O
to	O
census	O
data	O
SARS-CoV-2	S-Organism
SARS-CoV-2	S-Organism
SARS-CoV-2	S-Organism
SARS-CoV-2	S-Organism
Omicron	S-Organism
Plasmodium	B-Organism
 falciparum	I-Organism
 malaria	S-Disease
Omicron 	S-Organism
A	O
total	O
of	O
1483	O
samples	O
from	O
441	O
participants	O
living	O
in	O
76	O
households	O
were	O
tested	O
Of	O
the	O
441	O
participants	O
245	O
55	O
6	O
were	O
female	O
and	O
their	O
mean	O
SD	O
age	O
was	O
16	O
04	O
16	O
04	O
years	O
By	O
the	O
end	O
of	O
the	O
Delta	O
wave	O
and	O
before	O
widespread	O
vaccination	O
adjuste	O
wave	O
84	O
8	O
95	O
CrI	O
67	O
9	O
93	O
7	O
of	O
unvaccinated	O
previously	O
seronegative	O
individuals	O
were	O
infected	O
for	O
the	O
first	O
time	O
and	O
50	O
8	O
95	O
CrI	O
40	O
6	O
59	O
7	O
of	O
unvaccinated	O
already	O
seropositive	O
individuals	O
were	O
likely	O
reinfected	O
leading	O
to	O
an	O
overall	O
seropositivity	O
of	O
96	O
0	O
95	O
CrI	O
93	O
4	O
97	O
9	O
in	O
this	O
population	O
These	O
results	O
suggest	O
a	O
lower	O
probability	O
of	O
reinfection	O
in	O
individuals	O
with	O
higher	O
preexisting	O
antibody	O
levels	O
There	O
was	O
evidence	O
of	O
household	O
clustering	O
of	O
seroprevalence	O
was	O
67	O
7	O
95	O
credible	O
interval	O
CrI	O
62	O
5	O
72	O
6	O
in	O
the	O
study	O
population	O
During	O
the	O
subsequent	O
seroconversion	O
No	O
significant	O
associations	O
were	O
found	O
between	O
seroconversion	O
and	O
gender	O
household	O
size	O
or	O
recen	O
n	O
this	O
cohort	O
study	O
in	O
a	O
rural	O
population	O
in	O
eastern	O
Uganda	O
there	O
was	O
evidence	O
of	O
very	O
high	O
infection	O
rates	O
throughout	O
the	O
pandemic	O
inconsistent	O
with	O
national	O
level	O
case	O
data	O
and	O
high	O
reinfection	O
rates	O
during	O
the	O
Protection	O
against	O
Facing	O
a	O
warming	O
climate	O
 malaria 	B-Organism
mosquito vectors	I-Organism
arthropod	B-Organism
vectors	I-Organism
many	O
tropical	O
species	O
including	O
the	O
of	O
several	O
infectious	O
diseases	O
will	O
be	O
displaced	O
to	O
higher	O
latitudes	O
and	O
elevations	O
These	O
shifts	O
are	O
frequently	O
projected	O
for	O
the	O
future	O
but	O
rarely	O
documented	O
in	O
the	O
present	O
day	O
Here	O
we	O
use	O
one	O
of	O
the	O
most	O
comprehensive	O
datasets	O
ever	O
compiled	O
by	O
medical	O
entomologists	O
to	O
track	O
the	O
observed	O
range	O
limits	O
of	O
African	O
anti-SARS-CoV-2 (	S-Chemical_Substance
Natural	O
products	O
play	O
an	O
essential	O
role	O
in	O
new	O
drug	O
discovery	O
In	O
the	O
present	O
study	O
we	O
determined	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
related	O
coronavirus	O
2	O
antioxidant	O
antiplasmodial	O
and	O
antimicrobial	O
activities	O
of	O
parasites	S-Organism
Studies	O
of	O
in	O
wild	O
animal	O
populations	O
often	O
rely	O
on	O
molecular	O
methods	O
to	O
both	O
detect	O
and	O
quantify	O
infections	O
However	O
method	O
accuracy	O
is	O
likely	O
to	O
be	O
influenced	O
by	O
the	O
sampling	O
approach	O
taken	O
prior	O
to	O
 nucleic acid	S-Chemical_Substance
extraction	O
Avian	B-Organism
Haemosporidia	I-Organism
are	O
studied	O
primarily	O
through	O
the	O
blood	S_Anatomical_Substances
screening	O
of	O
host	O
and	O
a	O
range	O
of	O
storage	O
mediums	O
are	O
available	O
for	O
the	O
short	O
to	O
long	O
term	O
preservation	O
of	O
samples	O
Previous	O
research	O
has	O
suggested	O
that	O
storage	O
medium	O
choice	O
may	O
impact	O
the	O
accuracy	O
of	O
PCR	O
based	O
parasite	O
detection	O
however	O
this	O
relationship	O
has	O
never	O
been	O
explicitly	O
tested	O
and	O
may	O
be	O
exacerbated	O
by	O
the	O
duration	O
of	O
sample	O
storage	O
These	O
considerations	O
could	O
also	O
be	O
especially	O
critical	O
for	O
sensitive	O
molecular	O
methods	O
used	O
to	O
quantify	O
infection	O
qPCR	O
To	O
test	O
the	O
effect	O
of	O
storage	O
medium	O
and	O
duration	O
o	O
The	O
goal	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
burden	O
of	O
 transfusion-transmitted	B-Disease
 infections	I-Disease
TTIs	S-Disease
hepatitis B	B-Organism
virus	I-Organism
HBV	S-Organism
 hepatitis C 	B-Organism
virus 	I-Organism
HCV	S-Organism
human	B-Organism
immunodeficiency	I-Organism
virus	E-Organism
HIV	S-Organism
syphilis	S-Disease
malarial	B-Organism
parasite	I-Organism
in	O
and	O
 Blood	S_Anatomical_Substances
ABO	O
MP	O
Groups	O
and	O
Rh	O
Type	O
System	O
among	O
voluntarily	O
blood	S_Anatomical_Substances
donors	O
in	O
Khyber	O
Pakhtunkhwa	O
KPK	O
Pakistan	O
It	O
is	O
a	O
retrospective	O
single	O
center	O
cross	O
sectional	O
study	O
This	O
study	O
was	O
conducted	O
from	O
June	O
2020	O
to	O
September	O
2021	O
16	O
months	O
at	O
the	O
frontier	O
foundation	O
 thalassemia	S-Disease
center	O
Peshawar	O
KPK	O
Donors	O
were	O
physically	O
healthy	O
and	O
fit	O
for	O
donation	O
Donors	O
with	O
physical	O
disabilities	O
and	O
or	O
having	O
co	O
morbid	O
conditions	O
were	O
excluded	O
from	O
the	O
report	O
All	O
the	O
samples	O
were	O
screened	O
for	O
 anti-HIV	S-Medication
anti-HCV	S-Medication
HBsAg,	S-Protien
Syphilis	S-Disease
Malarial 	B-Organism
Parasite	I-Organism
via	O
ELISA	O
kit	O
and	O
Immune	O
Chromatographic	O
Technique	O
ICT	O
respectively	O
A	O
total	O
of	O
6311	O
blood	O
donations	O
were	O
evaluated	O
The	O
majority	O
of	O
the	O
donations	O
92	O
were	O
from	O
VNRBD	O
voluntary	O
non	O
remunerated	O
blood	O
donation	O
while	O
only	O
8	O
came	O
from	O
replacement	O
donors	O
Amongst	O
6311	O
blood	O
donations	O
1	O
50	O
n	O
95	O
were	O
infected	O
at	O
least	O
with	O
one	O
pathogen	S-Organism
HBV	O
positive	O
cases	O
were	O
0	O
855	O
n	O
54	O
HCV	O
positive	O
cases	O
were	O
0	O
316	O
n	O
20	O
syphilis 	S-Disease
positive	O
were	O
0	O
30	O
n	O
19	O
and	O
MP	O
positive	O
cases	O
were	O
only	O
0	O
031	O
n	O
2	O
HBV	O
HCV	O
syphilis 	S-Disease
malaria	S-Disease
infections	O
rates	O
were	O
found	O
to	O
be	O
low	O
as	O
compared	O
to	O
the	O
previous	O
data	O
published	O
while	O
no	O
case	O
was	O
reported	O
for	O
HIV	O
The	O
study	O
also	O
revealed	O
the	O
distribution	O
pattern	O
of	O
the	O
aforementioned	O
pathogens	O
in	O
blood	O
groups	O
and	O
the	O
Rh	O
type	O
system	O
of	O
the	O
reactive	O
samples	O
nThe	O
lower	O
reported	O
in	O
our	O
study	O
indicates	O
the	O
awareness	O
among	O
the	O
people	O
of	O
Peshawar	O
about	O
TTIs	O
and	O
their	O
precautions	O
The	O
prevalence	O
rate	O
that	O
we	O
are	O
reporting	O
is	O
less	O
than	O
previously	O
published	O
articles	O
in	O
the	O
same	O
domain	O
Domesticated	B-Organism
animals	I-Organism
play	O
a	O
role	O
in	O
maintaining	O
residual	O
transmission	O
of	O
Plasmodium	B-Organism
parasites 	I-Organism
humans	S-Organism
by	O
offering	O
alternative	O
blood 	S_Anatomical_Substances
meal	O
sources	O
for	O
malaria 	S-Disease
vectors	O
to	O
survive	O
on	O
However	O
the	O
blood	S_Anatomical_Substances
 animals	S-Organism
treated	O
with	O
veterinary	O
formulations	O
of	O
the	O
anti-helminthic	B-Medication
drug	I-Medication
ivermectin	S-Medication
can	O
have	O
an	O
insecticidal	O
effect	O
on	O
adult	O
malaria vector	B-Organism
mosquitoes	I-Organism
This	O
study	O
therefore	O
assessed	O
the	O
effects	O
of	O
treating	O
cattle	O
with	O
long	O
acting	O
injectable	O
formulations	O
of	O
ivermectin	S-Medication
on	O
the	O
survival	O
of	O
an	O
important	O
 malaria vector	B-Organism
species	O
to	O
determine	O
whether	O
it	O
has	O
potential	O
as	O
a	O
complementary	O
vector	O
control	O
measure	O
Eight	O
head	O
of	O
a	O
local	O
breed	O
of	O
cattle	O
were	O
randomly	O
assigned	O
to	O
either	O
one	O
of	O
two	O
treatment	O
arms	O
2	O
2	O
cattle	O
injected	O
with	O
one	O
of	O
two	O
long	O
acting	O
formulations	O
of	O
 ivermectin	S-Medication
with	O
the	O
BEPO	O
Both	O
formulations	O
released	O
mosquitocidal	O
concentrations	O
of	O
ivermectin	S-Medication
until	O
210	O
days	O
post	O
treatment	O
hazard	O
ratio	O
1	O
The	O
treatments	O
significantly	O
reduced	O
 mosquito	S-Organism
survival	O
with	O
average	O
median	O
survival	O
time	O
of	O
4	O
5	O
days	O
post	O
feeding	O
The	O
lethal	O
concentrations	O
to	O
kill	O
50	O
of	O
the	O
Anopheles 	S-Organism
LC	O
nThis	O
long	O
lasting	O
formulation	O
of	O
ivermectin	S-Medication
zoophagic	B-Organism
mosquitoes	I-Organism
that	O
are	O
responsible	O
at	O
least	O
in	O
part	O
for	O
residual	O
malaria	S-Disease
injected	O
in	O
cattle	O
could	O
complement	O
insecticide	O
treated	O
nets	O
by	O
suppressing	O
field	O
populations	O
of	O
transmission	O
The	O
impact	O
of	O
this	O
approach	O
will	O
of	O
course	O
depend	O
on	O
the	O
field	O
epidemiological	O
context	O
Complementary	O
studies	O
will	O
be	O
necessary	O
to	O
characterize	O
ivermectin	S-Medication
withdrawal	O
times	O
and	O
potential	O
environmental	O
toxicity	O
Spiroindolone	S-Medication
pyrazoleamide	S-Medication
antimalarial 	B-Chemical_Substance
compounds 	I-Chemical_Substance
Plasmodium falciparum 	B-Protien
P-type ATPase	I-Protien
PfATP4	S-Protien
and	O
induce	O
disruption	O
of	O
and	O
targe	O
intracellular	O
Na	O
A	O
genetically	O
engineered	O
P. falciparum	B-Organism
Dd2 strain 	I-Organism
Sublethal	O
treatment	O
with	O
PA21A092 	S-Medication
caused	O
significant	O
p	O
0	O
001	O
alterations	O
in	O
the	O
abundances	O
of	O
91	O
Plasmodium 	B-Organism
gene	O
transcripts	O
whereas	O
only	O
21	O
transcripts	O
were	O
significantly	O
altered	O
due	O
to	O
sublethal	O
treatment	O
with	O
KAE609	S-Medication
In	O
the	O
metabolomic	O
data	O
a	O
substantial	O
alteration	O
fourfold	O
in	O
the	O
abundances	O
of	O
carbohydrate	O
metabolites	O
in	O
the	O
presence	O
of	O
either	O
compound	O
was	O
found	O
The	O
estimated	O
rates	O
of	O
macromolecule	O
syntheses	O
between	O
the	O
two	O
antimalarial	O
treated	O
conditions	O
were	O
also	O
comparable	O
except	O
for	O
the	O
rate	O
of	O
lipid	O
synthesis	O
A	O
closer	O
examination	O
of	O
parasite	O
metabolism	O
in	O
the	O
presence	O
of	O
either	O
compound	O
indicated	O
statistically	O
significant	O
differences	O
in	O
enzymatic	O
activities	O
associated	O
with	O
synthesis	O
of	O
phosphatidylcholine	S-Chemical_Substance
phosphatidylserine	S-Chemical_Substance
 phosphatidylinositol	S-Chemical_Substance
malaria parasites	B-Organism
 protein kinases	B-Protien
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
via	O
phospholipid	O
dependent	O
signalling	O
in	O
response	O
to	O
the	O
ionic	O
perturbation	O
induced	O
by	O
the	O
Na	O
Malaria 	S-Disease
continues	O
to	O
be	O
a	O
global	O
problem	O
due	O
to	O
the	O
limited	O
efficacy	O
of	O
current	O
drugs	O
and	O
the	O
natural	O
products	O
are	O
a	O
potential	O
source	O
for	O
discovering	O
new	O
antimalarial	O
agents	O
Therefore	O
the	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
phytochemical	O
properties	O
cytotoxic	O
effect	O
antioxidant	O
and	O
antiplasmodial	O
activities	O
of	O
Sonchus	B-Organism
 arvensis	I-Organism
L. leaf	E-Organism
extracts	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
The	O
extracts	O
from	O
 S. arvensis	B-Organism
L. leaf	I-Organism
were	O
prepared	O
by	O
successive	O
maceration	O
with	O
n-hexane	S-Chemical_Substance
ethyl 	B-Chemical_Substance
acetate	I-Chemical_Substance
ethanol	S-Chemical_Substance
and	O
and	O
then	O
subjected	O
to	O
quantitative	O
phytochemical	O
analysis	O
using	O
standard	O
methods	O
The	O
antimalarial	O
activities	O
of	O
crude	O
extracts	O
were	O
tested	O
in	O
vitro	O
against	O
Plasmodium	B-Organism
falciparum 	I-Organism
3D7 strain	E-Organism
while	O
the	O
Peter	O
s	O
4	O
day	O
suppressive	O
test	O
model	O
with	O
P. berghei	B-Organism
-infected mice 	I-Organism
was	O
used	O
to	O
evaluate	O
the	O
in	O
vivo	O
antiplasmodial	O
hepatoprotective	O
nephroprotective	O
and	O
immunomodulatory	O
activities	O
The	O
cytotoxic	O
tests	O
were	O
also	O
carried	O
out	O
using	O
human	O
hepatic	O
cell	O
lines	O
in	O
3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide	S-Chemical_Substance
MTT	O
assay	O
 n-hexane	S-Chemical_Substance
ethyl acetate	S-Chemical_Substance
ethanolic extracts 	S-Chemical_Substance
 S. arvensis	B-Organism
L. leaf	I-Organism
The	O
and	O
exhibited	O
good	O
in	O
vitro	O
antiplasmodial	O
activity	O
with	O
IC	O
nThis	O
study	O
highlights	O
the	O
antiplasmodial	O
activities	O
of	O
S. arvensis 	B-Organism
L. leaf	I-Organism
ethyl acetate	S-Chemical_Substance
 P. falciparum	B-Organism
 P. berghei 	B-Organism
extract	O
against	O
as	O
well	O
as	O
the	O
antioxidant	O
nephroprotective	O
hepatoprotective	O
and	O
immunomodulatory	O
activities	O
with	O
low	O
toxicity	O
These	O
results	O
indicate	O
the	O
potential	O
of	O
Sonchus	B-Organism
malaria	S-Disease
arvensis L.	I-Organism
to	O
be	O
developed	O
into	O
a	O
new	O
antimalarial	O
drug	O
candidate	O
However	O
the	O
compounds	O
and	O
transmission	O
blocking	O
strategies	O
for	O
 S. arvensis L. 	B-Organism
extracts	O
are	O
essential	O
for	O
further	O
study	O
control	O
of	O
African	O
region	O
accounts	O
for	O
95	O
of	O
all	O
malaria 	S-Disease
cases	O
and	O
96	O
of	O
malaria	S-Disease
deaths	O
with	O
under	O
five	O
children	O
accounting	O
for	O
80	O
of	O
all	O
deaths	O
in	O
the	O
region	O
This	O
study	O
assessed	O
the	O
socioeconomic	O
determinants	O
of	O
malaria	S-Disease
prevalence	O
and	O
provide	O
evidence	O
on	O
the	O
socioeconomic	O
profile	O
of	O
malaria	B-Disease
infection	I-Disease
among	O
under	O
five	O
children	O
in	O
11	O
SSA	O
countries	O
This	O
study	O
used	O
data	O
from	O
the	O
2010	O
to	O
2020	O
Demographic	O
and	O
Health	O
Survey	O
DHS	O
The	O
survey	O
used	O
a	O
two	O
stage	O
stratified	O
cluster	O
sampling	O
design	O
based	O
on	O
the	O
sampling	O
frame	O
of	O
the	O
population	O
and	O
housing	O
census	O
of	O
countries	O
included	O
Statistical	O
analyses	O
relied	O
on	O
Pearson	O
s	O
χ2	O
using	O
the	O
CHAID	O
decision	O
tree	O
algorithm	O
and	O
logistic	O
regression	O
implemented	O
in	O
R	O
V	O
4	O
6	O
malaria	B-Disease
 infection	I-Disease
Of	O
8547	O
children	O
considered	O
24	O
2	O
95	O
confidence	O
interval	O
CI	O
23	O
4	O
25	O
05	O
had	O
Also	O
the	O
prevalence	O
of	O
malaria	B-Disease
infection	I-Disease
seems	O
to	O
increase	O
with	O
age	O
The	O
following	O
variables	O
are	O
statistically	O
associated	O
with	O
the	O
prevalence	O
of	O
malaria	B-Disease
infection	I-Disease
among	O
under	O
five	O
children	O
under	O
five	O
child	O
s	O
age	O
maternal	O
education	O
sex	O
of	O
household	O
head	O
household	O
wealth	O
index	O
place	O
of	O
residence	O
and	O
African	O
region	O
where	O
mother	O
child	O
pair	O
lives	O
Children	O
whose	O
mothers	O
have	O
secondary	O
education	O
have	O
about	O
56	O
lower	O
risk	O
odds	O
ratio	O
0	O
44	O
95	O
CI	O
0	O
40	O
0	O
48	O
of	O
malaria	B-Disease
infection	I-Disease
and	O
73	O
lower	O
odds	O
ratio	O
0	O
37	O
95	O
CI	O
0	O
32	O
0	O
43	O
among	O
children	O
living	O
in	O
the	O
richest	O
households	O
compared	O
to	O
children	O
living	O
in	O
the	O
poorest	O
households	O
The	O
findings	O
of	O
this	O
study	O
provide	O
unique	O
insights	O
on	O
how	O
socioeconomic	O
and	O
demographic	O
variables	O
especially	O
maternal	O
education	O
level	O
significantly	O
predicts	O
under	O
five	O
malaria	O
prevalence	O
across	O
the	O
SSA	O
region	O
Therefore	O
ensuring	O
that	O
malaria	O
interventions	O
are	O
underpinned	O
by	O
a	O
multisectoral	O
approach	O
that	O
comprehensively	O
tackles	O
the	O
interplay	O
of	O
maternal	O
education	O
and	O
other	O
socioeconomic	O
variables	O
will	O
be	O
critical	O
in	O
attaining	O
malaria	O
prevention	O
and	O
control	O
targets	O
in	O
SSA	O
Cerebral	B-Disease
malaria 	I-Disease
Malarial	B-Disease
retinopathy	I-Disease
malarial	B-Disease
 retinopathy	I-Disease
red	B-Anatomical_Substances
blood	I-Anatomical_Substances
CM	O
remains	O
a	O
common	O
cause	O
of	O
death	O
of	O
children	O
in	O
Africa	O
with	O
annual	O
mortality	O
of	O
400	O
000	O
is	O
a	O
unique	O
set	O
of	O
fundus	O
signs	O
which	O
has	O
diagnostic	O
and	O
prognostic	O
value	O
in	O
CM	O
Assessment	O
of	O
is	O
now	O
widely	O
utilised	O
in	O
clinical	O
care	O
and	O
routinely	O
incorporated	O
into	O
clinical	O
studies	O
to	O
refine	O
entry	O
criteria	O
As	O
a	O
visible	O
part	O
of	O
the	O
central	O
nervous	O
system	O
the	O
retina 	S_Anatomical_Substances
provides	O
insights	O
into	O
the	O
pathophysiology	O
of	O
this	O
infectious	O
small-vessel	B-Anatomical_Substances
vasculitis	I-Anatomical_Substances
with	O
adherent	O
parasitised	O
cells	S_Anatomical_Substances
Fluorescein	O
angiography	O
and	O
optical	O
coherence	O
tomography	O
OCT	O
have	O
shown	O
that	O
patchy	O
capillary	O
non	O
perfusion	O
is	O
common	O
and	O
causes	O
ischaemic	O
changes	O
in	O
the	O
 retina 	S_Anatomical_Substances
in	O
CM	O
It	O
is	O
likely	O
this	O
is	O
mirrored	O
in	O
the	O
brain	O
and	O
may	O
cause	O
global	O
neurological	O
impairments	O
evident	O
on	O
developmental	O
follow	O
up	O
Three	O
types	O
of	O
 blood-retina	S_Anatomical_Substances
barrier	O
breakdown	O
are	O
evident	O
large	O
focal	O
punctate	O
and	O
vessel	O
leak	O
Punctate	O
and	O
large	O
focal	O
leak	O
 brain	S_Anatomical_Substances
haemorrhage	O
in	O
formation	O
are	O
associated	O
with	O
severe	O
swelling	O
and	O
fatal	O
outcome	O
Vessel	O
leak	O
and	O
capillary	O
non	O
perfusion	O
are	O
associated	O
with	O
moderate	O
brain	O
swelling	O
and	O
neurological	O
sequelae	O
These	O
findings	O
imply	O
that	O
death	O
and	O
neurological	O
sequelae	O
have	O
separate	O
mechanisms	O
and	O
are	O
not	O
a	O
continuum	O
of	O
severity	O
Each	O
haemorrhage	O
causes	O
a	O
temporary	O
uncontrolled	O
outflow	O
of	O
fluid	O
into	O
the	O
tissue	O
The	O
rapid	O
accumulation	O
of	O
haemorrhages	O
as	O
evidenced	O
by	O
multiple	O
focal	O
leaks	O
is	O
a	O
proposed	O
mechanism	O
of	O
severe	O
brain	O
swelling	O
and	O
death	O
Current	O
studies	O
aim	O
to	O
use	O
optic	O
nerve	O
head	O
OCT	O
to	O
identify	O
patients	O
with	O
severe	O
brain	O
swelling	O
and	O
macula	O
OCT	O
to	O
identify	O
those	O
at	O
risk	O
of	O
neurological	O
sequelae	O
n摘要	O
脑型疟疾	O
CM	O
仍为非洲儿童死亡的一个常见原因	O
每年的死亡人数可达40万人	O
疟疾性视网膜病变为具有独特眼底体征的一系列改变	O
对CM具有诊断和预后价值	O
在临床工作中	O
对于疟疾性视网膜病变的评估已得到广泛应用	O
并常规纳入临床研究以完善入选标准	O
作为中枢神经系统中唯一肉眼可见的组织	O
视网膜提供了对这种寄生于红细胞的传染性小血管炎的病理生理学了解的有用信息	O
荧光素血管造影和相干光断层扫描	O
OCT	O
显示	O
斑片状毛细血管无灌注很常见	O
并导致CM患者的视网膜缺血性改变	O
这些病理性改变可能反映在大脑中的病变	O
并导致在发育的随访中出现了明显的的全神经系统损伤	O
三种类型的血	O
视网膜屏障破坏是显而易见的	O
大面积病灶	O
点状病灶和血管渗漏	O
点状和大面积病灶渗漏	O
出血形成	O
与严重的脑组织肿胀和致命的临床解决有关	O
血管渗漏和毛细血管无灌注与中度脑组织肿胀和神经系统后遗症有关	O
这些发现意味着死亡和神经系统后遗症具有不同的机制	O
并不是严重后遗症的结局	O
每一次出血都会导致液体暂时不受控制地流出到组织中	O
多处病灶渗漏表明	O
出血的快速积累	O
是严重脑肿胀和死亡的可能机制	O
目前的研究旨在使用视盘OCT来识别严重脑水肿的患者	O
以及使用黄斑OCT来识别那些具有神经系统后遗症风险的患者	O
biomineral	B-Chemical_Substance
haemozoin	I-Chemical_Substance
synthetic	B-Chemical_Substance
 analogue	I-Chemical_Substance
β-haematin	E-Chemical_Substance
The	O
or	O
its	O
has	O
been	O
the	O
focus	O
of	O
several	O
target	O
based	O
screens	O
for	O
activity	O
against	O
Plasmodium	B-Organism
falciparum 	I-Organism
parasites	E-Organism
ogether	O
with	O
the	O
known	O
βH	O
crystal	O
structure	O
the	O
availability	O
of	O
this	O
screening	O
data	O
makes	O
the	O
target	O
amenable	O
to	O
both	O
structure	O
based	O
and	O
ligand	O
based	O
virtual	O
screening	O
In	O
this	O
study	O
molecular	O
docking	O
and	O
machine	O
learning	O
techniques	O
including	O
Bayesian	O
and	O
support	O
vector	O
machine	O
classifiers	O
were	O
used	O
in	O
sequence	O
to	O
screen	O
the	O
in	O
 silico ChemDiv 300k	I-Chemical_Substance
Representative Compounds	I-Chemical_Substance
library	O
for	O
inhibitors	O
of	O
βH	O
with	O
retained	O
activity	O
against	O
P. falciparum	S-Organism
We	O
commercially	O
obtained	O
and	O
tested	O
a	O
prioritised	O
set	O
of	O
inhibitors	O
and	O
identified	O
the	O
coumarin	S-Chemical_Substance
 iminodipyridinopyrimidine	S-Chemical_Substance
chemotypes	O
as	O
potent	O
in	O
vitro	O
inhibitors	O
of	O
βH	O
and	O
whole	O
cell	O
parasite	O
growth	O
HBV	S-Disease
 HCV	S-Disease
 HIV	S-Disease
 HTLV	S-Disease
 syphilis	S-Disease
 malaria 	S-Disease
transfusion-transmitted	B-Disease
infections 	I-Disease
 blood	S_Anatomical_Substances
blood	S_Anatomical_Substances
 blood 	S_Anatomical_Substances
blood	S_Anatomical_Substances
malaria	S-Disease
 HBsAg	S-Protien
HBsAb	S-Protien
HBcAbs	S-Protien
 HCV	S-Disease
HIV	S-Disease
 HTLV-I and -I	S-Disease
syphilis	S-Disease
HBV	S-Disease
HCV	S-Disease
 HIV	S-Disease
 syphilis	S-Disease
 HTLV-I/-II 	S-Disease
Testing	O
of	O
donors	O
for	O
markers	O
of	O
TTIs	O
such	O
as	O
is	O
mandatory	O
in	O
Saudi	O
Arabia	O
This	O
study	O
determined	O
the	O
prevalence	O
of	O
all	O
tested	O
TTIs	O
among	O
donors	O
in	O
the	O
western	O
region	O
of	O
Saudi	O
Arabia	O
nThis	O
retrospective	O
study	O
included	O
5	O
473	O
donors	O
who	O
attended	O
the	O
donation	O
center	O
at	O
the	O
Security	O
Force	O
Hospital	O
SFH	O
located	O
in	O
the	O
western	O
region	O
of	O
Saudi	O
Arabia	O
from	O
January	O
1	O
2015	O
to	O
December	O
31	O
2018	O
The	O
prevalence	O
of	O
TTIs	O
was	O
determined	O
and	O
classified	O
as	O
per	O
year	O
gender	O
age	O
type	O
of	O
donors	O
first	O
time	O
vs	O
returned	O
donors	O
category	O
of	O
donation	O
replacement	O
vs	O
volunteer	O
and	O
blood	O
group	O
nAll	O
donors	O
100	O
were	O
screened	O
for	O
TTIs	O
by	O
serological	O
assays	O
and	O
nucleic	O
acid	O
tests	O
NATs	O
Reactive	O
samples	O
to	O
serological	O
assays	O
were	O
as	O
follow	O
57	O
1	O
07	O
292	O
5	O
34	O
388	O
7	O
1	O
13	O
0	O
24	O
5	O
0	O
09	O
8	O
0	O
15	O
21	O
0	O
83	O
and	O
0	O
0	O
The	O
NAT	O
results	O
for	O
revealed	O
50	O
0	O
91	O
1	O
0	O
0002	O
and	O
3	O
0	O
05	O
reactive	O
samples	O
respectively	O
Reactive	O
donations	O
to	O
screening	O
serology	O
tests	O
of	O
were	O
neither	O
confirmed	O
nor	O
declined	O
by	O
their	O
corresponding	O
confirmatory	O
assays	O
Most	O
reactive	O
samples	O
to	O
TTI	O
tests	O
were	O
associated	O
with	O
male	O
gender	O
first	O
time	O
donor	O
replacement	O
donation	O
and	O
O	O
blood	O
group	O
nThis	O
study	O
highlights	O
the	O
strong	O
adherence	O
to	O
TTI	O
testing	O
policy	O
and	O
low	O
prevalence	O
of	O
TTI	O
markers	O
among	O
blood	O
donors	O
in	O
the	O
western	O
region	O
of	O
Saudi	O
Arabia	O
Asymptomatic	B-Disease
malaria	I-Disease
 infections	E-Disease
have	O
received	O
less	O
attention	O
than	O
symptomatic	O
malaria	B-Disease
infections	I-Disease
in	O
major	O
studies	O
Few	O
epidemiological	O
studies	O
on	O
asymptomatic	B-Disease
 malaria	I-Disease
infections 	E-Disease
have	O
often	O
focused	O
on	O
pregnant	O
women	O
and	O
children	O
under	O
five	O
years	O
of	O
age	O
as	O
the	O
most	O
vulnerable	O
groups	O
However	O
there	O
is	O
limitation	O
on	O
data	O
regarding	O
asymptomatic	B-Disease
infections	I-Disease
among	O
the	O
old	O
adult	O
populations	O
particularly	O
in	O
the	O
study	O
area	O
Therefore	O
this	O
study	O
determined	O
the	O
prevalence	O
o	O
asymptomatic	B-Disease
malaria	I-Disease
infection	E-Disease
by	O
microscopy	O
and	O
its	O
determinants	O
among	O
residents	O
of	O
Ido	O
Ekiti	O
Southwestern	O
Nigeria	O
A	O
hospital	O
based	O
cross	O
sectional	O
study	O
was	O
conducted	O
between	O
July	O
and	O
September	O
2021	O
among	O
232	O
consenting	O
apparently	O
healthy	O
individuals	O
aged	O
40	O
years	O
and	O
above	O
who	O
were	O
recruited	O
during	O
a	O
free	O
health	O
screening	O
program	O
using	O
a	O
standardised	O
interviewer	O
administered	O
questionnaire	O
The	O
questionnaire	O
sought	O
information	O
on	O
respondents	O
socio	O
demographics	O
presence	O
and	O
types	O
of	O
co	O
morbidity	O
and	O
the	O
prevention	O
methods	O
being	O
adopted	O
against	O
 malaria	B-Disease
 infection	I-Disease
asymptomatic Plasmodium	B-Organism
falciparum	I-Organism
Plasmodium 	B-Organism
falciparum	I-Organism
Venous	O
blood	O
samples	O
were	O
collected	O
and	O
processed	O
for	O
asymptomatic	O
infections	O
using	O
Giemsa	O
stained	O
blood	O
smear	O
microscopy	O
Data	O
were	O
analysed	O
using	O
SPSS	O
version	O
21	O
Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
identify	O
factors	O
associated	O
with	O
asymptomatic	O
infections	O
Of	O
the	O
total	O
232	O
respondents	O
19	O
0	O
48	O
232	O
were	O
confirmed	O
to	O
be	O
infected	O
with	O
Plasmodium	O
falciparum	O
95	O
confidence	O
interval	O
CI	O
14	O
1	O
24	O
6	O
Lack	O
of	O
formal	O
education	O
Adjusted	O
odds	O
ratio	O
AOR	O
5	O
298	O
95	O
CI	O
2	O
184	O
13	O
997	O
being	O
diabetic	O
AOR	O
4	O
681	O
95	O
CI	O
1	O
669	O
16	O
105	O
and	O
not	O
sleeping	O
under	O
Long	O
Lasting	O
Insecticide	O
Net	O
LLINs	O
AOR	O
4	O
594	O
95	O
CI	O
1	O
194	O
14	O
091	O
were	O
the	O
determinants	O
of	O
was	O
19	O
Lack	O
of	O
formal	O
education	O
being	O
diabetic	O
and	O
not	O
sleeping	O
under	O
LLINs	O
were	O
the	O
determinants	O
of	O
asymptomatic	O
infections	O
The	O
prevalence	O
of	O
asymptomatic	O
infection	O
Plasmodium	B-Organism
 falciparum	I-Organism
parasite	S-Organism
is	O
a	O
that	O
causes	O
asymptomatic	B-Disease
symptomatic	B-Disease
malaria	I-Disease
infections	E-Disease
 humans	S-Organism
depending	O
on	O
various	O
factors	O
These	O
infections	O
are	O
also	O
a	O
major	O
cause	O
of	O
anemia	S-Disease
in	O
intertropical	O
countries	O
such	O
as	O
Gabon	O
Past	O
studies	O
have	O
clearly	O
demonstrated	O
that	O
inflammatory	O
markers	O
such	O
as	O
cytokines 	S-Protien
 malaria disease	S-Disease
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
However	O
the	O
clinical	O
manifestations	O
of	O
severe	O
malaria 	S-Disease
vary	O
according	O
to	O
the	O
level	O
of	O
transmission	O
and	O
more	O
information	O
is	O
needed	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
factors	O
involved	O
As	O
such	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
circulating	O
levels	O
of	O
nine	O
cytokines	S-Protien
P. falciparum	B-Organism
infections	S-Disease
in	O
asymptomatic	O
and	O
symptomatic	O
in	O
Gabonese	O
children	O
and	O
their	O
roles	O
in	O
the	O
pathogenesis	O
of	O
anemia	O
Blood	O
samples	O
were	O
collected	O
from	O
241	O
children	O
aged	O
3	O
to	O
180	O
months	O
in	O
Lastourville	O
south	O
eastern	O
Gabon	O
Diagnosis	O
of	O
P	O
falciparum	O
infection	O
was	O
performed	O
using	O
Rapid	O
Diagnosis	O
Tests	O
microscopy	O
and	O
nested	O
PCR	O
 Th1	S-Protien
 plasma 	S_Anatomical_Substances
Levels	O
in	O
the	O
IFN-γ	S-Protien
 TNF-α	S-Protien
IL-6	S-Protien
IL-12p70	S-Protien
Th17	S-Protien
IL-17A	S-Protien
 IL-22	S-Protien
 Th2	S-Protien
(IL-10	S-Protien
IL-4	S-Protien
 IL-13	S-Protien
 cytokines	S-Protien
were	O
measured	O
by	O
ELISA	O
Data	O
showed	O
that	O
 IL-6	S-Protien
IFN-γ	S-Protien
, IL-12p70	S-Protien
IL-10	S-Protien
IL-13 	S-Protien
levels	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
 symptomatic	B-Disease
P. falciparum	I-Disease
infection 	E-Disease
compared	O
to	O
uninfected	O
children	O
IL-10	S-Protien
levels	O
were	O
significantly	O
higher	O
in	O
symptomatic	O
children	O
than	O
in	O
asymptomatic	O
children	O
who	O
had	O
moderately	O
increased	O
levels	O
compared	O
to	O
uninfected	O
controls	O
Moreover	O
only	O
 IL-10 	S-Protien
IL-6	S-Protien
IL-10	S-Protien
levels	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
severe	O
malarial	O
anemia	O
compared	O
to	O
children	O
with	O
uncomplicated	O
malaria	O
who	O
had	O
significantly	O
lower	O
levels	O
than	O
children	O
with	O
moderate	O
malarial 	B-Disease
anemia	I-Disease
 P. falciparum	S-Organism
Th2 cytokines	S-Protien
Th1	S-Protien
anemia	S-Disease
malaria	S-Disease
These	O
data	O
indicate	O
that	O
the	O
progression	O
of	O
infection	O
towards	O
an	O
advanced	O
stage	O
in	O
children	O
is	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
type	O
and	O
or	O
These	O
inflammatory	O
mediators	O
could	O
serve	O
as	O
potential	O
predictors	O
of	O
for	O
patients	O
 Leishmaniasis	S-Disease
Malaria	S-Disease
 Chagas	S-Disease
 Human	B-Disease
African	I-Disease
Trypanosomiasis	E-Disease
Tropical	B-Disease
 vector-borne	B-Disease
diseases	I-Disease
and	O
neglected	O
with	O
a	O
limited	O
number	O
of	O
medication	O
therapies	O
include	O
 Chromones	S-Chemical_Substance
heterocyclic	B-Chemical_Substance
compounds	I-Chemical_Substance
are	O
a	O
large	O
class	O
of	O
with	O
significant	O
applications	O
This	O
heterocycle	O
has	O
long	O
aroused	O
the	O
interest	O
of	O
scientists	O
and	O
the	O
general	O
public	O
from	O
biosynthetic	O
and	O
synthetic	O
points	O
of	O
view	O
owing	O
to	O
its	O
interesting	O
pharmacological	O
activities	O
Chromones	S-Chemical_Substance
and	O
their	O
hybrids	O
and	O
isomeric	O
forms	O
proved	O
to	O
be	O
an	O
exciting	O
scaffold	O
to	O
investigate	O
these	O
diseases	O
The	O
in	O
vitro	O
activities	O
of	O
 benzopyran	S-Chemical_Substance
Chromone	S-Chemical_Substance
Chromane	S-Chemical_Substance
and	O
a	O
panel	O
of	O
other	O
related	O
class	O
compounds	O
against	O
Trypanosoma	B-Organism
 brucei 	I-Organism
rhodesiense	E-Organism
Trypanosoma	B-Organism
brucei	I-Organism
gambiense	E-Organism
Trypanosoma	B-Organism
cruzi	I-Organism
and	O
numerous	O
Leishmanial	O
and	O
Malarial	O
species	O
were	O
investigated	O
in	O
our	O
previous	O
studies	O
The	O
current	O
article	O
briefly	O
describes	O
the	O
neglected	O
diseases	O
and	O
the	O
current	O
treatment	O
This	O
review	O
aims	O
to	O
attempt	O
to	O
find	O
better	O
alternatives	O
by	O
scrutinizing	O
natural	O
and	O
synthetic	O
derivatives	O
for	O
which	O
chromones	S-Chemical_Substance
and	O
their	O
analogues	O
were	O
discovered	O
to	O
be	O
a	O
new	O
and	O
highly	O
effective	O
scaffold	O
for	O
the	O
treatment	O
of	O
neglected	O
diseases	O
including	O
compounds	O
with	O
dual	O
activity	O
or	O
activity	O
against	O
multiple	O
parasites	O
Additionally	O
the	O
efficacy	O
of	O
other	O
new	O
scaffolds	O
was	O
also	O
thoroughly	O
examined	O
This	O
article	O
also	O
discusses	O
prospects	O
for	O
identifying	O
more	O
unique	O
targets	O
for	O
the	O
disease	O
focusing	O
on	O
flavonoids	S-Chemical_Substance
as	O
drug	O
molecules	O
that	O
are	O
less	O
cytotoxic	O
and	O
high	O
antiprotozoal	O
potential	O
It	O
also	O
emphasizes	O
the	O
changes	O
that	O
can	O
be	O
made	O
while	O
searching	O
for	O
potential	O
therapies	O
comparing	O
existing	O
treatments	O
against	O
protozoal	O
diseases	O
and	O
the	O
advantages	O
of	O
the	O
newer	O
chromone	O
analogues	O
over	O
them	O
Finally	O
the	O
structure	O
activity	O
relationship	O
at	O
each	O
atom	O
of	O
the	O
chromone	S-Chemical_Substance
has	O
also	O
been	O
highlighted	O
Diabetes	B-Disease
Mellitus	I-Disease
is	O
one	O
of	O
the	O
highest	O
contributors	O
to	O
global	O
mortality	O
exceeding	O
numbers	O
of	O
even	O
the	O
three	O
major	O
infectious	O
diseases	O
in	O
the	O
world	O
namely	O
Tuberculosis	S-Disease
HIV AIDS	S-Disease
Malaria	S-Disease
DM	O
is	O
characterised	O
by	O
increased	O
serum	O
levels	O
of	O
glucose	O
caused	O
by	O
a	O
loss	O
of	O
 beta cells	S_Anatomical_Substances
of	O
the	O
pancreatic	B-Anatomical_Substances
islets	I-Anatomical_Substances
responsible	O
for	O
the	O
secretion	O
of	O
insulin	S-Chemical_Substance
Upon	O
accumulation	O
of	O
data	O
via	O
a	O
wide	O
array	O
of	O
literature	O
surveys	O
it	O
has	O
been	O
found	O
that	O
Thioredoxin	B-Protien
Interacting	I-Protien
Protein 	E-Protien
TXNIP	S-Protien
presents	O
itself	O
as	O
a	O
vital	O
factor	O
in	O
controlling	O
the	O
production	O
and	O
loss	O
of	O
 beta	B-Anatomical_Substances
islet	I-Anatomical_Substances
cells	E-Anatomical_Substances
TXNIP	S-Protien
inhibits	O
the	O
action	O
of	O
the	O
Thioredoxin	B-Protien
 protein	I-Protien
found	O
in	O
the	O
 beta cells	S_Anatomical_Substances
thereby	O
rendering	O
it	O
ineffective	O
in	O
maintaining	O
the	O
cellular	O
redox	O
balance	O
causing	O
oxidative	O
stress	O
and	O
subsequent	O
consequences	O
ultimately	O
leading	O
to	O
aggravation	O
of	O
the	O
disease	O
TRX	O
exists	O
in	O
the	O
form	O
of	O
two	O
isoforms	O
TRX1	S-Protien
TRX2	S-Protien
cytosol	S_Anatomical_Substances
nucleus	S_Anatomical_Substances
which	O
is	O
located	O
in	O
the	O
and	O
at	O
times	O
translocate	O
to	O
the	O
and	O
TRX	S-Protien
which	O
is	O
located	O
in	O
the	O
nucleus	O
TRX	S-Protien
is	O
responsible	O
for	O
the	O
maintenance	O
of	O
the	O
normal	O
cellular	O
redox	O
balance	O
by	O
reducing	O
the	O
oxidised	O
proteins	O
formed	O
by	O
the	O
Reactive	O
Oxygen	O
Species	O
ROS	O
with	O
the	O
help	O
of	O
NADPH dependant 	B-Protien
TRX 	I-Protien
Reductase	E-Protien
This	O
proves	O
to	O
be	O
essential	O
in	O
the	O
pathogenesis	O
of	O
Diabetes 	B-Disease
Mellitus	I-Disease
as	O
the	O
beta	O
cells	O
of	O
the	O
pancreatic	O
islets	O
lack	O
a	O
sufficient	O
amount	O
of	O
antioxidant	O
systems	O
Thus	O
inhibition	O
of	O
TXNIP	S-Protien
has	O
become	O
essential	O
in	O
the	O
survival	O
of	O
beta	O
cells	O
not	O
only	O
enhancing	O
insulin	O
secretion	O
and	O
sensitivity	O
but	O
also	O
alleviating	O
the	O
diseases	O
associated	O
with	O
Diabetes	S-Disease
TXNIP	S-Protien
Hence	O
is	O
discovered	O
to	O
be	O
a	O
unique	O
therapeutic	O
target	O
in	O
the	O
management	O
of	O
DM	O
Adult	O
immunisation	O
has	O
recently	O
emerged	O
as	O
an	O
area	O
of	O
emphasis	O
in	O
research	O
and	O
policy	O
Increasing	O
life	O
expectancy	O
outbreaks	O
like	O
COVID-19	S-Disease
and	O
the	O
endemic	O
nature	O
of	O
diseases	O
like	O
dengue	S-Disease
malaria	S-Disease
have	O
underscored	O
its	O
importance	O
Therefore	O
this	O
study	O
was	O
carried	O
out	O
to	O
assess	O
hesitancy	O
and	O
the	O
factors	O
influencing	O
the	O
uptake	O
of	O
vaccines	O
in	O
adults	O
A	O
descriptive	O
cross	O
sectional	O
study	O
was	O
conducted	O
among	O
the	O
medical	O
students	O
and	O
doctors	O
affiliated	O
to	O
a	O
medical	O
college	O
and	O
tertiary	O
care	O
hospital	O
in	O
Delhi	O
India	O
and	O
their	O
immediate	O
family	O
members	O
in	O
January	O
2021	O
Online	O
data	O
collection	O
was	O
done	O
using	O
the	O
Google	O
Form	O
platforms	O
Data	O
on	O
awareness	O
and	O
perceptions	O
regarding	O
adult	O
vaccination	O
and	O
immunisation	O
status	O
of	O
participants	O
was	O
collected	O
The	O
dataset	O
was	O
exported	O
in	O
the	O
Microsoft	O
Excel	O
format	O
and	O
analysed	O
with	O
IBM	O
SPSS	O
Version	O
25	O
Armonk	O
NY	O
IBM	O
Corp	O
nA	O
total	O
of	O
461	O
adults	O
responded	O
to	O
the	O
survey	O
The	O
most	O
common	O
reasons	O
for	O
vaccine	O
hesitancy	O
were	O
fear	O
of	O
side	O
effects	O
51	O
41	O
lack	O
of	O
awareness	O
of	O
vaccines	O
49	O
46	O
and	O
the	O
lack	O
of	O
national	O
guidelines	O
on	O
adult	O
vaccination	O
32	O
97	O
Hesitancy	O
for	O
vaccines	O
among	O
those	O
who	O
were	O
informed	O
by	O
healthcare	O
workers	O
of	O
vaccine	O
availability	O
was	O
highest	O
for	O
zoster	O
vaccine	O
97	O
80	O
and	O
least	O
for	O
tetanus	O
toxoid	O
57	O
62	O
Significant	O
hesitancy	O
was	O
also	O
observed	O
for	O
Reduced	O
vaccine	O
uptake	O
due	O
to	O
vaccine	O
hesitancy	O
in	O
adulthood	O
is	O
a	O
major	O
health	O
concern	O
Framing	O
national	O
guidelines	O
for	O
adult	O
vaccination	O
in	O
India	O
and	O
awareness	O
generation	O
to	O
create	O
a	O
public	O
demand	O
for	O
adult	O
vaccination	O
warrants	O
prioritization	O
pneumococcal,	S-Disease
human papillomavirus	S-Disease
influenza	S-Disease
varicella	S-Disease
Cerebral	B-Disease
malaria	I-Disease
is	O
a	O
manifestation	O
of	O
malaria	S-Disease
caused	O
by	O
plasmodium	S-Organism
infection	O
It	O
has	O
a	O
high	O
mortality	O
rate	O
and	O
severe	O
neurological	O
sequelae	O
existing	O
a	O
significant	O
research	O
gap	O
and	O
requiring	O
further	O
study	O
at	O
the	O
molecular	O
level	O
We	O
downloaded	O
the	O
GSE117613	O
dataset	O
from	O
the	O
Gene	O
Expression	O
Omnibus	O
GEO	O
database	O
to	O
determine	O
the	O
differentially	O
expressed	O
genes	O
DEGs	O
between	O
the	O
CM	O
group	O
and	O
the	O
control	O
group	O
Weighted	O
gene	O
coexpression	O
network	O
analysis	O
WGCNA	O
was	O
applied	O
to	O
select	O
the	O
module	O
and	O
hub	O
genes	O
most	O
relevant	O
to	O
CM	O
The	O
common	O
genes	O
of	O
the	O
key	O
module	O
and	O
DEGs	O
were	O
selected	O
to	O
perform	O
further	O
analysis	O
The	O
least	O
absolute	O
shrinkage	O
and	O
selection	O
operator	O
LASSO	O
logistic	O
regression	O
and	O
support	O
vector	O
machine	O
recursive	O
feature	O
elimination	O
SVM	O
RFE	O
were	O
applied	O
to	O
screen	O
and	O
verify	O
the	O
diagnostic	O
markers	O
of	O
CM	O
Eventually	O
the	O
hub	O
genes	O
were	O
validated	O
in	O
the	O
external	O
dataset	O
Gene	O
set	O
enrichment	O
analysis	O
GSEA	O
was	O
applied	O
to	O
investigate	O
the	O
possible	O
roles	O
of	O
the	O
hub	O
genes	O
nThe	O
GO	O
and	O
KEGG	O
results	O
showed	O
that	O
DEGs	O
were	O
enriched	O
in	O
some	O
neutrophil	O
mediated	O
pathways	O
and	O
associated	O
with	O
some	O
lumen	O
structures	O
Combining	O
LASSO	O
and	O
the	O
SVM	O
RFE	O
algorithms	O
LEF1 	S-Gene
IRAK3	S-Gene
were	O
identified	O
as	O
potential	O
hub	O
genes	O
in	O
CM	O
Through	O
the	O
GSEA	O
enrichment	O
results	O
we	O
found	O
that	O
LEF1	S-Gene
IRAK3	S-Gene
participated	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
blood	O
brain	O
barrier	O
BBB	O
which	O
contributed	O
to	O
improving	O
the	O
prognosis	O
of	O
CM	O
nThis	O
study	O
may	O
help	O
illustrate	O
the	O
pathophysiology	O
of	O
CM	O
at	O
the	O
molecular	O
level	O
LEF1	S-Gene
IRAK3	S-Gene
can	O
be	O
used	O
as	O
diagnostic	O
biomarkers	O
providing	O
new	O
insight	O
into	O
the	O
diagnosis	O
and	O
prognosis	O
prediction	O
in	O
pediatric	O
CM	O
malaria	S-Disease
malaria 	S-Disease
malaria	B-Disease
infection	I-Disease
 malaria	B-Disease
infection	I-Disease
malaria	B-Disease
 infection	I-Disease
malaria	B-Disease
infection	I-Disease
 malaria	B-Disease
infection	I-Disease
Livelihood	O
activities	O
and	O
human	S-Organism
movements	O
participate	O
in	O
the	O
epidemiology	O
of	O
vector-borne	B-Disease
 diseases	I-Disease
and	O
influence	O
risk	O
in	O
elimination	O
settings	O
In	O
Saudi	O
Arabia	O
where	O
transmission	O
intensity	O
varies	O
geographically	O
it	O
is	O
vital	O
to	O
understand	O
the	O
components	O
driving	O
transmission	O
within	O
specific	O
areas	O
In	O
addition	O
shared	O
social	O
behavioural	O
and	O
occupational	O
characteristics	O
within	O
communities	O
may	O
provoke	O
the	O
risk	O
of	O
This	O
study	O
aims	O
to	O
understand	O
the	O
relationship	O
between	O
human	O
mobility	O
livelihood	O
activities	O
and	O
the	O
risk	O
of	O
in	O
the	O
border	O
region	O
of	O
Jazan	O
to	O
facilitate	O
further	O
strategic	O
 malaria	S-Disease
interventions	O
In	O
addition	O
the	O
study	O
will	O
complement	O
and	O
reinforce	O
the	O
existing	O
efforts	O
to	O
eliminate	O
malaria	S-Disease
on	O
the	O
Saudi	O
and	O
Yemen	O
border	O
by	O
providing	O
a	O
deeper	O
understanding	O
of	O
human	S-Organism
movement	O
and	O
livelihood	O
activities	O
An	O
unmatched	O
case	O
control	O
study	O
was	O
conducted	O
A	O
total	O
of	O
261	O
participants	O
were	O
recruited	O
for	O
the	O
study	O
including	O
81	O
cases	O
of	O
confirmed	O
malaria	S-Disease
through	O
rapid	O
diagnostic	O
tests	O
RDTs	O
and	O
microscopy	O
and	O
180	O
controls	O
in	O
the	O
Baish	O
Governorate	O
in	O
Jazan	O
Provinces	O
Saudi	O
Arabia	O
Individuals	O
who	O
received	O
 malaria	S-Disease
tests	O
were	O
interviewed	O
regarding	O
their	O
livelihood	O
activities	O
and	O
recent	O
movement	O
travel	O
history	O
A	O
questionnaire	O
was	O
administered	O
and	O
the	O
data	O
was	O
captured	O
electronically	O
STATA	O
software	O
version	O
16	O
was	O
used	O
to	O
analyse	O
the	O
data	O
Bivariate	O
and	O
multivariate	O
analyses	O
were	O
conducted	O
to	O
determine	O
if	O
engaging	O
in	O
agricultural	O
activities	O
such	O
as	O
farming	O
and	O
animal	O
husbandry	O
recent	O
travel	O
history	O
outside	O
of	O
the	O
home	O
village	O
within	O
the	O
last	O
30	O
days	O
and	O
participating	O
in	O
spiritual	O
gatherings	O
were	O
related	O
to	O
status	O
A	O
logistical	O
regression	O
model	O
was	O
used	O
to	O
investigate	O
components	O
associated	O
with	O
After	O
adjusting	O
several	O
confounding	O
factors	O
individuals	O
who	O
reported	O
travelling	O
away	O
from	O
their	O
home	O
village	O
in	O
the	O
last	O
30	O
days	O
OR	O
11	O
5	O
95	O
CI	O
4	O
43	O
29	O
9	O
and	O
those	O
who	O
attended	O
a	O
seasonal	O
night	O
spiritual	O
gathering	O
OR	O
3	O
04	O
95	O
CI	O
1	O
10	O
8	O
42	O
involved	O
in	O
animal	O
husbandry	O
OR	O
2	O
52	O
95	O
CI	O
1	O
10	O
5	O
82	O
and	O
identified	O
as	O
male	O
OR	O
4	O
57	O
95	O
CI	O
1	O
43	O
14	O
7	O
were	O
more	O
likely	O
to	O
test	O
positive	O
for	O
Human	O
movement	O
and	O
livelihood	O
activities	O
especially	O
at	O
nighttime	O
should	O
be	O
considered	O
malaria	O
risk	O
factors	O
in	O
malaria	O
elimination	O
settings	O
mainly	O
when	O
the	O
targeted	O
area	O
is	O
limited	O
to	O
a	O
confined	O
borderland	O
area	O
 malaria 	S-Disease
Estimating	O
risk	O
associated	O
with	O
work	O
locations	O
and	O
travel	O
across	O
a	O
region	O
provides	O
local	O
health	O
officials	O
with	O
information	O
useful	O
to	O
mitigate	O
possible	O
transmission	O
paths	O
of	O
malaria 	S-Disease
as	O
well	O
as	O
understand	O
the	O
risk	O
of	O
exposure	O
for	O
local	O
populations	O
This	O
study	O
investigates	O
malaria 	S-Disease
exposure	O
risk	O
by	O
analysing	O
the	O
spatial	O
pattern	O
of	O
malaria	S-Disease
cases	O
primarily	O
Plasmodium	B-Organism
vivax	I-Organism
in	O
Ubon	O
Ratchathani	O
and	O
Sisaket	O
provinces	O
of	O
Thailand	O
using	O
an	O
ecological	O
niche	O
model	O
and	O
machine	O
learning	O
to	O
estimate	O
the	O
species	O
distribution	O
of	O
 P. vivax 	S-Organism
malaria	S-Disease
and	O
compare	O
the	O
resulting	O
niche	O
areas	O
with	O
occupation	O
type	O
work	O
locations	O
and	O
work	O
related	O
travel	O
routes	O
A	O
maximum	O
entropy	O
model	O
was	O
trained	O
to	O
estimate	O
the	O
distribution	O
of	O
 P. vivax	S-Organism
malaria	S-Disease
for	O
a	O
period	O
between	O
January	O
2019	O
and	O
April	O
2020	O
capturing	O
estimated	O
malaria	S-Disease
occurrence	O
for	O
these	O
provinces	O
A	O
random	O
simulation	O
workflow	O
was	O
developed	O
to	O
make	O
region	O
based	O
case	O
data	O
usable	O
for	O
the	O
machine	O
learning	O
approach	O
This	O
workflow	O
was	O
used	O
to	O
generate	O
a	O
probability	O
surface	O
for	O
the	O
ecological	O
niche	O
regions	O
The	O
resulting	O
niche	O
regions	O
were	O
analysed	O
by	O
occupation	O
type	O
home	O
and	O
work	O
locations	O
and	O
work	O
related	O
travel	O
routes	O
to	O
determine	O
the	O
relationship	O
between	O
these	O
variables	O
and	O
malaria	S-Disease
occurrence	O
A	O
one	O
way	O
analysis	O
of	O
variance	O
ANOVA	O
test	O
was	O
used	O
to	O
understand	O
the	O
relationship	O
between	O
predicted	O
malaria	S-Disease
occurrence	O
and	O
occupation	O
type	O
The	O
MaxEnt	O
full	O
name	O
model	O
indicated	O
a	O
higher	O
occurrence	O
of	O
P. vivax	S-Organism
malaria 	S-Disease
in	O
forested	O
areas	O
especially	O
along	O
the	O
Thailand	O
Cambodia	O
border	O
The	O
ANOVA	O
results	O
showed	O
a	O
statistically	O
significant	O
difference	O
between	O
average	O
malaria	S-Disease
risk	O
values	O
predicted	O
from	O
the	O
ecological	O
niche	O
model	O
for	O
rubber	O
plantation	O
workers	O
and	O
farmers	O
the	O
two	O
main	O
occupation	O
groups	O
in	O
the	O
study	O
The	O
rubber	O
plantation	O
workers	O
were	O
found	O
to	O
be	O
at	O
higher	O
risk	O
of	O
exposure	O
to	O
malaria	S-Disease
than	O
farmers	O
in	O
Ubon	O
Ratchathani	O
and	O
Sisaket	O
provinces	O
of	O
Thailand	O
nThe	O
results	O
from	O
this	O
study	O
point	O
to	O
occupation	O
related	O
factors	O
such	O
as	O
work	O
location	O
and	O
the	O
routes	O
travelled	O
to	O
work	O
being	O
risk	O
factors	O
in	O
malaria	S-Disease
occurrence	O
and	O
possible	O
contributors	O
to	O
transmission	O
among	O
local	O
populations	O
The	O
incidence	O
of	O
zoonotic	B-Disease
Plasmodium knowlesi	I-Disease
infections	E-Disease
in	O
humans	S-Disease
is	O
rising	O
in	O
Southeast	O
Asia	O
leading	O
to	O
clinical	O
studies	O
to	O
monitor	O
the	O
efficacy	O
of	O
anti	O
malarial	O
treatments	O
for	O
knowlesi	B-Disease
malaria	I-Disease
One	O
of	O
the	O
key	O
outcomes	O
of	O
anti	O
malarial	O
drug	O
efficacy	O
is	O
parasite	S-Organism
clearance	O
For	O
Plasmodium	B-Organism
falciparum	I-Organism
 parasite	S-Organism
parasite	S-Organism
parasite	S-Organism
parasite	S-Organism
parasite 	S-Organism
parasite	S-Organism
P. knowlesi 	S-Organism
clearance	O
is	O
typically	O
estimated	O
using	O
a	O
two	O
stage	O
method	O
that	O
involves	O
estimating	O
clearance	O
for	O
individual	O
patients	O
followed	O
by	O
pooling	O
of	O
individual	O
estimates	O
to	O
derive	O
population	O
estimates	O
An	O
alternative	O
approach	O
is	O
Bayesian	O
hierarchical	O
modelling	O
which	O
simultaneously	O
analyses	O
all	O
time	O
patient	O
profiles	O
to	O
determine	O
clearance	O
This	O
study	O
compared	O
these	O
methods	O
for	O
estimating	O
clearance	O
in	O
treatment	O
efficacy	O
studies	O
with	O
typically	O
fewer	O
measurements	O
per	O
patient	O
due	O
to	O
high	O
susceptibility	O
to	O
anti	O
malarials	O
 knowlesi	B-Disease
 malaria	I-Disease
 parasite	S-Organism
Using	O
clearance	O
data	O
from	O
714	O
patients	O
with	O
and	O
enrolled	O
in	O
three	O
trials	O
the	O
Worldwide	O
Antimalarial	O
Resistance	O
Network	O
WWARN	O
Parasite	O
Clearance	O
Estimator	O
PCE	O
standard	O
two	O
stage	O
approach	O
and	O
Bayesian	O
hierarchical	O
modelling	O
were	O
compared	O
Both	O
methods	O
estimate	O
the	O
parasite	O
clearance	O
rate	O
from	O
a	O
model	O
that	O
incorporates	O
a	O
lag	O
phase	O
slope	O
and	O
tail	O
phase	O
for	O
the	O
parasitaemia	O
profiles	O
nThe	O
standard	O
two	O
stage	O
approach	O
successfully	O
estimated	O
the	O
parasite	O
clearance	O
rate	O
for	O
678	O
patients	O
with	O
36	O
5	O
patients	O
excluded	O
due	O
to	O
an	O
insufficient	O
number	O
of	O
available	O
parasitaemia	O
measurements	O
The	O
Bayesian	O
hierarchical	O
estimation	O
method	O
was	O
applied	O
to	O
the	O
parasitaemia	O
data	O
of	O
all	O
714	O
patients	O
Overall	O
the	O
Bayesian	O
method	O
estimated	O
a	O
faster	O
population	O
mean	O
parasite	O
clearance	O
0	O
36	O
h	O
95	O
credible	O
interval	O
0	O
18	O
0	O
65	O
compared	O
to	O
the	O
standard	O
two	O
stage	O
method	O
0	O
26	O
h	O
95	O
confidence	O
interval	O
0	O
11	O
0	O
46	O
with	O
better	O
model	O
fits	O
compared	O
visually	O
Artemisinin	B-Medication
based	I-Medication
combination therapy 	E-Medication
P. knowlesi	S-Organism
chloroquine	S-Medication
P. knowlesi 	S-Organism
chloroquine	S-Medication
ACT	O
is	O
more	O
effective	O
in	O
treating	O
as	O
confirmed	O
by	O
both	O
methods	O
with	O
a	O
mean	O
estimated	O
parasite	O
clearance	O
half	O
life	O
of	O
2	O
5	O
and	O
3	O
6	O
h	O
respectively	O
using	O
the	O
standard	O
two	O
stage	O
method	O
and	O
1	O
8	O
and	O
2	O
9	O
h	O
using	O
the	O
Bayesian	O
method	O
nFor	O
clinical	O
studies	O
of	O
with	O
frequent	O
parasite	O
measurements	O
the	O
standard	O
two	O
stage	O
approach	O
WWARN	O
s	O
PCE	O
is	O
recommended	O
as	O
this	O
method	O
is	O
straightforward	O
to	O
implement	O
For	O
studies	O
with	O
fewer	O
parasite	O
measurements	O
per	O
patient	O
the	O
Bayesian	O
approach	O
should	O
be	O
considered	O
Regardless	O
of	O
method	O
used	O
ACT	O
is	O
more	O
efficacious	O
than	O
confirming	O
the	O
findings	O
of	O
the	O
original	O
trials	O
An	O
obligatory	O
step	O
in	O
the	O
complex	O
life	O
cycle	O
of	O
the	O
malaria parasite	B-Organism
is	O
sporogony	O
which	O
occurs	O
during	O
the	O
oocyst	O
stage	O
in	O
adul	O
female	B-Organism
Anopheles	I-Organism
mosquitoes	E-Organism
Sporogony	O
is	O
metabolically	O
demanding	O
and	O
successful	O
oocyst	O
maturation	O
is	O
dependent	O
on	O
host	O
lipids	O
In	O
insects	O
lipid	O
energy	O
reserves	O
are	O
mobilized	O
by	O
adipokinetic	O
hormones	O
AKHs	O
We	O
hypothesized	O
that	O
 Plasmodium 	B-Organism
falciparum	I-Organism
infection	O
activates	O
Anopheles gambiae 	S-Organism
AKH	O
signaling	O
and	O
lipid	O
mobilization	O
We	O
profiled	O
the	O
expression	O
patterns	O
of	O
AKH	O
pathway	O
genes	O
and	O
 AgAkh1 	S-Protien
peptide	O
levels	O
in	O
An. gambiae 	B-Organism
uring	O
starvation	O
after	O
blood	O
feeding	O
and	O
following	O
infection	O
and	O
observed	O
a	O
significant	O
time	O
dependent	O
up	O
regulation	O
of	O
AKH	O
pathway	O
genes	O
and	O
peptide	O
levels	O
during	O
infection	O
Depletion	O
of	O
 AgAkh1	S-Protien
 AgAkhR	S-Protien
by	O
RNAi	O
reduced	O
salivary	O
gland	O
sporozoite	O
production	O
while	O
synthetic	O
 AgAkh1	S-Protien
peptide	O
supplementation	O
rescued	O
sporozoite	O
numbers	O
Inoculation	O
of	O
uninfected	O
 female	B-Organism
 mosquitoes	I-Organism
with	O
supernatant	O
from	O
 P. falciparum	B-Organism
infected	O
midguts	O
activated	O
AKH	O
signaling	O
Clearly	O
identifying	O
the	O
parasite	O
molecules	O
mediating	O
AKH	O
signaling	O
in	O
P. falciparum	B-Organism
porogony	O
is	O
paramount	O
Long	O
read	O
DNA	O
sequencing	O
techniques	O
such	O
as	O
nanopore	O
are	O
especially	O
useful	O
for	O
characterizing	O
complex	O
sequence	O
rearrangements	O
which	O
occur	O
in	O
some	O
genetic	O
diseases	O
and	O
also	O
during	O
evolution	O
Analyzing	O
the	O
sequence	O
data	O
to	O
understand	O
such	O
rearrangements	O
is	O
not	O
trivial	O
due	O
to	O
sequencing	O
error	O
rearrangement	O
intricacy	O
and	O
abundance	O
of	O
repeated	O
similar	O
sequences	O
in	O
genomes	O
The	O
LAST	O
and	O
dnarrange	O
software	O
packages	O
can	O
resolve	O
complex	O
relationships	O
between	O
DNA	O
sequences	O
and	O
characterize	O
changes	O
such	O
as	O
gene	O
conversion	O
processed	O
pseudogene	O
insertion	O
and	O
chromosome	O
shattering	O
They	O
can	O
filter	O
out	O
numerous	O
rearrangements	O
shared	O
by	O
controls	O
e	O
g	O
healthy	O
humans	O
versus	O
a	O
patient	O
to	O
focus	O
on	O
rearrangements	O
unique	O
to	O
the	O
patient	O
One	O
useful	O
ingredient	O
is	O
last	O
train	O
which	O
learns	O
the	O
rates	O
probabilities	O
of	O
deletions	O
insertions	O
and	O
each	O
kind	O
of	O
base	O
match	O
and	O
mismatch	O
These	O
probabilities	O
are	O
then	O
used	O
to	O
find	O
the	O
most	O
likely	O
sequence	O
relationships	O
alignments	O
which	O
is	O
especially	O
useful	O
for	O
DNA	O
with	O
unusual	O
rates	O
such	O
as	O
DNA	O
from	O
Plasmodium 	B-Organism
falciparum 	I-Organism
malaria	O
with	O
80	O
a	O
t	O
This	O
is	O
also	O
useful	O
for	O
less	O
studied	O
species	O
that	O
lack	O
reference	O
genomes	O
so	O
the	O
DNA	O
reads	O
are	O
compared	O
to	O
a	O
different	O
species	O
genome	O
We	O
also	O
point	O
out	O
that	O
a	O
reference	O
genome	O
with	O
ancestral	O
alleles	O
would	O
be	O
ideal	O
Maternal	B-Disease
 malaria 	I-Disease
and	O
infections	O
during	O
pregnancy	O
are	O
risk	O
factors	O
for	O
fetal	O
growth	O
restriction	O
We	O
assessed	O
the	O
impact	O
of	O
preventive	O
treatment	O
in	O
pregnancy	O
on	O
maternal 	B-Disease
malaria	I-Disease
and	O
fetal	O
growth	O
Between	O
2003	O
and	O
2006	O
we	O
enrolled	O
1	O
320	O
pregnant	O
Malawian	O
women	O
14	O
26	O
gestation	O
weeks	O
in	O
a	O
randomized	O
trial	O
and	O
treated	O
them	O
with	O
two	O
doses	O
of	O
 sulfadoxine-pyrimethamine	S-Medication
at	O
enrollment	O
and	O
between	O
28	O
34	O
gestation	O
weeks	O
with	O
monthly	O
SP	O
from	O
enrollment	O
until	O
37	O
gestation	O
weeks	O
or	O
with	O
monthly	O
SP	O
and	O
azithromycin	S-Medication
wice	O
at	O
enrollment	O
and	O
between	O
28	O
and	O
34	O
gestation	O
weeks	O
AZI	O
SP	O
Participants	O
were	O
seen	O
at	O
4	O
week	O
intervals	O
until	O
36	O
completed	O
gestation	O
weeks	O
and	O
weekly	O
thereafter	O
At	O
each	O
visit	O
we	O
collected	O
dried	O
blood	O
spots	O
for	O
real	O
time	O
polymerase	O
chain	O
reaction	O
diagnosing	O
of	O
malaria	O
parasitemia	O
and	O
in	O
a	O
random	O
subgroup	O
of	O
341	O
women	O
we	O
measured	O
fetal	O
biparietal	O
diameter	O
and	O
femur	O
length	O
with	O
ultrasound	O
For	O
the	O
monthly	O
SP	O
versus	O
the	O
control	O
group	O
the	O
odds	O
ratios	O
OR	O
95	O
CI	O
of	O
malaria	O
parasitemia	O
during	O
the	O
second	O
third	O
and	O
both	O
trimesters	O
combined	O
were	O
0	O
79	O
0	O
46	O
1	O
37	O
0	O
58	O
0	O
37	O
0	O
92	O
and	O
0	O
64	O
0	O
42	O
0	O
98	O
respectively	O
The	O
corresponding	O
ORs	O
for	O
the	O
AZI	O
SP	O
versus	O
control	O
group	O
were	O
0	O
47	O
0	O
26	O
0	O
84	O
0	O
51	O
0	O
32	O
0	O
81	O
and	O
0	O
50	O
0	O
32	O
0	O
76	O
respectively	O
Differences	O
between	O
the	O
AZI	O
SP	O
and	O
the	O
monthly	O
SP	O
groups	O
were	O
not	O
statistically	O
significant	O
The	O
interventions	O
did	O
not	O
affect	O
fetal	O
biparietal	O
diameter	O
and	O
femur	O
length	O
growth	O
velocity	O
The	O
results	O
suggest	O
that	O
preventive	O
maternal	O
treatment	O
with	O
monthly	O
SP	O
reduced	O
malaria	O
parasitemia	O
during	O
pregnancy	O
in	O
Malawi	O
and	O
that	O
the	O
addition	O
of	O
azithromycin	O
did	O
not	O
provide	O
much	O
additional	O
antimalarial	O
effect	O
Aedes	B-Organism
 aegypti	I-Organism
mosquitoes	E-Organism
are	O
the	O
main	O
vectors	O
of	O
arboviruses	S-Organism
 peritrophic matrix	B-Anatomical_Substances
is	O
an	O
extracellular	O
layer	O
that	O
surrounds	O
the	O
blood	B-Anatomical_Substances
bolus	I-Anatomical_Substances
It	O
acts	O
as	O
an	O
immune	O
barrier	O
that	O
prevents	O
direct	O
contact	O
o	O
bacteria	S-Organism
midgut 	B-Anatomical_Substances
 epithelial	I-Anatomical_Substances
 cells 	E-Anatomical_Substances
 blood	S_Anatomical_Substances
digestion	O
Here	O
we	O
describe	O
a	O
heme-dependent	B-Chemical_Substance
peroxidase	I-Chemical_Substance
 heme peroxidase 1	E-Chemical_Substance
hereafter	O
referred	O
to	O
as	O
HPx1	O
HPx1	O
promotes	O
PM	O
assembly	O
and	O
antioxidant	O
ability	O
modulating	O
vector	O
competence	O
Mechanistically	O
the	O
heme	O
presence	O
in	O
a	O
blood	O
meal	O
induces	O
HPx1	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
E75	O
transcription	O
factor	O
HPx1	O
knockdown	O
increases	O
midgut	O
reactive	O
oxygen	O
species	O
ROS	O
production	O
by	O
the	O
DUOX NADPH oxidase	S-Chemical_Substance
HPx1	S-Chemical_Substance
DUOX	S-Chemical_Substance
HPx1	S-Chemical_Substance
Zika 	S-Disease
dengue	S-Disease
levels	O
reduce	O
microbiota	O
growth	O
while	O
enhancing	O
epithelial	O
mitosis	O
a	O
response	O
to	O
tissue	O
damage	O
However	O
simultaneous	O
silencing	O
was	O
not	O
able	O
to	O
rescue	O
bacterial	O
population	O
growth	O
as	O
explained	O
by	O
increased	O
expression	O
of	O
antimicrobial	O
peptides	O
AMPs	O
which	O
occurred	O
only	O
after	O
double	O
knockdown	O
This	O
result	O
revealed	O
hierarchical	O
activation	O
of	O
ROS	O
and	O
AMPs	O
to	O
control	O
microbiota	O
produced	O
a	O
100	O
fold	O
decrease	O
in	O
2	O
midgut	O
infection	O
demonstrating	O
the	O
essential	O
role	O
of	O
the	O
mosquito	O
PM	O
in	O
the	O
modulation	O
of	O
arbovirus	O
vector	O
competence	O
Our	O
data	O
show	O
that	O
the	O
PM	O
connects	O
blood	O
digestion	O
to	O
midgut	O
immunological	O
sensing	O
of	O
the	O
microbiota	O
and	O
viral	O
infections	O
Chagas	B-Disease
disease 	I-Disease
oCD	S-Disease
The	O
oral	O
transmission	O
of	O
in	O
Venezuela	O
announced	O
its	O
appearance	O
in	O
2007	O
Different	O
from	O
other	O
populations	O
affected	O
by	O
oCD	S-Disease
and	O
despite	O
close	O
supervision	O
during	O
treatment	O
with	O
nitroheterocyclic	B-Medication
drugs	I-Medication
the	O
result	O
was	O
treatment	O
failure	O
We	O
studied	O
genetic	O
features	O
of	O
natural	O
bloodstream	O
parasite	S-Organism
populations	O
and	O
populations	O
after	O
treatment	O
of	O
nine	O
patients	O
of	O
this	O
outbreak	O
In	O
total	O
we	O
studied	O
six	O
hemoculture	O
isolates	O
eight	O
Pre	O
Tx	O
blood	O
samples	O
and	O
17	O
samples	O
collected	O
at	O
two	O
or	O
three	O
Post	O
Tx	O
time	O
points	O
between	O
2007	O
and	O
2015	O
Parasitic	O
loads	O
were	O
determined	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
qPCR	O
and	O
discrete	O
typing	O
units	O
DTU	O
minicircle	O
signatures	O
and	O
Malaria	S-Disease
is	O
responsible	O
for	O
over	O
435	O
000	O
deaths	O
annually	O
mostly	O
occurring	O
in	O
sub	O
Saharan	O
Africa	O
Detecting	O
 Plasmodium	B-Organism
spp. sporozoites 	I-Organism
in	O
the	O
salivary	B-Anatomical_Substances
 glands 	I-Anatomical_Substances
Anopheles	S-Organism
Diptera	S-Organism
Culicidae	O
vectors	O
with	O
Plasmodium	B-Organism
falciparum 	I-Organism
circumsporozoite	S-Protien
enzyme	O
linked	O
immunosorbent	O
assay	O
csELISA	O
is	O
an	O
important	O
surveillance	O
method	O
However	O
current	O
technological	O
advances	O
are	O
intellectual	O
property	O
and	O
often	O
require	O
of	O
distribution	O
and	O
highly	O
trained	O
users	O
The	O
transition	O
into	O
paper	O
based	O
rapid	O
plataforms	O
would	O
allow	O
for	O
decentralization	O
of	O
survillance	O
especially	O
in	O
areas	O
where	O
it	O
was	O
virtually	O
eliminated	O
The	O
addition	O
of	O
bio	O
based	O
materials	O
have	O
shown	O
the	O
potential	O
to	O
improve	O
binding	O
of	O
target	O
antigens	O
while	O
being	O
widely	O
available	O
Here	O
we	O
evaluate	O
the	O
use	O
of	O
chitosan 	S-Chemical_Substance
cellulose	B-Chemical_Substance
 nanocrystals 	I-Chemical_Substance
as	O
antibody	O
carriers	O
and	O
substrate	O
coatings	O
on	O
96	O
well	O
plates	O
and	O
on	O
wax	O
hydrophobized	O
paper	O
plates	O
for	O
the	O
detection	O
of	O
 P. vivax VK210 	S-Organism
and P. vivax VK247	S-Organism
To	O
further	O
improve	O
the	O
user	O
friendliness	O
of	O
the	O
paper	O
plates	O
a	O
quantitative	O
photograph	O
image	O
based	O
color	O
analysis	O
was	O
done	O
Interactions	O
between	O
the	O
materials	O
and	O
the	O
assay	O
antibodies	O
were	O
studied	O
by	O
quartz	O
crystal	O
microbalance	O
with	O
dissipation	O
monitoring	O
QCM	O
D	O
Overall	O
the	O
addition	O
of	O
chitosan	O
increased	O
the	O
interaction	O
with	O
antibodies	O
and	O
enhanced	O
signaling	O
in	O
all	O
tests	O
This	O
work	O
demonstrated	O
that	O
the	O
adaptation	O
of	O
a	O
PcsELISA	O
shows	O
potential	O
as	O
a	O
cost	O
effective	O
alternative	O
assay	O
platform	O
easily	O
adaptable	O
in	O
deployable	O
testing	O
sites	O
that	O
also	O
showed	O
reduction	O
in	O
reagent	O
volumes	O
by	O
80	O
and	O
assay	O
run	O
time	O
by	O
seventh	O
While	O
dipstick	O
assays	O
were	O
previously	O
developed	O
paper	O
based	O
assays	O
are	O
a	O
cost	O
effective	O
and	O
field	O
deployable	O
alternative	O
reducing	O
volumes	O
of	O
reagents	O
that	O
could	O
be	O
used	O
in	O
malaria	O
control	O
and	O
elimination	O
settings	O
 insects	S-Organism
antimicrobial	B-Protien
 peptides	I-Protien
AMPs	S-Protien
AMPs	S-Protien
AMPs	S-Protien
 African	B-Organism
malaria 	I-Organism
mosquito,	E-Organism
is	O
highly	O
dependent	O
on	O
several	O
signaling	O
cascade	O
pathways	O
such	O
as	O
the	O
Toll	O
pathway	O
In	O
the	O
antibacterial	O
immunity	O
largely	O
depends	O
on	O
the	O
activation	O
of	O
downstream	O
signaling	O
and	O
effector	O
responses	O
leading	O
to	O
the	O
synthesis	O
and	O
secretion	O
of	O
soluble	O
effector	O
molecules	O
such	O
as	O
are	O
acute	O
infection	O
response	O
peptides	O
secreted	O
into	O
the	O
hemolymph	O
upon	O
bacterial	O
stimulation	O
The	O
transcription	O
of	O
innate	O
immunity	O
genes	O
encoding	O
fo	O
 eukaryotes 	B-Anatomical_Substances
 kinases	B-Anatomical_Substances
orchestrates	I-Anatomical_Substances
Mechanisms	O
of	O
cell	O
division	O
are	O
remarkably	O
diverse	O
suggesting	O
the	O
underlying	O
molecular	O
networks	O
among	O
the	O
process	O
of	O
chromosome	O
segregation	O
and	O
cytokinesis	O
during	O
cell	O
division	O
through	O
precise	O
spatiotemporal	O
regulation	O
of	O
their	O
catalytic	O
activities	O
by	O
distinct	O
scaffolds	O
 antihypertension	B-Medication
drugs 	I-Medication
Radical	O
cure	O
of	O
A	O
drug	O
repurposing	O
screen	O
reveals	O
are	O
active	O
against	O
Sequence	O
variation	O
among	O
antigenic	O
Malaria 	S-Disease
is	O
one	O
of	O
the	O
biggest	O
impediments	O
to	O
global	O
progress	O
In	O
Peru	O
it	O
is	O
still	O
a	O
major	O
public	O
health	O
problem	O
Measures	O
of	O
health	O
and	O
economic	O
burden	O
due	O
to	O
malaria	S-Disease
are	O
relevant	O
considerations	O
for	O
the	O
assessment	O
of	O
current	O
policies	O
We	O
used	O
estimates	O
from	O
the	O
Global	O
Burden	O
of	O
Diseases	O
Study	O
2019	O
for	O
malaria i	S-Disease
Peru	O
grouped	O
by	O
gender	O
and	O
age	O
from	O
1990	O
to	O
2019	O
Results	O
are	O
presented	O
as	O
absolute	O
numbers	O
and	O
age	O
standardized	O
rates	O
with	O
95	O
uncertainty	O
intervals	O
UI	O
We	O
collected	O
economic	O
data	O
from	O
the	O
World	O
Bank	O
and	O
The	O
National	O
Institute	O
of	O
Statistics	O
and	O
Informatics	O
of	O
Peru	O
and	O
Loreto	O
to	O
calculate	O
the	O
economic	O
burden	O
of	O
productivity	O
loss	O
EBPL	O
using	O
the	O
human	O
capital	O
approach	O
Economic	O
values	O
were	O
presented	O
in	O
constant	O
dollars	O
soles	O
and	O
percentages	O
nRates	O
of	O
deaths	O
years	O
of	O
life	O
lost	O
YLLs	O
years	O
lived	O
with	O
disability	O
YLDs	O
and	O
disability	O
adjusted	O
life	O
years	O
DALYs	O
as	O
well	O
as	O
the	O
EBPL	O
were	O
drastically	O
reduced	O
from	O
1990	O
to	O
2019	O
DALYs	O
had	O
a	O
greater	O
percentage	O
of	O
YLDs	O
in	O
2019	O
than	O
in	O
1990	O
DALYs	O
rates	O
showed	O
no	O
preference	O
between	O
sexes	O
but	O
the	O
1	O
year	O
age	O
group	O
had	O
the	O
highest	O
DALYs	O
values	O
over	O
the	O
study	O
period	O
We	O
found	O
that	O
the	O
EBPL	O
due	O
to	O
malaria	O
for	O
Loreto	O
was	O
considerably	O
higher	O
than	O
Peru	O
s	O
in	O
terms	O
of	O
GDP	O
percentage	O
nOur	O
study	O
shows	O
that	O
the	O
fight	O
against	O
malaria	O
in	O
Peru	O
reduced	O
remarkably	O
the	O
impact	O
of	O
the	O
disease	O
since	O
1990	O
however	O
during	O
the	O
last	O
decade	O
the	O
estimates	O
were	O
stable	O
or	O
even	O
increased	O
Our	O
results	O
help	O
to	O
measure	O
the	O
malaria	O
impact	O
on	O
the	O
health	O
status	O
of	O
the	O
Peruvian	O
population	O
as	O
well	O
as	O
the	O
economic	O
pressure	O
that	O
it	O
exerts	O
constituting	O
remarkable	O
tools	O
for	O
policymaking	O
aimed	O
at	O
reducing	O
the	O
burden	O
of	O
this	O
disease	O
Strengthening	O
the	O
malaria	O
elimination	O
program	O
is	O
important	O
to	O
achieve	O
the	O
elimination	O
of	O
the	O
disease	O
in	O
the	O
coming	O
years	O
nThis	O
study	O
was	O
supported	O
by	O
the	O
Universidad	O
Nacional	O
Toribio	O
Rodríguez	O
de	O
Mendoza	O
and	O
FONDECYT	O
Contrato	O
Nº	O
09	O
2019	O
FONDECYT	O
BMINC	O
INV	O
and	O
FONDECYT	O
BM	O
Perú	O
Program	O
INCORPORACIÓN	O
DE	O
INVESTIGADORES	O
E038	O
2019	O
01	O
Registry	O
Number	O
64007	O
The	O
imminent	O
risk	O
o	O
zoonoses	S-Disease
malari	B-Organism
parasites	I-Organism
is	O
not	O
far	O
from	O
reality	O
in	O
India	O
as	O
has	O
been	O
observed	O
in	O
the	O
case	O
of	O
Plasmodium	B-Organism
knowlesi 	I-Organism
nd	O
so	O
is	O
possible	O
with	O
The	O
qPCR	O
primers	O
were	O
designed	O
in	O
house	O
with	O
fluorescence	O
labeled	O
probes	O
HEX	O
for	O
Pk	O
and	O
FAM	O
for	O
Pc	O
DNA	O
samples	O
of	O
Pk	O
and	O
Pc	O
were	O
used	O
as	O
templates	O
and	O
further	O
the	O
qPCR	O
assay	O
was	O
evaluated	O
in	O
250	O
symptomatic	O
and	O
asymptomatic	O
suspected	O
human	O
blood	O
samples	O
from	O
malaria	O
endemic	O
areas	O
of	O
North	O
Eastern	O
states	O
of	O
India	O
nThe	O
qPCR	O
assay	O
successfully	O
amplified	O
the	O
target	O
18S	O
rRNA	O
gene	O
segment	O
from	O
Pk	O
and	O
Pc	O
and	O
was	O
highly	O
specific	O
for	O
Pk	O
and	O
Pc	O
parasites	O
only	O
as	O
no	O
cross	O
reactivity	O
was	O
observed	O
with	O
nThe	O
multiplex	O
qPCR	O
assay	O
was	O
observed	O
to	O
be	O
robust	O
quick	O
cost	O
effective	O
and	O
highly	O
sensitive	O
as	O
compared	O
to	O
the	O
currently	O
available	O
conventional	O
PCR	O
methods	O
Further	O
validation	O
of	O
the	O
multiplex	O
qPCR	O
assay	O
in	O
field	O
setting	O
is	O
desirable	O
especially	O
from	O
the	O
high	O
risk	O
populations	O
We	O
anticipate	O
that	O
the	O
multiplex	O
qPCR	O
assay	O
would	O
prove	O
to	O
be	O
a	O
useful	O
tool	O
in	O
mass	O
screening	O
and	O
surveillance	O
programs	O
for	O
detection	O
of	O
non	O
human	O
malaria	O
parasites	O
toward	O
the	O
control	O
and	O
elimination	O
of	O
malaria	O
from	O
India	O
by	O
2030	O
Malaria	B-Medication
 rapid 	I-Medication
diagnostic tests 	E-Medication
mRDTs	S-Medication
ve	O
played	O
an	O
important	O
role	O
in	O
the	O
early	O
detection	O
of	O
clinical	O
 malaria 	S-Disease
in	O
an	O
endemic	O
area	O
While	O
several	O
mRDTs	O
are	O
currently	O
on	O
the	O
market	O
the	O
availability	O
of	O
mRDTs	O
with	O
high	O
sensitivity	O
and	O
specificity	O
will	O
merit	O
the	O
fight	O
against	O
malaria	O
We	O
evaluated	O
the	O
field	O
performance	O
of	O
a	O
novel	O
Malaria	S-Disease
 Malaria	S-Disease
Malaria	S-Disease
HRP-2	B-Gene
gene	I-Gene
malaria	B-Organism
parasites	I-Organism
 HRP-2	B-Gene
gene	I-Gene
P	O
f	O
P	O
v	O
Tri	O
line	O
and	O
One	O
Step	O
One	O
Step	O
rapid	O
test	O
kits	O
in	O
Pwani	O
Tanzania	O
In	O
a	O
cross	O
sectional	O
study	O
conducted	O
in	O
Bagamoyo	O
and	O
Kibiti	O
districts	O
in	O
Tanzania	O
symptomatic	O
patients	O
were	O
tested	O
using	O
the	O
SD	O
BIOLINE	O
One	O
Step	O
Malaria	O
P	O
f	O
P	O
v	O
Tri	O
line	O
and	O
One	O
Step	O
Malaria	O
P	O
f	O
rapid	O
test	O
kits	O
microscope	O
and	O
quantitative	O
Polymerase	O
Chain	O
Reaction	O
qPCR	O
An	O
additional	O
qPCR	O
assay	O
was	O
carried	O
out	O
to	O
detect	O
Histidine	O
Rich	O
Protein	O
2	O
HRP	O
2	O
gene	O
deletion	O
on	O
mRDT	O
negative	O
but	O
microscope	O
and	O
qPCR	O
positive	O
samples	O
Microscope	O
results	O
confirmed	O
by	O
qPCR	O
were	O
used	O
for	O
analysis	O
where	O
qPCR	O
was	O
used	O
as	O
a	O
reference	O
method	O
nThe	O
sensitivity	O
and	O
specificity	O
of	O
One	O
Step	O
P	O
f	O
P	O
v	O
Tri	O
line	O
mRDTs	O
were	O
96	O
0	O
CI	O
93	O
5	O
97	O
7	O
and	O
98	O
3	O
CI	O
96	O
8	O
99	O
2	O
respectively	O
One	O
Step	O
P	O
f	O
mRDT	O
had	O
sensitivity	O
and	O
specificity	O
of	O
95	O
2	O
CI	O
92	O
5	O
97	O
1	O
and	O
97	O
9	O
CI	O
96	O
3	O
99	O
0	O
respectively	O
Positive	O
predictive	O
value	O
PPV	O
was	O
97	O
6	O
CI	O
95	O
4	O
98	O
7	O
and	O
negative	O
predictive	O
value	O
NPV	O
was	O
96	O
2	O
CI	O
95	O
5	O
98	O
3	O
for	O
the	O
One	O
Step	O
P	O
f	O
P	O
v	O
Tri	O
line	O
mRDTs	O
respectively	O
while	O
One	O
Step	O
P	O
f	O
mRDT	O
had	O
positive	O
predictive	O
value	O
PPV	O
and	O
negative	O
predictive	O
value	O
NPV	O
of	O
97	O
0	O
CI	O
94	O
8	O
98	O
3	O
and	O
96	O
7	O
CI	O
94	O
9	O
97	O
9	O
respectively	O
9	O
8	O
CI	O
7	O
84	O
11	O
76	O
of	O
all	O
samples	O
tested	O
and	O
reported	O
to	O
be	O
malaria	O
negative	O
by	O
mRDT	O
had	O
deletion	O
One	O
Step	O
Malaria	O
P	O
f	O
P	O
v	O
Tri	O
line	O
and	O
One	O
Step	O
P	O
f	O
rapid	O
test	O
kits	O
have	O
similar	O
sensitivity	O
and	O
specificity	O
as	O
the	O
standard	O
mRDT	O
that	O
is	O
currently	O
in	O
the	O
market	O
demonstrating	O
the	O
potential	O
to	O
contribute	O
in	O
the	O
fight	O
against	O
malaria	O
in	O
endemic	O
settings	O
However	O
the	O
identified	O
population	O
with	O
deletion	O
pose	O
a	O
threat	O
to	O
the	O
current	O
mRDT	O
usability	O
in	O
the	O
field	O
and	O
warrants	O
further	O
investigations	O
Malaria	B-Disease
in pregnancy	I-Disease
MiP	E-Disease
is	O
a	O
public	O
health	O
problem	O
in	O
the	O
Brazilian	O
Amazon	O
region	O
that	O
requires	O
special	O
attention	O
due	O
to	O
associated	O
serious	O
adverse	O
consequences	O
such	O
as	O
low	O
birth	O
weight	O
increased	O
prematurity	O
and	O
spontaneous	O
abortion	O
rates	O
In	O
Brazil	O
there	O
have	O
been	O
no	O
comprehensive	O
epidemiological	O
studies	O
of	O
MiP	O
In	O
this	O
study	O
we	O
aimed	O
to	O
explore	O
the	O
spatial	O
and	O
spatiotemporal	O
patterns	O
of	O
MiP	O
in	O
Brazil	O
and	O
epidemiologically	O
characterize	O
this	O
population	O
of	O
pregnant	O
women	O
over	O
a	O
period	O
of	O
15	O
years	O
nWe	O
performed	O
a	O
national	O
scale	O
ecological	O
analysis	O
using	O
a	O
Bayesian	O
space	O
time	O
hierarchical	O
model	O
to	O
estimate	O
the	O
incidence	O
rates	O
of	O
MiP	O
between	O
1	O
January	O
2004	O
and	O
31	O
December	O
2018	O
We	O
mapped	O
the	O
high	O
incidence	O
clusters	O
among	O
pregnant	O
women	O
aged	O
10	O
49	O
years	O
old	O
using	O
a	O
Poisson	O
model	O
and	O
we	O
characterized	O
the	O
population	O
based	O
on	O
data	O
from	O
the	O
Epidemiological	O
Surveillance	O
Information	O
System	O
for	O
Malaria	O
SIVEP	O
Malaria	O
nWe	O
consolidated	O
the	O
data	O
of	O
61	O
833	O
women	O
with	O
MiP	O
in	O
Brazil	O
Our	O
results	O
showed	O
a	O
reduction	O
of	O
50	O
1	O
95	O
CI	O
47	O
3	O
to	O
52	O
9	O
in	O
the	O
number	O
of	O
malaria	O
cases	O
over	O
the	O
period	O
analysed	O
with	O
nThis	O
nationwide	O
study	O
provides	O
robust	O
evidence	O
that	O
despite	O
the	O
reduction	O
in	O
the	O
number	O
of	O
MiP	O
cases	O
in	O
the	O
country	O
it	O
remains	O
a	O
serious	O
public	O
health	O
problem	O
especially	O
for	O
young	O
pregnant	O
women	O
Our	O
analyses	O
highlight	O
focus	O
areas	O
for	O
strengthening	O
interventions	O
to	O
control	O
and	O
eliminate	O
MiP	O
nFAPESP	O
and	O
CNPq	O
Brazil	O
Difficulties	O
associated	O
with	O
the	O
assessment	O
of	O
glucose-6-phosphate	B-Anatomical_Substances
dehydrogenase 	I-Anatomical_Substances
G6PDd)	S_Anatomical_Substances
particularly	O
in	O
remote	O
areas	O
hinders	O
the	O
safe	O
use	O
of	O
 8-aminoquinolines 	S-Medication
primaquine 	S-Medication
tafenoquine	S-Medication
This	O
cross	O
sectional	O
study	O
was	O
conducted	O
in	O
41	O
 malaria-	S-Disease
endemic	O
municipalities	O
of	O
six	O
states	O
in	O
the	O
Brazilian	O
Amazon	O
between	O
2014	O
and	O
2018	O
Male	O
individuals	O
were	O
screened	O
for	O
G6PDd	S_Anatomical_Substances
using	O
the	O
qualitative	O
Fluorescent	O
Spot	O
Test	O
using	O
fingerpick	O
collected	O
whole	O
blood	O
samples	O
Point	O
and	O
interval	O
estimates	O
of	O
the	O
G6PDd	O
prevalence	O
were	O
calculated	O
for	O
each	O
state	O
Deficient	O
samples	O
were	O
genotyped	O
for	O
the	O
most	O
prevalent	O
variants	O
in	O
the	O
Amazon	O
Frequencies	O
of	O
nThis	O
is	O
one	O
of	O
the	O
largest	O
surveys	O
ever	O
conducted	O
in	O
Latin	O
America	O
covering	O
the	O
entire	O
malaria	S-Disease
endemic	O
area	O
in	O
the	O
Brazilian	O
Amazon	O
These	O
results	O
indicate	O
that	O
an	O
important	O
proportion	O
of	O
the	O
population	O
is	O
at	O
risk	O
of	O
hemolysis	O
if	O
exposed	O
to	O
PQ	O
and	O
its	O
congener	O
drug	O
tafenoquine	S-Medication
The	O
adoption	O
of	O
G6PDd	S_Anatomical_Substances
G6PDd	S_Anatomical_Substances
screening	O
protocols	O
is	O
essential	O
to	O
ensure	O
the	O
safety	O
of	O
individuals	O
treated	O
with	O
those	O
drugs	O
and	O
should	O
also	O
be	O
considered	O
when	O
implementing	O
malaria	S-Disease
elimination	O
strategies	O
nA	O
total	O
of	O
14	O
847	O
individuals	O
were	O
included	O
of	O
which	O
5	O
6	O
presented	O
G6PDd	O
The	O
state	O
of	O
Acre	O
had	O
the	O
highest	O
G6PDd	O
prevalence	O
8	O
3	O
followed	O
by	O
Amapá	O
5	O
8	O
Pará	O
5	O
7	O
Rondônia	O
5	O
4	O
Roraima	O
4	O
2	O
and	O
Amazonas	O
4	O
0	O
From	O
828	O
genotyped	O
samples	O
African	O
A	O
nBrazilian	O
Ministry	O
of	O
Health	O
Fundação	O
de	O
Amparo	O
à	O
Pesquisa	O
do	O
Estado	O
do	O
Amazonas	O
FAPEAM	O
